Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-15-287911.txt : 20150812 0001193125-15-287911.hdr.sgml : 20150812 20150812145822 ACCESSION NUMBER: 0001193125-15-287911 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150812 DATE AS OF CHANGE: 20150812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CareDx, Inc. CENTRAL INDEX KEY: 0001217234 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 943316839 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36536 FILM NUMBER: 151046688 BUSINESS ADDRESS: STREET 1: 3260 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 415-287-2300 MAIL ADDRESS: STREET 1: 3260 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: XDx, Inc. DATE OF NAME CHANGE: 20071010 FORMER COMPANY: FORMER CONFORMED NAME: EXPRESSION DIAGNOSTICS INC DATE OF NAME CHANGE: 20030203 10-Q 1 d933029d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-36536

CareDx, Inc.

(Exact name of registrant as specified in its charter)

Delaware

94-3316839

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

3260 Bayshore Boulevard

Brisbane, California 94005

(Address of principal executive offices and zip code)

(415) 287-2300

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

There were 11,887,409 shares of the registrant’s Common Stock issued and outstanding as of July 29, 2015.

CareDx, Inc.

TABLE OF CONTENTS


	Page No.
PART I. FINANCIAL INFORMATION		3

Item 1. Unaudited Condensed Financial Statements		3
Condensed Balance Sheets as of June 30, 2015 and December 31, 2014		3
Condensed Statements of Operations for the Three and Six Months Ended June 30, 2015 and 2014		4
Condensed Statements of Cash Flows for the Six Months Ended June 30, 2015 and 2014		5
Notes to Condensed Financial Statements		6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		19
Item 3. Quantitative and Qualitative Disclosures About Market Risk		30
Item 4. Controls and Procedures		30

PART II. OTHER INFORMATION		31
Item 1. Legal Proceedings		31
Item 1A. Risk Factors		31
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		31
Item 3. Defaults Upon Senior Securities		31
Item 4. Mine Safety Disclosures		31
Item 5. Other Information		31
Item 6. Exhibits		31
Signatures		32
Exhibit Index		33

PART I. FINANCIAL INFORMATION

ITEM 1.

UNAUDITED CONDENSED FINANCIAL STATEMENTS

CareDx, Inc.

Condensed Balance Sheets

(Unaudited)

(In thousands, except share and per share data)


	June 30,			December 31,
	2015			2014
				(Note 2)
Assets
Current assets:
Cash and cash equivalents	$	36,894		$	36,431
Accounts receivable		1,706			2,687
Inventory		731			686
Prepaid and other assets		674			542

Total current assets		40,005			40,346
Property and equipment, net		2,559			1,968
Intangible assets, net		6,650			6,650
Goodwill		12,005			12,005
Restricted cash		147			147
Other noncurrent assets		—			25

Total assets	$	61,366		$	61,141


Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,203		$	1,128
Accrued payroll liabilities		2,051			1,684
Accrued and other liabilities		1,840			1,616
Accrued royalties		268			241
Deferred revenue		500			505
Current portion of long-term debt		2,380			5,961

Total current liabilities		8,242			11,135
Deferred rent, net of current portion		1,554			1,684
Deferred revenue, net of current portion		417			471
Long-term debt, net of current portion		13,389			5,451
Contingent consideration		963			1,074
Other liabilities		28			28

Total liabilities		24,593			19,843
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock: $0.001 par value; 10,000,000 shares authorized at June 30, 2015 and December 31, 2014; no shares issued and outstanding at June 30, 2015 and December 31, 2014		—			—
Common stock: $0.001 par value; 100,133,900 and 100,000,000 shares authorized at June 30, 2015 and December 31, 2014, respectively; 11,838,794 and 11,803,970 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively		12			12
Additional paid-in capital		201,595			200,661
Accumulated deficit		(164,834	)		(159,375	)

Total stockholders’ equity		36,773			41,298

Total liabilities and stockholders’ equity	$	61,366		$	61,141

The accompanying notes are an integral part of these unaudited condensed financial statements.

CareDx, Inc.

Condensed Statements of Operations

(Unaudited)

(In thousands, except share and per share data)


	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014

Revenue:
Testing revenue	$	7,044		$	6,710		$	14,139		$	12,544
Collaboration and license revenue		85			66			205			156

Total revenue		7,129			6,776			14,344			12,700

Operating expenses:
Cost of testing		2,508			2,403			5,218			4,565
Research and development		2,510			792			3,931			1,512
Sales and marketing		2,526			1,610			4,549			3,084
General and administrative		2,329			2,316			5,034			4,111
Change in estimated fair value of contingent consideration		142			—			(111	)		—

Total operating expenses		10,015			7,121			18,621			13,272


Loss from operations		(2,886	)		(345	)		(4,277	)		(572	)

Interest expense, net		(256	)		(644	)		(1,083	)		(1,192	)
Other (expense) income, net		(43	)		366			(97	)		(163	)

Loss before income taxes		(3,185	)		(623	)		(5,457	)		(1,927	)
Income tax benefit		—			1,500			—			1,500

Net (loss) income	$	(3,185	)	$	877		$	(5,457	)	$	(427	)


Net (loss) income per share (Note 3):
Basic	$	(0.27	)	$	0.87		$	(0.46	)	$	(0.42	)

Diluted	$	(0.27	)	$	0.13		$	(0.46	)	$	(0.42	)


Shares used to compute net (loss) income per share:
Basic		11,835,405			1,013,128			11,824,993			1,012,769

Diluted		11,835,405			6,939,568			11,824,993			1,012,769

The accompanying notes are an integral part of these unaudited condensed financial statements.

CareDx, Inc.

Condensed Statements of Cash Flows

(Unaudited)

(In thousands)


	Six Months Ended June 30,
	2015			2014
Operating activities:
Net loss	$	(5,457	)	$	(427	)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization		358			222
Stock-based compensation		692			185
Amortization of deferred revenue		(59	)		(23	)
Amortization of debt discount and non-cash interest expense		450			349
Revaluation of contingent consideration to estimated fair value		(111	)		—
Revaluation of warrants to estimated fair value		—			283
Gain on remeasurement of embedded derivative		—			(118	)
Non-cash income tax benefit		—			(1,500	)
Changes in operating assets and liabilities:
Accounts receivable		981			545
Inventory		(45	)		(96	)
Prepaid and other assets		(108	)		(2,152	)
Accounts payable		(116	)		1,123
Accrued payroll liabilities		367			(196	)
Accrued and other liabilities		274			2,117
Accrued royalties		27			721

Net cash (used in) provided by operating activities		(2,747	)		1,033

Investing activities:
Purchase of property and equipment		(733	)		(164	)
Payment for acquisition, net of cash acquired (Note 11)		—			(376	)

Net cash used in investing activities		(733	)		(540	)

Financing activities:
Payment of initial public offering costs		—			(909	)
Proceeds from debt, net of issuance costs		15,625			4,982
Proceeds from exercise of stock options		42			5
Principal payments on debt and capital leases		(11,724	)		(1,827	)

Net cash provided by financing activities		3,943			2,251

Net increase in cash and cash equivalents		463			2,744
Cash and cash equivalents at beginning of period		36,431			5,128

Cash and cash equivalents at end of period	$	36,894		$	7,872

The accompanying notes are an integral part of these unaudited condensed financial statements.

CareDx, Inc.

Notes to Unaudited Condensed Financial Statements

1. ORGANIZATION

CareDx, Inc., (“CareDx” or the “Company”) is a commercial stage company that develops, markets and delivers diagnostic surveillance solutions for organ transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient’s lifetime. The Company’s one commercialized testing solution, the AlloMap heart transplant molecular test (“AlloMap”), an FDA-cleared test, is a blood-based test used to monitor for acute cellular rejection in heart transplant recipients. The Company was incorporated in Delaware in December 1998, as Hippocratic Engineering, Inc. In April 1999, the Company changed its name to BioCardia, Inc., in June 2002 to Expression Diagnostics, Inc., in July 2007 to XDx, Inc. and in March 2014 to CareDx, Inc. The Company’s operations are based in Brisbane, California and it operates in one segment.

Reverse Stock Split, and Increase in Authorized Shares

On July 1, 2014, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to reflect a 1 for 6.85 reverse stock split (the “Reverse Stock Split”) of the Company’s outstanding common stock and convertible preferred stock. The Reverse Stock Split became effective July 14, 2014. The par value per share was not adjusted as a result of the Reverse Stock Split. All authorized, issued and outstanding shares of common stock, convertible preferred stock, options and warrants to purchase common or preferred stock and related per share amounts contained in the financial statements have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented.

Initial Public Offering

On July 22, 2014, the Company closed its initial public offering (“IPO”) of 4,000,000 shares of its common stock, and issued an additional 220,000 shares of common stock on August 13, 2014 pursuant to the exercise of the over-allotment option granted to its underwriters. The public offering price of the shares sold in the offering was $10.00 per share. The total proceeds from the offering to the Company, net of underwriting discounts and commissions of $3.0 million, were $39.2 million. After deducting offering expenses payable by the Company of $3.7 million, net proceeds to the Company were $35.5 million. Upon the closing of the IPO, all shares of convertible preferred stock then outstanding converted into 6,048,220 shares of common stock, and a subordinated convertible note previously issued by the Company in the principal amount of $5.0 million converted into 510,777 shares of common stock. In addition, all of our convertible preferred stock warrants were converted into warrants to purchase common stock.

Shelf Filing

On August 10, 2015, the Company filed a registration statement on Form S-3 with the Securities and Exchange Commission which will allow the Company to raise up to $75 million from the capital markets. See Note 12.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The condensed balance sheet as of December 31, 2014 has been derived from audited financial statements as of that date but does not include all of the financial information required by U.S. GAAP for complete financial statements. Operating results for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.

The accompanying unaudited condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K filed on March 31, 2015 with the SEC.

Use of Estimates

The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts

of revenues and expenses in the unaudited condensed financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers, (v) the fair value of assets and liabilities, (vi) the valuation of warrants to purchase convertible preferred stock, (vii) the determination of fair value of the Company’s common stock, (viii) the fair value of contingent consideration in a business acquisition, (ix) the fair value of the embedded features associated with the subordinated convertible note, (x) the fair value of the embedded features associated with long-term debt, (xi) measurement of stock-based compensation expense, (xii) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xiii) any impairment of long-lived assets including in-process technology and goodwill and (xiv) legal contingencies. Actual results could differ from those estimates.

Concentrations of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper, and various bank deposit accounts. These financial instruments were held in Company accounts at two financial institutions. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.

The Company is also subject to credit risk from its accounts receivable which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers. For the six months ended June 30, 2015 and 2014, approximately 50% and 49%, respectively, of testing revenue was derived from Medicare. No other payers represented more than 10% of testing revenue for these periods. At June 30, 2015 and December 31, 2014 approximately 40% and 78%, respectively, of accounts receivable was from Medicare. No other payer represented more than 10% of accounts receivable at June 30, 2015 and December 31, 2014.

Cash Equivalents

Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist primarily of amounts invested in money market funds and checking accounts.

Impairment of Long-lived Assets

The Company evaluates its long-lived assets for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. The Company then compares the carrying amounts of the assets with the future net undiscounted cash flows expected to be generated by such asset. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value determined using discounted estimates of future cash flows. The Company has not identified any such impairment losses to date.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which the Company would transact, and it takes into consideration the assumptions that market participants would use when pricing the asset or liability. The Company’s assessment of the significance of a particular input to the fair value measurement of an asset or liability requires management to make judgments and to consider specific characteristics of that asset or liability.

The carrying amounts of certain of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. The carrying amounts of the convertible preferred stock warrant liability and contingent consideration liability represent their fair values.

Testing Revenue

The Company recognizes revenue for tests delivered when the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery has occurred or services rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured.

The first criterion is satisfied when a third-party payer makes a coverage decision or enters into a contractual arrangement with the Company for the test. The second criterion is satisfied when the Company performs the test and delivers the test result to the ordering physician. The third criterion is satisfied if the third-party payer’s coverage decision or reimbursement contract specifies a price for the test. The fourth criterion is satisfied based on management’s judgments regarding the collectability of the fees charged under the arrangement. Such judgments include review of past payment history. AlloMap testing may be considered investigational by some payers and not covered under their reimbursement policies. Others may cover the test, but not pay a set or determinable amount. As a result, in the absence of a reimbursement agreement or sufficient payment history, collectability cannot reasonably be assured so revenue is not recognized at the time the test is delivered.

If all criteria set forth above are met, revenue is recognized. When the first, third or fourth criteria are not met but third-party payers make a payment to the Company for tests performed, the Company recognizes revenue on the cash basis in the period in which the payment is received.

Revenue is recognized on the accrual basis net of adjustments for differences between amounts billed and the estimated receipts from payers. The amount the Company expects to collect may be lower than the agreed upon amount due to several factors, such as the amount of patient co-payments, the existence of secondary payers and claim denials. Estimated receipts are based upon historical payment practices of payers. Differences between estimated and actual cash receipts are recorded as an adjustment to revenue, which have been immaterial to date.

During the three and six months ended June 30, 2015, the Company changed its revenue recognized from one and three of its payers, respectively, from a cash basis to an accrual basis based on the Company’s consistent history of obtaining reimbursement from these three payers. The impact of this change in accounting estimate is to increase revenues by $79,000 and $127,000 and to reduce net loss per share by $0.01 for the three and six months ended June 30, 2015.

Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are excluded from revenue in the statements of operations.

Collaboration and License Revenue

The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis.

Cost of Testing

Cost of testing reflects the aggregate costs incurred in delivering the Company’s AlloMap test results to clinicians. The components of cost of testing are materials and service costs, direct labor costs, including stock-based compensation, equipment and infrastructure expenses associated with testing samples, shipping, logistics and specimen processing charges to collect and transport samples and allocated overhead including rent, information technology, equipment depreciation and utilities and royalties. Costs associated with performing tests (except royalties) are recorded as the test is processed regardless of whether and when revenue is recognized with respect to that test. As a result, our cost of testing as a percentage of revenue may vary significantly from period to period because we do not recognize all revenue in the period in which the associated costs are incurred. Royalties for licensed technology, calculated as a percentage of test revenues, are recorded as license fees in cost of testing at the time the test revenues are recognized.

Business Combinations

In accordance with ASC 805, Business Combinations, the Company determines and allocates the purchase price of an acquired business to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, royalty rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.

Goodwill and indefinite-lived intangible assets including acquired in-process technology are reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that goodwill or indefinite-lived intangible assets may be impaired. The Company’s goodwill evaluation is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company assesses qualitative factors to determine if its sole reporting unit’s fair value is more likely than not to exceed its carrying value, including goodwill. In the event the Company determines that it is more likely than not that its reporting unit’s fair value is less than its carrying amount, quantitative testing is performed comparing recorded values to estimated fair values. If the fair value exceeds the carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, then the Company would calculate the potential impairment loss by comparing the implied fair value of goodwill with the carrying value. If the implied fair value of goodwill is less than the carrying value, then an impairment charge would be recorded. The Company performs its annual evaluation of goodwill during the fourth quarter of each fiscal year. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of the asset to its carrying value, without consideration of any recoverability test.

In those circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, Distinguishing Liabilities from Equity, the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company remeasures this liability each reporting period and records changes in the fair value as a component of operating expenses.

Transaction costs associated with these acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company’s operating results from the date of acquisition.

Stock-based Compensation

The Company uses the Black-Scholes option pricing model (“Black-Scholes Model”), which requires the use of estimates such as stock price volatility and expected option lives, to value employee stock options. The Company estimates the expected option lives using historical data, volatility using data of similar companies in the diagnostics industry, risk-free rates based on the implied yield currently available in the U.S. Treasury zero-coupon issues with a remaining term equal to the expected option lives, and dividend yield based on the Company’s expectations and historical data.

The Company uses the straight-line attribution method for recognizing compensation expense. Compensation expense is recognized on awards ultimately expected to vest and reduced for forfeitures that are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on the Company’s historical experience.

Compensation expense for stock options issued to nonemployees is calculated using the Black-Scholes Model and is recorded over the service performance period. Options subject to vesting are required to be periodically remeasured over their service performance period, which is generally the same as the vesting period.

Warrants

The Company had freestanding warrants enabling counterparties to purchase shares of its convertible preferred stock which were converted to warrants to purchase common stock on the Company’s IPO date.

In accordance with the accounting guidance regarding distinguishing liabilities from equity, freestanding warrants for convertible preferred stock that are contingently redeemable are classified as liabilities on the balance sheet and recorded at their estimated fair value. These warrants are remeasured at each balance sheet date and any change in estimated fair value is recognized in other (expense) income, net, on the statements of operations.

Upon the completion of the Company’s IPO in July 2014, preferred stock warrants were converted into warrants to purchase common stock, and, accordingly, the liability was reclassified to equity and became no longer subject to remeasurement.

The Company has issued warrants to purchase shares of its common stock in connection with financing activities (see Note 9). The Company accounts for these warrants as equity at fair value on the date the warrants are issued. The fair value of the outstanding warrants is estimated using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the warrants, expected volatility and risk-free interest rate. Certain of these inputs are subjective and require significant analysis and judgment to develop. For the estimate of the expected term, the Company uses the full remaining contractual term of the warrant.

Comprehensive Loss

Net loss and comprehensive loss are the same for all periods presented.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled to when products are transferred to customers. On July 9, 2015, the FASB decided to delay the effective date of the new standard by one year. The standard would become effective for us beginning in the first quarter of 2018. Early application would be permitted in 2017. Entities would have the option of using either a full retrospective or a modified retrospective approach to adopt this new guidance. The Company is currently evaluating the impact of adopting the new revenue standard on its financial statements.

2014 were $176,000 and $76,000, respectively. Debt discount and issuance costs, non-current, as of June 30, 2015 and December 31, 2014 were $214,000 and $11,000, respectively. There is no impact from the adoption of ASU 2015-03 on the unaudited condensed statements of operations or in the loss per share calculations.

In April 2015, the FASB issued ASU 2015-05 Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) (“ASU 2015-05”). This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This ASU will be effective for annual periods, including interim periods beginning after December 15, 2015. Early adoption is permitted. An entity can elect to adopt the amendments either (1) prospectively to all arrangements entered into or materially modified after the effective date or (2) retrospectively. For prospective transition, the only disclosure requirements at transition are the nature of and reason for the change in accounting principle, the transition method, and a qualitative description of the financial statement line items affected by the change. For retrospective transition, the disclosure requirements at transition include the requirements for prospective transition and quantitative information about the effects of the accounting change. The Company is currently evaluating the impact of adopting ASU 2015-05 on its financial statements.

3. NET (LOSS) INCOME PER SHARE

Basic and net (loss) income per share has been computed by dividing the net (loss) income by the weighted-average number of common shares outstanding during the period.

For the three months ended June 30, 2014, common share equivalents have been included in diluted net income per share, as the effect to net income per share is dilutive. For the three and six months ended June 30, 2015, and for the six months ended June 30, 2014, all common share equivalents have been excluded from diluted net loss per share as the effect to net loss per share would be antidilutive. Our common share equivalents include convertible preferred stock, the subordinated convertible note, options and warrants to purchase common and convertible preferred stock, and restricted stock units. Common share equivalents for convertible preferred stock and the subordinated convertible note are determined using the if-converted method. Common share equivalents for options and warrants to purchase common and convertible preferred stock are determined using the treasury-stock method.

The following tables set forth the computation of the Company’s basic and diluted net (loss) income per share (in thousands, except share and per share data):


	Three Months Ended June 30,					Six Months Ended June 30,
	2015			2014		2015			2014
Numerator:
Net (loss) income	$	(3,185	)	$	877	$	(5,457	)	$	(427	)
Add: interest expense related to subordinated convertible note, less gain on change in fair value of derivative related to subordinated convertible note		—			15		—			—

Net (loss) income attributable to common stockholders	$	(3,185	)	$	892	$	(5,457	)	$	(427	)


Denominator:
Weighted-average shares used to compute basic net (loss) income per common share		11,835,405			1,013,128		11,824,993			1,012,769
Effect of potentially dilutive securities:
Employee stock options		—			381,434		—			—
Convertible preferred stock		—			5,355,280		—			—
Subordinated convertible note		—			189,726		—			—

Weighted-average shares used to compute diluted net (loss) income per common share		11,835,405			6,939,568		11,824,993			1,012,769

Net (loss) income per share
Net (loss) income per common share - basic	$	(0.27	)	$	0.87	$	(0.46	)	$	(0.42	)

Net (loss) income per common share - diluted	$	(0.27	)	$	0.13	$	(0.46	)	$	(0.42	)

The following potentially dilutive securities have been excluded from diluted net (loss) income per share, because their effect would be antidilutive:


	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Shares of common stock subject to outstanding options		1,515,154		469,163		1,515,154		907,318
Shares of common stock subject to outstanding common stock warrants		576,096		82,190		576,096		82,190
Shares of common stock subject to conversion from preferred stock warrants		—		541,613		—		541,613

Subordinated convertible note		—		—		—		233,311
Convertible preferred stock		—		—		—		6,048,220
Restricted stock units		112,800		—		112,800		—

Total common stock equivalents		2,204,050		1,092,966		2,204,050		7,812,652

4. FAIR VALUE MEASUREMENTS

The Company records its financial assets and liabilities at fair value except for its debt, which is recorded at amortized cost. The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:

•

Level 1: Inputs which include quoted prices in active markets for identical assets and liabilities.

•

Level 2: Inputs other than Level I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table sets forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis, as of June 30, 2015 and December 31, 2014 (in thousands):


	June 30, 2015
	Fair Value Measured Using
	(Level 1)		(Level 2)		(Level 3)		Total Balance
Assets
Money market funds	$	33,463	$	—	$	—	$	33,463

Liabilities
Contingent consideration	$	—	$	—	$	963	$	963

Debt	$	—	$	15,104	$	—	$	15,104


	December 31, 2014
	Fair Value Measured Using
	(Level 1)		(Level 2)		(Level 3)		Total Balance
Assets
Money market funds	$	36,779	$	—	$	—	$	36,779

Liabilities
Contingent consideration	$	—	$	—	$	1,074	$	1,074

Debt	$	—	$	12,204	$	—	$	12,204

The following table presents the issuances, changes in fair value and reclassifications of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):


	Level 3
	Contingent Consideration Liability			Warrants to Purchase Convertible Preferred Stock			Derivative Liability Related to Subordinated Convertible Note			Total

Balance as of December 31, 2013	$	—		$	525		$	—		$	525
Issuance of financial instruments		2,313			—			239			2,552
Change in estimated fair value		(1,239	)		14			(239	)		(1,464	)
Reclassification to stockholders’ equity		—			(539	)					(539	)

Balance as of December 31, 2014		1,074			—			—			1,074
Change in estimated fair value		(111	)		—			—			(111	)

Balance as of June 30, 2015	$	963		$	—		$	—		$	963

The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers between Level 1, Level 2 and Level 3 categories during the periods presented.

In determining fair value, the Company uses various valuation approaches within the fair value measurement framework. The valuation methodologies used for the Company’s instruments measured at fair value and their classification in the valuation hierarchy are summarized below:

•

Money market funds - Investments in money market funds are classified within Level 1. At June 30, 2015 and December 31, 2014, money market funds were included on the balance sheets in cash and cash equivalents.

•

Contingent consideration - As of June 30, 2015, the Company had a contingent obligation to issue 227,845 shares of the Company’s common stock to the former owners of ImmuMetrix, Inc. in conjunction with the Company’s acquisition of ImmuMetrix, Inc. (see Note 11). The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States by June 10, 2020. The Company recorded its estimate of the fair value of the contingent consideration based on its evaluation of the probability of the achievement of the contractual conditions that would result in the payment of the contingent consideration. The fair value of the contingent consideration was estimated using the fair value of the shares to be paid if the contingency is met multiplied by management’s 65% estimate at June 30, 2015 and December 31, 2014 of the probability of success. The significant input in the Level 3 measurement not supported by market activity is the Company’s probability assessment of the milestone being met. The value of the liability is subsequently remeasured to fair value each reporting date, and the change in estimated fair value is recorded to a component of operating expenses until the milestone contingency is paid, expires or is no longer achievable. Increases (decreases) in the estimation of the probability percentage result in a directionally similar impact to the fair value measurement of the contingent consideration liability.

•

We determined the estimated fair value of our debt using the present value of payments discounted at an average borrowing rate from of a peer group of public companies, which is a Level 2 observable input.

•

Warrants to purchase convertible preferred stock—Prior to the Company’s IPO, the Company’s warrants to purchase convertible preferred stock were classified as Level 3. The valuation of the warrants used assumptions that are inherently subjective and involve significant management judgment. The significant unobservable input used in the fair value measurement of the warrant liability was the fair value of the underlying convertible preferred stock at the valuation remeasurement date. Generally, increases (decreases) in the fair value of the underlying stock would result in a directionally similar impact to the fair value measurement of the preferred stock warrants. A gain of $245,000 and loss of $283,000 in estimated fair value was recognized in other (expense) income, net in the statement of operations for the three and six months ended June 30, 2014, respectively. Upon the Company’s IPO in July 2014 certain warrants to purchase convertible preferred stock were converted into warrants to purchase common stock which were reclassified to equity and are no longer subject to remeasurement, while other warrants to purchase convertible preferred stock expired pursuant to their terms.

•

Derivative liability related to subordinated convertible note—On April 17, 2014, the Company issued a $5.0 million subordinated convertible promissory note to Illumina, Inc. that had some features that constituted embedded derivatives. The Company determined that the optional conversion or repayment upon a change in control is an equity call option with a potentially variable value to be received and meets the definition of a derivative which would be required to be bifurcated. The estimated fair value of this embedded derivative was affected by the estimated probability assigned to the various scenarios for the host instrument. As of April 17, 2014, management estimated repayment upon a change in control within the loan term at a 10% probability. As of June 30, 2014 management estimated repayment upon a change in control within the loan term at a 5% probability. The $239,000 original estimated fair value of the embedded derivative liability was included in accrued and other liabilities. At June 30, 2014, the fair value of the derivative was remeasured to

$120,000, resulting in a gain of $119,000, which was recorded in other (expense) income, net in the statement of operations for the three and six months ended June 30, 2014. Upon the Company’s IPO in July 2014, the subordinated convertible note was converted into common stock, and so the embedded conversion option was extinguished. Accordingly, the fair value of the derivative became $0, and a gain of $120,000 was recorded in other (expense) income, net. The significant unobservable input used in the fair value measurement of the derivative liability was the probability assigned to the various scenarios. Generally, increases (decreases) in the probability of the factors primarily impacting the valuation would result in a directionally similar impact to the fair value measurement of the derivative liability. Changes in estimated fair value were recognized in other (expense) income, net on the statements of operations.

The Company’s liabilities classified as Level 3 were valued based on unobservable inputs and management’s judgment due to the absence of quoted market prices, inherent lack of liquidity and the long-term nature of the financial instruments.

5. INVENTORIES

The following table summarizes the Company’s inventories (in thousands):


	June 30, 2015		December 31, 2014
Finished Goods	$	343	$	277
Raw Materials		388		409

Total Inventory	$	731	$	686

6. ACCRUED AND OTHER LIABILITIES

The following table represents the components of accrued and other liabilities (in thousands):


	June 30, 2015		December 31, 2014
Professional fees	$	113	$	273
Test sample processing fees		383		318
Accrued overpayments and refunds		117		146
Clinical Studies		289		144
Deferred rent – current portion		230		202
Capital leases – current portion		62		70
Other accrued expenses		646		463

Total accrued and other liabilities	$	1,840	$	1,616

7. COMMITMENTS AND CONTINGENCIES

Royalty Commitments

In November 2004, the Company entered into a license agreement with Roche Molecular Systems, Inc., or Roche, that grants the Company the right to use certain Roche technology relating to polymerase chain reaction, or PCR, and quantitative real-time PCR, in clinical laboratory services, including in connection with AlloMap. This is a non-exclusive license agreement in the United States covering claims in multiple Roche patents. The Company had disputed the combination services percentage Roche sought to apply under the agreement. The combination service percentage is a multiplier used to calculate royalties where licensed services are sold in combination with other services. From July 2011 through September 2014, the Company withheld payment of such royalties pending resolution of the matter. On February 11, 2014, Roche filed a demand for arbitration with the American Arbitration Association seeking a declaration that the Company had materially breached the Roche license agreement by failing to report and pay royalties owing to Roche in respect of licensed services performed by the Company after July 1, 2011. Since July 1, 2011, the Company fully accrued the unpaid royalties on the balance sheets, and the amount of the unpaid royalties has been reflected as an expense in the Company’s condensed statements of operations in the periods revenue was recorded to which the royalties relate.

In September 2014, the Company entered into a settlement and mutual release agreement with Roche whereby: (i) for the period beginning July 1, 2011 through June 30, 2014, the Company agreed to pay the amount of $2,827,220 in settlement of past royalties due; (ii) for the period beginning July 1, 2014 through September 30, 2014, the Company agreed to pay royalties based on the same combination services percentage used to determine the past royalties due; (iii) for the period beginning October 1, 2014 through September 30, 2017, Roche and the Company agreed to a downward adjustment of the combination services percentage used to determine the portion of the AlloMap testing revenue that is royalty bearing under the terms of the license; (iv) the Company agreed to report and pay quarterly royalties within 45 days of the end of each calendar quarter; (v) Roche agreed that, subject to the Company’s timely payment of all applicable royalties through such date, no further royalties will be payable by the Company for periods after September 30, 2017; (vi) the Company and Roche agreed to mutually release all claims under the license agreement through the settlement date; and (vii) Roche agreed to dismiss the arbitration claims. For all time periods, the contractual royalty rate in the license agreement was or will be applied to the applicable combination services percentage to determine the royalties’ payable for the AlloMap service.

Under the license agreement, the Company incurs royalty expenses as a percentage of combination services revenue and classifies those expenses as a component of cost of testing in the statements of operations. For the three months ended June 30, 2015 and 2014, royalty expenses in connection with the Roche agreement were $254,000 and $362,000, respectively. For the six months ended June 30, 2015 and 2014, royalty expenses in connection with the Roche agreement were $509,000 and $678,000, respectively.

Contingencies

The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, or results of operations.

8. COLLABORATION AND LICENSING AGREEMENTS

Laboratory Corporation of America Holdings (“LabCorp”)

In April 2012, CareDx and LabCorp entered into a collaboration and license agreement (“2012 Agreement”) to develop a lupus flare predictor test. The agreement provided for CareDx to license technology to LabCorp. Of the total arrangement consideration, the fair value of the license was assessed to be $1.0 million. The license term in the 2012 Agreement was the later of 10 years from the date of the agreement or the expiration of the last-to-expire patents and patent applications included in the CareDx technology licensed to LabCorp, unless the license was terminated by mutual agreement. The agreement provided that CareDx and LabCorp would share equally the costs of developing the lupus flare predictor test; however LabCorp’s share of the development cost was subject to certain limits at each stage of the arrangement.

Under the agreement, in 2012 LabCorp paid the Company a nonrefundable and non-creditable upfront license fee payment of $1,000,000, and a nonrefundable and non-creditable payment of $250,000 for certain lupus samples. The Company was to receive royalties in the high single digits from LabCorp on net sales of the commercialized flare predictor test or other tests developed using the samples sold.

Phase 1 of the project was completed in the first quarter of 2014.

On September 18, 2014, CareDx and LabCorp terminated the 2012 agreement. The termination agreement provides that:

•

CareDx transfer and assign to LabCorp, 300 “SAGE I” clinical samples and related clinical data and documentation that CareDx obtained from patients during the discovery phase of the collaboration;

•

CareDx grant a perpetual, non-exclusive worldwide, fully paid, sublicensable, royalty-free license to use any collaboration intellectual property and data for any and all purposes; and

•

LabCorp pay $500,000 to CareDx within 30 days of CareDx’s delivery of the clinical samples and clinical data and documentation. No further royalties, milestone fees or other fees will be payable by LabCorp after the termination date.

During the three months ended December 31, 2014, the Company delivered the clinical samples and the related clinical data and documentation to LabCorp, and accordingly recognized the $500,000 termination fee and the remaining $611,000 previously unrecognized license fee.

During the three and six months ended June 30, 2014, the Company recognized $1,800 and $31,200, respectively, in revenue under this arrangement, which consisted of amortization of the upfront license fee of $0 and $15,000, respectively, and reimbursement of research and development expenses of $1,800 and $16,200, respectively. Such revenues are included in collaboration and license revenue on the unaudited condensed statements of operations. No revenues were recorded in 2015.

Included in research and development expenses were $3,600 and $32,000 for the three and six months ended June 30, 2014, respectively, for development costs associated with the 2012 Agreement. No research and development expenses were recorded in 2015.

Diaxonhit (“DHT”)

In June 2013, the Company entered into an exclusive Distribution and Licensing Agreement with DHT, a French public company, whereby DHT will have the AlloMap test performed in a European laboratory and commercialize the test in the European Economic Area (“EEA”). The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.

Consideration under the agreement includes an upfront cash payment of approximately €387,500 ($503,000) that is designated to offset royalties earned by the Company in the first three years following the first commercial sale. The Company is entitled to receive royalties from DHT as a percent of net sales, as defined in the agreement, of AlloMap tests in the mid to high teens. Approximately €250,000 ($344,000) of the upfront payments is refundable under certain circumstances. Upon confirmation that the CE mark was in place, the Company also received an equity payment of DHT common stock with a value of €387,500 ($503,000). The CE mark is a mandatory conformity marking for certain products sold within the EEA. These shares were promptly sold by the Company in July 2013 for total consideration of $467,000.

Other consideration that may be earned by the Company includes agreed-upon per unit pricing for the supply of AlloMap products, and additional royalties that are payable upon the achievement of various sales milestones by DHT. In this arrangement, there is one combined unit of accounting.

Commercial sales began in the EEA in June 2014. Total revenues recognized from this arrangement for the three and six months ended June 30, 2014 were $1,000 and for the three and six months ended June 30, 2015 were $16,000 and $33,000, respectively.

CardioDx, Inc. (“CDX”)

In 2005, the Company entered into a services agreement with CDX, whereby the Company provided CDX with biological samples and related data and performed laboratory services on behalf of CDX. Each company granted the other a worldwide license under certain of its intellectual property rights. Pursuant to this agreement, CDX pays royalties to the Company of a low single-digit percentage of the cash collected from sales of CDX licensed products. In 2009, CDX terminated the services portion of this agreement, however, the royalty obligation from CDX continues until the tenth anniversary of the first commercial sale of a CDX licensed product. The first commercial sale of such product by CDX occurred in 2009, therefore the royalty obligation to the Company continues until 2019. Two board members of CDX serve on the Company’s board of directors and are affiliated with stockholders of the Company. Royalty revenues, recorded when earned, were $89,000 and $59,000 for the three months ended June 30, 2015 and 2014, respectively, and were $179,000 and $117,000 for the six months ended June 30, 2015 and 2014, respectively, and are included in collaboration and license revenue on the condensed statements of operations. The Company had receivable balances from CDX of $179,000 and $54,000 at June 30, 2015 and December 31, 2014, respectively.

9. DEBT

On January 30, 2015, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) which provides a secured term loan facility in an aggregate principal amount of up to $20.0 million. The Company borrowed the first advance of $16.0 million (“Draw A”) on January 30, 2015. Under the terms of the Loan Agreement, following a six month period from the closing date and until any time before December 31, 2015, the Company may, at its option, borrow from the lender a second advance of $4.0 million (“Draw B”), subject to the Company’s satisfaction of certain conditions described in the Loan Agreement. Draw A was used to payoff the Company’s existing term debt of $11.3 million. A loss on extinguishment of $0.6 million from the pay-off of the existing term loan was recognized as interest expense during the six months ended June 30, 2015. Draw A and Draw B each bear interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the lender.

A fully non-refundable commitment fee of $160,000 was paid on January 30, 2015 when Draw A for $16 million was received. An additional $40,000 loan fee will be payable if Draw B for $4 million is received. The loan has no prepayment penalty. Commitment fees are included in debt issuance costs which are amortized to interest expense using the effective interest method over the term of the loan. Debt discount and issuance costs, current, as of June 30, 2015 and December 31, 2014 were $176,000 and $76,000, respectively. Debt discount and issuance costs, non-current, as of June 30, 2015 and December 31, 2014 were $214,000 and $11,000, respectively.

In connection with the Loan Agreement, the Company agreed to issue to the lender detachable warrants to purchase shares of the Company’s common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche. The fair value of the warrants are reflected as a discount to the debt. As a result of Draw A, the Company issued to the lender a warrant to purchase an aggregate of 34,483 shares of the Company’s common stock, at an exercise price equal to $6.96 per share. The fair

value of the warrants was estimated to be $90,000 on January 30, 2015, using the Black-Scholes Model with the following assumptions: expected volatility of 39.83%, a contractual term of 5 years, risk-free interest rate of 1.18%, underlying common stock price of $7.06, and dividend yield of 0%. The warrants are included in stockholders’ equity with the offset to debt discount that is amortized over the term of the loan using the effective interest method. The warrants are not subject to remeasurement.

The Loan Agreement requires collateral by a security interest in all of the Company’s assets except intellectual property and contains customary affirmative and negative covenants including financial maintenance covenants, and also includes standard events of default, including payment defaults. Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. At June 30, 2015, the Company was in compliance with all loan covenants.

10. STOCK INCENTIVE PLANS

Stock Option Plans

Prior to its IPO, the Company had one active stock option plan, the 2008 Equity Incentive Plan (“2008 Plan”), one assumed stock option plan, the ImmuMetrix 2014 Equity Incentive Plan, and one terminated stock option plan, the 1998 Stock Plan.

Upon its IPO, the Company reserved 838,695 shares of common stock for issuance under a new 2014 Equity Incentive Plan (“2014 Plan”). The shares reserved for issuance under the 2014 Plan also include shares returned to the 2008 Plan as the result of expiration or termination of options, provided that the maximum number of shares that may be added to the 2014 Plan thereby is limited to a maximum of 865,252 shares. The number of shares available for issuance under the 2014 Plan also includes an annual increase on the first day of each year equal to the lessor of:

•

357,075 shares

•

4.0% of the outstanding shares of common stock as of the last day of the immediately preceding year; or

•

such other number of shares as the Company’s board of directors may determine.

The following table summarizes option activity and related information:


	Stock Options Outstanding			Weighted- average Exercise Price
Balance—December 31, 2014		1,031,804		$	7.36
Granted		525,078			7.74
Exercised		(17,884	)		2.35
Forfeited		(23,844	)		9.06

Balance—June 30, 2015		1,515,154		$	7.03

There were 444,108 shares available for the granting of stock options, restricted stock units and restricted stock from the 2014 Plan as of June 30, 2015.

Options outstanding and exercisable that have vested or are expected to vest as of June 30, 2015 are as follows:


	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value (In thousands)
Vested		576,815	$	5.14		7.41	$	1,750
Expected to Vest		938,339		8.20		9.30		396

Total		1,515,154					$	2,146

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock at June 30, 2015 for stock options that were in-the-money. The fair market value of the Company’s common stock as of June 30, 2015 was $6.50 per share.

The weighted-average grant-date fair value of options granted during the three and six months ended June 30, 2015 using the Black-Scholes Model was $2.10 and $2.62 per share, respectively.

Valuation Assumptions

The fair value of stock-based awards was estimated using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Expected term (in years)		5.8			5.3			6.0			5.1
Expected volatility		40.04	%		42.18	%		40.85	%		41.84	%
Risk-free interest rate		1.69	%		1.74	%		1.87	%		1.70	%
Expected dividend yield		—			—			—			—

2014 Employee Stock Purchase Plan

Our board of directors adopted our 2014 Employee Stock Purchase Plan (the “ESPP”) in March 2014 and our stockholders approved the ESPP in July 2014. However, our ESPP was not made available to our employees until January 1, 2015. The first offering period of the ESPP began on January 1, 2015 and ended June 30, 2015. Under the first offering period, 36,696 were purchased under the ESPP. At June 30, 2015, the proceeds from the issuance of shares were $0.2 million and a total of 186,473 shares of our common stock is available for sale under the ESPP.

The option price per share of common stock to be paid by a participant upon exercise of the participant’s option on the applicable exercise date for an offering period shall be equal to 85% of the lesser of the fair market value of a share of common stock on (a) the applicable grant date or (b) the applicable exercise date.

Restricted Stock Units

The Company’s 2014 Plan allows restricted stock units (“RSUs”) to be granted in addition to stock options. The RSUs vest annually over four years in equal increments. RSUs were granted by the Company for the first time in March 2015.

Unvested RSU activity for the six months ended June 30, 2015 is summarized below:


	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested balance at December 31, 2014		—			—
Granted		114,400		$	6.49
Vested		—			—
Forfeited		(1,600	)		6.49

Unvested balance at June 30, 2015		112,800		$	6.49

Non-Employee Director Equity-Based Compensation

For the three and six months ended June 30, 2015, the Company paid a portion of its non-employee directors’ compensation through the award of common shares. The stock awards are classified as equity-based compensation expense. Expenses associated with the awards were $75,000 and $123,000 for the three and six months ended June 30, 2015, respectively and are included in general and administrative expense in the condensed statement of operations. The shares issued and associated expenses were as follows:


Service Period Three Months Ended	Number of Shares Issued		Fair Market Value per Share at Date of Issuance		Fair Value of Shares Issued (In Thousands)
March 31, 2015		8,663		5.56	$	48
June 30, 2015		11,628		6.48		75

Total		20,291			$	123

The shares issued at each date were for services performed during the three-month period that ended one day prior to the date of issuance.

The Company’s results of operations include expense relating to employee and nonemployee stock-based payment awards from stock options and RSUs as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Cost of testing	$	54	$	9	$	69	$	9
Research and development		89		21		136		22
Sales and marketing		36		8		56		9
General and administrative		232		99		431		145

	$	411	$	137	$	692	$	185

At June 30, 2015, there was approximately $3.7 million of total unrecognized stock-based compensation from stock option and RSU grants, net of estimated forfeitures, related to non-vested stock option and RSUs granted that will be recognized on a straight-line basis over the remaining vesting period of 3.2 years.

11. BUSINESS COMBINATION

On June 10, 2014, in accordance with an agreement and plan of merger, the Company acquired ImmuMetrix, Inc. (“IMX”), a privately held development stage company working in new technologies using cell-free donor DNA (“cfDNA”) technology for the diagnosis, treatment and management of transplant rejection, immune disorders and diseases, including the development of a new, non-invasive test designed to detect the early stages of solid organ transplant rejection. The Company acquired all IMX assets associated with transplant diagnostics, including related immune repertoire and infectious diseases. An IMX successor company retained the limited assets not associated with transplant diagnostics. The acquisition was structured as a tax-free reorganization.

The Company acquired all of the issued and outstanding capital stock of IMX for the total estimated purchase price of $17.2 million consisting of $600,000 in cash; 911,364 shares of the Company’s Series G convertible preferred stock with an estimated fair value of $14.2 million, including 23,229 shares of the Company’s Series G convertible preferred stock with an estimated fair value of $369,000 as a result of the Company’s assumption of IMX outstanding stock options; and an additional payment of 227,845 shares of CareDx Series G convertible preferred stock if a future milestone is achieved. The Agreement provides that the milestone will be achieved if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States no later than six years after the closing date of the acquisition. All shares of Series G Preferred Stock and options to acquire Series G Preferred Stock converted into common stock and options to acquire common stock, respectively, immediately prior to the closing of the Company’s initial public offering. The additional shares to be paid for the achievement of the milestone will also be issued in common stock. The fair value of this contingent consideration was $2.3 million at the acquisition date, $1.1 million at December 31, 2014, and $963,000 at June 30, 2015.

The intellectual property acquired includes an exclusive license from Stanford University to a patent relating to the diagnosis of rejection in organ transplant recipients using cfDNA. The license provides for the Company to pay royalties to Stanford University on sales of the Company’s cfDNA tests.

IMX’s post-acquisition results of operations for the three and six months ending June 30, 2015 are included in the Company’s condensed statement of operations.

Pro Forma Impact of the Acquisition of IMX

The following table presents pro forma results of operations and gives effect to the IMX transaction as if the transaction had been consummated on January 1, 2013. The unaudited pro forma results of operations have been prepared for comparative purposes only and are not necessarily indicative of what would have occurred had the business combination been completed at the beginning of the period or of the results that may occur in the future. Furthermore, the pro forma financial information does not reflect the impact of any reorganization or operating efficiencies resulting from combining the two companies (in thousands, except per share data):


	Three Months Ended June 30, 2014			Six Months Ended June 30, 2014
Net revenue	$	6,776		$	12,700

Net loss	$	(518	)	$	(2,288	)

Net loss per common share - basic and diluted	$	(0.51	)	$	(2.26	)

The unaudited pro forma consolidated financial information was prepared using the acquisition method of accounting and is based on the historical financial information of the Company and IMX, reflecting the Company’s and IMX’s results of operations for the three and six month periods ending June 30, 2014. The historical financial information has been adjusted to give effect to the pro forma events that are: (i) directly attributable to the acquisition, (ii) factually supportable and (iii) expected to have a continuing impact on the combined results. The unaudited pro forma consolidated financial information reflects: (a) the removal of acquisition-related costs of $1.6 million and $1.7 million incurred by both CareDx and IMX for the three and six months ended June 30, 2014, respectively, including the removal of $0.2 million of IMX stock-based compensation expense that resulted from modifications to options in anticipation of the acquisition; (b) the removal of a $1.5 million tax benefit for the three and six months ended June 30, 2014 that resulted from the acquisition; (c) the addition of salaries, benefits and fees for IMX employees and consultants retained after the acquisition. Acquisition related expenses are primarily included in general and administrative expenses.

12. SUBSEQUENT EVENT

Shelf Filing

On August 10, 2015, the Company filed a registration statement on Form S-3 (“Shelf Filing”) with the Securities and Exchange Commission which will allow the Company to raise up to $75 million from the capital markets. In addition, on August 10, 2015 the Company entered into an At The Market Issuance Sales Agreement (the “2015 ATM Agreement”), with Cantor Fitzgerald and Company (“Cantor”) under which it may sell shares of its common stock from time to time in an aggregate amount not to exceed $19 million per year per the 2015 ATM Agreement and not to exceed $75 million in total per the Shelf Filing. Cantor may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The NASDAQ Global Market, on any other existing trading market for the Company’s common stock or to or through a market maker. Cantor also may sell the shares in privately negotiated transactions, subject to the Company’s prior approval. The Company will pay Cantor a commission equal to 3% of the gross proceeds of the sales price of all shares sold through it as sales agent under the 2015 ATM Agreement.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed financial statements and related notes included elsewhere in Item 1 of Part I of this Quarterly Report on Form 10-Q and with the audited financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 as filed with the Securities and Exchange Commission on March 31, 2015.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” and the negative and plural forms of these words and similar expressions are intended to identify forward-looking statements.

These forward-looking statements may include, but are not limited to, statements concerning the following:

•

our ability to generate revenue from sales of AlloMap and future solutions, if any, and our ability to increase the commercial success of AlloMap;

•

our plans and ability to develop and commercialize new solutions, including cell-free DNA, or cfDNA, solutions for the surveillance of heart and kidney transplant recipients;

•

our ability to achieve, maintain and expand reimbursement coverage from payers for AlloMap and future solutions, if any;

•

the outcome or success of our clinical trial collaborations and observational studies;

•

our compliance with federal, state and foreign regulatory requirements;

•

the favorable review of AlloMap and our future solutions, if any, in peer-reviewed publications;

•

our ability to protect and enforce our intellectual property rights, our strategies regarding filing additional patent applications to strengthen our intellectual property rights, and our ability to defend against intellectual property claims that may be brought against us;

•

our anticipated cash needs and our anticipated uses of our funds, including our estimates regarding operating expenses and capital requirements;

•

anticipated trends and challenges in our business and the markets in which we operate; and

•

our ability to comply with the requirements of being a public company.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.

You should read this report and the documents that we reference in this report and have filed with the SEC as exhibits with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. We qualify all forward-looking statements by these cautionary statements.

Overview and Recent Developments

We are a commercial stage company that develops, markets and delivers diagnostic surveillance solutions for organ transplant recipients to help clinicians make personalized treatment decisions throughout a patient’s lifetime. Our one commercialized testing solution, the AlloMap heart transplant molecular test, is a blood-based test used to monitor heart transplant recipients for moderate or acute cellular rejection. We believe the use of AlloMap, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a heart transplant. In particular, we believe AlloMap can improve patient care by helping healthcare providers to avoid the use of unnecessary, invasive surveillance biopsies and to determine the appropriate dosage levels of immunosuppressants. We believe that there is a significant unmet need for post-transplant surveillance solutions and are applying our expertise in transplantation towards the development of additional solutions for other organ transplant recipients, including recipients of kidney transplants.

Since the launch of AlloMap in January 2005 we have performed more than 70,000 commercial AlloMap tests, including more than 11,000 tests in 2014, in our Brisbane, California laboratory. In 2014, the test was used in 110 of the approximately 129 heart transplant management centers in the U.S. We believe that there is an opportunity for AlloMap outside of the U.S. and through recent partnerships we have expanded the AlloMap offering to Europe and Canada. We believe that we are not currently capacity constrained and that our current facility can support a substantial increase in AlloMap testing volume.

Financial Operations Overview

Testing Revenue

Our testing revenue is derived from AlloMap tests which represented 98% and 99% of our total revenues for the three and six months ended June 30, 2015, respectively, and 98% and 99% for the three and six months ended June 30, 2014, respectively. Our testing revenue depends on a number of factors, including (i) the number of tests performed; (ii) establishment of coverage policies by third-party insurers and government payers; (iii) our ability to collect from payers with whom we do not have positive coverage determination, which often requires that we pursue a case-by-case appeals process; (iv) our ability to recognize revenue on tests billed prior to the establishment of reimbursement policies, contracts or payment histories; (v) our ability to expand into markets outside of the United States; and (vi) how quickly we can successfully commercialize new product offerings.

We currently market AlloMap to healthcare providers through our direct sales force that targets transplant centers and their physicians, coordinators and nurse practitioners. The healthcare providers that order the tests and on whose behalf we provide our testing services are generally not responsible for the payment of these services. As of June 30, 2015, the list price of AlloMap was $3,600 per test. However, amounts actually received by us vary from payer to payer based on each payer’s internal coverage practices and policies. We generally bill third-party payers upon delivery of an AlloMap score report to the ordering physician. As such, we take the assignment of benefits and the risk of collection from the third-party payer and individual patients.

As of June 30, 2015 and 2014, the number of tests for which results were delivered and billed, but for which the associated revenue had not been recognized because our revenue recognition criteria were not met, and taking into account claim status and possibility of collection, was approximately 3,400 and 3,300, respectively. We cannot provide any assurance as to when, if ever, or to what extent any of these amounts will be collected.

Collaboration and License Revenue

Revenue from our collaboration and license agreements was not more than 2% of total revenues for each period presented. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. Our performance obligations under the collaboration and license agreements may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. We make judgments that affect the periods over which we recognize revenue. We periodically review our estimated periods of performance based on the progress under each arrangement and account for the impact of any change in estimated periods of performance on a prospective basis.

Cost of Testing

Cost of testing reflects the aggregate costs incurred in delivering our AlloMap test results to clinicians. The components of our cost of testing are materials and service costs, direct labor costs, including stock-based compensation, equipment and infrastructure expenses associated with testing samples, shipping, logistics and specimen processing charges to collect and transport samples and allocated overhead including rent, information technology, equipment depreciation and utilities and royalties. Costs associated with performing tests (except royalties) are recorded as the test is processed regardless of whether and when revenue is recognized with respect to that test. Royalties incurred for licensed technology, calculated as a percentage of test revenues, are recorded as license fees in cost of testing at the time the test revenues are recognized.

Royalties included in cost of testing are associated with a license from Roche Molecular Systems, Inc., or Roche. In September 2014, we agreed with Roche to a downward adjustment of the combination services percentage used to determine the portion of the AlloMap service that is royalty bearing under the terms of the license with Roche. As part of this agreement no further royalties will be payable by us for periods after September 30, 2017. We expect cost of testing to increase, in absolute dollars, as the number of tests we perform increases. However, due to the fixed nature of expenses associated with direct labor, equipment and infrastructure, we expect the cost per test will decrease over time as volume increases.

Research and Development Expenses

Research and development expenses represent costs incurred to develop new surveillance solutions as well as continued efforts related to our AlloMap test. These expenses include payroll and related expenses, consulting expenses, laboratory supplies, and certain allocated expenses as well as amounts incurred under certain collaborative agreements. Research and development costs are expensed as incurred. We record

accruals for estimated study costs comprised of work performed by contract research organizations under contract terms. We expect our research and development expenses will increase in absolute dollars in future periods as we invest in research and discovery work to develop new surveillance solutions, as well as clinical outcomes studies for AlloMap.

Sales and Marketing Expenses

Sales and marketing expenses represent costs incurred to sell, promote and increase awareness of our AlloMap test to both clinicians and payers, including education of patients, clinicians and payers. Sales and marketing expenses include payroll and related expenses, educational and promotional expenses, and infrastructure expenses, including allocated facility and overhead costs. Compensation related to sales and marketing includes annual salaries and eligibility for quarterly or semi-annual commissions or bonuses based on the achievement of predetermined sales goals or other management objectives.

General and Administrative Expenses

General and administrative expenses include costs for our executive, finance, accounting and human resources functions. Costs consist primarily of payroll and related expenses, professional service fees related to billing and collection, accounting, legal and other contract and administrative services and related infrastructure expenses, including allocated facility and overhead costs. We expect to incur additional expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission and The NASDAQ Global Market, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect our general and administrative expenses will increase in absolute dollars related to anticipated testing volume and collections growth.

Interest Expense, Net

Interest Expense, Net is associated with borrowings under our loan agreements.

Other (Expense) Income, Net

For the three and six months ended June 30, 2014, Other (Expense) Income, Net is primarily associated with the remeasurement of the estimated fair value of warrants to purchase shares of our convertible preferred stock which were converted to common stock warrants upon the closing of our initial public offering on July 22, 2014, and changes in the estimated fair value of derivative associated with our subordinated convertible debt. For the three and six months ended June 30, 2015, Other (Expense) Income, Net is primarily state franchise taxes.

Results of Operations

Comparison of the Three Months Ended June 30, 2015 and June 30, 2014

(In thousands except for Allomap results)


	Three Months Ended June 30,
	2015			2014

Allomap results delivered		3,259			3,024

Revenue:
Testing revenue	$	7,044		$	6,710
Collaboration and license revenue		85			66

Total revenue		7,129			6,776

Operating expenses:
Cost of testing		2,508			2,403
Research and development		2,510			792
Sales and marketing		2,526			1,610
General and administrative		2,329			2,316
Change in estimated fair value of contingent consideration		142			—

Total operating expenses		10,015			7,121


Loss from operations		(2,886	)		(345	)

Interest expense, net		(256	)		(644	)
Other (expense) income, net		(43	)		366

Loss before income taxes		(3,185	)		(623	)
Income tax benefit		—			1,500

Net (loss) income	$	(3,185	)	$	877

Testing Revenue

Testing revenue increased by $330,000 or 5%, for the three months ended June 30, 2015 compared to the same period of 2014. AlloMap test results delivered increased by approximately 235 or 8% for the three months ended June 30, 2015 as compared to the three months ended June 30, 2014. The revenue mix changed such that a lower mix of test volume was recognized from payers from whom we recognize revenue on an accrual rather than a cash basis.

Collaboration and License Revenue

Collaboration and license revenue increased by approximately $19,000, or 29%, for the three months ended June 30, 2015 compared to the same period in 2014 primarily due to an increase in royalties of $30,000 from CardioDx partially offset by a reduction in other collaboration revenue.

Cost of Testing

Cost of testing increased by approximately $105,000, or 4%, broadly in line with an increase in testing revenue.

Research and Development

Research and development expenses increased by $1.7 million, or 217%, for the three months ended June 30, 2015 compared with the same period in 2014. The increase was primarily due to an increase in headcount related expenses of $0.6 million, increased expenditure of $0.2 million in the area of cell-free DNA technology, an increase in clinical trial expenses of $0.3 million and an increase in expenditure of $0.6 million in various research and development activities. We expect our research and development expenses will increase in absolute dollars in future periods as we invest in research and discovery work to develop our cell-free DNA technology, as well as clinical outcomes studies for new tests, if and when developed.

Sales and Marketing

Sales and marketing expenses increased by approximately $0.9 million, or 57%, for the three months ended June 30, 2015 compared with the same period in 2014. The increase was primarily related to increased headcount and consulting expenses of $0.3 million, an increase of $0.3 million in marketing programs such as physician forums, speaker programs and advertising and $0.3 million in other marketing expenses as we ramp up our commercialization efforts . We expect sales and marketing expenses to increase in the future as we continue to expand our presence in the diagnostic surveillance market.

General and Administrative

General and administrative expenses were essentially flat for the three months ended June 30, 2015 compared with the same period of 2014 primarily due to a $0.4 million increase in headcount related costs, increased professional expenses of $0.2 million, partially offset by decreased legal and audit expenses of $0.6 million. We anticipate our general and administrative expenses will increase as we continue to operate as a public company.

Change in Fair Value of Contingent Consideration

The consideration for our business combination with ImmuMetrix, Inc. includes a future payment that is contingent upon the achievement of a specified milestone. We recorded a contingent consideration liability at its fair value in June 2014, at the acquisition date. We revalue our contingent consideration obligation each reporting period. Changes in the fair value of our contingent consideration obligation are recognized as a component of operating expense within our condensed statements of operations.

Interest Expense, Net

Interest Expense, Net decreased by $390,000 for the three months ended June 30, 2015 compared with the same period of 2014. Interest Expense, Net in the quarter ended June 30, 2015 reflects interest expense of $0.3 million from a term loan that the Company entered into in January 2015. Interest Expense, Net in the quarter ended June 30, 2014 reflects interest associated with the $5.0 million Illumina subordinated convertible note issued in April 2014 with interest at 8% and expenses associated with a previous term loan which had a higher effective interest rate and was subsequently paid off in January 2015.

Other (Expense) Income, Net

Other (expense) income, net for the three months ended June 30, 2015 was $43,000 as a result of state franchise taxes. We recorded other (expense) income, net of $0.4 million for the three months ended June 30, 2014 for the remeasurement of the estimated fair value of warrants to purchase shares of our convertible preferred stock of $0.3 million and $0.1 million for the derivative bifurcated from our Illumina debt. Upon our July 2014 IPO, the preferred stock warrants converted into common stock warrants and the then fair value of such warrants was reclassified to additional paid-in capital. The common stock warrants are not subject to remeasurement.

Income Tax Benefit

In conjunction with the acquisition of IMX a tax benefit of $1.5 million was recognized during the three months ended June 30, 2014. This benefit resulted from the expectation that amortization of the in-process technology acquired, when completed and placed in service, is not expected to be deductible for tax purposes, as the transaction was structured as a tax-free reorganization. Accordingly, a deferred tax liability was recorded at the acquisition date for the difference between the financial reporting and tax basis of the acquired in-process technology. While the in-process technology is considered an indefinite lived intangible asset, this asset is expected to be amortized or impaired prior to the expiration of net operating loss carryforwards available to us.

Comparison of the Six Months Ended June 30, 2015 and June 30, 2014

(In thousands except for Allomap results)


	Six Months Ended June 30,
	2015			2014

Allomap results delivered		6,370			5,817

Revenue:
Testing revenue	$	14,139		$	12,544
Collaboration and license revenue		205			156

Total revenue		14,344			12,700

Operating expenses:
Cost of testing		5,218			4,565
Research and development		3,931			1,512
Sales and marketing		4,549			3,084
General and administrative		5,034			4,111
Change in estimated fair value of contingent consideration		(111	)		—

Total operating expenses		18,621			13,272


Loss from operations		(4,277	)		(572	)

Interest expense, net		(1,083	)		(1,192	)
Other (expense) income, net		(97	)		(163	)

Loss before income taxes		(5,457	)		(1,927	)
Income tax benefit		—			1,500

Net (loss) income	$	(5,457	)	$	(427	)

Testing Revenue

Testing revenue increased by $1.6 million, or 13%, for the six months ended June 30, 2015 compared to the same period of 2014. AlloMap test results delivered increased by approximately 550 or 10% for the six months ended June 30, 2015 as compared to the six months ended June 30, 2014. The revenue mix changed such that a higher mix of test volume was recognized from payers from whom we recognize revenue on an accrual rather than a cash basis.

Collaboration and License Revenue

Collaboration and license revenue increased by $49,000 or 31%, for the six months ended June 30, 2015 compared to the same period in 2014 primarily due to $20,000 in increased revenue recognized from our collaboration with Diaxonhit and an increase in royalties of $62,000 from CardioDx, partially offset by decreases in collaboration revenue of $31,000 and $2,000 from LabCorp and other collaborations, respectively.

Cost of Testing

Cost of testing increased by approximately $0.7 million or 14%, for the six months ended June 30, 2015 compared to the same period in 2014. The increase was primarily a result of increased expenditure on laboratory consumables of $0.3 million and increased headcount related costs of $0.6 million, partially offset by reduced royalty rates and therefore expenses of $0.2 million. We expect to see our cost of testing increase in absolute dollars as we expect test volumes to increase in the future.

Research and Development

Research and development expenses increased by $2.4 million, or 160%, for the six months ended June 30, 2015 compared with the same period in 2014. The increase was primarily due to an increase in headcount related expenses of $0.8 million, increased expenditure of $0.7 million in the area of cell-free DNA technology, an increase in facilities expense of $0.4 million, an increase in consulting expenses of $0.1 million and an increase in expenditure of $0.4 million in various research and development activities. We expect our research and development expenses will increase in absolute dollars in future periods as we invest in research and discovery work to develop our cell-free DNA technology, as well as clinical outcomes studies for AlloMap and new tests, if and when developed.

Sales and Marketing

Sales and marketing expenses increased by approximately $1.5 million or 48%, for the six months ended June 30, 2015 compared with the same period in 2014. The increase was primarily related to increased headcount and consulting expenses of $0.6 million, and an increase of $0.5 million in marketing programs such as physician forums, speaker programs and advertising and $0.4 million in other marketing expenses as we ramp up our commercialization efforts. We expect sales and marketing expenses to increase in the future as we continue to expand our presence in the diagnostic surveillance market.

General and Administrative

General and administrative expenses increased by approximately $0.9 million, or 22%, for the six months ended June 30, 2015 compared with the same period of 2014, primarily due to a $0.9 million increase in head-count related costs, $0.3 million increase in expenses associated with being a public company, offset in part by decreased legal and recruiting costs of $0.3 million. We anticipate our general and administrative expenses will increase as we continue to operate as a public company.

Change in Fair Value of Contingent Consideration

Interest Expense, Net

Interest Expense, Net decreased by $0.1 million for the six months ended June 30, 2015 compared with the same period of 2014. Interest Expense, Net in the quarter ended June 30, 2015 includes a loss on extinguishment of $0.6 million as the company paid off a previous term loan in January 2015, and interest expense of $0.4 million on the new term loan. Interest Expense, Net for the six months ended June 30, 2014 includes reflects interest associated with the $5.0 million Illumina subordinated convertible note issued in April 2014 with interest at 8% and expenses associated with a previous term loan which had a higher effective interest rate and was subsequently paid off in January 2015.

Other (Expense) Income, Net

Other (expense) income, net for the six months ended June 30, 2015 was $97,000 consisting primarily of state franchise taxes. We recorded other (expense) income, net of $0.2 million for the six months ended June 30, 2014 which consisted of $0.3 million of other (expense) income for remeasurement of the convertible preferred warrants, partially offset by $0.1 million of other income for remeasurement of the derivative associated with the Illumina subordinated convertible note.

Income Tax Benefit

In conjunction with the acquisition of IMX a tax benefit of $1.5 million was recognized during the six months ended June 30, 2014. This benefit resulted from the expectation that amortization of the in-process technology acquired, when completed and placed in service, is not expected to be deductible for tax purposes, as the transaction was structured as a tax-free reorganization. Accordingly, a deferred tax liability was recorded at the acquisition date for the difference between the financial reporting and tax basis of the acquired in-process technology. While the in-process technology is considered an indefinite lived intangible asset, this asset is expected to be amortized or impaired prior to the expiration of net operating loss carryforwards available to us.

Cash Flows for the Six Months Ended June 30, 2015 and 2014

The following table summarizes the primary sources and uses of cash for the periods presented:


	Six Months Ended June 30,
(in thousands)	2015			2014

Net cash (used in) provided by:
Operating activities	$	(2,747	)	$	1,033
Investing activities		(733	)		(540	)
Financing activities		3,943			2,251

Net increase in cash and cash equivalents	$	463		$	2,744

Operating Activities

Net cash provided by or used in operating activities consists of net income or loss, adjusted for certain non-cash items in the statements of operations and changes in operating assets and liabilities.

Cash used in operating activities for the six months ended June 30, 2015 was $2.7 million. The net loss of $5.5 million includes $1.3 million of net non-cash expenses, which primarily comprised of non-cash interest expenses of $0.4 million as a result of the non-cash portion of a loss on extinguishment from a previous debt and the issuance costs associated with new debt, stock-based compensation expense of $0.7 million, and depreciation and amortization of $0.4 million, partially offset by a revaluation gain of $0.1 million on a contingent consideration liability driven by a decrease in our stock price. A decrease in net operating assets of $1.4 million primarily comprised of a decrease in accounts receivable of $1.0 million as our reimbursement efforts improved over the six month period ended December 31, 2014, and increases in accounts payable and accrued and other liabilities of $0.2 million, an increase in payroll liabilities of $0.4 million as a result of employee bonuses, offset by increases in inventory, prepaid expenses and other assets of $0.2 million.

Net cash provided by operating activities for the six months ended June 30, 2014 was $1.0 million and reflected (i) the net loss of $0.4 million, (ii) net non-cash items using cash $0.6 million, including non-cash income tax benefit in conjunction with business combination of $1.5 million, partially offset by revaluation of warrants to estimated fair value of $0.3 million, amortization of debt discount and non-cash interest expense of $0.3 million and depreciation and amortization of $0.2 million, and (iii) a net cash inflow from changes in balances of operating assets and liabilities of $2.1 million. The most significant items comprising the changes in balances of operating assets and liabilities was an increase in unpaid deferred initial public offering costs of $1.9 million included in prepaid and other assets, offset by an increase in accrued and other liabilities of $2.1 million, primarily representing accrued initial public offering costs of $1.1 million, and increased professional fees of $0.7 million. Other significant items comprising the changes in balances of operating assets and liabilities were increased accounts payable of $1.1 million, increased royalties of $0.7 million and decreased accounts receivable of $0.5 million.

Investing Activities

During the six months ended June 30, 2015, net cash used in investing activities was $0.7 million for purchases of property and equipment. During the six months ended June 30, 2014 we used $0.5 million for investing activities, primarily comprised of $0.4 million for our acquisition of ImmuMetrix and $0.2 million to purchase property and equipment.

We expect capital expenditures to increase modestly as we expand our research and discovery work to develop new transplant surveillance solutions. We believe that we are not currently capacity constrained and that our current facility can support a substantial increase in testing volume and support new surveillance solutions currently being developed.

Financing Activities

For the six months ended June 30, 2015, net cash provided by financing activities was $3.9 million and consisted primarily of $15.6 million in net proceeds received from a new term loan in January 2015, partially offset by the pay-off of a previous term loan of $11.3 million and $0.4 million of payments made on capital leases.

Net cash provided by financing activities for the six months ended June 30, 2014 of $2.3 million was primarily due to $5.0 million of proceeds from our subordinated convertible debt, net of issuance costs, partially offset by principal payments on our term debt of $1.8 million and payment of initial public offering costs of $0.9 million.

Liquidity and Funding Requirements

Since our inception, substantially all of our operations have been financed through the issuance of our convertible preferred stock, the issuance of common stock in our July 2014 initial public offering, the incurrence of debt, and cash received from AlloMap testing revenues. Through June 30, 2015, we have received net proceeds of $151 million from the issuances of preferred stock, including preferred stock issued on conversion of promissory notes, $35.5 million from our initial public offering, $35.3 million in net proceeds from debt issuances including $5.0 million from a subordinated convertible note and approximately $146 million from AlloMap testing revenues. As of June 30, 2015, we had cash and cash equivalents of $36.9 million and $15.7 million of debt outstanding under our long-term debt and capital lease obligations.

We plan to use the $35.5 million of net proceeds from our initial public offering and the $15.6 million in net proceeds from debt issuances as of June 30, 2015 for research and development, including research aimed at expanding the clinical utility of AlloMap and the development of new solutions for the surveillance of heart and kidney transplants, sales and marketing activities, general and administrative expenses and for working capital and other general corporate purposes. A portion of the net proceeds may also be used to acquire or invest in complementary businesses, technologies, services or products. We have no current agreements or commitments with respect to any such potential future acquisition or investment.

We currently anticipate that our cash and cash equivalents and projected cash receipts from AlloMap sales to customers will be sufficient to fund our operations for at least the next 18 months. We cannot be certain that any of our development of new transplant surveillance solutions will be successful or that we will be able to raise sufficient additional funds, if necessary, to see these programs through to a successful result.

Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risk and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed financial statements, which have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP. The preparation of these unaudited condensed financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes in our critical accounting policies and estimates during the three and six months ended June 30, 2015, as compared to those disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Critical Accounting Policies and Significant Judgments and Estimates” in our Annual Report on Form 10-K filed with the SEC on March 31, 2015.

The Company has issued warrants to purchase shares of its common stock in connection with the issuance of debt on January 30, 2015. The Company accounted for these warrants as equity at fair value on the date the warrants were issued. The fair value of the outstanding warrants was estimated using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”). The Black-Scholes Model requires inputs such as the expected term of the warrants, expected volatility and risk-free interest rate. These inputs are subjective and require significant analysis and judgment to develop. For the estimate of the expected term, the Company used the full remaining contractual term of the warrant.

Factors Affecting Our Performance

The Number of AlloMap Tests We Receive and Report

The growth of our business is tied to the number of AlloMap tests we receive and report. Historically, less than two percent of tests received are not reported due to improper sampling or damage in transit or other causes. We incur costs of collecting and shipping all samples and a portion of the costs where we cannot ultimately issue a score report. As a result, the number of samples received largely directly correlates to the number of score reports.

How We Recognize Revenue

Medicare and certain other payers with agreed upon reimbursement rates and a predictable history of collections allows us to recognize the related revenue on an accrual basis. For the six months ended June 30, 2015 and 2014, 35% and 38%, respectively, of our revenue was

recognized when cash was received. Until we achieve our revenue recognition criteria for a larger number of payers, we will continue to recognize a large portion of our revenue when cash is received. Because we often need to appeal prior to being paid for certain tests, it can take over a year for a test to result in revenue being recorded, and for a portion of our tests, we may never realize revenue.

Additionally, as we commercialize new products, we will need to achieve our revenue recognition criteria for each payer for each new product prior to being able to recognize the related revenue on an accrual basis. Because the timing and amount of cash payments received from payers is difficult to predict, we expect our revenue may fluctuate significantly in any given quarter. In addition, even if we begin to accrue larger amounts of revenue related to AlloMap, when we introduce new products, we do not expect we will be able to recognize revenue from new products on an accrual basis for some period of time.

Continued Adoption of and Reimbursement for AlloMap

Our reimbursement rate has steadily increased over time since the launch of AlloMap, as payers adopt coverage policies and fewer payers consider AlloMap as experimental and investigational. The rate at which our tests are covered and reimbursed has, and is expected to continue to vary by payer. As of June 30, 2015, we had been reimbursed for approximately 80% of AlloMap results delivered in the twelve months ended December 31, 2014. Reimbursement performance is reviewed using a lagging metric of six months as any period less than this is considered not to be reflective of future performance, as the reimbursement process can typically take six months or more to complete depending on the payer. Revenue growth depends on our ability to achieve broader reimbursement from third party payers, to expand the number of tests per patient and the base of ordering physicians.

Development of Additional Products

We rely on sales of AlloMap to generate the majority of our revenue. Our product development pipeline includes other surveillance solutions for organ transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient’s lifetime. Accordingly, we expect to invest in research and development in order to develop additional products. Our success in developing new products will be important in our efforts to grow our business by expanding the potential market for our products and diversifying our sources of revenue.

Timing of Research and Development Expenses

Our spending on experiments may vary substantially from quarter to quarter. We also spend to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. The timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are acquired in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses can affect our financial results. We conduct clinical studies to validate our new products as well as on-going clinical and outcome studies to further the published evidence to support our commercialized AlloMap test. Spending on research and development for both experiments and studies, may vary significantly by quarter depending on the timing of these various expenses.

Contractual Obligations

During the six months ended June 30, 2015, there was a material increase in our contractual obligations and commitments. On January 30, 2015, we entered into a Loan and Security Agreement (the “Loan Agreement”) which provides a secured term loan facility in an aggregate principal amount of up to $20.0 million. We borrowed the first advance of $16.0 million (“Draw A”) on January 30, 2015. Under the terms of the Loan Agreement, following a six month period from the closing date and until any time before December 31, 2015, the Company may, at its option, borrow from the lender a second advance of $4.0 million (“Draw B”), subject to the Company’s satisfaction of certain conditions described in the Loan Agreement. Draw A was used to pay-off the Company’s existing term debt of $11.3 million. Draw A and Draw B each bear interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the lender.

The maturity date of the loan is December 1, 2018. Principal pay-down of the loan begins on January 1, 2016 with the loan being payable in 36 equal monthly installments. The principal pay-down of the loan may be delayed to July 1, 2016 with the loan being payable in 30 equal monthly installments, if on December 31, 2015, the Company has achieved certain net product revenue milestones as described in the Loan Agreement. There have otherwise been no material changes since our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 as filed with the Securities and Exchange Commission on March 31, 2015.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements.

JOBS Act Accounting Election

We are an emerging growth company, as defined in the Jumpstart Our Business startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Recent Accounting Pronouncements

In April 2015, the FASB issued ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). This ASU requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is applicable to the Company beginning January 1, 2016. However, early adoption of ASU 2015-03 is permitted and the Company adopted ASU 2015-03 as of January 1, 2015 using the retrospective method as required. Debt discount and issuance costs, current, as of June 30, 2015 and December 31, 2014 were $176,000 and $76,000, respectively. Debt discount and issuance costs, non-current, as of June 30, 2015 and December 31, 2014 were $215,000 and $11,000, respectively. There is no impact from the adoption of ASU 2015-03 on the unaudited condensed statements of operations or in the loss per share calculations.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rates. We had cash and cash equivalents of $36.9 million at June 30, 2015, which consist of bank deposits and money market funds. Such interest-bearing instruments carry a degree of risk; however, we have not been exposed to, nor do we anticipate being exposed to, material risks due to changes in interest rates. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our unaudited condensed financial statements.

All of our revenues are recognized in U.S. dollars. Upfront payments received from the collaboration agreement in the European Union (see Note 8 to our unaudited condensed financial statements included in this Quarterly Report) were paid in foreign currency and converted to U.S. dollars. As a result, factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets will affect our financial results. Although the impact of currency fluctuations on our financial results has been immaterial to date, there can be no guarantee the impact of currency fluctuations related to our international activities will not be material in the future.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), as of the end of the period covered by this report. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Based upon the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective to ensure that information required to be disclosed in the reports we file and submit under the Securities Exchange Act of 1934, as amended, is (i) recorded, processed, summarized and reported as and when required and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely discussion regarding required disclosure. We believe

the condensed financial statements included in this Form 10-Q for the quarter ended June 30, 2015 present, in all material respects, our financial position, statements of operations and cash flows for the periods presented in conformity with U.S. generally accepted accounting principles.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three month period covered by this Quarterly Report on Form 10-Q that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are not currently a party to any material legal proceedings that we believe are material to our business, financial condition or results of operations. We may from time to time become involved in legal proceedings arising in the ordinary course of business.

ITEM 1A. RISK FACTORS

We operate in a rapidly changing environment that involves a number of risks that could materially and adversely affect our business, financial condition, operating results or cash flows. For a detailed discussion of the risk factors that should be understood by any investor contemplating an investment in our stock, you should carefully consider the factors discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 as filed with the Securities and Exchange Commission on March 31, 2015, which is incorporated herein by reference. There have been no material changes from the risk factors previously disclosed in the Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Sales of Unregistered Securities

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The exhibits listed in the Exhibit Index to this Quarterly Report on Form 10-Q are incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		CAREDX, INC.
		(Registrant)

Date: August 12, 2015	By:	/s/ Peter Maag
		Peter Maag
		President and Chief Executive Officer
		(Principal Executive Officer)

	By:	/s/ Kenneth E. Ludlum
		Kenneth E. Ludlum
		Chief Financial Officer
		(Principal Accounting and Financial Officer)

EXHIBIT INDEX


Exhibit Number

31.1		Certification of Periodic Report by Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Periodic Report by Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

EX-31.1 2 d933029dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Peter Maag, certify that:

I have reviewed this Quarterly Report on Form 10-Q of CareDx, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d933029dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kenneth E. Ludlum, certify that:

I have reviewed this Quarterly Report on Form 10-Q of CareDx, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 4 d933029dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Peter Maag, Chief Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

the Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, (the “Periodic Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of CareDx, Inc.

I, Kenneth E. Ludlum, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of CareDx, Inc.

EX-101.INS 5 cdna-20150630.xml XBRL INSTANCE DOCUMENT

75000000

5000000

387500

503000

600000

10.00

11887409

239000

7872000

120000

2827220

5.56

1515154

100133900

7.03

11838794

0.001

10000000

11838794

0.001

6.48

1515154

1840000

646000

2051000

36773000

13389000

28000

113000

201595000

230000

963000

1554000

2380000

500000

1203000

963000

-164834000

24593000

61366000

417000

12000

8242000

268000

62000

3700000

2146000

61366000

6650000

731000

147000

2559000

1706000

343000

40005000

12005000

674000

36894000

388000

383000 396000 179000 117000 576815 1750000 938339 289000 8.20 176000 214000

40000

963000

15104000

33463000

963000

176000 214000

838695

444108

186473

112800

6.49

15104000

963000

33463000

525000

5128000

357075

525000

1031804

100000000

7.36

11803970

0.001

10000000

11803970

0.001

1616000

463000

1684000

41298000

5451000

28000

273000

200661000

202000

1074000

1684000

5961000

505000

1128000

1074000

-159375000

19843000

61141000

471000

12000

11135000

241000

70000

25000

61141000

6650000

686000

147000

1968000

2687000

277000

40346000

12005000

542000

36431000

409000

318000 54000 146000 144000 76000 11000

1074000

12204000

36779000

1074000

76000 11000

12204000

1074000

36779000

611000

20000000

90000

16000000

160000

4000000

6.96

34483

7.06

220000 19000000 0.10

23229

369000

227845

2300000

911364

14200000

17200000

0.145985401

4000000

3000000

3700000

39200000

35500000

510777

5000000

6048220

0.05

500000

963000

227845

0.65 2500

0.040

1100000

0.65

0.0200

11300000

0.3983

0.0118

0.00

P5Y

-0.42

1033000

P5Y1M6D

0.0170

7812652

0.4184

0.00

1012769

-0.42

164000

1827000

-427000

12700000

119000

-1192000

376000

156000

12544000

909000

-572000

96000

31200

-163000

-545000

1000

117000

118000

-1927000

16200

-427000

2152000

-1500000

4982000

185000

283000

15000

3084000

349000

2117000

2744000

13272000

-540000

2251000

1512000

4565000

5000

185000

4111000

-196000

1123000

721000

222000

-1500000

23000 0

678000

200000

1700000

32000

9000

145000

22000

0.49

82190

907318

541613

0.10

6048220

233311

-2288000

12700000

-2.26 1500000 Q2

-0.46

-2747000

P6Y

Draw A and Draw B each bear interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the lender.

<div> The following table presents pro forma results of operations and gives effect to the IMX transaction as if the transaction had been consummated on January 1, 2013. The unaudited pro forma results of operations have been prepared for comparative purposes only and are not necessarily indicative of what would have occurred had the business combination been completed at the beginning of the period or of the results that may occur in the future. Furthermore, the pro forma financial information does not reflect the impact of any reorganization or operating efficiencies resulting from combining the two companies (in thousands, except per share data):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> Three Months Ended June 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Six Months Ended June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net revenue </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,776</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,700</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net loss </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(518</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,288</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net loss per common share - basic and diluted </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.51</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2.26</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

2015

<div> The following table presents the issuances, changes in fair value and reclassifications of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Contingent Consideration Liability</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Warrants to Purchase Convertible Preferred Stock</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Derivative Liability Related to Subordinated Convertible Note</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance as of December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">525</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">525</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Issuance of financial instruments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,313</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">239</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,552</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Change in estimated fair value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,239</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(239</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,464</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Reclassification to stockholders’ equity </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(539</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(539</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance as of December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,074</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,074</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Change in estimated fair value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(111</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(111</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance as of June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">963</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">963</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

false

<div> Business Combinations In accordance with ASC 805, Business Combinations, the Company determines and allocates the purchase price of an acquired business to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, royalty rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. Goodwill and indefinite-lived intangible assets including acquired in-process technology are reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that goodwill or indefinite-lived intangible assets may be impaired. The Company’s goodwill evaluation is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company assesses qualitative factors to determine if its sole reporting unit’s fair value is more likely than not to exceed its carrying value, including goodwill. In the event the Company determines that it is more likely than not that its reporting unit’s fair value is less than its carrying amount, quantitative testing is performed comparing recorded values to estimated fair values. If the fair value exceeds the carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, then the Company would calculate the potential impairment loss by comparing the implied fair value of goodwill with the carrying value. If the implied fair value of goodwill is less than the carrying value, then an impairment charge would be recorded. The Company performs its annual evaluation of goodwill during the fourth quarter of each fiscal year. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of the asset to its carrying value, without consideration of any recoverability test.   In those circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, Distinguishing Liabilities from Equity, the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company remeasures this liability each reporting period and records changes in the fair value as a component of operating expenses. Transaction costs associated with these acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company’s operating results from the date of acquisition. </div>

<div> Testing Revenue The Company recognizes revenue for tests delivered when the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery has occurred or services rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. The first criterion is satisfied when a third-party payer makes a coverage decision or enters into a contractual arrangement with the Company for the test. The second criterion is satisfied when the Company performs the test and delivers the test result to the ordering physician. The third criterion is satisfied if the third-party payer’s coverage decision or reimbursement contract specifies a price for the test. The fourth criterion is satisfied based on management’s judgments regarding the collectability of the fees charged under the arrangement. Such judgments include review of past payment history. AlloMap testing may be considered investigational by some payers and not covered under their reimbursement policies. Others may cover the test, but not pay a set or determinable amount. As a result, in the absence of a reimbursement agreement or sufficient payment history, collectability cannot reasonably be assured so revenue is not recognized at the time the test is delivered.   If all criteria set forth above are met, revenue is recognized. When the first, third or fourth criteria are not met but third-party payers make a payment to the Company for tests performed, the Company recognizes revenue on the cash basis in the period in which the payment is received. Revenue is recognized on the accrual basis net of adjustments for differences between amounts billed and the estimated receipts from payers. The amount the Company expects to collect may be lower than the agreed upon amount due to several factors, such as the amount of patient co-payments, the existence of secondary payers and claim denials. Estimated receipts are based upon historical payment practices of payers. Differences between estimated and actual cash receipts are recorded as an adjustment to revenue, which have been immaterial to date. During the three and six months ended June 30, 2015, the Company changed its revenue recognized from one and three of its payers, respectively, from a cash basis to an accrual basis based on the Company’s consistent history of obtaining reimbursement from these three payers. The impact of this change in accounting estimate is to increase revenues by $79,000 and $127,000 and to reduce net loss per share by $0.01 for the three and six months ended June 30, 2015. Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are excluded from revenue in the statements of operations. </div>

0.0187

23844

<div> 11. BUSINESS COMBINATION On June 10, 2014, in accordance with an agreement and plan of merger, the Company acquired ImmuMetrix, Inc. (“IMX”), a privately held development stage company working in new technologies using cell-free donor DNA (“cfDNA”) technology for the diagnosis, treatment and management of transplant rejection, immune disorders and diseases, including the development of a new, non-invasive test designed to detect the early stages of solid organ transplant rejection. The Company acquired all IMX assets associated with transplant diagnostics, including related immune repertoire and infectious diseases. An IMX successor company retained the limited assets not associated with transplant diagnostics. The acquisition was structured as a tax-free reorganization. The Company acquired all of the issued and outstanding capital stock of IMX for the total estimated purchase price of $17.2 million consisting of $600,000 in cash; 911,364 shares of the Company’s Series G convertible preferred stock with an estimated fair value of $14.2 million, including 23,229 shares of the Company’s Series G convertible preferred stock with an estimated fair value of $369,000 as a result of the Company’s assumption of IMX outstanding stock options; and an additional payment of 227,845 shares of CareDx Series G convertible preferred stock if a future milestone is achieved. The Agreement provides that the milestone will be achieved if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States no later than six years after the closing date of the acquisition. All shares of Series G Preferred Stock and options to acquire Series G Preferred Stock converted into common stock and options to acquire common stock, respectively, immediately prior to the closing of the Company’s initial public offering. The additional shares to be paid for the achievement of the milestone will also be issued in common stock. The fair value of this contingent consideration was $2.3 million at the acquisition date, $1.1 million at December 31, 2014, and $963,000 at June 30, 2015.   The intellectual property acquired includes an exclusive license from Stanford University to a patent relating to the diagnosis of rejection in organ transplant recipients using cfDNA. The license provides for the Company to pay royalties to Stanford University on sales of the Company’s cfDNA tests. IMX’s post-acquisition results of operations for the three and six months ending June 30, 2015 are included in the Company’s condensed statement of operations. Pro Forma Impact of the Acquisition of IMX The following table presents pro forma results of operations and gives effect to the IMX transaction as if the transaction had been consummated on January 1, 2013. The unaudited pro forma results of operations have been prepared for comparative purposes only and are not necessarily indicative of what would have occurred had the business combination been completed at the beginning of the period or of the results that may occur in the future. Furthermore, the pro forma financial information does not reflect the impact of any reorganization or operating efficiencies resulting from combining the two companies (in thousands, except per share data):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> Three Months Ended June 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Six Months Ended June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net revenue </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,776</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,700</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net loss </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(518</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,288</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net loss per common share - basic and diluted </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.51</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2.26</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The unaudited pro forma consolidated financial information was prepared using the acquisition method of accounting and is based on the historical financial information of the Company and IMX, reflecting the Company’s and IMX’s results of operations for the three and six month periods ending June 30, 2014. The historical financial information has been adjusted to give effect to the pro forma events that are: (i) directly attributable to the acquisition, (ii) factually supportable and (iii) expected to have a continuing impact on the combined results. The unaudited pro forma consolidated financial information reflects: (a) the removal of acquisition-related costs of $1.6 million and $1.7 million incurred by both CareDx and IMX for the three and six months ended June 30, 2014, respectively, including the removal of $0.2 million of IMX stock-based compensation expense that resulted from modifications to options in anticipation of the acquisition; (b) the removal of a $1.5 million tax benefit for the three and six months ended June 30, 2014 that resulted from the acquisition; (c) the addition of salaries, benefits and fees for IMX employees and consultants retained after the acquisition. Acquisition related expenses are primarily included in general and administrative expenses. </div>

<div> The shares issued and associated expenses were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Service Period Three Months Ended </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares Issued</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Fair Market Value per Share at Date of Issuance</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Fair Value of Shares Issued (In Thousands)</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> March 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,663</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.56</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,628</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.48</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20,291</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">123</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-0.01

20291

2204050

2016-01-01

The Company agreed to issue to the lender detachable warrants to purchase shares of the Company's common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche.

10-Q 0001217234

<div> The following potentially dilutive securities have been excluded from diluted net (loss) income per share, because their effect would be antidilutive:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Shares of common stock subject to outstanding options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,515,154</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">469,163</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,515,154</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">907,318</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Shares of common stock subject to outstanding common stock warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">576,096</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">82,190</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">576,096</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">82,190</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Shares of common stock subject to conversion from preferred stock warrants </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">541,613</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">541,613</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Subordinated convertible note </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">233,311</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Convertible preferred stock </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,048,220</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Restricted stock units </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">112,800</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">112,800</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total common stock equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,204,050</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,092,966</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,204,050</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,812,652</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom"> </td> </tr> </table> </div>

<div> 9. DEBT  On January 30, 2015, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) which provides a secured term loan facility in an aggregate principal amount of up to $20.0 million. The Company borrowed the first advance of $16.0 million (“Draw A”) on January 30, 2015. Under the terms of the Loan Agreement, following a six month period from the closing date and until any time before December 31, 2015, the Company may, at its option, borrow from the lender a second advance of $4.0 million (“Draw B”), subject to the Company’s satisfaction of certain conditions described in the Loan Agreement. Draw A was used to payoff the Company’s existing term debt of $11.3 million. A loss on extinguishment of $0.6 million from the pay-off of the existing term loan was recognized as interest expense during the six months ended June 30, 2015. Draw A and Draw B each bear interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the lender. The maturity date of the loan is December 1, 2018. Principal pay-down of the loan begins on January 1, 2016 with the loan being payable in 36 equal monthly installments. The principal pay-down of the loan may be delayed to July 1, 2016 with the loan being payable in 30 equal monthly installments, if on December 31, 2015, the Company has achieved certain net product revenue milestones as described in the Loan Agreement. A fully non-refundable commitment fee of $160,000 was paid on January 30, 2015 when Draw A for $16 million was received. An additional $40,000 loan fee will be payable if Draw B for $4 million is received. The loan has no prepayment penalty. Commitment fees are included in debt issuance costs which are amortized to interest expense using the effective interest method over the term of the loan. Debt discount and issuance costs, current, as of June 30, 2015 and December 31, 2014 were $176,000 and $76,000, respectively. Debt discount and issuance costs, non-current, as of June 30, 2015 and December 31, 2014 were $214,000 and $11,000, respectively. In connection with the Loan Agreement, the Company agreed to issue to the lender detachable warrants to purchase shares of the Company’s common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche. The fair value of the warrants are reflected as a discount to the debt. As a result of Draw A, the Company issued to the lender a warrant to purchase an aggregate of 34,483 shares of the Company’s common stock, at an exercise price equal to $6.96 per share. The fair value of the warrants was estimated to be $90,000 on January 30, 2015, using the Black-Scholes Model with the following assumptions: expected volatility of 39.83%, a contractual term of 5 years, risk-free interest rate of 1.18%, underlying common stock price of $7.06, and dividend yield of 0%. The warrants are included in stockholders’ equity with the offset to debt discount that is amortized over the term of the loan using the effective interest method. The warrants are not subject to remeasurement. The Loan Agreement requires collateral by a security interest in all of the Company’s assets except intellectual property and contains customary affirmative and negative covenants including financial maintenance covenants, and also includes standard events of default, including payment defaults. Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. At June 30, 2015, the Company was in compliance with all loan covenants. </div>

9.06

<div> Comprehensive Loss Net loss and comprehensive loss are the same for all periods presented. </div>

Non-accelerated Filer

<div> Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The condensed balance sheet as of December 31, 2014 has been derived from audited financial statements as of that date but does not include all of the financial information required by U.S. GAAP for complete financial statements. Operating results for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. The accompanying unaudited condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K filed on March 31, 2015 with the SEC. </div>

2018-12-01

<div> 6. ACCRUED AND OTHER LIABILITIES The following table represents the components of accrued and other liabilities (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Professional fees </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">113</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">273</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Test sample processing fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">383</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">318</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accrued overpayments and refunds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">117</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">146</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Clinical Studies </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">289</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">144</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Deferred rent – current portion </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">230</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">202</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Capital leases – current portion </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">62</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">646</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">463</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total accrued and other liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,840</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,616</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.

<div> 8. COLLABORATION AND LICENSING AGREEMENTS  Laboratory Corporation of America Holdings (“LabCorp”) In April 2012, CareDx and LabCorp entered into a collaboration and license agreement (“2012 Agreement”) to develop a lupus flare predictor test. The agreement provided for CareDx to license technology to LabCorp. Of the total arrangement consideration, the fair value of the license was assessed to be $1.0 million. The license term in the 2012 Agreement was the later of 10 years from the date of the agreement or the expiration of the last-to-expire patents and patent applications included in the CareDx technology licensed to LabCorp, unless the license was terminated by mutual agreement. The agreement provided that CareDx and LabCorp would share equally the costs of developing the lupus flare predictor test; however LabCorp’s share of the development cost was subject to certain limits at each stage of the arrangement. Under the agreement, in 2012 LabCorp paid the Company a nonrefundable and non-creditable upfront license fee payment of $1,000,000, and a nonrefundable and non-creditable payment of $250,000 for certain lupus samples. The Company was to receive royalties in the high single digits from LabCorp on net sales of the commercialized flare predictor test or other tests developed using the samples sold. Phase 1 of the project was completed in the first quarter of 2014. On September 18, 2014, CareDx and LabCorp terminated the 2012 agreement. The termination agreement provides that:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">CareDx transfer and assign to LabCorp, 300 “SAGE I” clinical samples and related clinical data and documentation that CareDx obtained from patients during the discovery phase of the collaboration;</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">CareDx grant a perpetual, non-exclusive worldwide, fully paid, sublicensable, royalty-free license to use any collaboration intellectual property and data for any and all purposes; and</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">LabCorp pay $500,000 to CareDx within 30 days of CareDx’s delivery of the clinical samples and clinical data and documentation. No further royalties, milestone fees or other fees will be payable by LabCorp after the termination date.</td> </tr> </table> During the three months ended December 31, 2014, the Company delivered the clinical samples and the related clinical data and documentation to LabCorp, and accordingly recognized the $500,000 termination fee and the remaining $611,000 previously unrecognized license fee. During the three and six months ended June 30, 2014, the Company recognized $1,800 and $31,200, respectively, in revenue under this arrangement, which consisted of amortization of the upfront license fee of $0 and $15,000, respectively, and reimbursement of research and development expenses of $1,800 and $16,200, respectively. Such revenues are included in collaboration and license revenue on the unaudited condensed statements of operations. No revenues were recorded in 2015. Included in research and development expenses were $3,600 and $32,000 for the three and six months ended June 30, 2014, respectively, for development costs associated with the 2012 Agreement. No research and development expenses were recorded in 2015.   Diaxonhit (“DHT”) In June 2013, the Company entered into an exclusive Distribution and Licensing Agreement with DHT, a French public company, whereby DHT will have the AlloMap test performed in a European laboratory and commercialize the test in the European Economic Area (“EEA”). The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014. Consideration under the agreement includes an upfront cash payment of approximately €387,500 ($503,000) that is designated to offset royalties earned by the Company in the first three years following the first commercial sale. The Company is entitled to receive royalties from DHT as a percent of net sales, as defined in the agreement, of AlloMap tests in the mid to high teens. Approximately €250,000 ($344,000) of the upfront payments is refundable under certain circumstances. Upon confirmation that the CE mark was in place, the Company also received an equity payment of DHT common stock with a value of €387,500 ($503,000). The CE mark is a mandatory conformity marking for certain products sold within the EEA. These shares were promptly sold by the Company in July 2013 for total consideration of $467,000. Other consideration that may be earned by the Company includes agreed-upon per unit pricing for the supply of AlloMap products, and additional royalties that are payable upon the achievement of various sales milestones by DHT. In this arrangement, there is one combined unit of accounting. Commercial sales began in the EEA in June 2014. Total revenues recognized from this arrangement for the three and six months ended June 30, 2014 were $1,000 and for the three and six months ended June 30, 2015 were $16,000 and $33,000, respectively. CardioDx, Inc. (“CDX”) In 2005, the Company entered into a services agreement with CDX, whereby the Company provided CDX with biological samples and related data and performed laboratory services on behalf of CDX. Each company granted the other a worldwide license under certain of its intellectual property rights. Pursuant to this agreement, CDX pays royalties to the Company of a low single-digit percentage of the cash collected from sales of CDX licensed products. In 2009, CDX terminated the services portion of this agreement, however, the royalty obligation from CDX continues until the tenth anniversary of the first commercial sale of a CDX licensed product. The first commercial sale of such product by CDX occurred in 2009, therefore the royalty obligation to the Company continues until 2019. Two board members of CDX serve on the Company’s board of directors and are affiliated with stockholders of the Company. Royalty revenues, recorded when earned, were $89,000 and $59,000 for the three months ended June 30, 2015 and 2014, respectively, and were $179,000 and $117,000 for the six months ended June 30, 2015 and 2014, respectively, and are included in collaboration and license revenue on the condensed statements of operations. The Company had receivable balances from CDX of $179,000 and $54,000 at June 30, 2015 and December 31, 2014, respectively. </div>

<div> Fair Value of Financial Instruments Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which the Company would transact, and it takes into consideration the assumptions that market participants would use when pricing the asset or liability. The Company’s assessment of the significance of a particular input to the fair value measurement of an asset or liability requires management to make judgments and to consider specific characteristics of that asset or liability. The carrying amounts of certain of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. The carrying amounts of the convertible preferred stock warrant liability and contingent consideration liability represent their fair values. </div>

<div> Reverse Stock Split, and Increase in Authorized Shares On July 1, 2014, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to reflect a 1 for 6.85 reverse stock split (the “Reverse Stock Split”) of the Company’s outstanding common stock and convertible preferred stock. The Reverse Stock Split became effective July 14, 2014. The par value per share was not adjusted as a result of the Reverse Stock Split. All authorized, issued and outstanding shares of common stock, convertible preferred stock, options and warrants to purchase common or preferred stock and related per share amounts contained in the financial statements have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented. </div>

<div> Concentrations of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper, and various bank deposit accounts. These financial instruments were held in Company accounts at two financial institutions. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits. The Company is also subject to credit risk from its accounts receivable which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers. For the six months ended June 30, 2015 and 2014, approximately 50% and 49%, respectively, of testing revenue was derived from Medicare. No other payers represented more than 10% of testing revenue for these periods. At June 30, 2015 and December 31, 2014 approximately 40% and 78%, respectively, of accounts receivable was from Medicare. No other payer represented more than 10% of accounts receivable at June 30, 2015 and December 31, 2014. </div>

<div> 1. ORGANIZATION  CareDx, Inc., (“CareDx” or the “Company”) is a commercial stage company that develops, markets and delivers diagnostic surveillance solutions for organ transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient’s lifetime. The Company’s one commercialized testing solution, the AlloMap heart transplant molecular test (“AlloMap”), an FDA-cleared test, is a blood-based test used to monitor for acute cellular rejection in heart transplant recipients. The Company was incorporated in Delaware in December 1998, as Hippocratic Engineering, Inc. In April 1999, the Company changed its name to BioCardia, Inc., in June 2002 to Expression Diagnostics, Inc., in July 2007 to XDx, Inc. and in March 2014 to CareDx, Inc. The Company’s operations are based in Brisbane, California and it operates in one segment. Reverse Stock Split, and Increase in Authorized Shares On July 1, 2014, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to reflect a 1 for 6.85 reverse stock split (the “Reverse Stock Split”) of the Company’s outstanding common stock and convertible preferred stock. The Reverse Stock Split became effective July 14, 2014. The par value per share was not adjusted as a result of the Reverse Stock Split. All authorized, issued and outstanding shares of common stock, convertible preferred stock, options and warrants to purchase common or preferred stock and related per share amounts contained in the financial statements have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented. Initial Public Offering On July 22, 2014, the Company closed its initial public offering (“IPO”) of 4,000,000 shares of its common stock, and issued an additional 220,000 shares of common stock on August 13, 2014 pursuant to the exercise of the over-allotment option granted to its underwriters. The public offering price of the shares sold in the offering was $10.00 per share. The total proceeds from the offering to the Company, net of underwriting discounts and commissions of $3.0 million, were $39.2 million. After deducting offering expenses payable by the Company of $3.7 million, net proceeds to the Company were $35.5 million. Upon the closing of the IPO, all shares of convertible preferred stock then outstanding converted into 6,048,220 shares of common stock, and a subordinated convertible note previously issued by the Company in the principal amount of $5.0 million converted into 510,777 shares of common stock. In addition, all of our convertible preferred stock warrants were converted into warrants to purchase common stock. Shelf Filing On August 10, 2015, the Company filed a registration statement on Form S-3 with the Securities and Exchange Commission which will allow the Company to raise up to $75 million from the capital markets. See Note 12. </div>

-111000

<div> Options outstanding and exercisable that have vested or are expected to vest as of June 30, 2015 are as follows:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted Average Remaining Contractual Life (Years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Aggregate Intrinsic Value (In thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">576,815</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.14</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.41</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,750</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected to Vest </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">938,339</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.20</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.30</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">396</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,515,154</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,146</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> 4. FAIR VALUE MEASUREMENTS  The Company records its financial assets and liabilities at fair value except for its debt, which is recorded at amortized cost. The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Level 1: Inputs which include quoted prices in active markets for identical assets and liabilities.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Level 2: Inputs other than Level I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</td> </tr> </table> The following table sets forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis, as of June 30, 2015 and December 31, 2014 (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center">June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center">Fair Value Measured Using</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(Level 3)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total Balance</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33,463</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33,463</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Liabilities </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Contingent consideration </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">963</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">963</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Debt </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,104</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,104</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="16"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center">Fair Value Measured Using</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(Level 3)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total Balance</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,779</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,779</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Liabilities </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Contingent consideration </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,074</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,074</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Debt </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,204</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,204</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The following table presents the issuances, changes in fair value and reclassifications of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Contingent Consideration Liability</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Warrants to Purchase Convertible Preferred Stock</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Derivative Liability Related to Subordinated Convertible Note</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance as of December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">525</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">525</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Issuance of financial instruments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,313</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">239</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,552</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Change in estimated fair value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,239</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(239</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,464</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Reclassification to stockholders’ equity </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(539</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(539</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance as of December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,074</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,074</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Change in estimated fair value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(111</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(111</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance as of June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">963</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">963</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers between Level 1, Level 2 and Level 3 categories during the periods presented. In determining fair value, the Company uses various valuation approaches within the fair value measurement framework. The valuation methodologies used for the Company’s instruments measured at fair value and their classification in the valuation hierarchy are summarized below:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Money market funds - Investments in money market funds are classified within Level 1. At June 30, 2015 and December 31, 2014, money market funds were included on the balance sheets in cash and cash equivalents.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Contingent consideration - As of June 30, 2015, the Company had a contingent obligation to issue 227,845 shares of the Company’s common stock to the former owners of ImmuMetrix, Inc. in conjunction with the Company’s acquisition of ImmuMetrix, Inc. (see Note 11). The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States by June 10, 2020. The Company recorded its estimate of the fair value of the contingent consideration based on its evaluation of the probability of the achievement of the contractual conditions that would result in the payment of the contingent consideration. The fair value of the contingent consideration was estimated using the fair value of the shares to be paid if the contingency is met multiplied by management’s 65% estimate at June 30, 2015 and December 31, 2014 of the probability of success. The significant input in the Level 3 measurement not supported by market activity is the Company’s probability assessment of the milestone being met. The value of the liability is subsequently remeasured to fair value each reporting date, and the change in estimated fair value is recorded to a component of operating expenses until the milestone contingency is paid, expires or is no longer achievable. Increases (decreases) in the estimation of the probability percentage result in a directionally similar impact to the fair value measurement of the contingent consideration liability.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">We determined the estimated fair value of our debt using the present value of payments discounted at an average borrowing rate from of a peer group of public companies, which is a Level 2 observable input.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Warrants to purchase convertible preferred stock—Prior to the Company’s IPO, the Company’s warrants to purchase convertible preferred stock were classified as Level 3. The valuation of the warrants used assumptions that are inherently subjective and involve significant management judgment. The significant unobservable input used in the fair value measurement of the warrant liability was the fair value of the underlying convertible preferred stock at the valuation remeasurement date. Generally, increases (decreases) in the fair value of the underlying stock would result in a directionally similar impact to the fair value measurement of the preferred stock warrants. A gain of $245,000 and loss of $283,000 in estimated fair value was recognized in other (expense) income, net in the statement of operations for the three and six months ended June 30, 2014, respectively. Upon the Company’s IPO in July 2014 certain warrants to purchase convertible preferred stock were converted into warrants to purchase common stock which were reclassified to equity and are no longer subject to remeasurement, while other warrants to purchase convertible preferred stock expired pursuant to their terms.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left"> Derivative liability related to subordinated convertible note—On April 17, 2014, the Company issued a $5.0 million subordinated convertible promissory note to Illumina, Inc. that had some features that constituted embedded derivatives. The Company determined that the optional conversion or repayment upon a change in control is an equity call option with a potentially variable value to be received and meets the definition of a derivative which would be required to be bifurcated. The estimated fair value of this embedded derivative was affected by the estimated probability assigned to the various scenarios for the host instrument. As of April 17, 2014, management estimated repayment upon a change in control within the loan term at a 10% probability. As of June 30, 2014 management estimated repayment upon a change in control within the loan term at a 5% probability. The $239,000 original estimated fair value of the embedded derivative liability was included in accrued and other liabilities. At June 30, 2014, the fair value of the derivative was remeasured to $120,000, resulting in a gain of $119,000, which was recorded in other (expense) income, net in the statement of operations for the three and six months ended June 30, 2014. Upon the Company’s IPO in July 2014, the subordinated convertible note was converted into common stock, and so the embedded conversion option was extinguished. Accordingly, the fair value of the derivative became $0, and a gain of $120,000 was recorded in other (expense) income, net. The significant unobservable input used in the fair value measurement of the derivative liability was the probability assigned to the various scenarios. Generally, increases (decreases) in the probability of the factors primarily impacting the valuation would result in a directionally similar impact to the fair value measurement of the derivative liability. Changes in estimated fair value were recognized in other (expense) income, net on the statements of operations. </td> </tr> </table> The Company’s liabilities classified as Level 3 were valued based on unobservable inputs and management’s judgment due to the absence of quoted market prices, inherent lack of liquidity and the long-term nature of the financial instruments. </div>

2015-01-30

<div> The following table represents the components of accrued and other liabilities (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Professional fees </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">113</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">273</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Test sample processing fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">383</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">318</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued overpayments and refunds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">117</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">146</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Clinical Studies </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">289</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">144</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Deferred rent – current portion </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">230</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">202</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Capital leases – current portion </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">62</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">647</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">463</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total accrued and other liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,840</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,616</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

0.4085

<div> The following tables set forth the computation of the Company’s basic and diluted net (loss) income per share (in thousands, except share and per share data):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="55%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Numerator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net (loss) income </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,185</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">877</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5,457</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(427</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Add: interest expense related to subordinated convertible note, less gain on change in fair value of derivative related to subordinated convertible note </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net (loss) income attributable to common stockholders </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,185</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">892</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5,457</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(427</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Denominator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted-average shares used to compute basic net (loss) income per common share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,835,405</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,013,128</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,824,993</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,012,769</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Effect of potentially dilutive securities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Employee stock options </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">381,434</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Convertible preferred stock </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,355,280</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Subordinated convertible note </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">189,726</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Weighted-average shares used to compute diluted net (loss) income per common share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,835,405</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,939,568</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,824,993</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,012,769</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net (loss) income per share </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net (loss) income per common share - basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.27</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.87</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.46</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.42</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net (loss) income per common share - diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.27</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.13</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.46</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.42</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom"> </td> </tr> </table> </div>

<div> The Company’s results of operations include expense relating to employee and nonemployee stock-based payment awards from stock options and RSUs as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cost of testing </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">89</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">136</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Sales and marketing </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">232</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">99</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">431</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">145</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">411</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">137</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">692</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">185</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table summarizes the Company’s inventories (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Finished Goods </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">343</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">277</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Raw Materials </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">388</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">409</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total Inventory </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">731</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">686</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px; font-size:0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

0.00

7.74

--12-31 CareDx, Inc.

<div> 5. INVENTORIES The following table summarizes the Company’s inventories (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Finished Goods </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">343</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">277</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Raw Materials </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">388</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">409</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total Inventory </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">731</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">686</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table sets forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis, as of June 30, 2015 and December 31, 2014 (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center">June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center">Fair Value Measured Using</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(Level 3)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total Balance</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33,463</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33,463</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Liabilities </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Contingent consideration </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">963</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">963</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Debt </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,104</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,104</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="16"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center">Fair Value Measured Using</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(Level 3)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total Balance</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,779</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,779</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Liabilities </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Contingent consideration </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,074</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,074</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Debt </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,204</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,204</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   </div>

11824993

Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.

<div> Cost of Testing Cost of testing reflects the aggregate costs incurred in delivering the Company’s AlloMap test results to clinicians. The components of cost of testing are materials and service costs, direct labor costs, including stock-based compensation, equipment and infrastructure expenses associated with testing samples, shipping, logistics and specimen processing charges to collect and transport samples and allocated overhead including rent, information technology, equipment depreciation and utilities and royalties. Costs associated with performing tests (except royalties) are recorded as the test is processed regardless of whether and when revenue is recognized with respect to that test. As a result, our cost of testing as a percentage of revenue may vary significantly from period to period because we do not recognize all revenue in the period in which the associated costs are incurred. Royalties for licensed technology, calculated as a percentage of test revenues, are recorded as license fees in cost of testing at the time the test revenues are recognized. </div>

<div> The following table summarizes option activity and related information:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Stock Options Outstanding</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- average Exercise Price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance—December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,031,804</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.36</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">525,078</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.74</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(17,884</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.35</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(23,844</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.06</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance—June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,515,154</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.03</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

525078

<div> Impairment of Long-lived Assets The Company evaluates its long-lived assets for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. The Company then compares the carrying amounts of the assets with the future net undiscounted cash flows expected to be generated by such asset. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value determined using discounted estimates of future cash flows. The Company has not identified any such impairment losses to date. </div>

<div> 7. COMMITMENTS AND CONTINGENCIES Royalty Commitments In November 2004, the Company entered into a license agreement with Roche Molecular Systems, Inc., or Roche, that grants the Company the right to use certain Roche technology relating to polymerase chain reaction, or PCR, and quantitative real-time PCR, in clinical laboratory services, including in connection with AlloMap. This is a non-exclusive license agreement in the United States covering claims in multiple Roche patents. The Company had disputed the combination services percentage Roche sought to apply under the agreement. The combination service percentage is a multiplier used to calculate royalties where licensed services are sold in combination with other services. From July 2011 through September 2014, the Company withheld payment of such royalties pending resolution of the matter. On February 11, 2014, Roche filed a demand for arbitration with the American Arbitration Association seeking a declaration that the Company had materially breached the Roche license agreement by failing to report and pay royalties owing to Roche in respect of licensed services performed by the Company after July 1, 2011. Since July 1, 2011, the Company fully accrued the unpaid royalties on the balance sheets, and the amount of the unpaid royalties has been reflected as an expense in the Company’s condensed statements of operations in the periods revenue was recorded to which the royalties relate.   In September 2014, the Company entered into a settlement and mutual release agreement with Roche whereby: (i) for the period beginning July 1, 2011 through June 30, 2014, the Company agreed to pay the amount of $2,827,220 in settlement of past royalties due; (ii) for the period beginning July 1, 2014 through September 30, 2014, the Company agreed to pay royalties based on the same combination services percentage used to determine the past royalties due; (iii) for the period beginning October 1, 2014 through September 30, 2017, Roche and the Company agreed to a downward adjustment of the combination services percentage used to determine the portion of the AlloMap testing revenue that is royalty bearing under the terms of the license; (iv) the Company agreed to report and pay quarterly royalties within 45 days of the end of each calendar quarter; (v) Roche agreed that, subject to the Company’s timely payment of all applicable royalties through such date, no further royalties will be payable by the Company for periods after September 30, 2017; (vi) the Company and Roche agreed to mutually release all claims under the license agreement through the settlement date; and (vii) Roche agreed to dismiss the arbitration claims. For all time periods, the contractual royalty rate in the license agreement was or will be applied to the applicable combination services percentage to determine the royalties’ payable for the AlloMap service. Under the license agreement, the Company incurs royalty expenses as a percentage of combination services revenue and classifies those expenses as a component of cost of testing in the statements of operations. For the three months ended June 30, 2015 and 2014, royalty expenses in connection with the Roche agreement were $254,000 and $362,000, respectively. For the six months ended June 30, 2015 and 2014, royalty expenses in connection with the Roche agreement were $509,000 and $678,000, respectively. Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, or results of operations. </div>

2.35

11824993

2.62

2015-06-30

<div> Collaboration and License Revenue The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis. </div>

<div> Use of Estimates The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers, (v) the fair value of assets and liabilities, (vi) the valuation of warrants to purchase convertible preferred stock, (vii) the determination of fair value of the Company’s common stock, (viii) the fair value of contingent consideration in a business acquisition, (ix) the fair value of the embedded features associated with the subordinated convertible note, (x) the fair value of the embedded features associated with long-term debt, (xi) measurement of stock-based compensation expense, (xii) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xiii) any impairment of long-lived assets including in-process technology and goodwill and (xiv) legal contingencies. Actual results could differ from those estimates. </div>

17884

<div> Stock-based Compensation The Company uses the Black-Scholes option pricing model (“Black-Scholes Model”), which requires the use of estimates such as stock price volatility and expected option lives, to value employee stock options. The Company estimates the expected option lives using historical data, volatility using data of similar companies in the diagnostics industry, risk-free rates based on the implied yield currently available in the U.S. Treasury zero-coupon issues with a remaining term equal to the expected option lives, and dividend yield based on the Company’s expectations and historical data. The Company uses the straight-line attribution method for recognizing compensation expense. Compensation expense is recognized on awards ultimately expected to vest and reduced for forfeitures that are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on the Company’s historical experience. Compensation expense for stock options issued to nonemployees is calculated using the Black-Scholes Model and is recorded over the service performance period. Options subject to vesting are required to be periodically remeasured over their service performance period, which is generally the same as the vesting period. </div>

<div> Unvested RSU activity for the six months ended June 30, 2015 is summarized below:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Grant-Date Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Unvested balance at December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">114,400</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,600</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Unvested balance at June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">112,800</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Cash Equivalents Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist primarily of amounts invested in money market funds and checking accounts. </div>

<div> 10. STOCK INCENTIVE PLANS  Stock Option Plans Prior to its IPO, the Company had one active stock option plan, the 2008 Equity Incentive Plan (“2008 Plan”), one assumed stock option plan, the ImmuMetrix 2014 Equity Incentive Plan, and one terminated stock option plan, the 1998 Stock Plan. Upon its IPO, the Company reserved 838,695 shares of common stock for issuance under a new 2014 Equity Incentive Plan (“2014 Plan”). The shares reserved for issuance under the 2014 Plan also include shares returned to the 2008 Plan as the result of expiration or termination of options, provided that the maximum number of shares that may be added to the 2014 Plan thereby is limited to a maximum of 865,252 shares. The number of shares available for issuance under the 2014 Plan also includes an annual increase on the first day of each year equal to the lessor of:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="1%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">357,075 shares</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="1%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">4.0% of the outstanding shares of common stock as of the last day of the immediately preceding year; or</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="1%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">such other number of shares as the Company’s board of directors may determine.</td> </tr> </table> The following table summarizes option activity and related information:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Stock Options Outstanding</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- average Exercise Price</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance—December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,031,804</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.36</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">525,078</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.74</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(17,884</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.35</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(23,844</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.06</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance—June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,515,154</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.03</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> There were 444,108 shares available for the granting of stock options, restricted stock units and restricted stock from the 2014 Plan as of June 30, 2015. Options outstanding and exercisable that have vested or are expected to vest as of June 30, 2015 are as follows:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted Average Remaining Contractual Life (Years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Aggregate Intrinsic Value (In thousands)</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">576,815</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.14</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.41</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,750</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected to Vest </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">938,339</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.20</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.30</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">396</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,515,154</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,146</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock at June 30, 2015 for stock options that were in-the-money. The fair market value of the Company’s common stock as of June 30, 2015 was $6.50 per share. The weighted-average grant-date fair value of options granted during the three and six months ended June 30, 2015 using the Black-Scholes Model was $2.10 and $2.62 per share, respectively. Valuation Assumptions The fair value of stock-based awards was estimated using the Black-Scholes option-pricing model using the following weighted-average assumptions:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Expected term (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40.04</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42.18</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40.85</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41.84</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.69</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.74</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.87</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.70</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> 2014 Employee Stock Purchase Plan Our board of directors adopted our 2014 Employee Stock Purchase Plan (the “ESPP”) in March 2014 and our stockholders approved the ESPP in July 2014. However, our ESPP was not made available to our employees until January 1, 2015. The first offering period of the ESPP began on January 1, 2015 and ended June 30, 2015. Under the first offering period, 36,696 were purchased under the ESPP. At June 30, 2015, the proceeds from the issuance of shares were $0.2 million and a total of 186,473 shares of our common stock is available for sale under the ESPP. The option price per share of common stock to be paid by a participant upon exercise of the participant’s option on the applicable exercise date for an offering period shall be equal to 85% of the lesser of the fair market value of a share of common stock on (a) the applicable grant date or (b) the applicable exercise date. Restricted Stock Units The Company’s 2014 Plan allows restricted stock units (“RSUs”) to be granted in addition to stock options. The RSUs vest annually over four years in equal increments. RSUs were granted by the Company for the first time in March 2015. Unvested RSU activity for the six months ended June 30, 2015 is summarized below:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Grant-Date Fair Value</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Unvested balance at December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">114,400</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,600</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Unvested balance at June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">112,800</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   Non-Employee Director Equity-Based Compensation For the three and six months ended June 30, 2015, the Company paid a portion of its non-employee directors’ compensation through the award of common shares. The stock awards are classified as equity-based compensation expense. Expenses associated with the awards were $75,000 and $123,000 for the three and six months ended June 30, 2015, respectively and are included in general and administrative expense in the condensed statement of operations. The shares issued and associated expenses were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Service Period Three Months Ended </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares Issued</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Fair Market Value per Share at Date of Issuance</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Fair Value of Shares Issued (In Thousands)</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> March 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,663</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.56</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,628</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.48</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20,291</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">123</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The shares issued at each date were for services performed during the three-month period that ended one day prior to the date of issuance. The Company’s results of operations include expense relating to employee and nonemployee stock-based payment awards from stock options and RSUs as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cost of testing </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">89</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">136</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Sales and marketing </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">232</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">99</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">431</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">145</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">411</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">137</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">692</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">185</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> At June 30, 2015, there was approximately $3.7 million of total unrecognized stock-based compensation from stock option and RSU grants, net of estimated forfeitures, related to non-vested stock option and RSUs granted that will be recognized on a straight-line basis over the remaining vesting period of 3.2 years. </div>

<div> Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled to when products are transferred to customers. On July 9, 2015, the FASB decided to delay the effective date of the new standard by one year. The standard would become effective for us beginning in the first quarter of 2018. Early application would be permitted in 2017. Entities would have the option of using either a full retrospective or a modified retrospective approach to adopt this new guidance. The Company is currently evaluating the impact of adopting the new revenue standard on its financial statements. In April 2015, the FASB issued ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). This ASU requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is applicable to the Company beginning January 1, 2016. However, early adoption of ASU 2015-03 is permitted and the Company adopted ASU 2015-03 as of January 1, 2015 using the retrospective method as required. Debt discount and issuance costs, current, as of June 30, 2015 and December 31, 2014 were $176,000 and $76,000, respectively. Debt discount and issuance costs, non-current, as of June 30, 2015 and December 31, 2014 were $214,000 and $11,000, respectively. There is no impact from the adoption of ASU 2015-03 on the unaudited condensed statements of operations or in the loss per share calculations. In April 2015, the FASB issued ASU 2015-05 Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) (“ASU 2015-05”). This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This ASU will be effective for annual periods, including interim periods beginning after December 15, 2015. Early adoption is permitted. An entity can elect to adopt the amendments either (1) prospectively to all arrangements entered into or materially modified after the effective date or (2) retrospectively. For prospective transition, the only disclosure requirements at transition are the nature of and reason for the change in accounting principle, the transition method, and a qualitative description of the financial statement line items affected by the change. For retrospective transition, the disclosure requirements at transition include the requirements for prospective transition and quantitative information about the effects of the accounting change. The Company is currently evaluating the impact of adopting ASU 2015-05 on its financial statements. </div>

<div> 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The condensed balance sheet as of December 31, 2014 has been derived from audited financial statements as of that date but does not include all of the financial information required by U.S. GAAP for complete financial statements. Operating results for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. The accompanying unaudited condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K filed on March 31, 2015 with the SEC. Use of Estimates The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers, (v) the fair value of assets and liabilities, (vi) the valuation of warrants to purchase convertible preferred stock, (vii) the determination of fair value of the Company’s common stock, (viii) the fair value of contingent consideration in a business acquisition, (ix) the fair value of the embedded features associated with the subordinated convertible note, (x) the fair value of the embedded features associated with long-term debt, (xi) measurement of stock-based compensation expense, (xii) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xiii) any impairment of long-lived assets including in-process technology and goodwill and (xiv) legal contingencies. Actual results could differ from those estimates. Concentrations of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper, and various bank deposit accounts. These financial instruments were held in Company accounts at two financial institutions. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits. The Company is also subject to credit risk from its accounts receivable which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers. For the six months ended June 30, 2015 and 2014, approximately 50% and 49%, respectively, of testing revenue was derived from Medicare. No other payers represented more than 10% of testing revenue for these periods. At June 30, 2015 and December 31, 2014 approximately 40% and 78%, respectively, of accounts receivable was from Medicare. No other payer represented more than 10% of accounts receivable at June 30, 2015 and December 31, 2014. Cash Equivalents Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist primarily of amounts invested in money market funds and checking accounts. Impairment of Long-lived Assets The Company evaluates its long-lived assets for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. The Company then compares the carrying amounts of the assets with the future net undiscounted cash flows expected to be generated by such asset. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value determined using discounted estimates of future cash flows. The Company has not identified any such impairment losses to date. Fair Value of Financial Instruments Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which the Company would transact, and it takes into consideration the assumptions that market participants would use when pricing the asset or liability. The Company’s assessment of the significance of a particular input to the fair value measurement of an asset or liability requires management to make judgments and to consider specific characteristics of that asset or liability. The carrying amounts of certain of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. The carrying amounts of the convertible preferred stock warrant liability and contingent consideration liability represent their fair values. Testing Revenue The Company recognizes revenue for tests delivered when the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery has occurred or services rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. The first criterion is satisfied when a third-party payer makes a coverage decision or enters into a contractual arrangement with the Company for the test. The second criterion is satisfied when the Company performs the test and delivers the test result to the ordering physician. The third criterion is satisfied if the third-party payer’s coverage decision or reimbursement contract specifies a price for the test. The fourth criterion is satisfied based on management’s judgments regarding the collectability of the fees charged under the arrangement. Such judgments include review of past payment history. AlloMap testing may be considered investigational by some payers and not covered under their reimbursement policies. Others may cover the test, but not pay a set or determinable amount. As a result, in the absence of a reimbursement agreement or sufficient payment history, collectability cannot reasonably be assured so revenue is not recognized at the time the test is delivered.   If all criteria set forth above are met, revenue is recognized. When the first, third or fourth criteria are not met but third-party payers make a payment to the Company for tests performed, the Company recognizes revenue on the cash basis in the period in which the payment is received. Revenue is recognized on the accrual basis net of adjustments for differences between amounts billed and the estimated receipts from payers. The amount the Company expects to collect may be lower than the agreed upon amount due to several factors, such as the amount of patient co-payments, the existence of secondary payers and claim denials. Estimated receipts are based upon historical payment practices of payers. Differences between estimated and actual cash receipts are recorded as an adjustment to revenue, which have been immaterial to date. During the three and six months ended June 30, 2015, the Company changed its revenue recognized from one and three of its payers, respectively, from a cash basis to an accrual basis based on the Company’s consistent history of obtaining reimbursement from these three payers. The impact of this change in accounting estimate is to increase revenues by $79,000 and $127,000 and to reduce net loss per share by $0.01 for the three and six months ended June 30, 2015. Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are excluded from revenue in the statements of operations. Collaboration and License Revenue The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis. Cost of Testing Cost of testing reflects the aggregate costs incurred in delivering the Company’s AlloMap test results to clinicians. The components of cost of testing are materials and service costs, direct labor costs, including stock-based compensation, equipment and infrastructure expenses associated with testing samples, shipping, logistics and specimen processing charges to collect and transport samples and allocated overhead including rent, information technology, equipment depreciation and utilities and royalties. Costs associated with performing tests (except royalties) are recorded as the test is processed regardless of whether and when revenue is recognized with respect to that test. As a result, our cost of testing as a percentage of revenue may vary significantly from period to period because we do not recognize all revenue in the period in which the associated costs are incurred. Royalties for licensed technology, calculated as a percentage of test revenues, are recorded as license fees in cost of testing at the time the test revenues are recognized. Business Combinations In accordance with ASC 805, Business Combinations, the Company determines and allocates the purchase price of an acquired business to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, royalty rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. Goodwill and indefinite-lived intangible assets including acquired in-process technology are reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that goodwill or indefinite-lived intangible assets may be impaired. The Company’s goodwill evaluation is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company assesses qualitative factors to determine if its sole reporting unit’s fair value is more likely than not to exceed its carrying value, including goodwill. In the event the Company determines that it is more likely than not that its reporting unit’s fair value is less than its carrying amount, quantitative testing is performed comparing recorded values to estimated fair values. If the fair value exceeds the carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, then the Company would calculate the potential impairment loss by comparing the implied fair value of goodwill with the carrying value. If the implied fair value of goodwill is less than the carrying value, then an impairment charge would be recorded. The Company performs its annual evaluation of goodwill during the fourth quarter of each fiscal year. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of the asset to its carrying value, without consideration of any recoverability test.   In those circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, Distinguishing Liabilities from Equity, the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company remeasures this liability each reporting period and records changes in the fair value as a component of operating expenses. Transaction costs associated with these acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company’s operating results from the date of acquisition. Stock-based Compensation The Company uses the Black-Scholes option pricing model (“Black-Scholes Model”), which requires the use of estimates such as stock price volatility and expected option lives, to value employee stock options. The Company estimates the expected option lives using historical data, volatility using data of similar companies in the diagnostics industry, risk-free rates based on the implied yield currently available in the U.S. Treasury zero-coupon issues with a remaining term equal to the expected option lives, and dividend yield based on the Company’s expectations and historical data. The Company uses the straight-line attribution method for recognizing compensation expense. Compensation expense is recognized on awards ultimately expected to vest and reduced for forfeitures that are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on the Company’s historical experience. Compensation expense for stock options issued to nonemployees is calculated using the Black-Scholes Model and is recorded over the service performance period. Options subject to vesting are required to be periodically remeasured over their service performance period, which is generally the same as the vesting period. Warrants The Company had freestanding warrants enabling counterparties to purchase shares of its convertible preferred stock which were converted to warrants to purchase common stock on the Company’s IPO date. In accordance with the accounting guidance regarding distinguishing liabilities from equity, freestanding warrants for convertible preferred stock that are contingently redeemable are classified as liabilities on the balance sheet and recorded at their estimated fair value. These warrants are remeasured at each balance sheet date and any change in estimated fair value is recognized in other (expense) income, net, on the statements of operations. Upon the completion of the Company’s IPO in July 2014, preferred stock warrants were converted into warrants to purchase common stock, and, accordingly, the liability was reclassified to equity and became no longer subject to remeasurement. The Company has issued warrants to purchase shares of its common stock in connection with financing activities (see Note 9). The Company accounts for these warrants as equity at fair value on the date the warrants are issued. The fair value of the outstanding warrants is estimated using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the warrants, expected volatility and risk-free interest rate. Certain of these inputs are subjective and require significant analysis and judgment to develop. For the estimate of the expected term, the Company uses the full remaining contractual term of the warrant. Comprehensive Loss Net loss and comprehensive loss are the same for all periods presented. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled to when products are transferred to customers. On July 9, 2015, the FASB decided to delay the effective date of the new standard by one year. The standard would become effective for us beginning in the first quarter of 2018. Early application would be permitted in 2017. Entities would have the option of using either a full retrospective or a modified retrospective approach to adopt this new guidance. The Company is currently evaluating the impact of adopting the new revenue standard on its financial statements. In April 2015, the FASB issued ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). This ASU requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is applicable to the Company beginning January 1, 2016. However, early adoption of ASU 2015-03 is permitted and the Company adopted ASU 2015-03 as of January 1, 2015 using the retrospective method as required. Debt discount and issuance costs, current, as of June 30, 2015 and December 31, 2014 were $176,000 and $76,000, respectively. Debt discount and issuance costs, non-current, as of June 30, 2015 and December 31, 2014 were $214,000 and $11,000, respectively. There is no impact from the adoption of ASU 2015-03 on the unaudited condensed statements of operations or in the loss per share calculations. In April 2015, the FASB issued ASU 2015-05 Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) (“ASU 2015-05”). This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This ASU will be effective for annual periods, including interim periods beginning after December 15, 2015. Early adoption is permitted. An entity can elect to adopt the amendments either (1) prospectively to all arrangements entered into or materially modified after the effective date or (2) retrospectively. For prospective transition, the only disclosure requirements at transition are the nature of and reason for the change in accounting principle, the transition method, and a qualitative description of the financial statement line items affected by the change. For retrospective transition, the disclosure requirements at transition include the requirements for prospective transition and quantitative information about the effects of the accounting change. The Company is currently evaluating the impact of adopting ASU 2015-05 on its financial statements. </div>

CDNA

Principal pay-down of the loan begins on January 1, 2016 with the loan being payable in 36 equal monthly installments. The principal pay-down of the loan may be delayed to July 1, 2016 with the loan being payable in 30 equal monthly installments, if on December 31, 2015, the Company has achieved certain net product revenue milestones as described in the Loan Agreement.

-0.46

<div> The fair value of stock-based awards was estimated using the Black-Scholes option-pricing model using the following weighted-average assumptions:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Expected term (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40.04</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42.18</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40.85</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41.84</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.69</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.74</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.87</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.70</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

<div> 3. NET (LOSS) INCOME PER SHARE  Basic and net (loss) income per share has been computed by dividing the net (loss) income by the weighted-average number of common shares outstanding during the period. For the three months ended June 30, 2014, common share equivalents have been included in diluted net income per share, as the effect to net income per share is dilutive. For the three and six months ended June 30, 2015, and for the six months ended June 30, 2014, all common share equivalents have been excluded from diluted net loss per share as the effect to net loss per share would be antidilutive. Our common share equivalents include convertible preferred stock, the subordinated convertible note, options and warrants to purchase common and convertible preferred stock, and restricted stock units. Common share equivalents for convertible preferred stock and the subordinated convertible note are determined using the if-converted method. Common share equivalents for options and warrants to purchase common and convertible preferred stock are determined using the treasury-stock method. The following tables set forth the computation of the Company’s basic and diluted net (loss) income per share (in thousands, except share and per share data):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="55%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Numerator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net (loss) income </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,185</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">877</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5,457</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(427</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Add: interest expense related to subordinated convertible note, less gain on change in fair value of derivative related to subordinated convertible note </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net (loss) income attributable to common stockholders </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,185</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">892</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5,457</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(427</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Denominator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted-average shares used to compute basic net (loss) income per common share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,835,405</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,013,128</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,824,993</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,012,769</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Effect of potentially dilutive securities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Employee stock options </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">381,434</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Convertible preferred stock </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,355,280</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Subordinated convertible note </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">189,726</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Weighted-average shares used to compute diluted net (loss) income per common share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,835,405</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,939,568</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,824,993</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,012,769</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net (loss) income per share </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net (loss) income per common share - basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.27</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.87</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.46</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.42</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net (loss) income per common share - diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.27</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.13</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.46</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.42</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The following potentially dilutive securities have been excluded from diluted net (loss) income per share, because their effect would be antidilutive:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Shares of common stock subject to outstanding options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,515,154</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">469,163</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,515,154</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">907,318</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Shares of common stock subject to outstanding common stock warrants </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">576,096</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">82,190</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">576,096</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">82,190</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Shares of common stock subject to conversion from preferred stock warrants </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">541,613</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">541,613</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Subordinated convertible note </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">233,311</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Convertible preferred stock </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,048,220</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Restricted stock units </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">112,800</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">112,800</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total common stock equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,204,050</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,092,966</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,204,050</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,812,652</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 0pt"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>    </div>

P3Y2M12D

ASU 2015-03

<div> 12. SUBSEQUENT EVENT  Shelf Filing On August 10, 2015, the Company filed a registration statement on Form S-3 (“Shelf Filing”) with the Securities and Exchange Commission which will allow the Company to raise up to $75 million from the capital markets. In addition, on August 10, 2015 the Company entered into an At The Market Issuance Sales Agreement (the “2015 ATM Agreement”), with Cantor Fitzgerald and Company (“Cantor”) under which it may sell shares of its common stock from time to time in an aggregate amount not to exceed $19 million per year per the 2015 ATM Agreement and not to exceed $75 million in total per the Shelf Filing. Cantor may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The NASDAQ Global Market, on any other existing trading market for the Company’s common stock or to or through a market maker. Cantor also may sell the shares in privately negotiated transactions, subject to the Company’s prior approval. The Company will pay Cantor a commission equal to 3% of the gross proceeds of the sales price of all shares sold through it as sales agent under the 2015 ATM Agreement. </div>

733000

11724000

-5457000

14344000

-1083000

205000

14139000

-4277000

45000

-97000

-981000

33000

179000

-5457000

108000

15625000

692000

4549000

450000

274000

463000

18621000

-733000

3943000

3931000

5218000

-111000

42000

692000

5034000

367000

-116000

27000

358000

P9Y3M18D 123000 The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014. 0.05 0 59000 1 P7Y4M28D 5.14 <div> Warrants The Company had freestanding warrants enabling counterparties to purchase shares of its convertible preferred stock which were converted to warrants to purchase common stock on the Company’s IPO date. In accordance with the accounting guidance regarding distinguishing liabilities from equity, freestanding warrants for convertible preferred stock that are contingently redeemable are classified as liabilities on the balance sheet and recorded at their estimated fair value. These warrants are remeasured at each balance sheet date and any change in estimated fair value is recognized in other (expense) income, net, on the statements of operations. Upon the completion of the Company’s IPO in July 2014, preferred stock warrants were converted into warrants to purchase common stock, and, accordingly, the liability was reclassified to equity and became no longer subject to remeasurement. The Company has issued warrants to purchase shares of its common stock in connection with financing activities (see Note 9). The Company accounts for these warrants as equity at fair value on the date the warrants are issued. The fair value of the outstanding warrants is estimated using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the warrants, expected volatility and risk-free interest rate. Certain of these inputs are subjective and require significant analysis and judgment to develop. For the estimate of the expected term, the Company uses the full remaining contractual term of the warrant. </div> 0 <div> Initial Public Offering On July 22, 2014, the Company closed its initial public offering (“IPO”) of 4,000,000 shares of its common stock, and issued an additional 220,000 shares of common stock on August 13, 2014 pursuant to the exercise of the over-allotment option granted to its underwriters. The public offering price of the shares sold in the offering was $10.00 per share. The total proceeds from the offering to the Company, net of underwriting discounts and commissions of $3.0 million, were $39.2 million. After deducting offering expenses payable by the Company of $3.7 million, net proceeds to the Company were $35.5 million. Upon the closing of the IPO, all shares of convertible preferred stock then outstanding converted into 6,048,220 shares of common stock, and a subordinated convertible note previously issued by the Company in the principal amount of $5.0 million converted into 510,777 shares of common stock. In addition, all of our convertible preferred stock warrants were converted into warrants to purchase common stock. </div> 0 2015-08-10 0.03

Roche

In September 2014, the Company entered into a settlement and mutual release agreement with Roche whereby (i) for the period beginning July 1, 2011 through June 30, 2014, the Company agreed to pay the amount of $2,827,220 in settlement of past royalties due; (ii) for the period beginning July 1, 2014 through September 30, 2014, the Company agreed to pay royalties based on the same combination services percentage used to determine the past royalties due; (iii) for the period beginning October 1, 2014 through September 30, 2017, Roche and the Company agreed to a downward adjustment of the combination services percentage used to determine the portion of the AlloMap testing revenue that is royalty bearing under the terms of the license; (iv) the Company agreed to report and pay quarterly royalties within 45 days of the end of each calendar quarter; (v) Roche agreed that, subject to the Company's timely payment of all applicable royalties through such date, no further royalties will be payable by the Company for periods after September 30, 2017.

September 2014

509000

P45D

The license term in the 2012 Agreement was the later of 10 years from the date of the agreement or the expiration of the last-to-expire patents and patent applications included in the CareDx technology licensed to LabCorp, unless the license was terminated by mutual agreement. 2014-09-18

56000

69000

431000

136000

600000

0.40

0.50

The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States by June 10, 2020.

-111000

It may sell shares of its common stock from time to time in an aggregate amount not to exceed $19 million per year per the 2015 ATM Agreement and not to exceed $75 million in total per the Shelf Filing.

112800

576096

1515154

0.10

865252

36696

0.85

200000

1 for 6.85

2014-07-14

114400

P4Y

1600

6.49

2015-03

The Company changed its revenue recognized from one and three of its payers, respectively, from a cash basis to an accrual basis based on the Company's consistent history of obtaining reimbursement from these three payers. The impact of this change in accounting estimate is to increase revenues by $79,000 and $127,000 and to reduce net loss per share by $0.01 for the three and six months ended June 30, 2015.

127000

2014-06-10

The milestone will be achieved if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States no later than six years after the closing date of the acquisition.

2500 2020-06-10 P6Y

1000000 250000 344000 387500 503000

467000

120000

-539000

-1464000

2552000

0.78

-1239000

2313000

0.10

-239000

239000

-539000

14000

250000

1000000

8663

48000

0.13

P5Y3M18D

189726

0.0174

1092966

5355280

0.4218

0.00

6939568

381434

1013128

0.87

877000

6776000

119000

-644000

66000

6710000

-345000

1800

366000

1000

59000

-623000

1800

892000

-1500000

-245000

1610000

7121000

792000

2403000

137000

2316000

15000

362000

200000

1600000

3600

8000

9000

99000

21000

82190

469163

541613

-518000

6776000

-0.51 1500000

-0.27

P5Y9M18D

0.0169

-0.01

11628

2204050

0.4004

0.00

11835405

2.10

-0.27

-3185000

7129000

-256000

85000

7044000

-2886000

-43000

16000

89000

-3185000

2526000

10015000

2510000

2508000

142000

411000

2329000

75000 0

254000

36000

54000

232000

89000

112800

576096

1515154

79000

500000 0001217234 cdna:LaboratoryCorpOfAmericaHoldingsMember 2014-10-01 2014-12-31 0001217234 us-gaap:ConvertibleSubordinatedDebtMember 2015-04-01 2015-06-30 0001217234 us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember 2015-04-01 2015-06-30 0001217234 us-gaap:ConvertiblePreferredStockMember 2015-04-01 2015-06-30 0001217234 cdna:PreferredStockWarrantMember 2015-04-01 2015-06-30 0001217234 us-gaap:StockOptionMember 2015-04-01 2015-06-30 0001217234 us-gaap:WarrantMember 2015-04-01 2015-06-30 0001217234 us-gaap:RestrictedStockUnitsRSUMember 2015-04-01 2015-06-30 0001217234 us-gaap:ResearchAndDevelopmentExpenseMember 2015-04-01 2015-06-30 0001217234 us-gaap:GeneralAndAdministrativeExpenseMember 2015-04-01 2015-06-30 0001217234 us-gaap:CostOfSalesMember 2015-04-01 2015-06-30 0001217234 us-gaap:SellingAndMarketingExpenseMember 2015-04-01 2015-06-30 0001217234 cdna:RoyaltyAgreementLiabilityMember 2015-04-01 2015-06-30 0001217234 2015-04-01 2015-06-30 0001217234 cdna:ImmumetrixIncMember 2014-04-01 2014-06-30 0001217234 us-gaap:ConvertibleSubordinatedDebtMember 2014-04-01 2014-06-30 0001217234 us-gaap:ConvertiblePreferredStockMember 2014-04-01 2014-06-30 0001217234 cdna:PreferredStockWarrantMember 2014-04-01 2014-06-30 0001217234 us-gaap:StockOptionMember 2014-04-01 2014-06-30 0001217234 us-gaap:WarrantMember 2014-04-01 2014-06-30 0001217234 us-gaap:RestrictedStockUnitsRSUMember 2014-04-01 2014-06-30 0001217234 us-gaap:ResearchAndDevelopmentExpenseMember 2014-04-01 2014-06-30 0001217234 us-gaap:GeneralAndAdministrativeExpenseMember 2014-04-01 2014-06-30 0001217234 us-gaap:CostOfSalesMember 2014-04-01 2014-06-30 0001217234 us-gaap:SellingAndMarketingExpenseMember 2014-04-01 2014-06-30 0001217234 cdna:LaboratoryCorpOfAmericaHoldingsMember 2014-04-01 2014-06-30 0001217234 us-gaap:ParentCompanyMembercdna:ImmumetrixIncMember 2014-04-01 2014-06-30 0001217234 cdna:RoyaltyAgreementLiabilityMember 2014-04-01 2014-06-30 0001217234 2014-04-01 2014-06-30 0001217234 2015-01-01 2015-03-31 0001217234 2012-01-01 2012-12-31 0001217234 us-gaap:MandatorilyRedeemablePreferredStockMember 2014-01-02 2014-12-31 0001217234 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2014-01-02 2014-12-31 0001217234 us-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMemberus-gaap:MinimumMember 2014-01-02 2014-12-31 0001217234 us-gaap:NewAccountingPronouncementEarlyAdoptionEffectMember 2014-01-02 2014-12-31 0001217234 us-gaap:ContingentConsiderationClassifiedAsEquityMember 2014-01-02 2014-12-31 0001217234 us-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMembercdna:MedicareMember 2014-01-02 2014-12-31 0001217234 2014-01-02 2014-12-31 0001217234 us-gaap:IPOMember 2014-07-01 2014-07-31 0001217234 2013-07-01 2013-07-31 0001217234 2013-06-01 2013-06-30 0001217234 cdna:LaboratoryCorpOfAmericaHoldingsMember 2012-04-01 2012-04-30 0001217234 us-gaap:MandatorilyRedeemablePreferredStockMember 2015-01-01 2015-06-30 0001217234 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2015-01-01 2015-06-30 0001217234 cdna:ImmumetrixIncMember 2015-01-01 2015-06-30 0001217234 us-gaap:ConvertibleSubordinatedDebtMember 2015-01-01 2015-06-30 0001217234 us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember 2015-01-01 2015-06-30 0001217234 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-06-30 0001217234 us-gaap:ConvertiblePreferredStockMember 2015-01-01 2015-06-30 0001217234 cdna:AmendmentMember 2015-01-01 2015-06-30 0001217234 cdna:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2015-01-01 2015-06-30 0001217234 cdna:TwoThousandAndFourteenEquityIncentivePlanMember 2015-01-01 2015-06-30 0001217234 us-gaap:SalesRevenueServicesNetMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:MinimumMember 2015-01-01 2015-06-30 0001217234 us-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMemberus-gaap:MinimumMember 2015-01-01 2015-06-30 0001217234 cdna:PreferredStockWarrantMember 2015-01-01 2015-06-30 0001217234 us-gaap:StockOptionMember 2015-01-01 2015-06-30 0001217234 us-gaap:WarrantMember 2015-01-01 2015-06-30 0001217234 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-06-30 0001217234 us-gaap:NewAccountingPronouncementEarlyAdoptionEffectMember 2015-01-01 2015-06-30 0001217234 cdna:AtMarketIssuanceSalesAgreementMember 2015-01-01 2015-06-30 0001217234 us-gaap:ContingentConsiderationClassifiedAsEquityMember 2015-01-01 2015-06-30 0001217234 cdna:ImmumetrixIncMembercdna:ContingentPaymentMember 2015-01-01 2015-06-30 0001217234 us-gaap:SalesRevenueServicesNetMemberus-gaap:CustomerConcentrationRiskMembercdna:MedicareMember 2015-01-01 2015-06-30 0001217234 us-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMembercdna:MedicareMember 2015-01-01 2015-06-30 0001217234 us-gaap:InterestExpenseMember 2015-01-01 2015-06-30 0001217234 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-06-30 0001217234 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-06-30 0001217234 us-gaap:CostOfSalesMember 2015-01-01 2015-06-30 0001217234 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-06-30 0001217234 cdna:LaboratoryCorpOfAmericaHoldingsMember 2015-01-01 2015-06-30 0001217234 cdna:RoyaltyAgreementLiabilityMember 2015-01-01 2015-06-30 0001217234 2015-01-01 2015-06-30 0001217234 cdna:ImmumetrixIncMember 2014-01-02 2014-06-30 0001217234 us-gaap:ConvertibleSubordinatedDebtMember 2014-01-02 2014-06-30 0001217234 us-gaap:ConvertiblePreferredStockMember 2014-01-02 2014-06-30 0001217234 us-gaap:SalesRevenueServicesNetMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:MinimumMember 2014-01-02 2014-06-30 0001217234 cdna:PreferredStockWarrantMember 2014-01-02 2014-06-30 0001217234 us-gaap:StockOptionMember 2014-01-02 2014-06-30 0001217234 us-gaap:WarrantMember 2014-01-02 2014-06-30 0001217234 us-gaap:RestrictedStockUnitsRSUMember 2014-01-02 2014-06-30 0001217234 us-gaap:SalesRevenueServicesNetMemberus-gaap:CustomerConcentrationRiskMembercdna:MedicareMember 2014-01-02 2014-06-30 0001217234 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-02 2014-06-30 0001217234 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-02 2014-06-30 0001217234 us-gaap:CostOfSalesMember 2014-01-02 2014-06-30 0001217234 us-gaap:SellingAndMarketingExpenseMember 2014-01-02 2014-06-30 0001217234 cdna:LaboratoryCorpOfAmericaHoldingsMember 2014-01-02 2014-06-30 0001217234 us-gaap:ParentCompanyMembercdna:ImmumetrixIncMember 2014-01-02 2014-06-30 0001217234 cdna:RoyaltyAgreementLiabilityMember 2014-01-02 2014-06-30 0001217234 2014-01-02 2014-06-30 0001217234 cdna:WarrantsToPurchaseCommonStockMember 2015-01-30 2015-01-30 0001217234 cdna:TrancheATermLoanFacilityMember 2015-01-30 2015-01-30 0001217234 2015-01-30 2015-01-30 0001217234 cdna:ImmumetrixIncMembercdna:ContingentPaymentMember 2014-12-31 2014-12-31 0001217234 cdna:ImmumetrixIncMembercdna:ContingentPaymentMemberus-gaap:SeriesGPreferredStockMember 2014-12-31 2014-12-31 0001217234 cdna:TwoThousandAndFourteenEquityIncentivePlanMember 2014-01-01 2014-01-01 0001217234 cdna:ImmumetrixIncMember 2015-06-30 2015-06-30 0001217234 cdna:ImmumetrixIncMembercdna:ContingentPaymentMember 2015-06-30 2015-06-30 0001217234 cdna:ImmumetrixIncMembercdna:ContingentPaymentMemberus-gaap:SeriesGPreferredStockMember 2015-06-30 2015-06-30 0001217234 cdna:LaboratoryCorpOfAmericaHoldingsMember 2014-09-18 2014-09-18 0001217234 us-gaap:IPOMember 2014-06-30 2014-06-30 0001217234 us-gaap:CommonStockMember 2014-07-22 2014-07-22 0001217234 us-gaap:ConvertibleSubordinatedDebtMember 2014-07-22 2014-07-22 0001217234 us-gaap:IPOMember 2014-07-22 2014-07-22 0001217234 cdna:AmendmentMember 2014-07-01 2014-07-01 0001217234 cdna:ImmumetrixIncMember 2014-06-10 2014-06-10 0001217234 cdna:ImmumetrixIncMemberus-gaap:SeriesGPreferredStockMember 2014-06-10 2014-06-10 0001217234 cdna:ImmumetrixIncMembercdna:ContingentPaymentMemberus-gaap:SeriesGPreferredStockMember 2014-06-10 2014-06-10 0001217234 cdna:ImmumetrixIncMemberus-gaap:EmployeeStockOptionMemberus-gaap:SeriesGPreferredStockMember 2014-06-10 2014-06-10 0001217234 us-gaap:IPOMember 2014-04-17 2014-04-17 0001217234 us-gaap:SubsequentEventMember 2015-08-10 2015-08-10 0001217234 2014-08-13 2014-08-13 0001217234 cdna:WarrantsToPurchaseCommonStockMember 2015-01-30 0001217234 us-gaap:CommonStockMember 2015-01-30 0001217234 cdna:TrancheBTermLoanFacilityMember 2015-01-30 0001217234 cdna:TrancheATermLoanFacilityMember 2015-01-30 0001217234 2015-01-30 0001217234 us-gaap:MandatorilyRedeemablePreferredStockMember 2014-12-31 0001217234 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2014-12-31 0001217234 us-gaap:UpFrontPaymentArrangementMember 2014-12-31 0001217234 us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001217234 us-gaap:RestrictedStockUnitsRSUMember 2014-12-31 0001217234 us-gaap:NewAccountingPronouncementEarlyAdoptionEffectMember 2014-12-31 0001217234 us-gaap:ContingentConsiderationClassifiedAsEquityMember 2014-12-31 0001217234 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001217234 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001217234 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001217234 2014-12-31 0001217234 us-gaap:MandatorilyRedeemablePreferredStockMember 2014-01-01 0001217234 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2014-01-01 0001217234 cdna:TwoThousandAndFourteenEquityIncentivePlanMember 2014-01-01 0001217234 us-gaap:ContingentConsiderationClassifiedAsEquityMember 2014-01-01 0001217234 2014-01-01 0001217234 us-gaap:MandatorilyRedeemablePreferredStockMember 2015-06-30 0001217234 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2015-06-30 0001217234 us-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0001217234 us-gaap:RestrictedStockUnitsRSUMember 2015-06-30 0001217234 cdna:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2015-06-30 0001217234 cdna:StockOptionsAndRestrictedStockUnitsAndRestrictedStockMembercdna:TwoThousandAndFourteenEquityIncentivePlanMember 2015-06-30 0001217234 cdna:TwoThousandAndFourteenEquityIncentivePlanMember 2015-06-30 0001217234 us-gaap:NewAccountingPronouncementEarlyAdoptionEffectMember 2015-06-30 0001217234 us-gaap:ContingentConsiderationClassifiedAsEquityMember 2015-06-30 0001217234 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0001217234 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0001217234 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0001217234 cdna:TrancheBTermLoanFacilityMember 2015-06-30 0001217234 2015-06-30 0001217234 2015-03-31 0001217234 cdna:RoyaltyAgreementLiabilityMembercdna:ScenarioOneMember 2014-09-30 0001217234 2014-06-30 0001217234 2015-07-29 0001217234 us-gaap:IPOMember 2014-07-22 0001217234 cdna:ImmumetrixIncMember 2014-06-10 0001217234 cdna:DiaxonhitMember 2013-06-30 0001217234 cdna:IlluminaIncMember 2014-04-17 0001217234 us-gaap:MaximumMemberus-gaap:SubsequentEventMember 2015-08-10 0001217234 us-gaap:IPOMember 2014-07-31 iso4217:USD iso4217:EUR iso4217:USD shares shares pure cdna:CommercialTests cdna:Segment

EX-101.SCH 6 cdna-20150630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Organization link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Net (Loss) Income Per Share link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Accrued and Other Liabilities link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Collaboration and Licensing Agreements link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Stock Incentive Plans link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Business Combination link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Subsequent Event link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Organization (Policies) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Net (Loss) Income Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Accrued and Other Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Stock Incentive Plans (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Business Combination (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Organization - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Summary of Significant Accounting Policies - Additional Information - Concentration of Credit Risk (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Net (Loss) Income Per Share - Computation of Basic and Diluted Net (Loss) Income Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Net (Loss) Income Per Share - Potentially Dilutive Securities Excluded from Diluted Net (Loss) Income Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Fair Value Measurements - Summary of Issuances, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Inventories - Summary of Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Accrued and Other Liabilities - Components of Accrued and Other Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Collaboration and Licensing Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Stock Incentive Plans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Stock Incentive Plans - Summary of Option Activity and Related Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Stock Incentive Plans - Summary of Options Outstanding and Exercisable Vested or Expected to Vest (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Stock Incentive Plans - Weighted-Average Assumptions Used to Fair Value of Share-Based Awards (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Stock Incentive Plans - Summary of Unvested RSU Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Stock Incentive Plans - Schedule of Shares Issued and Associated Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Stock Incentive Plans - Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Business Combination - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Business Combination - Schedule of Pro Forma Results of Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Subsequent Event - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 cdna-20150630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 cdna-20150630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 cdna-20150630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting for Certain Loans and Debt Securities Acquired in Transfer Disclosure [Text Block] Debt Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued and Other Liabilities Accounts Payable, Current Accounts payable Accounts Receivable [Member] Accounts Receivable [Member] Accounts Receivable, Net Accounts receivable Accrual for environmental loss contingencies maximum payment period. Accrual For Environmental Loss Contingencies Maximum Payment Period Maximum number of days from end of calendar quarter for royalty payment Accrued Clinical And Cost Of Other Studies Current Accrued Clinical And Cost Of Other Studies Current Clinical Studies Accrued Liabilities and Other Liabilities Accrued and other liabilities Total accrued and other liabilities Accrued Over payments And Refunds Accrued Over payments And Refunds Accrued overpayments and refunds Accrued Professional Fees, Current Professional fees Accrued Royalties, Current Accrued royalties Accrued Royalties Past due royalties Accrued Sample Processing Fees Accrued Sample Processing Fees Test sample processing fees Additional Cash and Cash Equivalent Related Text Cash equivalents maturity, description Additional Paid in Capital Additional paid-in capital Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Allocated Share-based Compensation Expense Share based compensation, Total expensed Amendment Flag Amendment Flag Amendment [Member] Amendment [Member] Amendment [Member] Amortization of Deferred Leasing Fees Amortization of upfront license fee The amount of amortization of deferred revenue during the period. Amortization Of Deferred Revenue Amortization of deferred revenue Amortization of Financing Costs and Discounts Amortization of debt discount and non-cash interest expense Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Assets Total assets Assets [Abstract] Assets Assets, Current Total current assets Assets, Current [Abstract] Current assets: Assets, Fair Value Disclosure Money market funds Assets, Fair Value Disclosure [Abstract] Assets At Market Issuance Sales Agreement [Member] At Market Issuance Sales Agreement [Member] At Market Issuance Sales Agreement [Member] Award Type [Axis] Award Type [Axis] Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition Cash Consideration Business Acquisition Cash Consideration Business acquisition purchase price, cash Business Acquisition Cost of Acquired Entity Transaction Costs Expensed During Period Business Acquisition Cost of Acquired Entity Transaction Costs Expensed During Period Acquisition-related costs Business Acquisition, Date of Acquisition Agreement Acquisition date Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Contingent obligation to issue common stock Shares issued, shares issuable upon achievement of future milestone, and options assumed Business Acquisition [Line Items] Business Acquisition [Line Items] Business acquisition pro forma earnings per share basic and diluted. Business Acquisition Pro Forma Earnings Per Share Basic And Diluted Net loss per common share - basic and diluted Business Acquisition, Pro Forma Information [Table Text Block] Schedule of Pro Forma Results of Operations Business Acquisitions Pro Forma Adjustment Increase (Decrease) in Income Tax Expense (Benefit) Business Acquisitions Pro Forma Adjustment Increase (Decrease) in Income Tax Expense (Benefit) Business combination pro forma removal (addition) in income tax benefit Business Acquisition, Pro Forma Net Income (Loss) Net loss Business Acquisition, Pro Forma Revenue Net revenue Business Combination, Consideration Transferred Estimated purchase price Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Estimated fair value Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Change in estimated fair value of contingent consideration Revaluation of contingent consideration to estimated fair value Business Combination, Contingent Consideration Arrangements, Description Milestone description Business Combination, Contingent Consideration, Liability, Noncurrent Contingent consideration Business Combination Disclosure [Text Block] Business Combination Business Combination Increase Decrease To Reflect Liabilities Acquired At Fair Value [Abstract] Business Combination Increase Decrease To Reflect Liabilities Acquired At Fair Value [Abstract] Business Combination Increase Decrease To Reflect Liabilities Acquired At Fair Value [Abstract] Business Combinations [Abstract] Business Combinations [Abstract] Business Combinations Policy [Policy Text Block] Business Combinations Capital Lease Obligations, Current Capital leases - current portion Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net increase in cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cash Equivalents Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate, Financial Effect Impact of change in accounting estimate Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Change in Accounting Method Accounted for as Change in Estimate [Member] Change in Accounting Method Accounted for as Change in Estimate [Member] Change In Control For Repayment Change In Control For Repayment Change in control for repayment Class of Stock [Domain] Class of Stock [Domain] Class of Warrant or Right, Exercise Price of Warrants or Rights Warrant to purchase of common stock, per share Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrant to purchase of common stock, shares Collaborative agreement contract value. Collaborative Agreement Contract Value Consideration of arrangement of license Collaborative Arrangement Disclosure [Text Block] Collaboration and Licensing Agreements Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Commitments and Contingencies Commitments and contingencies (Note 7) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, Capital Shares Reserved for Future Issuance Shares reserved for issuance of common stock Common Stock [Member] Common Stock [Member] Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock value Common stock: $0.001 par value; 100,133,900 and 100,000,000 shares authorized at June 30, 2015 and December 31, 2014, respectively; 11,838,794 and 11,803,970 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively Compensation Related Costs, Policy [Policy Text Block] Stock-based Compensation Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Credit Risk and Other Risks and Uncertainties Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration Risk, Percentage Concentration risk, percentage Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Classified as Equity, Fair Value Disclosure Contingent consideration Contingent Consideration Classified as Equity [Member] Significant Unobservable Inputs (Level 3), Contingent Consideration Liability [Member] Contingent Consideration Milestone Measurement Period One Contingent Consideration Milestone Measurement Period One Milestone measurement period Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Contingent Payment [Member] Contingent Payment [Member] Contingent consideration [Member] Contractual Obligation Maturity Date Contractual Obligation Maturity Date Contingent consideration maturity date Convertible Preferred Stock [Member] Convertible preferred stock [Member] Convertible Subordinated Debt Subordinated convertible promissory note issued Convertible Subordinated Debt [Member] Convertible Subordinated Debt [Member] Cost of Sales [Member] Cost of testing [Member] Cost of Sales, Policy [Policy Text Block] Cost of Testing Cost of Services Cost of testing Costs and Expenses [Abstract] Operating expenses: Credit Concentration Risk [Member] Credit Concentration Risk [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Customer Concentration Risk [Member] Customer Concentration Risk [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument, Basis Spread on Variable Rate Interest rate basis spread Debt Instrument, Date of First Required Payment Principal pay-down of loan begins date Debt Instrument, Description Loan agreement description Debt Instrument, Description of Variable Rate Basis Interest rate, description Debt Instrument Fair Value Carrying Value [Abstract] Debt Instrument Fair Value Carrying Value [Abstract] Debt Instrument Fair Value Carrying Value [Abstract] Debt Instrument, Fee Amount Non-refundable commitment fee Debt Instrument, Frequency of Periodic Payment Deferred principal amortization description Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Maturity Date Maturity date of term loan facility Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Issuance And Discount Component Of Recognized Debt Liability Current Debt Issuance And Discount Component Of Recognized Debt Liability Current Debt discount and issuance liability component, current Debt Issuance And Discount Component Of Recognized Debt Liability Non Current Debt Issuance And Discount Component Of Recognized Debt Liability Non Current Debt discount and issuance liability component, non-current Debt Instrument, Debt Default, Description of Violation or Event of Default Default interest rate description Deferred Rent Credit, Current Deferred rent - current portion Deferred Rent Credit, Noncurrent Deferred rent, net of current portion Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue [Domain] Deferred Revenue [Domain] Deferred Revenue, Current Deferred revenue Previously unrecognized license fee Deferred Revenue, Noncurrent Deferred revenue, net of current portion Depreciation, Depletion and Amortization Depreciation and amortization Derivative, Fair Value, Net Fair value of derivative Derivative Financial Instruments, Liabilities [Member] Significant Unobservable Inputs (Level 3), Derivative Liability Related to Subordinated Convertible Note [Member] Derivative, Gain (Loss) on Derivative, Net Gain on derivative Description Of Agreement Expected Expiration Year Description Of Agreement Expected Expiration Year Description of agreement expire term Diaxonhit [Member] Diaxonhit [Member] Diaxonhit (DHT) [Member] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Incentive Plans Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of Shares Issued and Associated Expense Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Net (loss) income per share Net (loss) income per share (Note 3): Earnings Per Share, Basic Net (loss) income per common share - basic Basic Loss Per Share Earnings Per Share, Basic and Diluted Impact on loss per share, change in accounting estimate Earnings Per Share, Diluted Diluted Net (loss) income per common share - diluted Earnings Per Share [Text Block] Net (Loss) Income Per Share Embedded Derivative, Fair Value of Embedded Derivative, Net Estimated fair value of embedded derivative liabilities Embedded Derivative, Gain on Embedded Derivative Gain on remeasurement of embedded derivative Employee-related Liabilities, Current Accrued payroll liabilities Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Total unrecognized stock-based compensation expense related to stock options and RSUs Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition RSUs granted remaining vesting period Employee Stock Option [Member] Stock Options [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity Component [Domain] Equity Component [Domain] Estimated fair value of warrants. Estimated Fair Value Of Warrants Estimated fair value of warrants Fair Value Adjustment of Warrants (Gain) loss in estimated fair value Revaluation of warrants to estimated fair value Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Significant Unobservable Inputs (Level 3) [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value Assumptions, Exercise Price Underlying common stock price Fair Value Assumptions, Expected Dividend Rate Dividend yield Fair Value Assumptions, Expected Term Contractual term of years Fair Value Assumptions, Expected Volatility Rate Expected volatility rate Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Liability Class [Axis] Liability Class [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value by Shareholders' Equity Class [Domain] Fair Value by Shareholders' Equity Class [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Fair Value Input Probability Of Achievement Fair Value Input Probability Of Achievement Probability of the achievement Fair Value, Inputs, Level 1 [Member] Fair Value Measured Using - (Level 1) [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Measured Using - (Level 2) [Member] Fair Value, Inputs, Level 3 [Member] Fair Value Measured Using - (Level 3) [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of Issuances, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Measurements Inter Transfers Between Levels Fair Value Measurements Inter Transfers Between Levels Transfers between Level 1, Level 2 and Level 3 categories during the periods Fair Value, Measurements, Recurring [Member] Recurring [Member] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Instruments Classified in Shareholders' Equity, Period Increase (Decrease) Reclassification to stockholders' equity Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Issuance of financial instruments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Change in estimated fair value Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Ending Balance Beginning Balance EX-101.PRE 10 cdna-20150630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R39.htm IDEA: XBRL DOCUMENT

Stock Incentive Plans - Summary of Option Activity and Related Information (Detail) - 6 months ended Jun. 30, 2015 - $ / shares	Total
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares, Beginning Balance	1,031,804
Number of Shares, Granted	525,078
Number of Shares, Exercised	(17,884)
Number of Shares, Forfeited	(23,844)
Number of Shares, Ending Balance	1,515,154
Weighted-average Exercise Price, Beginning Balance	$ 7.36
Weighted-average Exercise Price, Granted	7.74
Weighted-average Exercise Price, Exercised	2.35
Weighted-average Exercise Price, Forfeited	9.06
Weighted-average Exercise Price, Ending Balance	$ 7.03

ZIP 12 0001193125-15-287911-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-15-287911-xbrl.zip M4$L#!!0````(`$YW#$_/-R-!]_C+$\FZ;L3'T[LX+?YK\"W*X]%@D@[^="\_#N@I&0QNB^+^_.SLQX\?IUDV MFG_,Z7!R=S9`:/X5OU=O=SX8R%-*3_G2I>VZOC9^X?)^G?+7V+^^T?5N[_P;&?CR7# M2R]4/-['>>,;E5<:7LF^QJA8?:L9>'%675RY-6F\55:W)O-;\^(^:T9JK]C7 M(#6H(-5%]MC\S.RB?8S5'IMF&>CNIN=F5QNHC1^&M\T/V2L-/*51,LR;GR@O M-6!*TN]Q7C0_4UUK0)0GPPW$)<.&[TCC&]#YT499-V?99!R?S6Y;/#6]:WYB M5&1G5E+.X(XX2X:+!\`LO/S,)$6UYZ9%]LRKP=43,""#06E"QN=YJ6B7\?6@ MU.=S^ZGO3O+D[GYLM:[\6Y0-+:)VEJ-\XC:+K]^=6%U":!X[J(29`L;B1#CG()"GW/$XXG MA?38%;??+D_>XU_.VF.J.+#$GW^YC[23I3(O;29;\ M;_E7Y\YJ^I9<"*P)KKB0A!/+!5-2VM\-P[S\76+Q,C(.U0@)["_\D`I M-V#2Q\R./KFB)^^9MN._C'<5QI%`OF@`VH*D%J3`#+\,LA1_=YHG:9SGSO`? MTR1/K*A[47X+8I`GH[C2B*V%68;@,+RB5P(P$JT5Q^:7LW8`5D<[N/L6CT;6L#5,D.L7 M=YG\2]T_V&1/K:ZSD_>4F15=WQY8S>2!ECCIR/X3@.I\!]%)B]PIO"C+'H'& M7>Q@:RX06S7D,1H729Q[9616`'V?)FD5IFT/W5"2"TY9W3A M]%%-P2PO<=,&:VU^L`:E-)];FT)FPX!7SP">$P;&<20"4VB]7,\@1Q,?^5[H M4QS`)V+/R@*Q9D&<"KDT`2S>O0&3:_-?-H,4IWGEZV99E-Z4/K#[^'3+Y^BQ M=(M_1-GHXM[>N&Q>/TW!MF1;4U/7C):380`.LI$V^E=`!642QIX"'X8$.@Q" M\)Z=RL>U$X6P__$:&_M$O=%IK":A>2`1CSJB)\".'P)#2!+J(*Y]%T$TP9$? M:JD95S)@WA6(B;*>`KBI=@II]!;K[W\PZ?DCMEG+>.1`\!'=Q,%#G`V3?$=U M>\;:;E`WND:AEE1)#I;6]R4%=PN'U@<%9R3TB`MTA9X?+"1,G6)V$/%ZCI;5 ML?B7TE2O/#N+VA7?U&:TDF%B-/P9[2K#=+/47:1E8F) M43F-[QB;[*(:KR'`YJ(@$"&-Z#=A>EFN>VM/R\BKGE%Y'L'+:#_D^;1W2-F+ M"ER]]@NZVTMLNI7:-N%;Y>&-*BU94]IVL/;F+>\'KBO!528B1([K^^`M:XT< MCX0(O$;E<69"KDB5%<0G[^4IUX?WEG^/PH]?)_9/QW*B_3#@ MS/<)/$!F[P"1?% M;9PM_6F?$O="=J*E4A'K:6N^.C&TPK(*O[RZ_IRW4VS^&MP^5Q13!7$W-8!; MD0`9)C$27."`:H49#0$W.`"2RQ74ST.H)^GNQY/'.+Z,Q];<'!5QVY$&R!0+ M4LO)O8"C9F>LF;V=C$=QEMND5?'8/YSUL?/U&._PYFUS'N=T$%8W# MN,>&"%N?CC69WPT0:G!'HW()*1I_CI+1A]2+[I,B&O=O2#FVYH<((U:Q-K]_ M/>]=>7F7`-^#?Y.BM\/)[;I'/=F]X>U70<[7!<%I^6:7MNVZ(*`#=\,^M[PZ M.->"QUZKL#AY;^2J8+\*XDLBT6LR;/PM!']!+C:!73;OO?4OJ%5PIO'&B:E1 MZI](^!ZGT[BWZ(B9;TEI&L#E=U^;CNSVG!SBC.C;N,?X1+E*MS81-;S\*L#% M`MZO<91/LS+`^B,I;G]+)]_L/E_[X(?T'H*GRQA0#T&K2PVWO\+G@>Y#');D M"X7?917W-?QX`7:%)[W9.J9G&'*58Y"F2@=`F1,X@=W(P:_4ND$["/A5?B_C M(@*C.0JB+(7[ME+#6[U^?(F8(\ M4"[,JD1L#)!7@^DW$4@QB)$)DW(3P$8T`%<\3X9=FQJ7<\HQ M9XA2%4#L`5IH0D?`KYJ$@2$N-WBQSD5);;WB:`S5YJ-27WJHV[3)?:W>=A4! MH`/*[,&2F>['1?`P'$\M!7^=3$8_DG$/$ZHPNTHI5G6S#9(Z=O!LBTGVN/WF MX2Y"D)/WBI$:Q*<7KD?*.4BI%>3FK=7]@T=L\I^K6HS\/(JZJS2YC[/B\?,X M*K<(VQOOK:+W`D^@HY+BN"RZ"X[+`5Q[S1;5X MQ3AKUL_-.)KFC]Y&,?+DO4UBB899I-'S[>^$8:H4P"J2YED!HIG[*"D=@S2/ MYYL_>CY2-F)1O&9<7L1Q^#-&7202[)8';7@M7MOZ@-%">2^C'[^"WYUH^HN=K!`78Q"AFS)[:P M1(9(CB0V1@>>HL3UKX05-Z+,$V>;7GQ=G2Z^Q]F,-)M`AK>;IJ,>*I1=F)\E M_5]^_3VJ5!5\]W^#+4B`4%(3L2>MV8#[D,R^)2-5*IS`^[-2;=GH8K;HJ8B# M"8!?&#.'GAC61'UF;+PQA$K#:%PNM,$3UZ67^J68COJ\@]JF)+59LYQMP!Q, MV'IW6)-SQ82@"FGM`9>,.?/CP,;7QH/)E>J%%.I3>ACGY.7#FN67VDU:]O"0 MK5('P^9FUL&\P2>$+K/L\3];;>Q?;5@XLH^ONB])^Z/E:(9>&#'%C%!A4 MD%CA!=275#%P;:YX94V77+[7`MP'5Y\F:5_IHN4BPQ[H>L)8WPT"'YCF15;6 MMX0@9<>"74^UB[`A#P10,L4.1@RH)[.9KMHAF0U@-NY"6.P5LSR.)W:[V.[` M(?+'#]6_JBQG)*6$WSF1;:JX-1A]J8VF6&BD7+!6/`A8AV#)9M69KPVR[?4KQZ=G:BJ0M*RW"VG>C?6VIZE(!V?I3AB=&MYU1"? M6%X%E7RG9+U4*@B-A["'!>)2,F0(_.38U()F`1?.K+P:_@D#WFX9)(>.@9>V MW<\VU%956^9=$<))%DX+D/_YM^[.FBTH8NL8,L+9UOE3*4+A>T2A0-,`<14X MR'4#B00QVJ'4$!K0A=!IIJ41C6<+VH' M?84`+E-I)QBJA'@@1AE`OGTE64>H4%&!-*84<6&S#MRG]O^88*[1Q*>+_;>< M`(J;2/ M/"\(['J,1!JL,G(%MBY'*.5R84QBJS_L80BV):?S,:FEYDO!\*/BJ2[NWH=K MEV4,Y=#MV+''82U787=/`W MFB7JDJ$WEGKMDIJ?)V+E''-KXFQG@\.>_F-:16BFR'C=4]DK#N,GWS M'6T="]N!$RQ+-+XJP4)]#Z)]'B*I&%`HA(-TZ$I$0#]=[7`"@KA(L#"AL-I? M@J5?XMC1-%ZN,WI>=M-PXYM.#UHW'(H5%6 MC4/`4*GGM*O#QB&[J,9K".A;XY!##WA_&H<<&NDQ&X<<&IMNI;:=-0[I6FGW MTSCD$!T>GF5B'V?#:=7A09*U@A1'[?#P&MRMSB?1LG!#+%NN[PT`%.V^$!OL:L9N4ZZ?#0`3K;X0%$>;7J4:<-'KH`V9,&#QW8(5L6 M71V[P4,76EDV>,!2KDINIPT>.AA.V^`!KQ;&[&&#ARY4V&Y"P+6"._WL\-`% M&[1A[NVRPT,7&$'#A9&;9Z;#=7CHPGLJ.SR(#0-XX`X/7>!;[*M[@QT>7L-/ MJQ4+-M]65;=H;['%0Q>S?=GB01BF5C6FNQ8/71@\&SH;S8_3XJ&+42Q;/,`W M;0+888N'+L;3MGA0Y#D3?Z`6#QV`.V*+AQ?0[:'%`SU(BXQ+%@,55LH[[C'0QU[\+K`HQ:UB!V5-6^"Q'M4U7[#O"604*MSU&W M5>V[F`K+7DZJ/M%W7]7^59F`-A6E9QE[U:R?752U[V`XRZKVC#?U1MEG5?L. MD!RUJGT'^(1=#:0UX]*#JO9=Q$ZVJCVO]7_I0U7[#FP0L0IJFFU0MU7M.XA# M;%5[HI^*;K2K:K^G*NJM\>U815V6&^&72HIT7$2]@_&S:U]ZM:J67+@)^F`M'AV2K;#^R!K4W5AO9:ZV!& MQT$JA8*6A51P#U%)P92Z1B.WK-""J>-QF#"Q<-]0_=E^4,4;UC/[5P6A'UP= MOT!F`P][*Q3:EH>J`"VE;Z.T2#\8ZWN=S'ZPU$?]VE^]T+8\O)$"M/V@ZNTI MUC%8*K,D2IF&5-Z;*.>SQ&(W92D61>8ZW.IUQ%BOR_JI9>[\9PO_NB60'#@B M[&N=R2>R.Z@SV5"9YO]+3.YOI%X^S=F0,&E38O(XXW;,^I)+9'?F4_`W&@1V MR=!;2ZUTR:Y=K@L)088Y'G(\QI1+ MC.%&+*IT2?+LWN*^GZ[HKA076T_D_K.4XEJG^K"EN-@LJ=#]N[4+1M!;JK4(A9QHVWD8G-,&O.LG40%RIUD5W:<&.E,-J3OLVNYF1G MICCCHEP$H%)LD)DM2O"80`2>+3O.0U\B+NQV)A9@1`S1G)/0^"%9+`#(4[-4 M5&XGV"V86[3=L+-5=<8F&H_CD?M8_[2]<[AOSNS&*,XU>X&T]H@W.$3@G$_O MYIVC7],SNT:0IO"'UPM9JYF+S98,U"F6#;[.)HC+O0U(# M65A($_K!;`^7F9OR;>$MD>+=VFS3A[+61389AY/L,KZOMOXT;2?[[`?<_$,XE2`#38?/-F4L`4B0# M+V;&Q>:^!+34LKFA2(6DQN/]Z[>J28H/41+UH$Q[!`09BX]FUZ^KJ^O1 M7659N5U@J!),%XOPKCT:*>9(5=215+K2KDA!^P8JVC.9F.._%G["TKL4WC1@ M()JD>2JYFYBYKO%@0*T4TJXY\G)DU((]`"2#L8PFEH;5-BV.0R6GF2+LLH[EFJ!$FM:O.Z*`C^21P[1;5>S#6M9)!646(`,1&@U MQ^^N9+:`E#&:O4#5'[1^/YID<_P#?62W=O`@%-"(XD;M_HA&8`'.BJ^J&VF- MLY/Y.9[:0B:+O?%>;J+G0$?%BE-*4VSL0N8.PK24P^AXP;]3S/51 M.C/WADR6))&%6#%%44^>-H0+,T<20=.TCC)V*\6=T&-NS=.#=V1^8P#JF'JS MVRK5C>J!L-\A48).Z#'M6KOX517`8!6[KO$=X3NZ:W-9S+UWUV9VWN1*4'9U M;>)1>B\>8XH!FWZA0<2RMN2+X\X$&T3/HY.*AOXS7585<2__F"`)CN%8/!'E M$2^[*FX=%@`&3=1EQ31UAZA+A:\IN#?2-!1#M2PU>V0?S"J875TP;"=;LXKT MZ_+`;$#](`^,[6B"K;@CWE85EY.L.&U8KNE(+\=:-P`HB!6`8Z,(8 MH!?0(BZ51!MHSS"?(QMLUW`&,H2TKE_,Y@W/KE`9]>%Y7^Q-X& M4'L7>](!8J]]TQK;R/IY'E,/S-=_>+&/$'[R4KJKTW-U7V:7&=QISUEV9O@* MBXZLVWNWGHRF=CM?NKRPA?V(/-T>S&*I(Z09"&M2TF5CTYQB`LI_1`',*;8_ M#P#:&X%U.YR:PR[OMYNI%-N24=W_U9VR[8A\\I,_W9C20I@,'@\V^P5"],UX MM-'5G3]L_PO(W7!R$C1696%W-#*IT+:O?PM5W;'`PB['PF!O.L$(^ZC\WHU, M['"CCE]>B**HZ6C[P2+=R4[2A8KWXL`:S"/XGR)K+J_I)JALCHPUF%V1-P3- M,55%,%U#^D-FM6AXX4H6*W7\VNEHA"EHBHD1827$T9Y83W\'[>TZO)DS/2*\ M-\]5NJ/F]4-=,L3G.SA%Y0;YW,BL*G*:Q M?[=(41VYC:IN1URS]W*QKN.\;GX)'8\9JR.'-[-#C.J(-TQ=Y&U3U`1-DU51 M,`%*HW9>ZD#BCF2%]K""K\-R^YK=D24S)RS1CF%X[K?2FS#_)R@J_2\5_W:6 M/IY.,-"'W8!!3-G(-:7LKN=S#F1/1P*9*!"='SDJIHF`A<*21@JO6XIKJ(I) M-%$'6-6+7S6=B*I261^.0NB!D[I>(&-HDUH_;%+7B>MQ4A]LJ/0^K9E=(A-= M[FE:=S%H>OG@GKI_5\!7]<&.@$M-5;]WZNM@-S)@%.[67`?-9D[%&=C+S%_5 MBSHJTZPTIT!$3:WLU-^1HCT$XRK^Y>@,3N'1=I>-&^GKQ#XK**,;:SPPYB'= MF:>=GLWFZ+%([M,8U;<:HRV$%GOK;B,6QHOIVI(H@S0[63G?>GJ7[A2M=[I6 MJ^6R*@:LW-91#:'C8X$E-G2Q6="G.U$K/@J0+]&,OHN2T]+;E=]!O>;E!KVU M7C?'EV5W&20MZ#L7F[L^BPXW`R.Q_\5#\^$WSP^1S)NPO+934:)=Z5N5SIWV M^61YJDC],-A6,E:JI#'+,1OP)@BUMPE1KT:S#H*MHCC(N1(LQ(B MK*Q*=N?(OM$C"2'>F!0>1L%E2+75]PU_>_E9,+I.%G%[#I&*R=O/XBP]'$/?`W%\N"* M5I=4+7UOL:O`HK!I]N]U6-0\&JAJ1"3<(-@0QQMH:)5"_U?75)+IM"HK+ MNX8N\;*L*+"^:C)O$N*:KFP1P[:S2G@2$5LD3[N\81DT/T1A5!_HW7?/GHY/ M)5Q2&UL\-Y.QC657JR(.DG-1E\"*1IMY=Y68IN[+D@^G>=BCEN[PE/SL.KIE M$T'BK9$(5.LBT.\XA">:(ZI$40Q-=C)^)@U5>'W_&Y36JG:=DK9.5<98^(^0 MAI%6ZW/#$3&[HY,))HVNZLLWX>KU(;(OFJ2D7G*U.T$K,SA?C+(@R6K`V*+3 M**;9<[?>5XRJI+$7Q1,_].*GZY3.6!GI[&A!P.1%II(/4N+)*/$,L5G?M#<0 MF@+#G]TMXH2Y"8>[\#'WCUB7%*L=W^#8,+]X?E`$D9;)A/+3R+WL0=G"'AT= MP=(VWT<7PK8MD?4"IEGB[2%*&9PK(E&:]G87(UA"P_H0P^@*9$3Y\>TR[^%4V]&:)W6VD=(E&#I%<3%RNU]6^]LZOVR4X M^=OY&&QK:1612G_K^]NF+X#N;[SD5T3[9FH0NE M/K!;J6@P,64+MQE.WGOQGQ0MGP&;;AHF=-`;#J.U%&P:7A=4F'"<)SU(*E56 M!LG8>#9?-C:,\WIRMJW+61WQK(YMI=K#$%'`H*38M'Y"U!H78Z'0#''V$S1W)7&=A['H>J?MT=>LSLO+W!XM,S>.T-37 M#R"S$V1+&?/R()/8B6.%=(&L(YG]I!`XV5Q247$@]9FT0\Z`K,QY$9\9(H%@ MTLB*6M>-ZKWNP%WF"#GBKS(&\+>S8HZ1HV^^@]#39FQK8;B=)VPJN4;",\ M"](`0D.F')8%321;"&]2TMQ?-H^A*TP`P-\!9(,X-N^:`!R1 M7=E4C"S!&!:-U.IQ[#H9?889*HGI),R)C80DZ*.VF&0@-Z"2?/R?-E^\F>916]O M+R#+P";((F;A(K*A_<%2-0LB*RDLR6+^6V)`Z4)5TG:JOV`ICNJ"P@R2U>%E M!2NHZ9K#.ZIA.(INP547)Y*8U5^0C:IK=3VU`\K.P+(O"CHK-*=I8C7[XA&S M-3#I6Z^_W$.JA@$!JT6PQT9./<>1&\%/6ZTZHSA=V!.=!? M?$I(A+93]AUHV^S8*AYN3;;!MO4==(J@&T"=DXETA`J/G8E7HKK>>=61[,W8 M+9$NM_JV'A"]=V M$E?5@@$K5(.(%AS;M'C!LI%Y3`U4!-GE746P1?\(=:9G]M5+&?F#97[=CG''$2 M2_^J_MZ(I9P@]6L]$[U-DW'LSS/=J)J)GJ6H/QHFG;+'L\,N=NP]>&$ M8W];'/7&#]P=]6*N*'[(>?`?-_'\X(F;!A'C(B[&)(#TKX47<&G$B5>"\/TE M-P]`[*4/E./N07S"VUPTY7[T?^*D*U'YGHMB^`&_\(EY[,]HULHN/K(QM91:OZ_=6%;%8U*[#*?[#"F0`G5:P8]+1 MC1P&ZXYN.Y+%CU2,X0H6X2U8W'G1!0O6<6P!#]TPFGX(TK<3_\L/]^E;Z#G^ MFG-)^A307R[>FY]^N_[`6S>WMS?OWW#"/'W+N3<$UWU^_ M^_T-=PL\DW`?Z"/W*9IYX5LN;^+VYN,;3IVG%_EG;H&)IE$01(_(JBPE'S`< M3=C`S^.(8]!P<&41P!5@TJB4]#`7H(E[,'`2CDZG,+.1PY$OK]__DTLKQ2J] MA/.G[$[UZH,'C$QI"(T`W"`D9N@/Y^#.W[QPX<5//WBS^=OOOIK"6W+)`OP(O06$Q\?7?80FFCOXX/WA;*/(%ES#],2P0OPO1G\R,ZESQ?Q/$IH`FU$ M(,XMB>@FM9!*D&,=IMA$=1)%?,CTWB6``D=J8 M3@,VBO"2#P#!G]$4&O'")[@7Q?=>6.RPPFX5,PX'WQ_[%%J&AK)NXN4I&+EL M;)%ZQE_(`(]1AGZ(#__(>A\M$@`]N>3HUS&=IT@ZQQ0A>'OBI=Y/;W`Z_#S? M9VZ(>*'*_4+)_25_K;2?387\&SO.->OFD^U\XD:^OT%YP7^??C+!3JJ:'S!X?85&N-3 MU6[&U1^3XGU5^YX]Q&?_:\O`KP.$V"[;`,I=`^X1""&OAN-',=UU\R)-)I7[\SWE*2Y MW'[GN+?P`IV]Y6Z=?][RUQ]LYP-%2\1E,2!=G_K`58=X/X_U/)PF7_XPQ MU2][3;W4-+73JV'T&'OS7RZR?YN]//9$.1Z%1+P$2[M?$CNPDA@.HB09M@S^42'Z MOO+IIP%+WA_%2U'OA[*SP!V:X#CC]IP"=]B:,(I@YD89L^1JF3>%X[D[5B<" M/5R3+/0S<#DM7"GD=0KJ*W%O(^`LIU^4O#GC=@PY_3/SR%8OY,&2C5ME-L5X MGJWTY)HHV1$K,4E]E)Y>LDB MII.;\!.2&N>EEI*_A]%=0F.6IYJ5A,?TSN$8WNHI2(B!9DTU"6]ILL[+DHC; M&$23U^T1,31'Q@,:IPX2"AV#A"Q6E&>T3"ZY,3N,FV!4:@J0HU198!@'58Z8 MC@,O2?PI"Z-A="Z/;(U8/*@(]P%0QMN$>X?GZCBIC%E!*_XRM)V'P5"KF>7# MB+&T\IL81L3`93ZP3//!$%\MXO3-!98,\;#`DJ+N'EC2GR^N=/[TMQI,ZSLH M1.2-4:%<>+&/GS*$\]IAWQR+*S.$L4MEI*V6,*QQ;YD_[+B#-7"HBGS%93?2 MJ`',QT4,JWE"5[$LDF-ZRQMV3>%;IE_I.Q(C<\JZ.092K@5_*L9 M2]:/`8<93+XI<&\C,&-.+EG)BM/D@95OA>5VO494/E(2)[^$QU^[C]3R`C18 M<&,BV"`V'5/<15K9@Y%O.-S+;;)OD+[-U]?-O]AX<=7?6-HDN+/DJ#T\TI:$ M4WE>%5%Y292>>>(U\,3KBO$7!4Q0=%9W%"]],R>5FKMK,ZL,(%Y*N:Q_(D\7UJ1.[PG%]2*=A8C=SA6=?" MF_JI__B@O1U0\UW.O<7B><8]9+[NFR/QK[I-N@;V/35-[?W!WMCCC M=\;OC-]+P>^UF\(=XR[RBS.*R:6@O2A3\:PRGR%[&5;&":;6Z[+67YV_D3S3 M&:"S=#A#-C#(!CVASGZ!H=H59_S.^)WQ>[GX?5M^@=9\6,K)%=<]=Y,9ZHO? M2G3>87A&ZK7.GM>FI+ZF(_]G!,\(GA%\Z0CNG+BCC^0,9H'Y6YPI./8$J,GX[694L9J?K('/&NK3F\;!&3 MUT7'X!W=$$S7M$U;<[>FF9AY\;T?\F`BO"'LM'%^(>.^-\PLF$*'^<3_-WU# MRM]3;^8'3V\V.,WO\.\"!ZX*!&.;N^6JVYJOH=(Q]7C]N@XY;SR.X@DS3Q[] M]($S/X\X75`NV>?]S7UFMR_SC.YYF@MN0E,:S_"-+-=\7@DVRZ4QST_=8MV' M[(B%AUW(:G!#(\ND\GFJ_=0+[]DY4&S*GP!O^5-6YP&K4BSO)0E-,?M%T1![ M.BAG&SZQF&%A"2SC@;DSH&T_;@00H`$60DAR.VUMDOL)O'()'SSG,>:/O7&*]3.BF`OH/BYV/-`J^==OC/#R=T MCJ4YPI2UG6<[81E+%DF&0)E^G_%`62,%T_6S@C18Y`,XT+6-D:'M.A\` M*6PV!3#YPJR,PW)L<#1+7*J<6Q*0)Y?&X?D7'>X!#Z0?0:EMJ$)5N,"&L`^9A4G\CH5R54GR9QES3F.:/XM']Z,86"V M3?W03RF/.$Y:F*8` MATPBA^&""2*65P@%$5;<`/E#_UK`4U@N9,HAQZ3LYMB/QXM9DK(L244E$P<]'R2^RS29)E78I!_L9+1JQ+S^);.`\PJ0&^"]/0QQI"7AP_X5OLX89( M8H#S"YAB-;S5U57=3_P]Z?-C=N)(O"\'=' M]'_`[<>.:$<0'.P$[1E'@)M'Y[A;?5O=,W?>+QT0"4H8@P`'`+7,KW\SLZJP M$:0HB;MP/,<62:"6K*S<%R*K?BKF)0)5F9D]D6RX!QPI8(26AB@MUZ5.H:WR MD:5(79#Q4A50Y#6$[:SM#76E\E"H\2:"H2,L:FAU`CN>9DVI2+'*>P6B#&\8W' M>>ZUEYU.^:+PDTSP_.F>(@DJ7NSB0B:+;-?3"'L"(8+$O-,8MBY#(%#%/.G1 M]HM'J" MT:*#B19I)OZ(#;\3W8G&*'/P"BN$_FL84H'9S!]^+;.G['/&G1XJ%MHZ%;F. MURE;U4)@^\""RWSD'J1E+],/6,5+.*&[*,"67&Y9,"A#SLT;^/&&4I['J_GQ M$^<(Y6;2U2,,LL!^KUPT^5)HUG,0TT[YMF?T1^AY*/8C'TF`("+O0\R[YQ() M\LZL(.HX!O88^RXO1IK^@HT\)]'NU(3/$FM;-`A[T'N"#) MK]3Z,W^?S_XHW2+QXET&45-`*RAH;PG1(J3+WH3>+;Y,Q,>/(UC/FG M?.T!G+U?W.#>?4S>;XP&6Z5\"",_3E)QDDQ%PD:WR=07I^XB&X@G,MI('I'9 M`!]$EB+(.4H?-QX5;TYX@T2J788D$;A/V9!5/'5!6PO MK%U@>8A,5A3CL*+_#)<*WW+K`&.Q2(&Q%BPQM=O'Q`?R'[(%T.97S>\+EKH$ MHC(-KH52[/FSZT6<$#0X2T+ZA$M#)+OF!]J6KA8D(.1#LB M4!-3SA;I5V`-BE.`;3N!"5^BW949%L:9[0Y7T9*N%W@H."3,`">!,GJ%B'`5 M%-:?2*)7;$N(/NYU@B0/46M*OQ97X-[$'C=C`3U;\#:B2Y!I+1_'&+0?ZEB: MT:5K3Y`F`$A&Q9D22B0R4U!XS]44^RIG%\$OT/FS4AW0Y!GD3`K/#^X17!KW M.D+C#F-:K2+$I!P,3P[82[; MER@?,MUW/^2&BU;ID1I6'0E5&\1%9H_+9$$NF\-G9CXG@P&?F^W40[UV__+V MESIPBYVXXW&,?()M)O1(2W`G_UXD*:,H`!@80QAT41>\]M)[;"W,[B)\]N&^ M,*6D;(BG+<^Y_(L0HG-AY)2]O$J#XE=0$"40?XA2D!Q#J\;;#%1Q'HEE2),% MF0`3[XXT`6[3:\%=A[-P&1]BCS(",0>R1@:12!;Z'#M]DHT\7G2,<4,W?BQ2 MO7'@^K@?D+!\-X`-#9>WC!C*6`(MDI$7'VT@?#:$!S(?E*O8>AAP!C60SD%* M"@[C[(B#C-KD,V:V-M3]PL(Y(F@X#@OW3M:OF@Q$.'SL,Q685-2]H^D@-R.E MV"B6]IKX#]*,6IU**'A.5@1L5I5\IA1/N.&3H7\!]TD?`YV8XRQ.%DVYK8N= M`Q(IE`I0A0P>6YF+,+_W*&F%E>M#!X[H53(F5B438+"(8!G/(;W\.G6I.@.(/?G#0HC(6M<(KF+]#;BW5;@++.+4S34)V[`O>K8/_*9 MD2?G'D34+%K&R5V67_SDSQ$<\06J'(!97Q"Q7M^29@[B5+$AC;%DJ;#CZ2.XI0T5V>I8VZO4TTS#4[_IW[?UOB(]V)P?7SO>_)7!?LAE& M43SU?/1X)A?A9R95[*OGCS/L*GK7,F5%[?1E0],MN=?5NK+358?V:#A2=-OY M;BJ*^MUX_YNFVX:Q!3"OWO>3@4L#/QD#18)WMF_CZM@C3>]@_R-%1X0S.[*C M.JJ,W_:4GC90NGOOE8-VLB4[EZJVI=ZWJXM/PZLKJ7_YL7?QR?EZ:`"QV71/+/07LQFBX]> M&OL/+>DB'+>E#SF[[?]Z\?'_Y1\'O_[@J0)X?#2GF8$J MWWC<[(M>P/A/\FV&P/KN4?84CGOD#(B--]3^1IXBSYM$(?#`P2>GO(;Q%+XJ MK:(X4&Z"F?CN31B!;``[!?Z<9I#(#0H,'BG:SQ$\J)3R`)$6BG``;8S](,-* MPELO)LCI2W$FC/T4-TWJ,FRP!3I5*(/:SVR(I*Q.O#R"!C7Q<2H"F]P8`$CP M(@Y&R4B@J]V@-[)FA26?Q[MB?!CHC'!.F8NOZ@O(Q^(0`I&9(F#R+<6\L0&' M0>P!-TTC/^81/N&4EK!(,GBT)2?$29$/+\88DQ'%V:G''LIB'M-F`G_FD^#- M5H=*9V6%Y1,IK)$K.@7?SSV(Y5BZ>)RR+E+,H@JJ:DNW#":%%EQMM3+W%3`3 M>.AW'#7K9C$7/43XDCD9>K,IGB`_-\:*?V6*)FJ0$Y^9_YAJ).B%!AJ";9@%\/?AC\'# M$]O+\,-'DL/#NK(X,M1/>,`9CT=P,I;`0Q5Y8`HS'.0O4AS"=1:N)NS$N3X( M_PT\C"746B8I-MBMUHNIG#ASO3!GMM!`N4T2H/'_MSGUE=Z M^5M().,JI>C%,)*0.C'[!2FT&`5!!S)-N0$491B<6O@'TS+A('MM`=8"R.\* MG7!8[QMV,470922N<'XLE>>9%1P/BD5<1%D;WW6C%9^A6,22K@Q4V)OXC,'" M_482$)5VN?ZR4D0`VDD6UZ#3P,-3%IU_[>`DK35 MPE-H_5A9H*K%=/*NI;/[GCY?BU[B%P]E?H&?*PSA6?;DW3:$!+3TR!R(AA:@ M`\C<'XL1TJ1GD\&+=&X27@!UT.V/[E-4O^$N8AST!.\FM1[%T)V(K,-DBF%1 MA'CYH[(PQJAY)L5D-&`%!>`R(9(+AD'Y.@0%RY!4$">8$AT>+*#79Q%R=>NE MX&%F=EC7S9+1*B)JAQ$A2D(WKF@.\I!8I$\Q>U;G/<211*V$*E!MG%*S0;)@S\,,J>&N;M0*V2Y1X ML.*P63#`#0:B2]YT2GH%NWHHF*2%$"$,]6$`*'Y[ZTZ$\1K)\&+&A"3XY7_< M<.'&CP6]DS58XK'YH0LR&\F@8H6,@=6L,;.0X[;F;LPCM%F,(8LN`D$6L)O$ MDBC$D`44F[AS*O10L7!C'T.T61PVO@)SW*,$PT(P:0X1:P&CX+Y6)KO06H0L MDWD7K[T;/PQ+C)7[HJ)8X([8(`O``VI#4V9!8R2(M:41>MF\&$.)6UR&S<^Q MV'\E3RF91![3BD"N"+AVF)NEWXF8R:)B0\O*X]"X*Q;=PWR9^#5W&;'=9WZ! M^Z@0DE7JK]NBV-YYFINF48A.GS*3*K26S$:I9>E&A;EMO5K9X2"8;?S* M?S@)X)U[3:!/7BH<="]*@M];R1*KU>E8&[VZN_(LN]VAJK4ZBK+;+1ZP+LN& M;U11_]SK.#1PVT;]BU.O)OR)AY<<-PW^8*KV2^G3ZXH$[WA?6DNS=[.SAN`> M&^%HX'9(@GOW% M2D!#IT^*WC1PVP:=7BH,MZ](FAIO`[DKT&K$@CIJC>K,E9PY'9A3L>I)GGGI M+=KXI\50;XIWRHNNO&-&_$+V0?V$97\BC7+Q\?\QUSZ9]<4":AUJ_/'RE_&* M;.O:.''FXQ,%?E:Z^F`D-&XQ3\Z3F\(L5O*8L#0(BF%[QWQ.%9=3?CB\C@[+ MFHV]2H+MQ(_AK8#"U](T]J\7S-3/ARF<3JN26CME21L8,;>88S8_KT^&^Z\D MTK(T&!9Q1]XA45UA0:&(W+7"\Y#(/4*.(P[OE5ZN#?`N/^X$-NY6DGMC;Q;= MN4$E?5T6L7_O4CJPG$(X/=#.>RQN(4?E3R42X1#4>"'+)(XQH4@YJPP%2$&`[6([)]%DZQ;+?GN M1<`,2\,(69VSXC4K@.]7Z&`/5F\R!Z]#SA[B5/;9"Z+`F6 M1UGF45#EB*=2O`#A&(P@JCF0DW4>^S/A7LT]_ZMK013>?V'5A9IP\W*(>O[` MY?3)>/AD54#\]F/9>\..V1\-1[)FJ@/9&*BZW!VJ/5D?.7U;'0U-I;NZ("?^ M3:GA+.*J$`):"(7-3N:>*L4D/#0@>6ON5]MXROV*:_P_LBSUT&\O?:75_MUS M)Y(LEZ3OLHC%AS>[+_#.*@?TSI[UW+OW#-?I<&O,`4_.EJ&XN'7QS?4'I07_ M_)P[-'^5_GDQ^/IWO()&VZ@)4;IB!4$DGIU$;F").3"E&K_E[GIIU'MHZ_;T M8B?MIT4Y+C.:EC=7YY0ELE[PY5X0R:P`9=<>[8-##M/G"OYMJOSZ-.PHX:Y4 MU";_0'!]>@@0;@8LDOKI9_%H,`WI;1].!>@,<`5P,826ZO"X#J@?+L)\L*\B M1NOG[<*X3'R1HP+I6>:G=>RV%TT>J^SVW$RY<-_&MTOAY/OO;?2\-Y;-G7;+ M.JTV1]O8M-DV#QWGL2]SMO%BG^/6HCU.R$=^)`W+7HO?JMJRM!T?_/'MVFKO M&MF/;\\=\^#7^R2:;)6$NSTUD]S&G#N6A%]S4MM^KCGY9YW\<<1*5(R,ZLL] M?`7V7#%*KN'77S'S_>38LZ:TM.Z+@R<.QJI.D#"\.$RZZ5WY7$*WO_B&K4S: M,-:C.(:C//MUIJ^";8L]>H#8E^4-+GE7M^PI+;MAAVZ,2:/)9R\6[_EC)YP, M6.#B%LJI^4F$I>^_?[L:?)][\??E\FK:Y0D8V>8)F)=^^%Y_K.:-AU'$M6!G9? M-I1^5W9L=2`/^J.!I@P!UDJ?5??3%!!-ME!UKFZ[94@Z8>I3J*M_YUUA:U"J M"#GD=1U'<33#*1JHIJR_TA]F6P.B.YI_=-V>Z9 MHZYE.FI'LP&"%D!04PS%5'(8;F6CE4`([SJ]"+'8%0(0NT-M()L]8V3:/4?M#776)A4&`3Q3Y>(5 MVWB]:[?I)>/8G_/.)MO95G=H#ON*:SLEREJEIYT-\\2JA^ M1J%"$%4WQH>D2>S>3Z+[4'1]DMS)'=7W\UD;.W8;LCX[:MO\*0N(XB6<8800 MVQ>RII08(,8*,F.AIJQ86%Y[ED5`814$V,'XUFNO/,[\7/)FO8-H3#]^?9R_ MHH#IRWKUPFGAJ*Q5;W$A^?*&V&+ML>]ABX+@`H[MX7^][37H58=#Q8*?9'TP M'`&Y[0&=<+I]N0ODU^CWNZHRPG@@+*:J*"HP.DTWV&IKUU7A0'`6DT4`-^B5 MA&7[<5#ZT.FICFW+O7X7B$2O#RS8<#09N(\^Z/3U+K#B?=?T5%:55,G:S06/ MDH`B5B3G8"S4)Q&UAM_Q(VX-Q>V-W03&-U'^7 M(F)A@*PUG%LXO+<6Q=75=AK%9:V)3%H5S:0=+I"JF?I$H\=V;$/82IB*M94B M(]G')0A-@&=47V!:\&QY\.Q%I4_N>=\5?HYAS\TY-V%_ MNPT0NLI4]Y*>GBRN_\TSWHI5GWFNTHNLX`>-'VJ9JME236.CUX_)1_G*C1M6 MMZ6^O7C(-WO>7:73TE]><.8MAD@^CP(6GT'K!S>'GAQ%-#M62^F>7-#PJZ/# MM9;:W7&]N./;=7/81TX+3UD^9`TAJ&DR&9,KS4D.122?.-(7C+",8+E)&O66 M72WUI.Z<::@M2STI@;/!E//%E$W(\U)WNUTR5_)+=L&*?P^)G) M[@OTLF&U#1:EE;60"J/TU;69&R+2@*P!V:F#;!NL2M/UEJ[N.,'AW#6)_NH& MA@VE/NX[U("L`=EI4&JKI1AV2]-.PNIS+)3YBY>DL4]%)'F4;NB?H$E;5;66 MO>MF(`V5.`,JT6#*<6+*&6:1GE6*?@/%!HH-%,\)BN=N=*!Z&F77)2;HP8*\ M4XS:T%J:8K04\Z1$EZU(;"VEJ[6ZUIN+87BS)]YIV2"E6Z;6B)S/9!9G5KRB M@6,#QP:.QP+']5,]T4=IN:S+]G._*S4YLEY'HRCN>S$V$?DCZINR0.S8PQ&\),R MLO:=6*[:-:7[NVUI,.Q]I=.[KL4`S)IYN(Z#UO52NLRN5FKE"[T,I?]QPX4; M/^;W092Y;96Z5%&V$?5\22/)E1`+>)\9C@2/DH-E,+"V@O0!W\R-8?U?Z?'L M]_R7P:\_2_>W_OCV'7;@BK`410*C4]H]5M3PXID4X+M3=^P'.`FO;W$#8]U@ MU?EY[(?8\B>`$7AEBV@J+>886_FCIK05T0T-ZJMDY:]*'XI[&<3NO>24]Q#5P_$=M=`RV](WJ@1"#81@2UFMCS)86H5J M!&[>7PA!P\H#9:V#\&+A4]A>BEK#X"7%)CR/4@HG+UU[TRC&#CP#;^R5&RJ( MRN3ETYVYCRW)325L+,2RE%H<1#3INQ^*!4WH?")J^)/#RU@+KEX)7`B70@CL MRE9G6%THP69>O`O2F%$@)".L-1(V;IM0N9%KUHYH&:AP`>F\L,V;M$A8F9:Y M^QA-I[SQ5>W4WH.?L#YLB((3H'4,*]2VGB.4P[IW4B\O(&OP^,)/;ND&L*97 M5@:2[.A@:AGGYA@@YD$(9\B.2XT!Q#>A_U_L_8/=K?#V)6G6&FL"5X[WV$R5C?L,C-0(,:P8V&U8ZX]-\ZGP&9L"%<7>SU-84$$AQA1+:LGH[45Y:>6 M-`\6":T!H.UB8RGJ/U?JXJ:W-2P]$U=:M+%&<(BK-/`<6"2`CO4I8\?"D&VY M==2^N@G.W)21M0EK;L%N`!Z/G]3<*W:M[+;TN4"0\+!%E9[L]6O,D4QJ208; MQ)+N_?0V>P'&N?:H0HG[2(F5@.>ZQ<^"#IYZ+L#8*$2FD3Q)"0Z"2HXT76!)F9"Z]TT7X83`AC8U/R52 M,?4$QP&145'H]L]=GW>47,F>@6]ZH;C16)P)!LC(#:<@'DB#$Z!3U!N/MY.# M<_K18#,QS@K3W\-KB`O9H4X%?:"!C7=Y4SR_./!7@4MX9F'$FFA2Y2Y@63!3 M^MC&8^4[A5&H81U6DRKVD"/JZO/.,+RU(0D%]"0P]3@E.D@-)9==@?O"((5K`$01IY^`M$K"`^OI65Q+2Z(6BLB?7=YALYZ^,KJZ M"LL-UJOM1Q6SB0#X3'CZD7TJ]U+<8$WP*F)4>64O6Q<,Q5:FJ898&7*ZFG4= MY`9=$,,//28&9*2Q*CN56JJ6"[(AOS<9J6[E^C+KKPLMWDFT77^/]1YF(X>;XQH&%]Q*(!_[$NEE&R[#U567P5H$4M8H(D_=AFQ7"'B,P8&@^1TJ!>XXS]ET,TCX$[2QP@X;(ZV!1$? M8#9C%0%^><>:9=)9W$4!B%RD["!PNFU;!U&+]:6-66=;)BO"KZ;T"+(;D8/8 M3_Z4I]@:+J-^,0>PVE9M&&*!IQ(\5O-P.=CH;'_LM!6KQ=O.(_;!'X^^%U#G M8^4G!L(2#A4(.4KU."#L&R9*BD=';B/84`8&$($3CQ!C4B)UA,5^PI0Y3O=+ MU+LDPJRC_L218-5D4DE8?744FJS"J3` M%47I'O.#9K0E"-9>'L`W+T7-9NS-4WHWP-N/Z`1R%5R3]#'O'(M"%\R\@`.= M`SUR<*>2LBS_+,,P-DDC@ M#RA[F"/NQA/>%9IQZ8DW=8'PM`JMA86`P7\":?>;H+W1F/%#II(2H:'!2B.Y MXL_E>X+4.9>2@"R#B$S2M^3.YX&?$[AB2CN3B=T`=\@W5J"!;(2)-PY(EL$C M*A8$`:WGAOM:7C/K"FJ:>#]J>EXC2Q/^DG#!OX@#I<6^\(>M6UI'TY>-CJ[)CJT9LFT/1L.! MUNGI^G%8ATN0@2N;)&L,Q7NP!G\"*D(6+:0]X]+BV->QQRQ.[HS)G$@5F&TR M(>W<2]!,/-FDW_>F6%&MT3L"E3_N`YF\B>*]5^B%F_4)M"YW//9@%20DTGJ* MQ7I+"RS?!*PDGUQ.L]V)2MRH;NC.3NJ*?(HVY/LX!J6(YB M[/L>6#77@,""_/]"2B.P2DSGHB<>A&Z('[P/-D)&AXF!2$'&'K* M"&E>)IA=B+G+G"8T6CS)&>JW]E5;NO%"%.N`XR-*S4D3RY"#!B`;'JH1)9LZ MO?R[XWPNF]7IWC(%@^XIER!GN3R%W^;,EIX?/H!>!GR`&6J29,F`?S7LEYT= M'!DMA;2`!(OGX(T ME>4CRP^,"Y1$Z*X)/=UDG2W`#4.4HVLQ`H#<$F)9-/=#YLQ`]<0-W1MNO>"J M.%%4=_)OD+NY]13VDW!71!0&I!(R4*#*AR=)?H#"*P60>2"1)BB]$ZUFJF^V M,+:&E=I"[7$P52H',1=[$9RW'C`/9H5:8P)#.R%!&G`#38C,+\*O5DEO*`*0 M&P5@6V2+OU[`'Y&7D!K']0>N_?`=U>.2P)PRWB!L2-KU4F_%"MK2Y1S)/?E! MR!*2<),+\D-4N?$B)?X#'BKKR[[.#Y.IH.*`?+*93_PQ4ZFR;8BY:.O<7)^9 M"<0"T`"`TS&*L=K(?CB]]F6$E.D\L1<0FZT_T>16E$^/L18EQ'FID(. M23'GJIDXN-E_%7K*O')SM5$_R6=F M?8"/\<*;_.&[UVB51"4]G%SB]2A\E6OI?>:2V+XXJUC#P:"+C78&A@F`,2W9 M[AI#N:O:'%6&9];P\@M;)8&0(%\&2O[;I6^OEE@WV.HZE'!@)4=3UO_PE@+^W? M>UH5%5^Q4ZUS!!4!3Z=TQU?T_B4N*O_H`T5M'(6B@^#V:S.^=/ODD/S56SZ- M4NW'2]&Y:D<1%MROSLPA+%+Q]"Z!JG;>VB50C1UG]9X7R>\'?NB/08"Y2A<3 M_P3IO&9WWQZ*[[@3R;G3^8&H%QGGV5?.X__6D[H7^YI+\ M->7PZ?VG1/K=N8_U3`+/3;SD3*^!M6.4.+X==TZB6N7Q,H=+'DS*5`&>5G-Z M9B$"P/?8V`[WA)DI<\$04T1`IPNW`>&\.LFE,4!.YU%%/` M;"&1:9=%IPS=UOM]M2>/%$V7#KBT^_2\[O7X;#CR!#K`M$.VQ9JFPK?[!#QE2??A3/ MZ-0Z^JLT6YUG=>$,UA[&`Q M7R#,II27.H=9_7&*$>5PWUF4?SX#+\S%0L[YLF$POI1W6+EH?!M&073SB-_S MW;2E2Y9ODC+A-+^DC/9,/+:Q%H^27DK,S_:**:F8O)PD>5*^6BGL50`-98GS M?(LR/&@D&ID7*X+C9`GTQ2I7Q7H_.1!XM+WW,/=S)&1C)4`\(YE^P77,X7WA M1V5_L_3AL4CT+0>(9Q#-@)CO95*`)^;O$UVM@@;WRWOX73]*LP5F=+_[(5_Z MRN.DM((:-+S'H/IW/_#:$E1.(7CD@:$)BPGEB"2R[PF;JKA$B)'`;;F-[CU, MX5^ZDE3CBR;AL.3#E6J%B7I`@3_#6F6P`2JRD:3N37YH.:H=)NDA MK_;FYO5)8-&$C0+*5.*G5+3D'=5T*10)HD1[K/*"(&5AKHLY8"I`1R``5N\1 M&?&L@@.KVT*U6RC)_NDQR^]K)JMW07DQ`MITOBQ0)BD7TB,,C$1-(!@@CA[= M@`0#CM\H4D@85P-334!\2+EH(``1474G&#WPDCSW!2M48$HQB)Q8`Z*.3N6Y M8_@I$=A#B41Y90B^:C0CU"2F[@,=/E/=$U6@)]P_PF:$G$@\RH@!E2*4X,K% M63DU#%0\S,(O0^D*LQ(KE5AY-8I M1I&KBO+3\^+&S9^>8T)&DY1X4\L#U@-OFA:'T11-VWP@]?E+J,XK>!^O]<`H M5I+`0ZS:5\;[=*!(14'GROE]*%T4!1QI+"([Q(UG@4RD0Z1K(GTA.!B?L\A;90=I%*U@!;>Y3F=+_Y[2X);<]761LL/U\L MOZ%:6"[F2,\]E-)$%37XNSV$>J M]E04?",L<$I58,NJP\I:/^PNL`Q'$D&H*D^`FOH\`H'[5_RFP>$&A]-?<['U M4?K19!(F8AS';;0.46:_K@!2/9*2P'XJB_L3+_"):`IR64.TGR;6;>E3!!3W0=[S49%Y=`#]5RUR"NB2VY4[30I$Q+IP@P0?NT=[9#7B-<#;( M65')_/94@G*IW!/ND)T(%]AJF6@Q.7KI9'"(,B,MJ*Q$4*CR!8C%B@A#/!,B?DSR!-R M[\O0^5^Y-QQ=?H'#<8-[0.35%.H0$OG2H?/"`QN4'3"$H45H;H6S`*71%H4_ M`4^T:N%/TEYYT5U4KKA^BV4Q16_HL4$!ZC18JEB-J\] M:B[7'FUE!0'\V?4B3D0-"WS(PSQY1B4*!@01R<**ZXH-DHIL+6^Q+5UA936^ MR>4BM26.2NQRDBU?E"/F54/J2AP4R@V04A?-N?DK(5J634N56/%D8C[OX4HW M7!1V_S2060E9O67E8-:US)#P,H2EXRZB``Y5M1&1;3`:^T2=LKH(7/$L5,`C M*&^TBP+XW_WP[`-X*!\`?JY8[!\V$')V=^KC,%EH,5TO3`3UC]@_S*_D%7%FEHP2J,2`.[Q=J0(RP?> M,EX+<[58Q-`AL[<7%HSDN94*Q;1L$V2^$T)=:2=#1S`&7IY3D+4#&;7Z1>=# MQLJ*8,M*DF*%6G_JMN=%@@VT@<0 M;W0D@3^+LK98HA[$:EY=F,:A,KBYS13@'&8EG_/RRD7C(*.C="(HYN:E'+(G M*L=2-MCZ2'13/PW$&KCIMK`(.F=$="H+#2@]YKPVL].V6+W]*1E)B$Q6K-WH MH2O%'W3`8*#F.B8/)TM:H:'#!T,U. M-FL9XL<@HV+AU;$G2L;"U>)%;87YAPM(0VGFQG^*4JCSP!U[E?KB6+E6E,$G MFL/*&Y<0!`%8JK/,"JGF/J[U.(.`@7/+>818%DI=6#ML0N0D_QVW$V'UM4=Z M#E`B_XVI^`(8O(T"LXESU0WWES\/MU843>-EN9$SOJ,.#+-Y"J=$KRZC*;:0 M(!K-V#[O'UJX<0PV/QI6!W=Y(+LVJ82E995K;*VXA(PL"'OV1*:B[UA?'$O\ M4!EMRA[F\DZRF,]9P39Q$P3<6YP'%(H-YYK>_'(\:R M\JX+.MW]JN"[QW.H+5/K@OH>#1Y:J!*TRR)(?_#_CDM(!,5N?>>RQ(OO0`A, M2G(2$&;8"<*=2WJE$3*/.3S#'K[VT5-?8[@29I+,;I4+A+D(F*\APIJ5MVY` M_:!@="3Z0Y>4:#8UV8RYM817_"3Y1\2MF`.1I6DPJ*.^!AQT(LP..)U3(SU707O8T`]W"0 MLK`,@&!TF_=U(\O8\H8J)U3=%MI@83'W*/5=1UAK?T9&PNP<$*R9&:.V;"%[ MC4YV`AH#^N*9C9#*VT^G?E!0Q(O=("JM"1#1O_`-"-+=RC5OZFW$V'"+DTF[ MFY-)L\NMAF7JNU'M37B_WKB`OX@6/=UB(YQ.R8RQ.7G/IJJ9J&A>PML:+D=[ MK3(O;694*HK\M^Z$2ZO,[,V;%>3XSR-'BMLV>2^@]-E-A9C-Q%C7.NC=FB*5 MSPCM+,>$CEP__@?*UI?3D2CSF1>&3%B5RZU%@YJ:T^EHEB[;`TV1#6.DR;9F M4DBHXNB*/1A9RE%$@R)8I'\(G2.#C%0`S6&9]B@/_/-SI9)'ZK'>-"03W^>U M7KGBQ8/V$F!R5`0Y9#U.T&C!HJNB0F1!E@PC>HB2"R]`LDX/\3:3UUYZCP6* M487R4+T$_H)M]$(6;48Z;-XLAOF'8(A_WE)18\:F2`O(=M6JTF32.K+ML29] M$BEH,XQYHX91R$!1M.?+@!4S&TIQ*`80L7AA(`<>C(U"$B;O5)4V>#H3R9:+)0;/@(#<@91$8*YLN],D@AS/2.A()Y/07H2G5KXU(O` M997%YXNL"54A++0(=]ZM96DE1-5YWYR\OC8.-L/N*?]>3&X*17]S^$A(JG!- MR*%!XP6`>C'6W1[GQ:=K]GT0!>DKB51Q3/646=5T3H&()=#^G`,4& M.^-*JD!+:(1)@8F0"BN^YIIJYNZC++1"[EFK:"PKG"@*$0N/GS36)L=$A$)J M07OE5IE(-Z:"MJE/08RBH*TPMO#68_FM9U974FR9C:9\-_('LVJH?%GY@I-- M.EMLQ(4Q355K3. MT[U1@&+<^*&<1O-?5"K&R;]@>4&_$&I/8<%R`DKX+VK^>>K._.#QES5IE,2% MOJ#<#I2'%5Z^FL.I,-RB,L<8;`58[BQ20!?2\EFQXTVX6&'EUO86?AG6MDXM MN]K+][#'Y6AI(*1HO%!X2[A%T05DF0C:M7(8[*5$E#3EZA9V4LGS)"@PES<6 MD%028:VV;9)$B0!F5R5!`%//[MPG1#'F[MPK@C9:P"B%W)7;"F$?>+/'>99T#6,\$T?PPZW!(.RI- M#6/0Y&TTY$ENAG%WW$A@KC2.72^^(FP):!9Q:@A0_I%>V M!GJ2&E9SP4*T.#"4_^(G?_8IM!W_VAK9M$:JZG1,3=;-GBH;IM&7'14^`C55 M35VUX:VG<[]V339+@&`Z/4%"(E`@@C##-WX4]JIO(9<:LASQ@U#04:&]0\8I MF=0UC]`2XU,.2I8(4I""Z8*P;`;J@5G,;"11AJA--?U1!";QVY$+-B7-N4QL MYTR#],D2QE(CR!RP87UGL4@CR556R5&O_!.K$;";Q]@_'$(1%] M$%P!'CS^*O]>3N;P2H37GIQX)%SE%B42XN=H\\+7A'O@V@W_!-UD'B4`(K'I MNIXX1=B3)>06.W_"%C*_EY#X4!.ZCY9>]M-%P?Q`SV)AR;AH/LPL=`FC5Z15 M1.78I#+F!A3P)^O;4>T=*1Q" M*R;F^P-RDSEHA,2:V;6X#L8M,*QKCFAVS9U//D4P8*(7L^.&J/-,>,+3&H6C M2%VT[=W,"LS(\UG,QRH`CLQ)E)55=[$*+;U+S7^$=8L[W>B[DNN8>1WS#$01 MCB\!*W`+J3/4T@?Q'L1XYMP6-X`,IGX\D1$5R4L+G*6-'55GVAFH_M3U=B'`H67\-9!(H#NGKSG!2!\Q+PFZE'\*>)V?K;*7!F!1V<1 M->"C+IRJ\E/-V,)*F7B"^6+KS_4;6M/+IKQ+@^^R8]?LLJ@/%@_=3=;OL+A! MLH#P+8H-U@VZUBBY=D>;=29<*4^4!8_+^,8->6PC1I5@G1K663.<%%O9%?3` MJTS4VF6F>M^R'RT7>Z(*@HAMQ1[('6Z]J][@$RU;4:VZ3:EBZ_ M_.Y\NOC_4:+ZT>:CLTAVYO]L51R@E2#WP:\B5;CT5)6O@?:$Q#VA-._<(41^ M,^'[8QW/6)@B!K>3!)'PX$4*VJ:4)-^]"2.T5`%=CN\\('Z,MT0!9TQ($R+$ M568KG`^W.1UH01.5XPY\'=/CS$S&5`0Q(,3V`!VZ!ZI[SU\MA/N`$Q MCA8WMZ#\X/TOCL^I=)F3!_[42P'F:X2L+"BAF/TIJ)S84ZL4>'<+K",MS$UD M!!04-">R6+32B?'72F>!`I,T&CCR./"H`2"^UJ+S05]9$$43^=I-^`]H%B7^ M`ES#QVQ44GC&"^R)Y04!S1M[R")9]@T*))4U%N"_G$_K9TJ\B*X:@*1TSWQ& M&763U&[7ID"LO_OS>31&@C66AB$P?<_#,''NK[_``5CE`7BC6S%'4^_'";'M M$#5KV%7/C\CE[PJ$IR7PB`M%PT>&#TBTJ5?D(,._)']>Q`$I'7SZ_\'=8;8) MQJ!]WMJ,,9DLB82O=Q5JE!Q<)$>P$X'1>B!_@)3K84HJX%@4AS[SOF-$"[W# MTI$9S9YSP^O\,KLS$L;@!9"M=2YYK3O!1A5KQQ5)TKN@Y+!Y%>O"CJK0QA4Y< M'%Z0`4,HF9X]]KQ)(=(_>[E,G%L4"@Y[R1;(VL]24OQ"&-C&64=IEH2EYT5[ M1%2/WFUK62$?!"CE88(2OABSGL=B_BQ%IY"\68E&@_$[*/N)&7")V8XJH5%\ M=K-MYF6$OO%`6R0B@()L>GH+\*M%%[V("ZM]C_!*N,06Z'$1AFBU%,-N`8:M MP"[N2GU'M6\H>]+E^639I-BEMI@*R7%X*6B9(T8>:OCVY>:844H2=N2XNW7X8MQ_60$?FJU>@)V$4 M37`,Q)11'QB$63_*5)1U$49^?X-I4+QAO9+W03_CIYO#,CH>Y M1<@MLV;SN3U>BEVD=(LY_OUC)[MA.549LTK\>%F94MN&B3WI$Z*TJFUBI-FV M[65%*-G'/.3DGP"B;V%TC3&22(`N,$HE^>(!"H\IZA&M1:(A.W5:%C4D'S^3 M>"#D>M#?F'S_^H["?A(9FMKY_NUJ4&PK+.O+)J&ATC/[5E_6+465C7Y7EWL= MIRO;6L<>JIKC#)WA]XZB&-^M][_)JJK"Y#4A#;N$1R4D8GP+3"#P+J>D^/10 MU4,4PR(8=,YY9&#O,7_D,\O`<8"23"Z9F/D/#\4YP(LA;YW^-<*O+G/J_)7Z M(V_=#&<-AKIM.Z;<'8X&LJ$:NFS;(TM6>MV>:8QTJS=D;$1<*42^KK&P)\69":-IO1-W@*X MUI*V]78=1PV:?WJ8!.1-RD"H:Y/L@'SNWGA//SCD&N[33WY&E;4!_W;!_T74 MR7GZ49"74PQP7KA!#I<__.D&LWSX%Z:=5[/\WM;A.3H,#N`AS<*2WH/J#Q+;M`SGWCE=,(UC6,H^\W9/9L5JV:F[T\NDW M1S';ZHZ[?A[?"7?:AGIJ>WYQ[YN.>1*-^XZ%:`T+^C82L),C7UW=;NGZFVM> M;+>UD^MG]>JC;K^]9KQZMVGE]4:;">X`&0_UW!M;\]O"TW/7ZZ@2U,G)16K+ M5,V6:IZ>MG."%_X4U_Q"#4MKJ;MNB7UN(LDY]<9L[LZIKOFM8>JSN[@>+C9D M19A0'E"4;#^,1%.'5J?;U^1!=SB2C<%(EVW%LN6>T^D,E.%PJ#K'T7?4:$LC MY^*+]`_GCV]#Z>/0N?KVY<@;C18S;UB2;D)QMWG,.!7]27@]MJRB#:8@8EF8 M=R+J'E-VYRP@W*=6=-=9/P2_D/^+58181P2*YN2]-M_]L+:>S[0V.;Z6*ORL+/#S[H<5)7[*!7Y8PC<& MVB_7^N&GD5>?E6X6_H12V1"JA2&S1G&N-(W=F7JS"F"^J1A:?8]FC`!GTJ5$L,[_4&$3I4@^3%?6H,)NX6-;HF87,`$!8 MQ*Q8TNK=#^MKF'V@2O>\[+#W\VMKF@%6(%K"!JFB&W=`!4 M>%&&`\3HYUOX#^9U/7+4QSW$?H0'_%\.?*KME;`$.AZ?CC!CT:DS+[V-)E19 ME?*U5ASH5@+)FN93*U3VHVP^A4FPDOJ+Q(),!6%E]3.E_RPBECQ.5X$2_5@^ M3Y8R2V1Y@A4SQBM)^NZZ/#6H=G*HIF6HQAO,8D4"]M,%$E=1HST/?VY)GD^/ MLK*X6/@=<"X4GUJLR"]0KBJV(FXF_LS'I&&.F842@SXVX6.O%-";XW5Q)93H M1UC_:][UC%/;FN7B,V,760.R_2B.HVN>;WS]6'R,LPS1)Q#345`RYO5X*+UN M08D`U'5;-&"NVT9SOYK[E=TO_1>IF#M01=1W/U#WA"CF"`D8E#*<#2.!DH3L MHJYCAN%Y:5%,JENN(7H8#'UMM<]"DQ>&M)RI\:2=I?V]6U%)Z4FUAHNT5*@( ML\]BD<"!N?8^:_NR)LC_B9+0T@<2^430VO%D`>SGRC^=!B`4XIYW`Y`BTX/T M=\^=E/7B%?3!ZCX_2T`_7+Q\,_5.IC[3+('XYOJ#TH)_?MXHHEUDFOO26O MSOF%'64'XI!258']7D.1#O56FU?N]5(W M*D@#J2-2UKJG9>HXYITV.NFA)VUT@`:.#1S?'AS/72<=>-?[+5C5B%Y[$$BP M;(5R4F4K&K0X$[1H1-5#3]J(!@T<&SB^/3AN(JHN4=Y;*GC^M_>JM9KJ%IXI MQ(^O>J$)D]X@SV%U(VQ:TO7*LWA5@.B;/8PFUZ'!FR;7H,WG%1ARPLD*5JO3.:FF$(T-N8'4&[M`C;7]T)/N6()OX-C` ML8'C$<+QS:BC3;)"L^:WON;STDF;9(634D$:2.TC-*JE=$XJ8.ZX]]KHI8>> MM-$#&C@V<'Q[<#QWO;1)6#A+D41K:4W"0H,6!T"+1E0]]*2-:-#`L8'CVX/C MNNK%A?+$[-&-&[P\E!N2X.=*!Y>'"I>MV\NN&L@HZ_O'S&,OH2:2U)(O2188 M1YFTI/$M]DVE%E/38CM#;.P2>^/`31)JKD.]4RL=*'-9`CO-\#8_><>9=S^4 MNE=F#7NRCC.\HR:;D_K/5+O/P!!-`YD=-I`QK>JC.%1Y(?:F7@P9<8[7Z[,J-:?U%,;L_")F85-S3REG38X M<0XX<5XQ@!?6D8`K:6K)U5P]HEU-/1A1WBBGU12 MXW:NAFEJIT`=CU?8[),!'NWO7I+Z,](7\=K/G)?%]J;@)I32"2:/QG[=1,/'B))<3NK]*WG\6PBI[ M2,VY$8=V?W_,TR$5AWKN'(_G#,/>U/D#MVK70'Y'T3$OGO/YR-%`L8%B`\73 MA>*YJ\@;^F.,DU.63RXWM!&E&Y"=AO9Q'*G()Z3%GYT=4E5/0/MLJ$,#LM,@ MJ#N[4(V]X+BUBP:*#10;*)X3%-^6O>!_%F$A5%M7R%9@[EV@/=8.T$U$8@.I MXX;4,=^>,Q1>SRP7O(%C`\<&CN<'Q]W4>'A=#0:L,2"@\S6ODX!5#:*;T/\O MO)G&;IA,O3B1KKWTWO-"*<#$XJRT0JD(PZWOQ6X\OGWDHBP^X,$N^9^Q-X]B MS(V5YE[L1Y,V3AI[TCW^*XQ@@.796!JSVN)_:%3H091N&+NI=Q/%/JQSLL`J M##@$3,2&3T01"6_27CJ^?8#T(I0F7NK%,S_$3>>@:A6K4DB+!(:[-^=S^/('=_"S_=^>DN%)8H0%Y4I,$U!FL;NS+N/XC\)JO!V-A(\EMY& M$]!];A!2,-U$FD;QZLH8A>0'&&=%^0L\!Q@!/E>BZ?@RBQLIX`6<=+*8S6"W M_X4AK[T@NG]YC0SK%$MDJ(KR4[4H1B:/E>F8**KQTW,LHJB_BC?UO!I'X$W3 MXC":HFF;#Z0^?PE+\$S/OZQHA,4_2;)=&_NO"1E55@`FV9+SQ,:";3S)N)V M<%K1EIP41JG7HPEO5[OD6S6SP5A$H?QP'"PF,%W$,/R:J^W)K>>QE8[=Y)8F MP#_@-0P>!9C@1MI/<807$_WF$ISB)5A;>IY?!`,XV`1)4_2M$[+-DQ`6KA#ZPLDC:,97`86&HTQTBFQ%>`<,R^6HOL0 MV32\?S&;+3YZ:>P_M.#FCMMT$:+PWXMP3)/CY>3OUD[CCN&6)#X]6S?27]H++GP?`?A-):YF*0MOQ8LKN@R^)M?GA M713<4=&IVS(WA86,IX-/#FXFBF_FTIEI2GM)SH(;,,%A@(((1_:R;"6^&:_`&AC@VDT8::*1G>30K._44B#FIY$([-A.?7N"A_(M`A&W_\"%B# MLI`T@_7[\P`YQS62^M"](2B4\!)&LLR?\C.!_;^(H^2@K1Q!LAB/O21A<$F` M3)`(%2)DYXL,OES4S>4P@G88I?#^',5IL0GB5W!P_AV.[R$,I9D?P*Z!#0(H$>0`,K;((LAAE$!4$<'9DL5U`NP.A@D0KS.A$>A&X;@\ MP+E<#8`Q)@#:EI`E>7&W53$=.(VX,3BN2P@SF\-*V>*C.6$.+-E[F'LABM4+ M./R@LJLR1B`X`%U:^(Y/)#'&B<)("B)X*.;7!+EE&PE2##N#ISY,//[GS[!> M?L)\U2NN':P."X@`LA7N$&YB`O,2K70#`%[BPU)=6`05U/_DM3<;1` M;1MH)6JO@-QW@(6`[@#EF!5WC)&43N-HAJ^Z<"7@@MW$T6).0RU`9!G3G79# M4%5;*'G?^D`RX$*ZF04@`DH3TX5DI+)![`:QBZ*U*"F&I'/.:XZB'^IS[*.5)%HM(5]\OFRM$VWOGUA)=1U"TRRHMFY6J#3GP24. MD\V!=AV\=B`9S^8%J!HRW][H'V@MRVA5I]+4O/5E(DB)65L#FK8K%;9NCP_@M8>AUJ$-N M2XYTX_J$`3]JAME20+O!LPRB)&%?VCI]N21(97M!4&=67CJR"":-I0]<)7X#VA*26\3M`##%"@\2R`SPRC, MT`(`FS-$#![;TK`5(A>V\L3@U;K#O;9P9-K>2R>5W)`@6/LP*2B/A9R<@*]PU%F<@EEGL9 M2LX\]H."X:0C#+-%VP[9LM#>]:/95I!?^4&`/''5I*B'S>"E*'ZDV7&!%T&P M`"'8968FTN"`>Z`9+0'")TT]-UV040&_1ITJ]=,%CHN*_@1)VB0#02+L4F*! M)1&;,Z5HSE@"7UA"3#Q&=9C;4!9(`TFKS?1@,L=$`0G`H:`R8Q=M7O/-$7O8[#7JG&,/ECHA(C4CDS6N:N)-_3"SOI$ZFI\LIWG$ MX&@(6`#7ZN'CM3\%2H6P9L)!QFO*O)\8&FR@!F[$A]SI%"@DLV,P-I,SK8JE M`G"1SMH((R90/3CZJFX'9:7`A# MT8SD,"XEP?L_JFJ7/<)1VBW8DG8O_:QR1QG/%7R$NK&2T!%UP]U5Y)NB*$,& M-QR$W:/L=(MT:9Y;8!\0H`L_N<5[[HS'-/$-R,['V]'O*DY6PE3E?M=ROH#P)24*#--8NR,3B#Y#B- M8HQ;\-%##F?.-`9A?,F5OR6=8TMFQ#I@M'FN7;+2,)L+Q1LJ%!SELPN5,!CD M=VHY8&,GDNR6`F;*=[9`Z^HU>:;D$^@F1<_-,B(GC%G7>R@RU5R:$)/G2.3" M&+R>Y7\6$9X4=PX`5E$+%6$,D`(7U!IX+/"!K4^X_L)'0?5%)CX2DAR4^:3J M2F263XO]C[Z:^'?XY5__LDCD&]>=_S("I/D';GS@)V/05U'"^@H4IA<`7?H- M7I/^*A[]`Z2GRVD?:+R?CD"\1U2\0$F%,&0`F*,2`X2WOWC3O[WWHN#[YZ'> M-;2N)EP)_\[;T_^=[I&AU35;_K MCF);@^Y`=CJJ)ANJ8^4>.,A01EH%D:SOLJYK:[VA#61EJ71F_D[N=84^V!P-M MU!OJ_4'/^*["B[_AP?%SJ]XF0"00%V30,WXA'9!_9F%VO]!=FL)ZY01HP"]J M_GGJ`BUZ_&5%*G%=^Q\0>HH-@#(W#\E/3P@8F[?@*2P6N^T4MJ?D'_/=;:SC M;JB2=JR21EH)3@KU1 M&/W^TC=6MS,0&V.8*/!=;2N*:(X@_7\*_5\&\6O\8TFBI5_RSA!9VM+UIF=[ M\B"I#0,HPZ``H.RUK!C,UB"UA+Q+R6_/1&=U=5K(JH0Y3C_1=$2@PQPXY&6R M#RI1F/XBBR]?P#,^Q]'42Q)F3YEZWOZK=+^TD>N*TMS5)*G=9=/O:Z=:9\<[ M?26!/C*,_@J:E92X&+.&RB&&!E'0^"%P^YET=.GH=?ODD/S56U;M/6/[F5%T MK@E)T9T79S$EK*MG'B-^2I=`53MO[1*HAM60_,U1OA_XH3\&`>8J74S\$Z3S MFEU?DO>L4;R^2EM#YS=$^H$(8XAS>V8.$FQ3]JN$/9710$EQPCPGXJ3NA:Z\ MM7NA*?5]51K27T_ZW;F?`N4/R"MTIM?`VC%*'-^..SN^]^?.'"[)9RCL^R*+ MX_00WWASHK^QHG+-?N@_P[+Y0Q'ICK:.#3/_BO5KJ(4TZITK7=48@6"6A M/1&EK+(Y06H<_>FB]B[[TT M\<;^S`V2O[TWEJ*7M)'I]%1S)-O]@2H;CCZ2>\I0D9V>I8UZ/!7MI@H/95920K M0[TC&YIIR=V19L@CQS;Z9E@/[R4"O'8=-5J*]$BG!6CM1S`J%4+37(BUF M.;Y;D6!YC2`E<6+"@$K1I1\P$4X$G&+:/:L/@7%A[W[((\,PY7_L84`'_8JC MY,].W-1=%SKV%(2T4\R1ZFH_+47"E#.F<(U8NZ[G@:C(J]?]W7,GO'I=QL7+ M))@/;YI-A%DS]08E:.T7=J'93QA9.4Q34(!2(70>)+8D%N MFW/>,D4IEP$N"%)UF$?C@]DR MS!=O]C1.\X.A[6:'I]^(2U]+HYS)Y!P'D+@)0DO M<1`6"G642R04DNSSL=\]4=1AK^2RZ5EZF.#B%[.90^RX09(&9"_D$D?KPW\+ M[30;*#90;*!X3E`\-4O!>BE\R5(@N6D:^]<+YARO%#.[C0*0IT\F>O!-6!.Z M]8D?1RJ4-=:$H[4FG)J<>&8]*QLX-G!LX'A^<-Q$7ERBO+<>LH2_O;=7$]W\ MD=S!;IS"XZ=OV-[0K3[PP@B+GC>.]6;-;W;-YZ4N_Y/HG#>11;*U\;'__NATREQG?W3PY>ZS=16[8.JIAR4OZ3K>R\I:AZ2]7JBX^= M\\;AR#6CU>W6IYV?\\[AR+56QZHOO;1/+\Z1BT3KR>:0NHY0V\&\=PI+(T+' M?.*-%S'EURTG`9T^!VS6W*SY7*0C<_TUG\V#Z-'S>!,WUM=DO]Z"-^'T/SX^ MJ=MJR]#KJ_4=Z;8;3&E`=IZRV'HBW5_=Y[*AU,=]_[9!JMVW09M7NMCI:?0VP(]UV@RD-R%Y(F4\MWNBL MHE@;*#90;*!X3E`\?;O%=ESO*XO3P1A860AM`\<&C@T^J&M*,HL*W_O%?VDJJM+>42[JT6Q1:=MOIA2;TE[1+_AL3A.W M^.)<^"9Y^J0ER0:.#1P;.)X?',]+0]Q(2.3^BT9,/)HM*FWUY&SOC9C8B(D- M.VG@V,"Q@>.QPG']5&OZ=K+_T==KNG<^JR7DRKZ2/*7QRHOO_+&WHL-E`$/0 M7Y?3+]XXN@G]_WH3F->/X+DD3;;?>5)1AD['&)IR;S#LRD;7HBFR9?3[ M9K^K.Z9B'+KS9&T7R=A+%D&:8"YX-,>N,Y@BBN)PL)AXY3+P<'@P4AI)GL@K MQ;:1811ZI3Q3^1K/0YJS?J*2BPU%$VD:1S/V.XS!,U'I_2]7W^"/A/?%3+!1 M9=ZFLNE"N=2%,A-GRF2`OV\9SV\S:1VNX6(S]4ZF/M/6?;PC]BOEG:K*8?SS%_I-;!=>5_W`LP&JP^SRZ%6YUPZ?0DK(YX2,ZX=./ M@%A?]A(5'>H@[R4HN;](D3R`.=`\J:(EK]CHCJ.HCV:?NPX7/YJ-'CXL_JA< M;^NITQR=3SWNCKM_#J:'W:W>LJ6]MQZI^4C4` MMG+(.^YB,R^.7/C/[V#2&"OQ8&WA_5O+IG1?'-'W$AISZ!BOWNA M%[L!T3%W,O-#/TEC:MY[K4?W-B::&_O9D4V/'I0?.)8HJMT7N MJW;#4Q?%?]^$=YY81K% MC_U%',-?Y:CYK86S.X.>I?7Z`[DSZO=EPU`=N>OH'5GO=;6.U=/ZG='PR7#V MF1O?^*$,@NN4$@/"+FG^>NC,_>/QEA5$4(]E9K+@? MWD@\6GLQ@\%AF$1*5P6Z^QQROD<-X$[U4S$`O'(MLD!S\<=:"%;!O2;D6=-Y/*2G",BV@\79[WSJ5=) M9!L>@KV1M+8WBK\F%D]LC&&BP'>UK2@BLD]0YPSBU_A';23P=2S]A2_DZ.(8 M=P^2@3?V9M=>7`"+6@F0+@`H>VT/`9!+AH1GHK.Z6OM8Y;KB]#/PIBF!#KU1 MR,!D/YP`F'^1Q9O4*+U(WZW/9JBX'=N2'VM5.M M4V\#V=I.7TF=CPR=O[CWTD<7*(_O!OO'YE?'DMCUL15'C-:O=D8J]?[7_>`W M0Z[Y0Q'7CM8ZQ'DH2M7$0!_J&.AV%8_[(9U:[PL'2%2/7C__A!@O/29+%C!6N&#[,O7'J30;^ MG0]D?_(%Y/*7VUX7H<_>FB]B[[TT\<;^#&1\LCE4[++:R'1ZJCF2[?Y`E0U' M'\D]9:C(3L_21KV>9AJ&^EW_KK__38&S*\!LU[M_)K"35?-=LBE^AR?3Y")D MIG'1:LAAG8:&#UX\]A/O<^R/MP%V/XD,3>U\_W8U^#[WXN^LD='Z@[`MK6,9 M/54>#"Q--BP%CL2T3-D>]=5>5U%&_<'PNZDH,.7[WSKMCO&,L]@><-BI3#S_ M%WY#1GXR=H-_>6X\#">#5V%M!2#J<*A8$.L#X8CV5!Z``NGVY>[RL`V^OVN MJHQ&WU7$3!A9DW7UKW]9MZY\Y<,P]=/'+]X-Q1Z'Z2=WMO=5J^]_Z\.!#!Y: M()Z-VVSI=0LK7X.,/@U@>T&4P/7>OJNFJW=[`\OJR(-^'[8PM(:RK>FZK%EV MU]1,!\;1]EYYJ&+9)INEV98N/OUC^.GKY9>+X171]MR6^:(*/\]!WBDDV^Z/E9^8T.F(BOF6G44.[ MWT!`>0/![=+O#=Q#ZXRNJZ+JBUX.+TV<F/;`4KM]4^_NWYZK/6$Z M!:#!EW%Z2Z;3*8`3,6GA40'*6^_=#_7FU*D?NN'8QPHC!'@J-!+DH)=F'/92 M%$HNC!*+$Z#>G4D+"\?#%$N6(;(%T6BU-A)F+#*:6O-/&'!QC?]'EJ6>=P.0 M(H27_NZY$TF62RRG3$-$E?,U%M-51E;]/7,#=Z\P!'SX0^L M8)NO0_WYJ/#E`!#0WCP$]#<'`3)%T:?JB^I@6,# MQP:.^X#CN4>HX#2D?A9\JK3O1B=MUOS6UGQ>.FD_"K&S$;9Y'T=AXD]X`_F] M7NI&!6D@=43*6O>T3!W'O--&)SWTI(T.T,"Q@>/;@^.YZZ0#[WJ_K88;T6L/ M`HEJME3EI/K'-VAQ)FC1B*J'GK01#1HX-G!\>W#<1%1=HKRW5#3M;^]5:S75 M+3Q3B!]?]4(3)KU!GD-M,I9TD'HT;^$PFER'!F^:7(.&U)%?H,;:?NA)=RS!-W!L MX-C`\0CA^&;4T299H5GS6U_S>>FD3;+"2:D@#:3V$1K54CHG%3!WW'MM]-)# M3]KH`0T<&SB^/3B>NU[:)"RW! M<5WUXD)Y8O9HI=W-ZH8D#^6&)/BYTL'EH<)EZ_:RJP8R%592AM]2"Y^M-N8I M]_SY)R5U>!/GSHO=&^_3`M,1+J<#/UC`MU>W;NPEEXLT2=T0VZ6\O*O/(O39 M6PF-^5Z:>&-_Y@8)=6"I]/SIP[],HS.2.[:CRL;0&,FV.=+DKM(9.I:I.*.N M_EW_KFGO?U-56S.Z73V'UC.W5(;'P)NZBR#](PIO4B^>H9HQ\))Q[,_1-'XY M_8C3-W'^GNTYCNG]B( M?GPK13!\++EC]A[V.4HPE(YZ+/D,#'_@FIR;V/-FL/MVCA$O/M0R;O2C!'ZZ M<@,O^1P%_OAQ^\VNNKWN:-"SNW)''R+B.T/9[BJZ/.A;JJ;KQM#J]Y]L=C5S MXQL_E$$I_T6E]`S^!2/ZOQ"IFL*"Y<3_K_>+FG^>NC,_>/QEC<.*O+X(!\2; MKX!$R^DQM>2SL"1K>RL2"TG90J38FP;>.$T(&]P;P(0;1/$Q/`:H%M(=F2"V M3+S`!^H`[\`H^'!M-RXG"**/[IR&A[$30(@$[$X\$-_[+MATL;N7S#$&%Z/ M0L`N,Q8$0!PAP?15C&`)4Y7$HQ,@T!)"`:T^010/T6.Q+DFP.RE>+\L/0HGM&^ M8'GCVS""=3P6M@BG-@P1''>1BKYH;/8X>G0#_-PFU%C>]MR+<1)JU.;A M`Q^\A[$W3XOO_DSG!1-AYZ$$AI$$,(!/Q%`@!\0N>();!'/'`:XO_48B8*% MP=\A/`"T!&@:O(6CW82`VWP=@$QS!!H15C>ET=LPA@-+YIC6`IH9+Z,2/@"[ MP!0,X&WXDY@&:"Z,<.?&CU(",IX_]<=NF`)=G<;1#-_Q(Z+D_*]K;^PN$D^Z M]T"L`[698""6240[6S^CKOP]^'1_ZX]98[L"?`EI$0MC+[MJ;;BN'*I(J26@ MF8B.D]+YCMU@O`AH#-P=#%'>'[]]M!;D-)7#X6-*4\_#.T[K@#&*,$O9"0(2 MYTQ?+TB2_1K1=SV\ MV9_=1WS8B>$*W=![R4ZDK8M/HR6V8W<&%K"6H>Q86E\V>E9?[CJV)@\ MT[=-6[9LW90-P^[(7>3%RL#N=KJ*-NJIO:/K.;F8`5<%)`9Z-&O/L=_DF3[/ M@2J2IB>J4>PUSO=Y+JZZV"98NWU:OD3\\84>LDY;MW:[U?.*??T=A%`@ M.B>'UZ9FMI2.?6I8_=IM=]I'$*EXTN1>,,[30_D/:J=EVR\^_I]/"].UMFZ> M`J8?"UZ/HGCJ^:=(RC]H>LLVW@I>=]O*X064DPC@R56K!ZY:UJ%'__F<1>I*ND,9GGAPY55LFUC4VWX[&IS3=1IY%W_87-O7Z M&<^?I"Z%WJI0ZCB8*H=I>"0ZCTNNZONW7C"YR"C07(1?B9/Z.]QE.S/ M0^<,NXK>M4Q943M]V=!T2^YUM:[L=-6A/1J.%-UVOIN*`I.\_\W43*5C%P"Y M_8U77)VSN>O'^-IE//"3>92XP>44XVW^\.^\"0M6VU7,C**9`[.O]^3.8&C+ M1K^OR5VCZ\BV-51[EJ+U[*%Z\)B9'$+HFD;(R!B",I&>+/.WXQB:KWGTB^3! M/5ZX*3K2TT0*\D6ZM$CRX?OAQ!^[:13SL`>3\>+V;HZ!A[&"W`1V..^;$;QX_DL9]%"P8H#$W#N2FB+(Q2C$I#;STZ M!V#2=F4#*4Z,$3)XI>K&I/@<'KF`.\)HC'WT2*8X/(+8/$>_"1M MT62%;P,D(_?X.(P!H\Y$[6$6[\-#_#!.!Z(MR,-,4 MJQNSMR8>1L'Y(8R^H'">PFXQ9@)CE?!P8'0.E!P&[1*\;]V$3L6?P$[\*<8* MXM<("3S<\B99O-`$!M\DRN(E)*4:KC>;^2D%&CCA)*MV,/:]!`8+4)3=KR.JV:9;(0HD>I<)R'7=E%*'V" MNX:>,E"5%*-5C""4R,5)48:`[&X6GN2*L%1!%)?')2)7C;T\ABY;($:P)5&`*%?9`X&:!4Z+I]O2",,!_V5!@45D$"&Z`)EKO!&W M&5ZP=2TCY/4CLM6`7ZS8H\!7'L*>0P8YZ3U_AHU$5XY%@`*`ED^4AZF28,&7 M(!;J3F&1='P%`!+\5)`Z?,P`J/VQ51EGNL!]NN-QO&#;!#0&ACLI'"B7/'B0 MOY3<>AX+5A;!_KF85OL^"@?7'@7"4E@V#_#$4^%QR>)&UT9?`\F8<+C@39^) MZ.IHSNL4,?FQ$)N:9"&K]VZ2!XD"V/.(U>*IL)"X96'D#)**@$=E%[KF.E>8 M%(A2:;%D9C(T?7C+]('O^"+P+N:GPA)M*"DA(C^ MM7B9T1^T/A8"3Y36\K(%?65AS.YC!0E_U%JVUFEIFH)H4=@3_#9WDU*0-R:; M_`HK7[WT)Q9N$/^MD,XGUE]>?6DY)5D_<6>UK*/$BQ841QT1E>3B/%N]B]'- M2_O<\(PNQVE4V@C?[09[[;0R2BD(Q/*^@0Q']R&:%B1W\N]%DHH#VHP!\TU7 MMPQDES$;+A05$S=8B@$C"T3V,1R?BY37GHNB0\[!)1R6JSYI3O(1@G<%`-;O MK4S_81`0H&(8,'@L,G&X0("=A@F*T&.FC0+KQ#^1Z2#KAX]NG`\`TQ=GYS#F M\\*66L"*K_^=Y1/4TU,$#1`/6$R!A6.8/R5YC2DL-U^F.&[B\:BRM4`Z@R&F MBYC$B>*&8(QK+\O:8APKYS.`:X(Z$^^"0=;@$&[57P5I`%)Y[[@B1JR"QYQ8 MP7JX))B?ZS+O%CMDB%>@%KC;7VDR6(J_$NX1"H\S/TF$Y%<00=CT;71.TW)( M;N908!0!E5:]0D185 ML28[54$RQ,WB@SZ'=VXO^OW;ZF,MTUO*0\FO>R$;BO2-?6N$FZ^/DNVZ%TH^FTLW79W7LFO7M#QOK["DE"]-A311%/1?X M78$]<,I(67EHDDL8+E*.&,N0BNB_N6P-0C1<"U#MQQ%<)KHJUV@VA'=+"G59 M>H?5N@LDZXXS8F$IY-HAF0PF_IT_8?2<;,V96LUS.5N,_-VZ M,(B;:6P@2]QYN#9O.B6E2KQ7NS2Q^A9HFB&H-C@`*AM^9@(1N9[5&[J!V?)Y M1L=G^J>2)_PT(L@O<]544N'%[Q0NOP77E9]$AJ9VOG^[&GP'*'U?=F5IRZEF MEM:QC)XJ#P:6)AN6@JG]EBG;H[[:ZRK*J#\8,D>6_OXWC(9[AAMKJ_#9J$[" M4C4!++@P/K(J">HSJB34;VB7?M3*0NC'`5SLK-3%@1#5,?6A8CBV;.B*+AM& MOR/W>HHA*[JA.AVKKPRTT7<-[?A:V])VY6Q]$CKL:":>_\L@&B]P,/;B,)P, M6/+[EMP:5D<9#IR>K/0&<&]MIR,[-F#'W\G[C(/(BB7KRE__ MLG)=98SZPL2L+RP/%\'PD5MPATPJWTY6;/7^="S5U+J:K!C*0#94?2@[CCJ2 MG8&I:F9G8-BF<12>FC[F.9*)762^_\$%7PZXXY$VA$\T%YU)M!@O[8"+[D6; M.:7MKWBN\!3Y@IEW`5]'KT'L84\MTE06*BM@40*T MJGO^[!K%&2ZA4!Y]XKDQNG!AU@GVCF&?J:+Z95BF!G1M72S;8!!/-R8851Y/%F+G4^=_2&(GTA+GLR91`1K*8 M:J:@PYB9>6';,^1L;D`Y[JNE-FYX1GLO;J=0J"5?>^DH2X?!E!>L`#&%9TEX MPEHS5!\"%5U8-$P`*@`YK1(A8.*,!3LX@*0P,7.'P)L@%WJKSRAWAJ`EI;!N MLA$0!HS].=6["3,W6?F046Y+/6ZBR>Q1173$80"[*WZDF?LGO/3OQ>2&X023 M;9D@RD81]@_T5'%3M)_F10>RJU(>E[V%'K:`;`/>G>_=L\@,X:2?Y$-/BV=7 M-B<"\`#=$@0E.T4R,[DY167:P'C,`B2$JH_>^S$/PGCD,1S,Q?3D]'AU<5JA MFN%Z_(W$YVFEV6[/VPXT3SVYL+3!JM:A.YBXK,:(<*EDVM>!8,(]U]2 M>0(L6T`7\5O[JBW][CB?X0;\9^%C7$^N6R)MP/N7AZWP2C"@VRYF2 MVVG1&Y6'!/%P(/9RD)=48X0F4]R882?C`_E;U7>$=[YFJKSR"+Q6-(8P)QJ' M%8/$.FB)2TO4`BU,H&"C?_ZTBT,IA7AGHBBY[8>#B52,0 MSB4WCV#N<7Y16Q5W"FYGX@/8B2$FY&9([]$?*(`!`"-/;S@ID!08T?/GPB0! MG!8M`_!RQ8=!HW,39H9IQ%K1I8EUEI".B1@%@!OLR^,#54WY2^,P<2+A85Z( M=[`^$>:5WOKQ1$9>\"B65[;/$T_+HZW68%>KQMK-SH8OY)ZH-*LZ-5\`X^-1 M&U$(K"2EL#NX;`#BF-RDT?C/5M5J7;M!7-Z['\I!9"NSJ4(7K M4>HJ@QCN9K87.":XS`E#'#J4A[40)"<):*@3-(9./1>CTI;*._%+ERRNFTT%K#X\%&'#P_BR8(D5);P$!>`#;(3B M.8I@8:U[8KD,M_)KE+H/@+NA-_73I:5/!,;@0P4:%GIDK"O^*I#UL46K*RZ/ M;(NEJ-8\8)118(]57/*L8F83SWD31A,QZ;!,P4?$Z!=X-,]#EEK2V MY'#7"3?4C2G:DE$;(AR$"E%28`R;2!]E$:)B],`#O`"VXDT&"_0:,G66V4N* MD>A9INT1QH;K[W]3.[9M%*P5S][64I!EALM?&+.@TFN["O;61K!1==211T;? MD0VKWY,=8]"7]6%OJ(\L-'D]79EIU^+85>&R%P%T'%'>BX3'1O<"%Y9Y-;Z- M@KQHU#SVL8J2-(LF'L:`?,@90O_7\AL?\9'\Y\&O/[>X>I.):B33D'!:H$Z) M")5F5)&F!*I&-3@#4:\JB[7FZT*Z0OP;6"$CUA[H\M&CY_%1V',5Y2R?D@51 MLS')JI^/RJ.@;WT8*"9Q`31JMU5<$8^3AJ_95A(?H.TR@X(;^KD`-_'=FS!B MU1/]<+)(TAAH9^PG?\I3].K%/+:ZI*$!&257[J./(7;,AH"5^]P[%V:AX'H> M^HC"\->86`O*(O_UXD@&XH>%8'V\Q%Q[Q2*",U!Q6:%#X%%P'K`M'AZP`@PM M+NRBIAV*Q936N2*N@(W'%6XN=![*EA3>92!ST:H+V!4P'`P>2PD$=UB&D%5F MFRS&GIA^RA+:%^SVH.82>P6^7BQF""R7XH+Y*'=(G4&(1_P,/62T+N(>QD(M MKA,48M%TQ35V?RKQ\(/BA.LYJ$BV9_)0:5D50UBM+%G`"H1#[*->L'_&ARH62E8PP+%-3HHVL)&LA%)$L0"+B)`L'SNPF['#: MHD)8T6][5Z@ERZDK#Q6^]DJF(KSY(H-$3.?'==-EEBE!M6&ES'R+PV2!:+P` MJE@`7^-FKM!-1(-512`_H>2.:M<7^#>@#=;NQA/"\.]=UW]T;*?3[6E#>33L MJ;+AJ%W95KLCN6>;MC$R!B,0-@Y9__$;!XWTY>I;7N9QNB(Z8T5L!IIGD[QL M)$8\@C;1E(1\9DE(Y?DE(=4U[VSK^\/-W12%?*+D(?.UYXN(IOG?3/&J*`IO MHP)D>=.%ZH[9DTY>$W+]@_@'B@)B[?_\^\77H7SUV>D#\A4*(9`[749_-(V) MKV1`7SL!NM\E\K]O]ZC.O>Q(QKA$5@G(LZ+LI'20:I-/U,=XP0AGW\GM38#L MO,JDG6J]2U4U6H:BG-+MP!]?6-/':AO=4\#JX^4O_R#NTC"0X[XB;P)DY\5` M3KC.IMJR7LY!3JS,YE%PD).J"M>4V6S@]S9DHSK=^\1K?JI:RVZT@X:V-Q4_ M&P@^D[X_J_[H"WR1E3`I-[G%?%#XS_`_"_\.:SSL+DAJ9&A]O=/KR8K:MV6C MJQBR[6B.;/94W1I8JN/T#A\DA;"0"L"@,SA(FZ;.C6 M4'8&6D?N=77-Z6EV1^O;1Y'KK9?]_I8M/?1#:+OXQE#[_X7Q:5W_Q M_\BR]'`=!ZWK:/(HR?(>UEY7FI%H((]6D3Z#4'G@L@>?8Q]#("+*:[CX?%FN M!H(UWB*,_&(Y2<5P'VD.BQO`C[E[,183MG6[975-B04W\](K69;!NQ]8F6$`("DI+&7-E4*8>S6D MJB=#];F6SH;%AO)YL_743(?KILEP"!C)#9(HRW+,W@<:'V8%>*0,'43$%`M. MYZ&O#W-?9$3%4B6FGX>,$*RX]9M6O'CTW+D>K(K>,<"TOCTRR3C$P2564 MGYX7BJ3^]!RM&@T0XDTMCX$*O&E:'$93-&WS@5ZPA.J\NMEI*1U!'IXMQC?F%(;%V@-?]EDX]AR3#6D@)#NX MF"AN$*Y!N/172E!AE9.7&*^;K(MROXZPN"4\/?$!NZA/`C+IK-Q>>V<(UC24 M/\;H8:&N];#&JD0V(NGO'J@B):VMZ3?_ED.+XYOK#TH+_OFY:3F_'R"=1M=Y MI!M#(+5+5*..J/263$'GY\)LFM:?DT.S:5K_-H)XFZ;U1XW>QTONFZ;UIX'I M3=/Z-Q-,VS2M;R*N:J)W2LK9G@)"MS'GCC79UYS4BY\[=ZF@:5U_+!)RT[I^ M?V1U?Y&86YGT_`EKV3A7L+ZQ1P_CQ(D]UBW',(R6JMB9RZH4O(%N4"H M49ORW0]Y'$J<1;ER=RH6)$RXUZ?R4Q;'6`BZX>[7^K(SAXE+$B65BMYC5F:. M5$R"#4744&L9'D])?4=%GZ=RW:XU&Z0:36["_6G)\;C$GG2-;,,CUM5VZA$S M[<8CUDS=^`&YBVM%&O3JJD-`MNB;W(MU,A6'=@J='10A*GH-US^Y`T=B.R8[5LM4=^R^.QO9BMM63 M,S.]WA%KJ*>VYQ<>K]KJF#O.AS\O5]RPH-DC`3LY\M75[9:N[[@PP/%MVVYK M)U?WX?7N2/W-[5GO-A[8Q@-[8HZ"9LUO%5O/W??^-4K=X.1DI)-UL)_BM3_% M-;]0V]):JM&()TTD0W.#3G+-;Q-?=Q/%\E".7,#/E5",AVS[J_>RJT@0I9SI M[`I7!?:G9YX(/*H%=G$K-O?BA5SR+L;O\B;&K)$>\_#Q#H:\P@"51`FH)7.Y MI1C&F[#,\>7FMD]VWQ75.DOQ)N]^8!$GR^W+*):%0H&P7MJM)U-9,%;=A69G M!<+>/;<)\-K(%QCM'G[_T6J;"C8*8^%'APGXP8W>BRQ/GM;)HIYDJKA6/@(! MMAN68@7O3Z@;*FNV1_7;\/0V[*R5=X6#@>KZPA&4M+:JT*CPEZ7E\,)3C;T$ M[9+^G1<\[A%^=?7)_I%U&W;RINJTI-RQMN3*X>!TY3\<"Y0:S'ZZ2$>6S',& MN/GD3HTWL]/F3+=",YKXLY6A'-CQ_@/L_3$/S#PE=X79/G2MC+UM=,=Y@,>R M4:M]Z,"-O9WHCB/MSC3Z["X*W-0/_/3QY*B5H;1?7K'JIU-`:D-KJR^FR*>Q M0Z5MOS@"^C1VJ+9?7HYG[0[//>3CBY_\*4_1`NZCD(O9K['(\C@E.J6VK1=' MR9X$BJNOJ#=V(ANT.V>^PP'HRS>9!]`@B(F\_Q1O9L0Y,P2%#!2X7<5U+!G<2 MS:G""_R\;@?O>$&;#Q@*D&-$_]?AU>?/^>?!KS^#="Q]=.$M-A[&=>#@%)AP M&P43+Z8N2G/L\40=GCP)Q\#7_F<1/-);;>GOT;UWY\4M>I=^QS"&,,).3Q-< M35[))XWH(8\O/)$68>H'TO^XX<*-'W/<4GG9'18U@0V78)@((YHPQ&$._XDF M(OR'9KSV;F#'4;AR*%8X!]UE,-**(C_2MZPQ%&OR5)FQ)>E6R^I:%*/T+N]] M."ETE,+5M"6G)NZ)YF#MQ0">8\^;L(:*,!#U>!'=J?*F'10*]:/2UJ29'P34 MS`(VX0(44S?`YU3;:AD='4;(^Y(A?$O!3WZUE%+B!H4>6"B;X)KWANC5@"?1 M$X["T;*`HFJ+-42=:_C=]2?2]:/D(OC=./7'_MP-4VF!+=RRT#:.&84'RL%A M?$K6T(MA>."/"4#9&"S@"JLIA4N8!RL,`ER.:/H%8]AFUNT'NW^Q[BMI.7(M MC_UQJ[M\EW7=@XOK%FJ.XA"%]5&P%^^_&4L?KLM/KMG+@2.R\B:TG%I1&]K# MTMFOJX('BVWAL!S6BN)B,$2IA=^7JV])F;XRI.4!>D@V,2:)<`]^*04_MOEZ M<`Q>KHL:T&'75""N@(EPK\DWA,,PO*/.=-2*M$WOO?N!D0PQ']R38C-#44:- MT;84@%2B_P(<=Y,UZQ%HW#%Z$<8#,9G-M;"V_;=6,?Y?GA M;>J:=[;U_>'F;@)BG@XI8"6\\G5$T_SO,R[CM08B.R@:A7]@TW"Q_'_^_>+K M4+[Z[/0!!0MZ''7CD`?"%(ZO9'!?.\$(A9A_+-06_"D-&`[(W'.)QJUR)5-5J&_^\)49JMM[+B&T+G[R0]0 M_NY-4,,&9&^<@9QPMR2U9;V<@YQ8LZ2CX""G5@OCK(H?-5#EZ],*%*)+36@[FZ1]R?^NRR,*VB"_G=#RP`PY7F4/6"HZU3',(8/%.PQYB:/%S2V-3L5/B@$?Y!9BP3^\@`\KCX(1$^/` M31)_ZE,@#Y9+80!G952*DU`#K##QVA1["W\D6/HD&OM46^7>3V]%]`>OO4+1 M-AVSI2B\Q(VJZ?1A^B3PWJV**6J5JN*P^!VJ;S0.%A,6$G#CA5[L!O@;+F8R M\T,_26,77Q%[P.=P!>,(9@L3"D.`;:#OGU4"\F*W%$;`XX$PJ`BKR^"T^=X] M`0_:\C%V_=J/O]PV=MOVJ]OXRX]G[MW[ZNN$QS4JRN:=[=9YH7^5_GDQ^/IW MO()&VZAA4U=>?(>1=9]9Z!J579%8'1&)E0]9S9A.S;->$VM0VER=9YO'(&3O M7!#)K`#E[&,2T+^?K^(C12L^#3L6$)"]-B_"GN#Z]!#HT*9@Q@V.ZH*'R+[M MPZD`?45O/*D.CY_L0O6UZ4)U"/,2Q6`6A$?U1(U*=LNR#ET=8^^;-MOFCNMI M'XT9S=AQC9?S\@'6:X0G=ZE5M65IAR[NW*M0D^1,+RTO:FV8Y7H M#-GJF;E,F_OS=L_^*(MB5%+P*]["5/+<\2U+,B<7(54-8'Z$!'/@X?,,2QE1 MNY%W/^3.49FUL%D@(BRVA;D=`UAW^)SL=W'W'TDWRUW/6,9"/8[ MC%'LO$/9X+F#E@H$IYF-]JWY:YOV'V[.N7'P[]85V(^HFIR48G._\.9%FNP!3%>GUWS\A1O=<7+( MT>SSY=7$3VRCA\_V.:%`A2]>XE$5.#0Y3+P[+XCF:)[8.YEZ=?S1R:'WJ[T_ MI^?Y>6TXBGYRT5:O/F3M%*C9\4I?5R[V3$;BQLJP'D(">RT.O#VL?W/A5Z<7 M1OK:'3=2VG-JDN5Y@I4LP9,C9IJ^8XYV?%ONOCG1U-#?GFQJ-!&T;SJ.LH%B M`\4&BN<$QG#S^TC-]>:+^^)V#L4==$ZK7XX,_<%,N%_:BW.UGO/PJ49ZW_ M%F'LC:.;D%I=%>/*2_7/\JART?".E1C#1EO4(BQI2:%'<2D8EC*CVF!35KAZ M$7M)BT6V8^/'B"J\L1JH[WY8&I3%J8NV8Q3V?^^S#GF%A>*S]'+L(C^6`S_T M)%BWG[`69Y@2$'LSUP^QU=X="Y4I-'O4VQJ\3CW0EO,$_C+Q[_#C7_^R2.0; MUYW_,O"3<1`EL)/+:;$0WQ>V*0S)2:A6"M7J^\PB\I.OWD/:"V![O\'`TE_% M8'"^SG@<8;O*\.9S'(7PYYCU7OL,:L?XD?T[>QLKM:7PX8LW_=M[+PJ^?Q[J M74/K6K*LFJHB_U]%4Y;5D[5!S^K;NCY2A[WO*KSX&T*!`V'76%W?X`\C MS:0<2E(93'1(U]D-W'/]PPML=,<:EK**AB,_=,.Q#Y>IL.*K%)"9,C)ZV'[U M7:6_W\BYZN6?J7\JRYBI'>+;'/-;8(Q/43N_]+@"6>FV:.,^`]R=%RX\=EW[ M@#:Q.TX35J"POX"K-O-B!CV?;^;#UVCNCR5+L7XN+]"!F\TG**VS)=W?^AC? M`2P]^PI-6W'SU2;9Z3/F)^EQ(*`&F8/L_C[JE)[Q_(GT9,#IT?^OA M3-%D@;]C+46`5YA,O3BF=<`C8P&TMG3)&M7FX.^V2D?!RUOBP4H3;^Q/V"03 M(!%8[)(`-9VR\HTB78F^#0'C!+"PSR+F-R%E$D4KV2\PQ'VT"+`=(5#FXE@( MWD6";6O]D,@=+_#(>C/^9^'&*740A1%@F79;&KHQUH]DS3T)CF)DI)`S/^4- M)N'I#CR-$/.QPB,^!(/32!:GTYA>IP7:#TP'\F5I@L@V+&7QI&H5XD- M1EUI%DU$MQRBG5E,R'`@1V#G)$BAR+" M2D],0$+`]Q*^08&VU#(Y;Z/+LA7?_9`AVQ69>W8$5WQ7-Z0H/\"YUO+ZNVK'R`KOL[W*-W,W6A.+H4^OBV+S9 MNC00#/+"ORJMBTA>865(S6+"CC`2]"K#Q<()%X^+L49\8!&ZBPFVA*FKXEO- M,072RZ\$B+!X#?+&V&,W&"\"7N[WN&F=20\#S;[QX2(E12+W>Q1-2$=`@%\B M#RJ10"1ZH1O(WQ)/NHJFZ;U+'==S&JB;BFPH]?(/SKR*@&$K>V#S"-+LNA=E M!LF]CA8IBAF<+X(.L6"*U8*8$I`:K`PP@IL\E-I0BN)12?5GR@JPZ-&%G/NL2+>15L,=`$Y),1(MH^]5A MD_I-X>N%"2:1AU5A!5/*8-,XN/Y/"$,'50@>E>4Z\82)\%^]+#A$L/H["`;)/^)60 M`;7XV*>^X4)RXUNI$V9I2JTP98EC(,G#PO&%=3!IF["$'6$4!B@I3S)E6S`7 MMD!@QOD;3%Q'HG#[8\]-J":\./3Q+>Z0VJ7GJDFF7;!Y"Z,ROM82 M!=11>@:VS^JGP]4:QWY&F)F(O20S2F2*`-H\(XF#@)3W3V?+8:`H<]0*,#:& M@[@7C$<7'F,7NA[>!"O8&^(4VYP?8B$&)NLQLL46P4XYR>Y^#D2QE;)8G@OE M^/*38GF!RB[)X4Q&7RF)+UMIGFM8*9MEKGR0+:<@IX5I811\`Y2?[1MCNH9N M*'UC*/='`T&W4&GHZA'88S1VM+5MX_PV+^DRY%T=?'[ MIXO11=_Y]%5R^OW+;Y^^7GSZ7?I\^<=%_V)XM<8R@U;4A^LX:%TO)>GMP6B3 M;:?'C(33DGIS6(/25WZQZ`[AK:@3[^K44Z:*7WM>2#?=F[N,@--H,1-(B"U_ M:U^U17,(Y#/CL4>Z0'Z=:8#,YE*2A.CEWQWG<\4.A#2$%1-9(CXHJ3*"<>4! M06#V`WQ^^,`),E",&UQ,-:2@Y@K]"3@,96>6256:F.W M;L(@#;@!/&["%"Q^M1`O:@&8Y*H_RC77BSHA%`"7[:@>EP3FE/$&88,7/?#( MG%MKX&D!9%@VJ[QN"A/MUTA^-SFAV0#^?JAQ,R_=UY^3;$7+3UF4M& M%68[9:X<>@CMDC@=HQ@K86\>KOA2/2'-5_@$166"GW!6U1\MUR_((^42O85! M_PVR!K.E`L'E(!54?-5,'.YL+D:AR'T'`GBNC@F0>VLM#\4N0&M(A\-(QQ0%]8/H>))0*7W>,)U4@DJ\W!/A]S9>&"7$"(> M(^>9M71C'DXL"IY!_$(-+V?81#$R*VE.P%%]F[E_>IFK5:"MFR2+&2_YQ0@S M2>\>3?9.H'#SO93@O;)R"51?4#VJG16("TYW%6]5W,DJR/!6WN[/7 MLJ91?L6*+X"-6B\P'LH`2-/68&2.^1"0E@`,`";I[-7>4PH@>J M)2_?-G#+XT.K`,P)72+BBB`)(:+S3C%&%10(.\(-]B7QP>Z>VH< MD`H6Y-*+&&G[SX+W*67N*S^>R(#@@*%\>=*'ZI#$\Q',WCKLPA>KF^**(EO( M/=DEF,MNO@!BY-*I`&;<@4R'YC^\;,Q-Q^(':,@G`87+@W&R!:X41T3ON'SH MZMC5H0K7@V2H";>^DC`.,D3BA\!\BX8Q=B@/:R%(9A8@^!,D[%./+!U+G>>$ MU6Z!Y>MPMXSD9*#""P*;>'(FU->?FDL*X'[)"%;R>M`>'HJPF7DN4@QA+EP9 M3$I`!]@(Q3/4<1%G8.USB7U$^7ECX1&(,/%6A8Z*'QM/1K M[NZAU1671U8.0!D_%GLDD`0H7S(*[*5)R2PHS^,()2\I]<:W811$-ZQWWTW! M:LW`4+Q.@7<#%SA#*[1!@,HS3I%["TEM3&((HS9$.`@54`7*J-N!N70_"C&2 M(_-$3*4^P!@.YXN?_)F;Z^FCH!3?0JZY(:TX+%L?%<2_)(T7!95G'J'1FQE' MX>K]6[!980E+(Z18;+,Q;I:K5D0LW(35QZ`_D+\#;I>XVX+IT,05[M!QV%Y= M6'1.1BTTO0&Y]*FY-'$X,0NNHSH/4"4@<-XC3V*7B/"WI.@Z\&_RLT(A!'T; M%'O!S.8<%3D"B^_E9`ZO1'A]/!XMT"(BZL5<`9Z[X]K2K/1=B3@^W6"TC.S3R;_&6RC-Y'2R_[Z8)YN+A"N4!C`K(R MW`FO'^O>@&;%YA`U6)>0]IIH8+203%F'B2&R!*'O.$ MQ_EP3=!'FDUDC!79#9',HP`(,NN!7(<5N('T$^57L0P\DJKP4M1>+A'1%'ME M2X$0]T`!"\5W#O">C^Z`A&140Y3@E)6MA`@`L])56"WC_K?>^$^RIPKF M=U@4N"B)M7]D8JWDD%![>`N+(/9E33Z7OX7T/:6(%[)P1C%G6,!3$U*'"L([ MQ7\2.R4D8)X)$H[&?CQ>S)!%,QV>C^:MBA3#R%.8P28RT0`IMUQ$8++"-EV2JHL M`Q$"1=A'\8N*)R!72X46B.X="D,K[#93<)BGB0,EAT%9JD)'`)GO)RB>LCB& M$$@@8=;WB23"9$&'/@^8JM6Z1\"@+DND%`2"^N#\E0/B&N",66W$*<)UI30HG*]%.``3WD,KN[ ML+-Q.DOR_=B?NT(QN,UPE@46X0'#$/^\)0<10S5<3(Z!K9)&)^PZV?;060K' MP4)EL"BK.[F#V4!'0O6&+P-6S*3+XE`,(&+Q(MH$A-74_9,($(JO)3,2ORUE MZRZ;@K2KPE[9X(O$$_'M_E@$8&1`SB!*]V2EGQ$O0U(,_4JR&(DQ,_'QJ1>! MR[RT\T4J-(["3:Y8A8K'G:V$)/+5INY_+R8W!;])#A\)A3U<$^JYMR[&<8%X M">1AG#OR:O9],(VECM)S@\=:F^0*C;AHOJZJ^:TZ$;55%(=!SJ7OA.$A7GB3 MLJFV(&<73A0-9@L1S>S'3"8KR%CME5ME.NP:4ZZP_A9N/0E+F8'UW0^5NY$_ MF`GL?%GY@@\M6WWERA!/T#D>62J+J4_*BAJJMYB[`N0:C^:>AX]2-`6:7PG? MX+`Q0)`TYYF7_E+VEH":ERS`'I"46HS%)XDA^K;A2^.R,?4=C M"BRC0`O1/HA(!@9^>)-?ZSPE4X\8T]1_8.]E9F5`NU^%V;5D=<4V,B`Z9>PF MX0&%\,8CT5\,='_>D7UV?A_*O2]#YW_EWG!T^06.S@WNW<=D=<^<0Y$FEC#$ M3Y6B4"4TUR!A@9E9S`.@(D^%\M`YN':!Y2%X>ZDD&X=7)2:\*GS+#.JYO8\$#`H4O7U, M@'VZ/!:%-K]J?E\0MR4059U+-5"*/7]VO8@3$K2A1!AKQZL!YGM32'TJA1@#:H% M$Z[SH47L#)`9'_`1AIJ[J#_S]E6W0`*B&`22HH6-A9EP$Z2@^I[0]+FM&E#I M&H1Y3(KCEBG6+BMEH";C3;9(OP)K9CXGED6NB(1F&V=)Q+B*%@8!P2`X),Q` MD>-IE:!P)D=Q:2['J"P2R[U./!:Z1$)3>069Z9EHVV(ZQ?6$2Y!I+1\'R&&X MI@*-NO8$F0*`9!2=LDQ29O,4&51<)`8URLLO@E^@^<^A)!PH>#VN-<1)B(R3M8J@BX'6J8OI():MCA-@),K MWT(WB[N"X3C^+%MZF6SK9D?-1><2"12&9M$JKZR5U/!OKBZ0-,C""3/?`4^` M+RDE8FX_R?2SPTC'7^I`+G;#`QSXAGBI@6(@(@N8*H1>K`N\(%-%??`%J5/, M"D_A9,S&4P1Y(:&8WT=!H4`N(K)!`D[F50(2.8_$,H387*#,-D#@H"ME+J@A%!M8W=1*8DB'BS#$/]& MX7CB3YB;B-261[(Z8*3<&)T46*3BL1"E0@+>FC`;)G_Q#(1BI$R^]M)1E@Z# MD1MATN8A%*E'T@,EE,9XH]"$A>6,LL!8G)%BS'C*;"E$YQV51>`!"*O/*&NV MC#\4UTTA2IGI."7!45@BRX<\H\P6+RFJZ66TQ6'"C-0+C&>F@5P%K,0D9P(I M+]K$^#W&;"P)M>5QV5LHI03,;HP:93FN=Y(//2V>7=E=!<`#=*.D>':*U*RZ ME"A9:_UIH*7(!TW[+@\3(PR?@4@L.-ZX MLBS2%+DPRNY6GDZ.1)&4$2HV0M=$D,K<6K\J-K9%)OPYI[Y4L"*2:_A M,?U(MRAAA(_,;D4@HISP\MZR3!BQ.2JF042ND%V7Q;\6MH@1@``E/^=JB[2< M49!1_#:K.;.T;7Z]2"`GL_4']$+/T^*[/R^I'46;!P<"Z45H_PJR.+>L=D/( M#8RU=@&V#BZ%,R4>S2MHH(,Q2@:A:!$OHQ(9]X`+>>0]+%:UFE'MJ#M4['+? M&U8\8GD"3)U'+L#^NO;&+GG^/&D256T^9/DHRW6U!H$"?`EI.=L45ZT-]U?P MX"GYU,8L7Z-XOJ*P"%?Q&*4O[(_?/B;3MY8.I\CX67Y5PD61#&9UYJL\R20N MZE`'IJX]$?T/].B:![4?OH1=-478N>I+MF(6BLFM7C?]7-5CLW"-,GG@[G(> M2,5MV-P)/,Z3:\5?=#-M!R3A*ZS"LQ*GY< M+%%9R./(<$/0O%G-RS' M%J4_JI6&>[,>?CGTF"Y>OW=*90%:C;HQ M4.TL&8,+=8O$JU![PH%"Q$(6*'O]6,I%9C`2MOUW/ZQT4ESC#<\SWG!?&&Z0 M+,W$I$P:J1H)D@='E*&8(RLS\(V93%C%6N$4J`4T+`$H-(NZPH=87LDS$+F$ MQN]^J$5D&+N,!PN6!PGT&(L8Y#K?4P+L)%J$DRPZ97SK MPVI$E$C)XS_S@2>G$1(7EO7"778H]G%#9%H]+GZHA!,\/W*&Q0/^6TI!(O;" M:I:PB@8LE$S$*!_$W%,J:(77;@JR:>KQ*,=EQ,D/MD!25V0>Q<(#QV/6B\E, M%%W%J@L@36:5,F(6^3REA$"2/4"=+D1-%D,EBX&2+IY;EN3$0C*?VHA(-J`U M<77\W8KHI&QH+\\,\PMVA^L(4+A0OX?C8*GJ31[A5'%]5BBHF.L=SPVE:CH1 M3[,IACI6R`HSV"6597";/ZL.RIDF`A6'2Z)`)-"R!'9_98`DGG'"#B?P_Z2R M3AB=CCXG&!F)&+>15_1X&Q$VGU4S$O$:G*S.R)9,,] MX$@!([8T1&FYS`W2*A^9$`#])'>)<67-C9GJP>5(SM01%C7TFI4?$T)>/Q9V MS$T2`:NL6H^Y>>Y^%6$Y%/@`2YFMQ4V37D3G5`<>VI3+W#39:IE260H!I=-9 M,NBP0`WFU^`%3@H7N[B02>Y\X3[7O,8M&7`0","68`161O=B5@WPY=+,"FKT M+LOC+.L1G+;@%<5P_Y#D.#J$I%`2K";)F,4?UA*,%AT,UMLJ![6QM!7NX*4P M@Y9KFE*%1F"$1UR+"5@CHT8(5Q8!&W>'I_%*0SDL\Q>29]7*T?%8R:Q9!F M#WE#3NI5[@PE*OQK<1N9Q8%4@16S^+)A[*AJ5*9N4W M/N(CM87T"V6PA3I7T.63+#"$148?XH((PL8D=,U'Y:DXA3@10"NW55P13]:!K]E6$A^T-S8J.^9@G^)1<-D).>?0Q"SPO`>_>N3`+4ZSI M04JZ_1H3A4.Z_E\OCF10'N>D)R0+X0486KQ$#L4UB\64 MUEEW._%<:;S"Y:]`\O"IU!G*EYNKN&D:^]>+0I54'G(E^!JY$&IJ?+1+5SM7 MNY-WI7A$9-CWU"X"J);(ZRUFLMV)^%T6X"&F+S29D;)B=(5`I(*=&(5(2BU@ MH]SY"4;3^8BC6?4Z"ME,%M<)TW8S-YX_%?%,Q0G7U][`-.[LT?*R*M[Q6E)> MP`R$0^RC]_PP^%%[@F@]*)$34;2;M?@1)"?AS1IRCT!>5+Z&1O(2[87B!-SJ MAI2$>]B*#E5V0%@TCZVA4`'@KN"J*Q1R9%F111]R+@GET_EQW729RUI0;RSU MG]75I%N#51RY?ZG<=^C`S/:?O*K2\3#76Q>#C0!#>"F,O/"3A]',C*!4BG44 MK;(4U97P<+CU.45T5E@\Y%V6?,00M:[65*G^TQ.7].+SY0'C$&O\.#Q85L33 M987I<_/6I*3(5`S-)"UZI,JT5AP.JV&9`?O=#TO@SNAPKKO0)9MXP&G)W(>_ M!6@Q9\FX2645=05)"LI'1M>+OIR2Z4/4D>%U3B%_1J$]FGG4&JV5E7D]?"!=`8.^S46X.(O_*A3< M6HGO/NN$Q.J-U!Q_!G2JUI-?-\H!6EG4^.1 M`@8186!HRPJM>&.DPV%$Y0$P`C1G"QD:4*+*P>4MS&[CC+.6&%6I',+IG>B; MQVJ/AEY>>E0DBI(S`)10=J$^)"!/?XH`N;L_5ZSJ2^%-I6N39%!-2]8)010G MPE99NFEL/SP[::FD7;1(!57!$`OQHI^4O$=K9`2Q@SKQ(5.GN'>P&%>?BY,> MQ=6]^Z&T]%;^0$7!RG427[10BGG^>+^4NTO^).:5I$A#0CKR-!#QHJ45(SG( MR.<&CU3T&1X1L7+,-T`Q>'DUH"PV6I0&S'435@XEK1/C>3,NH>(4/<\<#/PH M.1@.'HLV`WIR"_03P?9'E!Q88/DDXLA9%G)Q<>QKWH>"Y#XJ?1T$A28@606A M`X.U::G8M%1L6BHV+16;EHI-2\6FI6+34K%IJ=BT5&Q:*C8M%9N6BDU+Q::E M8M-2<45+Q5.CRB_Y$4T1RRP>?QX.?W,?8*? M>4F4;:U?MP8C9S"PY7[?UF6CWQO(W:$VD,V>,3+MGJ/VACJL7WO_V^>LK.3< M?90GT7UV+X*(6LX!_2/W"!+)Y5]OBR4M:^?FL=FD?#,]G)P`8@%/KD"IK*"X`/3"XZX$/9=0_"O(+T5; M.4\3F&2YRECI021]9WES>;X`O,+IS'6NR?R!:W1$JGD[1_A-<:.,48%W.15/>!,.$0>C-RBBB[OB_R&B=YT\">4KHL/VFZGV>YJJVP/8
V M:_2TCMRU%4?NF8YN.:K9U7O*OINI5IS>93=(,?F7A[V@3ZO&_['DYF#RC%R* M/2LHE5EY1A2X/(S?\2:RRTO.%=*!?GFY;J+A%ZN*%ZX.(DZ)%/`YG@G8WN67 MP?"+W+_\XP_G\Q6\1.4'YHGW'LA`$"3`!6'+?WNOL,]S=S(1G^_]27K[M_== M[:?W(*$!/_O;^S$)9N^E:RKTAT\5EQD7/TS$^Y;QT_O,/)Y.RL_<\8&OHQ0D MYFQ.:_4KV_J^F7JO4_^EC!UQ#3K;3V'S^[5;H7G+E^B)S5?>6/\N7R^_3^** M_W\*_9^D@NZ3@'0W>;\$8;AP<,O@"ZMZC:JNIJ]852E?QD@'3E/QP+B!J<1BEJ^;BRLT+!XRRP\LEM&F]CF\UI[HA. M/"W*@=!U`SN(0.KZ__K]X7`T6D$ZTFA>_&7^0L&1BZE_#$=?X05O]JOT=?C_ MOLH7GP;#3_"-#%^):8:EZ*`/H"FBRSCY>=E,LDWB]6I<$TA`M2/H?;-M;_1B M&-W'[OQO[]E_][SL[6Q4?QL;M=K*V]BHV59WN]'M$+&C(UEYO.+)42M#:2O& M2P_]IU-`:D-KJR^FR*>Q0Z5MF^>]0[5M[P9+SUVL^E(?.WUR=$IM6]VS1G&U MW3EO.@Q7N'/F&^R\6$[<`XTZ%HJ424WE_.V]4J0G)-@7C+",#KD[AJ*V=K34 M76-Y`Z@&4`V@7J?G_H5\K\4OEB-]MNK97Q\>L?T`@$[/,!U]V)=['<.2#4W3 MY9[5UV1='P[4D6)8H_T'`-3F8>EMZ=/PJ_3AC\NKJY^EBT_]RX]#Z?/PBW3U M=^?+D(ZF/@OK_\BR]'`=!ZWK:/(HR?(>-E"(8&`!+=17S4NE#QCU++*;"['/ M&)Z#G7IXZ"F+T2,FFQ=E7WZ?Q_$M!2N$"PH%HE*@(NF5Y\+F":3%:G![+[-0 M"+H>E5K*/-U(QFAE*<^W+'BZV%P^ZWE4*OLT\0,":DA]A6S4(T-^YC1.52^0#5EV"<5?NF!FR%O:_8N>A'`R-1%']Q M]Y7&/B*]M[3Q\C/O\EPO"6,TZFL*2_!8M22Q36EJ_/"Z?G3 M8912UUU1)85JR:\I.\';W2[/]NZ'0GX\YCZDL4]R+,L%QZ@Q*I*_8B\L>G5= MF0R1W[)V*^]8.?BE[NP4CCJ5\W1_%OA;7E`%SQ%[G@&6IY:_:EDIKP(ETW,P M"E_:02C%UV*0ED2,.2GT(12U&`HY9FO*CUQG=+EX/5;1YP\^:TP7+1)XA?+= ML5&"N$7AI/`L%J/ZN0D2JP:)"5;Z>_8^Z+$D5?$D)GF\V/(.H>+ MIFJF;F+(ZMZM#UV(;ZX_*"WXY^>71TAE8C+%D$DL+DH:KA(H*N+RKFUR!X?* M%0A9^X5)@ZM'&5!T#'O>=ZS8,>RY.>T@SR MGQ8S3#>/XE_6&(5V[C,]U'/-FILUGYG7\5-5,=_[;?YQ(S5HR9?Q06^I+X_N M^7F'#'![>[0[+XX,V)+C:F^G:;8,\\6;/8W3_&!HN]GAZ<=JZ6MIE#.9_)*' M:8E"W[QF%!IEGS1R4XN@&RJ(&18J192S7R=>[-^Q(@GYV&C=7C?Z7LGEF_`1 M'V&,W8O9S"%VW"!)`[(7<@FE'!IP."F^RENX,8$\-B5+P@.W)-2&J6@O52^)*E(&N^)`J>%KLEW$;!1)2@;JP)1[%'NZN= MDE#66!..UIIP:G*B#A1^$BV`3.V1K;Q\TJ/ES@T<#[VE!HYG#,=-Y,4ERGM+ M`>I_>V^O)KKY([F#W3B%QT_?L+VA6WW@A=$,+_^Z&4`K)_U-Y3ZN._?-BBUV=)-LZ79AR[R MV^!*`[(CH=7'0IFOFI#TT[UOVZ#-JMUM=33KE+;=8$H#LA=2YE.+-SJK*-8& MB@T4&RB>$Q1/WVZQ'=?[RN)T[Z@G>^-\/TW9V&IU]6[+M!KG^]O9^=$XWT]- M5#VS$-H&C@T<&SB>'QQ/S7R[7D#%::[Q[^6WZ.N,63:!3L^:WL>9S MUT[K[WRIUK_,HL+W?O%?FHJJM'>4BWHT6U1>T:3M4$K5RT_3>+%CZ31.$[?X MXESX)GGZI"7)!HX-'!LXGA\#8P+&!X_G#<5VCET(G%_9HI3WQZBZ##^4N@_BYTFCQ(=O^ZKWLJL^CLJK- MXQ,IUANV/5WAP&C!FV-WD6`;5\^/>1_4=RLZGC8]';?:T]%2GM_343M<=\-F MZIU,W?3)6]F]D,]!#E9JZYBOA/4RS#]34\/\XUOM]UB$V)7_<"SP:G"\Z1'8 M]()LSGE7%*7I!5G-/67!]-&T5.\=NR3]&RLWI9$4+=(D=4,4>0]2V>7Y2%T7 M46RJ9DLU3ZI0R38V;EC=EFJ=G!6[.>\7;KRK=%JZNN-N' M&\=NF)X>130[5DOIGE3*^3:V;6LMM7M2)5":PS[JPS[]^-;74D=6L"0!N9`9 MDRNUI0Y%)-]$M87CNW.FH;:LTPJ;:##E?#&E:<)QWK)[4SGK=(E(`[(&9*?! MJC1=;^FJ>GA6=186H3^"9JT555KV'YP?$WN-C[]`/= M*R^^\\<>/=IS$V_2CV9S+TQ<3+OXA`ZT)/4FSKT;3Q(2;8N_]Z,D_12E__+2 M+]XXN@G]_WH3F->/)J,HYE_A]&_OO2CX_GFH=PVM:\FR:JJ* M_'\513&_7WT=?%=M]3NF(2F6KGQ7WDO^Y&_O_EIAM.UN_)` MZYNRT;,&#%2"R[A_ZX8WWD58?,`/Q_X\\#ZY,V]KL.M9G@^\56RC#XFIQG8!* M!"\.[U`GRC!T:SL=6+ICF!T-]F>JLC&$OYS12).M3L^T5'O0[>LZ[%1Y_QO> M(7Z%]GFA`YY\IFIMZ>I;[VKX?[^!(BD-_P'_IFM]G1&B>1T1NE[*$]O5LJV: M55_=>L%4&OD!G/.:U>YA29>AY"QN%DD*@[0(95M8+4+"&^N&C]+4#[R)Y$JQ M=^,G:4PW&%;EIH2W4A3"&'!O9]*5K$L?\?.R:, M,H-GL]!F?'KLSGVT*`0I^"%.X M\'1*53P^TFC219(L7+C'TI4;P$:.6$\)S.SA,H`7X<2+.>#\%+;]*"4>P"\1@>$PF)\F M91L+@Q:@#0*2_NN'N%OW!M9Z`P/$D)HYJ6WT00' MF/DI^DCA^\"]ER:X!.I`1,5/2F?CIGPHAB5%B`+$IL"APAO)36",J1\2-DA? M%B#W&+#!:%K!9QC*&:^G^6CEU?#2B?]_&T>+F%JXZ'V7F_NG%;1R$`=P-DBA'I0+,`1#SV+\##('U MA]Y-E/H8VXG0C%U@^F/*/VT5\P\*MZN\-A@HBN%-=SZ/(Y"`V[GD]K5P(XD: MS&$M8FVT*4XP@#,"Q&`6_2<8B1_-31PE.'R$Z):(;]D)P*1P?>$K-[\C2037 MCL.$;@L>/7OL'L7;)4K._EK$$@`$$]):?1`9(@]^_70W>`[:/_1D<_=_>R_J2 ME-#MF/80!01;TPW9&.@#V>[T--FT]?ZH.U"[IMX!*4'3WO_6T768.=_XYCLJ M0^*+-^=O7D[_B,*;KW#%!]XUOM%G5+[`5(X1%MWWOZEJ1S-*T'C.KJIB<7I! M99_^0/S>YX;[\"_3Z(SDCNV@B&B,9-L$$;&K=(:.92K.J*M_!R'1>O^;;((L M6=IP:=G5$X:;L-CSZ6VX&1T.S]"-ZN&Q!9>W<4%"0\*W.7Q`_*ZY9@D\UT49\LB9"!RE;&B=,A.I67R5!H]C MSTV\@Q%>A"AF1?&12@[ZX66X_/TQXF^W1)0VW\O2[>5<:!1'LWZ$5OP%7'C. MIJ(PZ7G3*/;8+U)LE0"D00'$4!$0KF`A^E,3.J%/L M=@B$-8JO<^?Z`1*4KU&?K%LD]]Q&P<2+DP&OE+Q/&-J=@36T^D/9L;0^>MGZ MQ-7G@:!T%V**E*0[3)Y_0C3?9V5-,Y'/LS5U_PEE.0ASI&*\A8A1HH4]P MD;K=U%U$P"W^3,\+O:E_G)?(+)&>%2NO*"?OXK2@<,U+:TL MW3Z]EXKV6>MR/L;]`BY;7:VL>M8NOKS!D>O'_W"#A>=,_KU(4G(.3__)B_$< MXS[M$@*O77[E*#VB[DXX8]/M/,66B'*#3A`OO,D?OGOM!T=KM51VF$>ULP"8ZI#'"`I=!8RPRGK/<_:TPOXDV/DQ MWGT5E2';TLKZ[=+2E^13A`XS>@^\QX0TY;9PP:!.%'G9!\C">O MH.];IL;@2RC,*<',AUM!%UC(Y!MN,VJR23QW'B,MV\`>GD0DP+' M:HV*].M+5C-]^.#%8S\Y4L8#@[8W8QP*&;BEZ61)_8Q@8^!I18K]S`/5J_&+(-:\G2N'XCF_I6/KN/1^M8 M,8E$6ALZ5OA.GMHX,^0#A(YYYUW4N)[8=W4CY8T/O'D,*Z'K#W\''G$-N"0% M_?48MZX#KIME`6*3K=0[3\<@:5:MBL>X:;7L&%ZW?+;1\21T5UC4"I)![S%_ MA$=%4%I*QACG'M90^AK]`]25R[QGP#^I/*LW<>Z`LMYX7[R9ZX=DY`B!N([3 MA1M@C-[6\BUTM=]5#+4K.XZJRS2"T[5-61_IJMGOZ(;=->%]1<7(G<_=?^D? M57OPU[\,H[].3.Z99'&XNS@OSZ3<;E>1!\H`+J_>L>1NIV?)`WT(MQ>DL8'-TX`P.MO-0OPI/MO#-<&W*45) M!R";Q2+N.G"35$XCF3\R=[$+*@7^PX_#H4,!Z5Y(J01)GL!//SN(DB% M?Y*?ZA:P=;Z(O2*::LOT8F`.U7Y/E[N#H2(;?4.5>\:@)]L#W5),9VBIML.R M^)2V8O(M/[WVXD9C$9/\V0O1[[^#?=7%$77LP:@_L#MR3QL!)>QV.W)WU%%D MLS_4!I;6T96>PIBDN'I+*RWLHFRKWEM,R]534,#J8N=N1;;OO`'O3';G7U>"8NMV!W>VKG:YF?]?YN9AMU=CJF:P# M2`'ZW'OZ.0K\\>/V,WU'M@ZD:6@"3[=ZLM$#RFOW1B-YY.@`%'4P4+K])S-] M9VY\XX?`T>>_J-3KE7_!:A?\0NFI4UBPG/C_]7Y1\\]3=^8'C[^LJ;)*F;'_ M+':C>2)7MK`6:WM+*6:?W;H3D$D\+VLP)IKE2,!_K@/6YP^R_,5L2O@[&[BN2P*\^'PI34#L M:F\$2-;A?3N0Q-S;\3B*)Y0TF^4"NUGBNW2S\-F/F'<:$X0G+--QX2>W\!\8 M)2@XC$D^Q!)AZ6-KQ<%@2F0!T'@:%5"GMR"HPKG0Q6*VX^`15H`IHV0DH=]` M<$W\J8\IT4EE%0S>TK4;T-J36\]CN:Z@N6-;^0F7A/U80M?8C.=(3D'6QUH? M"Z^-2`:GF"T:9XR!GKC)(F:O>RZ@0VD&&&%"N;GAA#)#>?XT"+O9)(4I)#^A MY;"J"_@499)BJK+'E.N?,645U.V6%/)\4\J3%`G?A+51YHS:/_9\F_,EP2*Y M'40H`"OQ'+;Y/PLX3!3_6S5'GP$<+UKAFE&^=]U%H\N87[460K_%L1I0)WAD M.?0".QYA$()[CCTL]YE0EH[NVAMCH8HPDH((SB\N)LMF*+"<6KH/B)\\(_<(L[]([4:5-=LZ_91D>5^X8#PIFC MV++MZ!UYU%5'9J?3TVU'9<*94!B?NY\"*"XP<\$-/B]`A!E?\HH'NQ([E=ZP MHZDC4(=590!ZHC&2G5[7D4=HQE"&?74T4HZBP`R'BL3`(@FX'+QJ"W*TO#B" MIK48>RO=JW$0H?,::;'/MS&G;5!=!%[2HE1-!-AEN90(W#BC!8>*_[^6O!,3 M%,S!S>NKP)R:5GV](JABM0RJP))O2-79AI"W8#1P5C;"XVI21J"!6+I>_(#D+]Y(MD'&:2184BF#-JUL0^'[4 MVXHHE])B4LN/>K>MB>^0UCM3M+>"V+D8DU"=S>^)2+LY]_Y=/Y:0AHW?R>OH ML"5F.RJO7\QNMK,"+NU,2$,Y"5"034]O`7ZUBF4V"!=6ZS_P"B)'N9ES23S+ MFH>LP"Z&EBYBZ;J^:K5E@<2,4R\1QC^+,\_I@2>[5V(OGQ>H-1CH&YHSZC@."R[`O M.\.^+EMVK]M53*L[&@Q9^@?P!UUL=+,-5-*YHR3)`MG&CU=>F@8DSV7>JGYN M97I,7E/I\+MJZ:K5Z3[`OS2CJRYGC0Z[MFEHFJQ;(*D977LD=[L6R&R.TNL" M#$S=@D-&2RF<\Y=H?.L5DKR?OX_G`@(-UB\6S9_YO80#@3!_\GX4*C"*('Z$)`91]4IO(V*&2_*1F=;W^9Q%ZDJ[4 MB8DT$TE*6%*+C'$Y9]-:MM8A!@M24&'%\-O<1=U2Q.!(DX7W*RQLPY49V,AW/Z_83.SAW+1;/*W_+.!. M>W%0/#=$9\`EPY0F[F,VN`=OP)]DX1QC`LG$C<7K,"-,R.'(IX*EKRXI-X^2 M7Q,J8@@S<^>P*/#FSN>P$9)\\S6)\R,+#-J)6FB+FRYBRI4MKAU&N/96RW[] M!$L9Z8K>5V1E9'2!$_8ZI`LW2K;VIFA@3/RW39 M6[#7,B0JFU1'G8&BV(ZL=LR!;-@8OV"`^-Y5NH9M#&RE@\9'1='0._XUYP_, M5,MM)C"?5JC]>L^MVUDTF*I4@[PF!:MQ+@,)LW*V];6A9,QJ(N+*.,5G66*L M(JN7&77ZH)4/'F#-X]LP"J*;1[$-8F=_N-?]*)ZW)$"3P$N2(A]DFR&NZ_(: MLUR$RY;]RF"SKWQP#"[8%G%?>^0CQ>@/[($E.W8/=#E-?62>X10.>A"WJEJEV=Y>%0M<;:)]9CLY_21[* M_D!BZ]H&7.^E(-$XQ;.Z)P22+E"S%X%$<;21INNJ/+!'0!]'MBH[6%BI/^SW M>U;/5,WAB-%'`(E1R7D\:IC`Q5>MW:&)@6B"Q1GUUU\=M)HE*%QXR24\(8)$ M6.$)K"BR#7`82M?<`!SFX,Y:'5[0Y-NP?? MCAB[08MJVRBEU*[>[4'A8JBZH17@8FBVHNT"+AIGPTK;?!%<7I9I6Y!D7@4\ MK6NBWF'8&B&1WK44^-PUC$YWN1G)L*,,S%%?'ECF2#9ZO1$(HB.@NST04'NJ M:@R,`2.T&A-$?=&2@=1UR@"0_%*0D`@?`I5>:YF*4DPJ2"ERV@_OHN!.!'84 M(G#(?S,=?'(H?"J^<4-6YWZ.A?^R2"<@'S&YP\2(=7&$)%#0K($L=: M36A*^[6ISX4#65%)J!`)\$\_O?T61M=H24+[Q07%?V#90M#)`I9?]@4KC:,9 M"`BPGV0IT]NM4((XT%$T8L!P0UXFD_2'2L_L6WT9[B(PFWY7EWL=IRO;6L<> MJIKC#)WA]PY>$ZLFTWPO\%FNG9D6;^2TX MK;VH:QKRZI8AKV\8\OQV(>7"ST\`OU+3LM('#,][_)KSL4$>(LZI6<:S(M=? MVHE*<,[5O#K MC.2>WC=E$$5&7MM M0-,V[B*$]$3DW;\*M);9>8"KHZO& M\[DOZ+7FH(]ILK8V1.'$LJ*.*A)65E^6,D-% M%-EK_4`KH+I!`)PS0*P$8)K&0`:2@?FR'476X([;(V>H&KUA!E&E;9M;P-0- M8+&ZHILH)PW*'YW<-XQNN2"2`YP,^QW5+FM7>+NY]7ASW%71&U>V'F\+`C77 MGU>?'U*R%=8BB!-V#:[FP4&5S\:_M@#1FKWM"Y-'43SUT%ER0LB,=<"L_:#R M$GCV=2ZL7,D)'4K9PKLOP!SF."I59(C>(1]_=?6\->?U$H\%9D[U56LHZST0 M80VKWY5M9>#(?6#LR@@K(&D'/;TGX;AG*@AZ6'*<9[NL$FY^MEBXN6UT]T@N M-X+C862U\SM>;7_'^TQ0OK*<64*+RH8]M+2GBF1*_145R2I[JEB@147]K"S3 MD%?TX'TJW("IC:\#1:=#9GE0TFH:RCJFVK4ZH/%BB8V#!W'T$K;L'#R9QIPP%5 MDX+G70G+$&.^F4\)U2Y5L,(L!_Y=*1.MDH0TQL"=A.+0;^&_44P9]M%URFN< MQ)X_NUZ`/DZA#B(*'J/H:75L6:RX@`\#CWEF&,R:EWHJU,[*ZJZPI?K)[B?\@ MS0`-;K$"&L;6%Y,-S4(,QL9851IYX8LLENA5>OK:(,61[AB=X4B3 MS9'9P90@+`W@Z+)FF*/>0!EH:D^KI$Y8E%*9\E/C& ME8$+-6LOKP/_AB#UT4V1KCR^5E![?4PR1?8;>-TU15SWS=9=V6,-/GP4]Z00 MOLIDX_"AAVY^M?Q7V^]P]G%8TLV$H!K%3I:.]L/'`AM',U$/ML'', M)W,8&*>XT\/0#G<8_&(%@7L=L7Y/A7HJC+P\TX@`T,-T7<5X6:)TC0=[TQ1B M5A!>X2[L37=6[%80H88%'`(6N`@G".;/K`;&Y?3;'+2J\/GM&1@X])7EHH;? MOCQILNYH?5LS>K+2!WW!<#13=H;XT1AV.KVA;@TP!)34>;.P]\UW-O6DWKOA^5&Q MBT(_G-6;JLG'*`D%0`H]N/(@`KPH+497V88[NKK##9->:U0ZTCUK1]5>9:+& M&V9]8C;"99A_]\E[SITE`!@,`'E:D`772WU9Q9,1;-WI]3@O[%JZ['1ZJCP: M]/NFT[=,JX\]DF'Z#AH_RF%(3VYL%Y)%P6S$Z!\%17K-`>PG+=G@-I*&EI_* M81%MUW;"?T^7MN_Y#)#6ZZJ^;UK_RDSP99`=(!-<.]),\)<`9UL0V5$F^*Y$ M@R/(:M1?D]5X[-QD3S9\@X-1;IC)08^`F,E.3Z".EQR%E+>-$]JM;\7@KM/& MXG%:1P9T36W,'P<\`&V7_L@Z@E9?T[@0KB)\=E\C.#L0H&:C**9HWJ14W1'D M4>\9R278<`*]E9O:F);E1'78[_=[MBVK!@@^QE`#.='6>[*J]#M]?3`8#=11 MV3FWDRVO3ES^@]49'GE>(EP(1PB?HN=VPUUL*=R>)3.S!/WG9R=U%18TH%?@ MLUD`9-\9#;N.8\G*P,:N-_TN",SJ0![T1P--&0*$E3ZKC6Z#`K*%@/BZS6ZC M1W?=N"](0%@%S6>0N,T@"C*!8>=^QMWL>[WZ/\``UN?I3WZZ$ M(AJPFF\>#OUZQ-J,AFW4S4S[#IBDVMV.9I5,):_9X);H?]VIH`%B%'N>Z+OV MY5E!H*O@636A&"]%2W*L*&K'V`)'V'3[!\T[>!V&;E9'#V/P5*4+T^^VBMZS ML?YSS)LV4DS(D5UK^_UO)EE$E5?7Y;ZU MV[[\R\+1AL*AAGFZ7;UK6@5L?>:&7D`:E\%?R&DY,NK8P2!-4'R-9Q+'M7O< M"(.6(/U,;^,^\`<+;"FJKFI/XT_]=K;J7SV$>F53;;O.L_RIG[PT]S%N=7M/ MJ=8;;@KD*+M3CFDMK?FU6;E[VPDP!ZO3L92GTW"W&'C[S-V],-"6%^`N.T6> M&64KM`-VLKROSB[W^@J>-4C@)'N$UDR&5T M7;GZY2AZ\8MX\$A/$N^D6K83KUA]>8L\_B*\.6[B"?N3=<,L[:]FZ;4XNG/, MK*MG8`\VAT,N'7?KL'+>FPD'\>G*(S* M^WYV9[+]G9I.57_+A[9V$U4>2*5%4F[D8KKP_@]S-+1[`U71Y5Y?,V3#UE39 M'@Y56>T,-4LUS6['&.:NFB)/7+W\V@:\^]]:SW9`^^LI\DC7T2V@6')7M0S9 M4KI=>]CO:&J/U]TP:WOMUN[F!:%>PXD4*!6Z.ELYI53I7M^PUXKQSY_J!L(^1C]70L3([K-BNMZQ?I7 M!)@XDW\ODA11Y'+Z3S>FFF3[W&IWU.MTU2Z0PY':`<*OP%9['4>V'1LP?:0, M#;/'"#\6HJF/RZG;0\5G,,/4V_^Z93[QA^=BE1-T[!_??5;+98>>VD!%J/:( MGH'LS8K-8YVJHQ5A,.G2JLK5*S>P0K3FOQZE8`W(VU$UM5ZP%@O?2>OXO>W1 M@BU6R/`&K>+S".P$KJ[0GXYP>T!H,3:]M+_RHK=1SBHK+D>N.RP;5/M*%LSV M\I"$W4&J6R);>X+#;KM,OQYVF_4>IU+<>MEZ^:*.TL#P8S>`>^=,9G[H)RFK M07*\U,.FK*BR$OO$+@J18T)JOPRO%M=,ND\13.CD37T0_3Y%*1K7+J=H6[P, M!7IE\@,R5&%J_.)A:;3)UVC-6$ZI=7IW[5WK/XZ MOF*GO%*1CC'6:PK7;5ZY2+/[U@";[1@JX`P(UGW9Z>G8N=WI#4V]JW=49V7O MG?KM%>Y<3:U'Q@_I"Q!-AT"RT\="N1#\.>&P+'6C.DV@*:QM0G[EM@B1W8N" MSZ^-M7RW;$,?V*;5D3L&9BEV.@/95@%TEJH.-$NW^J9F%AJ3O5`TW"DS1S`` MTE#RKV6JF^#,"YF[R%^U7\W=]P806]=>E@V]F;3#B6[W=`#2[1KV[@"B\^2C M[NE`Q-`TU=H=1`S>":VB.;\((@>,&=U;9VM24\^JJ?4:..ZPIS4AG:VIW;FWB=`E)I(QPUVMMX6(1ZNC6E%K?-5_NS-P+-Q MQ.Z&@,(X0J5MJJOM#1ON>CWH,D#G7M5JK8*+<+L^\OV9;C31OM5\PG3S&BCL M)/?6W%]PN$JYMX!KVIKH\"-/OLW`]9+<')4GWW;?1/+M,F9M,0]%K3@$SSOO M=AF46\K.4T7>K;6-UH0OR[O=,B_=#D';J*F93E(7@N^);).@&M%+`;B9W0U#7S1-,11SMTK0GG.W=\P5[-=QA1/+ MVMXA7V!9VXJRJWH,)YFU_32\7YBUK9Y[UO8FU_Z%6;"P9V[O%'?49N+-)RO:+[^VN.Z%O53PV]:%B.+9LZ`K&FO<[0]`V<'R?3[M9?83]I+MIU-OW9_VXC*5"F;7M95 MNYQUL8-\^CWL1:<0_$I^76T^_;92R_=Q0&@2ULRR[7S/J>5[V":&395Q<+^I MY?LX24!/I5(C8%^IY?O8'MI?--NNI"D_E5N^W63L?>P3B^(;Y3210R5C;[S= M%R9CZUD([/ZSL5^QMXVRL4DBLD\R&WL?6&[4R05[2\?>>=;R:T"XH9:G/RE9 M'2QO>1$9-:TK7G"C;J]C-8];+"#%=>U,FW<6T;K/@Z0U>%05]2*V4-*ZQXV MB79]LY*6O+>:^^ M/HI_RXFM>\`<2FRMF!TV3VS=JB-V-Y;(;;1$H$C<3B%[=3?[/J6,X3V(H*S- MSNEG"YO[SQ9F!G/3J-,/]YB05=CYWI(8"6]TZ]6D?&\0V7D6(R%#!1>.&B(O M3F-4'&VDZ;HJ#^S10#9&MBH[:$GI#_O]GM4S59-UWV;70]=.!B2[SV,D"Z^] MA8.DQD)\\R.I71WVUKD6("YTVQ&5O;! MQ'^,MP#-W:8SJI56C^<'Q_UD,JJ[SV1\I6>?>GMW.AWJ]0U;>EG9Q`TBO>F" M=C9Q\Q\:,_:2FZGN+C>3%$=,7N'6KY'W'$%,JS2&?VTMFH&B]$T34^AZ#FAN M(U65N[K3EYV^KG=Z*HB\73,K=E3*_2IO@>^-[8,F><4^:#`8SJ/"/_P3?,;( MSA3[-<=2,K[U9M[?WM^FZ?R7O_SE_OZ^G7CC]DUT]Y?^Q?_"V2G8`!6$+6`W M^6OY4(EW@\:/W_[Z^&,__>AA()PT\>%7C)C^V_N)Y__RAW?C M!JP,D?/@)^]_(PC\X8*>[J91_-B/XOGEU)F!+C]V_QX%&#F7L*'^^I?:&7[[ MZU_$$OAF_U+:[5_G>1(`6W#JQA3[]1L"3@9H8E)&_FWVH!=."H]ILJ[BT)/" M0W_]2V%P.$UV:,\]P;7W\JA.,`M^B<*;%+`6,Z.^/LX]=I2Y!3^SM!0-,/CP M#D_2E#&H\,F3A,QD[D8Q$AO[-!+`M=1'OH5<%?68CMPD^1R2G[]E7>XG.CRM@ZS MK(4?;,YO]_"_>$D*>EG*.<$WT)&3+U??WA@RE#PV1XD,+)HQD_+^0!\/1B]4 M#W-U'-G;/%+FESS=(WTBK.>-'BJYWT_W4'D$&;BO-$#I(B2TSW`U5'7;^P\ M2[%11WF>/'#L,X"L6"6_H`OS$"OG)O;8D8LXV3=TECL_N].$SJI*@D>)Z37U M!@M8?C&;+68>R/H/0.%VZGW9Z.R,O9Y=XWTYDY-L#/'G:F.(/_$#;`SQYW&> M38CXF9Q@?=?AXS]1<2,_@\2+A4=FZ9913Z`Q#,<@% MB/G_QTDGL[(WO<>,`)(/JG0GK'=UAH?)QIJA:)2$ M9UL*_ZR3C+#KFB]QYX7CF]GH+:6D8`GWB5?O+$'V`"W M>UM2=,T::F(-@(KXZ=*CVUK#%\PCK%`T/_1!@']K.&T;'<)94[..%&<_>?=Y M5NCG.`KASS%)Z$,W#AZ=231?MLAL^-)P.O7&.W9U'=^9=Q2-K&Z&9A^IMD8> M*UX/>@C*=BV?6E%@E)[$%4P<_NY;.U]+,8`O=>"[;J?A4Z?,ISZZ_X[B_B)) MHQG_&C^CN MJHU+O/A\N5NL[FQF4^KL]MAT=FS'A=3Z9M#1=PD=A4'G".V1.AH:-X+.SNR1 M##J:8C0>MQ<:!3>Q*--C.SI!U:Z6=6F,@MM*9MK0'KZSV[GZ;!NCX+F>\/$Z MR(_+;7VD9)W+4385\79?$>\83]TTCSQL'WNW+!_O02K>'-_Y-9F4YW2: MBMG5'U3;-+O6D0;99Z=Y-?9"%T!0D(1`#0TG^-L;.S:08$U@G5T@HNJ19CY^ M#MSPDSOS"J?U]3[Z>ALM$M`YG1"8X2)./2\QXL!35&1MWS_ MC]@\N8_3;XR=3:SU[F.MC_+,64B>K2I=^TA%P34A>^?9Q,Z?\_E:6A<=BAW#UMY<>,=SK`UUV%.T.=#D^7.?W<>W2"U69&(T M=MM3M=L>,B'CE#"\,=^>G/FV0>T5[9@,I7NDHOM&QY:DVU3Q/_02;N1QED]5S1J?9!)^?FQ/CN*L?[A6UFT#=0_3^.UI$:`)U]]3\ M[W@QH`G4?B:N\"1'(()1"!^+ZCVW9B9?(U$+#AZ;1>%>JC/B23T9':/NZ4!U M7>G^_]N[MMXV82C\BZIB;&Y3-:E5EBU2NTF][+5"#>J0$M+!Z-I_/U^`D$!: M9\5P2,Y+&X$QV-^Q?>Z'")V6Z]M``57Q+=/P0>Y&];1P'$/^->>W4;J\7(5) MV>1X`(2U74&9G'K)*PS;'6?8;E4?:;@R2N_14NG-Y#"DK=YIJTN/KAM.*U'V MM4=O+B"T;1&K+&&+:6$_(L'HU`U3S6_>)3@A/@:/(IJ9@[`K?1W6)'V;=1TEIUQY:^H46C7 ME;\NM;FT`!2UMY6_ZVV^#VVO+!9LZZCO5;,^$,1@NH,`$C?04:%6J%FP$)8> M:)IUV$WJ4SBO0E"?LC_#0O08%F*48:F@0YEWG"(G/%)"=0JJ4PZ6MIG%I-!!JHJ6;FC!A^=>H2)N-OJ><"C4<3J$6_N9_FBM_JX%91;VOL>JJ9N96 MG4\H-.O%Y'\RA:AH8S$-8`JUQ1>P3,\NQQ`S;A<_,L4Q1, MXX3O*G&XF/'I2W/QNJQ\,NXZ\'T@V&C@NS(;I,.`PC8IEDJ1U.9-:4U&, M*4_3.'D\",1LSW&`YR'[&Z;SYD+J)7/8,*!@W=[.Z_8.!"06;QTA:,R31BE& M[2)5QY@.M>KG-]ZGR%3V>BGRE.TXUV;)4\XY1M&"=&4UPA.VE9RHQP7FXR$G M&\G)+#GQ_][QD!-%G"!I[LR/N8I)1LU=-T1:!![W"!AJ[L8$&\;^PX<( M!=21@0;KS#8\YEKN"3RSNS$)NX9-P@W`\,P>%6RC$B?!2G!](H86''B@%*QO MP$$A0!V5]%G?>H!!Z8EIE`'N'R@EHZQ74^`%/@4:2+NUFB1RM>"/C$/7MK*: ME[M2J8$4HH:B(9@T<_00H47=H$6]3R!183%"T-"B?O`VJP'("2WJ2$Y=DA-: MU)&<.B`GC!V#APLDJTD/8Z;0O#OXF*EA[XZ@K636.C6:9P<.U'J6YDIH=9*= MK;ST(^FX\.*F*3$P&[@';R-@YC<"3O6PQNS(G(B!29PQD^4>!*@25!I<=)CK M<.\M@1C<$FBC(JGK^M"J!.].=3Z)PY=5\BLVI\NDIC?E6N8HA4!@49\Z8T%@ MMECDRS@)#:\"E0?*W,'8F@=*VG*H)?7+U+6`85)QBR)B>-NGZ"7FVU-GS."@ MF:%:FBHE1XT=U&V9_F1Q1I6S<::71[H\BZO;OBYHYNU%KA/_X!4$L# M!!0````(`$YW#$<1&UL550)``-3E\M54Y?+575X"P`!!"4.```$.0$``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`A@,V/QS[XMLAX%NAIQO\,L26)M%_)>$]$R+6`"/")T]` M/9H%49AP_<81OMNGWB<_B$+BE58XA!$-4=`V3T8L!%$$!1^L)1W^BDR(&W$8 M'B+N7MP@\HCWF;/%4?G4#%4-\NZSX_.?G2`B7XB#GU%UB^S+PCK9%X*$`D;U MWG>F?B`)3NIX0SI&$!PF`HZ].(1M[1#4-L[(BP56&:@#&-9>68O-<;(7(MCG;N"+?HY<&L0WH"OIA'(0T M'X;\NT,`U37=(`I8\'A$/!"2(1C(O##S<`%@%%DYG*E+'0+SX+X;Y`/TN/## M6'*H!V8/V@"$MF)X[-U7HSB#P)FRV*"3JA;L.P']]^>+*E-UP*47%A5_\<"U7L`!VH5Y[ MDZ!G+L7PEU?.-.`_$P$$#;D=R]+V(L3[X'A-^TR9F]J MVN75+P1]IK`ZK`AWY@0LR&@1T_DHD(2"F2D-[1MT&/>?'>X=M'(U3,F1Y.D1 M3`@UO&1 MQCGI3BHNF*8/[`[:9FN"6X&O8%8EGV034@Q'SAI7X5@:<:\J?THF/*K`R6/3 MTZ5E8AOD]$T$I@H1:)-.8;O4BGM2NX]V<>6B/.+L,W8Z)B(*T`H?+DELOQTD M"*_NLU%OXU20WR,0H3O<4;7@5M1HOQE'_U<6$@%+2[J+SUSUHNCOA@V&8('O MI>;W")04GEO%KKV2RCF6!_(2W@0PO?9GR!%ILXV9J6NYRTS-:&R;N97.]U;D M3[/'MH'?.9Q"QR+U`;>"5=V),7@/N%EH5/;KNFH;:F;:Y_.H'[MB&G3M=URTMB93\F038_K!J]M0TXT?H"=A+88>)@+CB62WS-!6]FQ#&: MI!4Y:)@RNQC9O*RU0E_;3*TX'6A9"^W9<_N,R(X-5J3/.1YLX@^M@6,P(;YE-39/6-BL+L6`S M/%XD5,@-4>+>OV4"=@:98S9Q,K5CQAU*2L=9U;P>;X:@MME6XMQJ>0YJ]M@- MX,V+Q5[]MN['V'3[M>2Z4':2P'/S:Q)X2V(#)I0EU,-X\?A;[*N9:/>X[_.M MSENF2#.(75(!=`"7-OH.\+H"XYNCGG0M[R3,'#&5%Q,B<3IWG.4Y2L,Y"4*1 M?G,:WP2Y3.XG_"7Y^KP+@@P<>3FL+G!ND>$Y?X*Z3F*ZDC>[.L M(:KKK7HU"HVZ!E&-V=H)9$14G1"5EC9">7;@,7)\,/ING:4?.H&*S!^N[P)ZM/(DV1;68Q'KD117\\$ MFG\QYCW[@6KAS7XV0=L`-Q)S'WVR:.( M"1KK+6+3=N^F*2Z7DB<6P"HO<$G$@,4ZLLNK&<92K4`ZHC'N&9T_$+Y`]VT- MP24E35->; MI#O<31N$_^XXK#>SV20ES@4&NV-KIWY(%FG]&6>+'?]2VAE3N79ZC`/),J/2 M^XN+D]ZSO'$M@-7;]^2@ M__6$;RBTCJ@A6TY.;#_'E&P*O.`K, MP;Y[0V`W/3.6S(X5JT[M8)LL+7E6%]9]'J6X/UP+/DG"46K1&W10OT:U&6E:S>S408"Z!M0OC*=Y7!:5N%C$15$@H,"S"] MF[?PJ2_"^*)PEENNE/"Z6F;B%7$682YR3*(62T4$@I%GW;HA,X;)B+'<@_." MZ9\6)&` MR7_&PDGLT),H65ZB^UHE:5-D(YD2LT#/,7AW\C!2VA M(EY=P>C6\`B&TL9!3YDVLS+$YLB,4QLU5IX<'%OL:I8D*\\?2JVM39EIDA:T(_FR[4RZKUB3[VI+M*MDY5ALYHH2^1)$=G?\<5N>Z>[H0!5.TTK M(]RKD%9X$`\+<#=X)K;[-/->6_[=='?XS6^@Y7B8O"HPG&U%;&QMXS4J&$F> MM$%1=Q9.GEGQ$!#>#!6L&)(\@G M$O]5'5;NTX299#U+4!2^9#?\/R!RJ,`2+(B\`IM653,I?*;$\S`:@P/'T9+] ME^/3(=W]7H%LCP9,X,M?]?7^'8DPUOV_.#B_E"JLNHZA@],-\0=ML!GSJSY" MK:G7+33Y[;F]`16J=@83AJB"E>AP=?J@^GK=0+/Q4+,FDMT7F$VCB._P[41/ M:R-2U>\&NLTKBT(2JPVMM'(W<&51WOLJNYV*A@(8T*09<;8"8\V[6>/SI@.: M6<;)]=;[HZXN&01CO$AX%\^+1A/N@VVB$^9"Z3)OF@V^CWP)ZZP!,7 MN+M]D%,3=E):Q4@*J>1]A^$L?E=6B`BT!)%;<@6&RBHF,3RPY'64=#,M?6ZQ M.R=]-Z4&DU83G<"H3/6CBU#=@*%49BXA\1O$\E(V>-= M+8BU]%%_%4857E14*:Y]1^!I'BEK:=4W%/ITR9PM+9Q"B2;'WG6>7F M5I&KRTZN[>GVVK(P2B/^;8JZ:9XK>H?45N:E;)Y9JOV@E;%YS;%')Y1)$='] MA]-"^N%25H:"-\\P`V'$%@6A-\_OF@@8*^/5F^?2/G%0BOCT/YSJJSX;LS*5 M>_-,T@MV4EQ7_<.)5$W@D>)>ZG[N`B8B3H9\[M!D&Y@G>AS0&>,QI\TD M`]B'N$RTF%\75B#>;+'C1]+&/OB MF\683),.LPO=EK'9/")<>J+0"16%"9MO'.&[TH,01"'Q2BN82.DH9S'N(IT@ M2=^*E(A^&')_"M3#-'Y@(#(KPD7B.IJ&M:$CA[9J+%)Y'YHWT_LVQ8FM5CO+ MB=S9FIQW%/T[AS"CNN']^*&XUYGF*!G2232-%ZQ%97_E^$$Z,;.,UDERY$1_ZR#1 M:L<$VE^D&4:\/DB',R=?H\64<)"FF*1X3@ZC4(0.Q9<9%5CW;:5#2'>(DZOS M?C@5;9@V\E\GQF_P(/;UC#"U1%AYBOM*75(4N#TGJ96GN0VPJ0FKS,K$7)6A:=!)4YE-+8X23N0!26 M:8`'2)*7/MS8VSF4#43C^,^+82%XZ M_HRY_IZ(AV^SQT&9F/B1KRH<6O4US;AJBF\W5Y-N*A-V1L#8>?X"EB^'&;4? MT]45#:)FY?Y*&WG%D-N5:R[7:\F18,D;C>CP9S2^8J`NU4QF MNKCY6RB);U+A)0:9HU=V-@DC;_W$3]RTM40 MK-\TZ%_:$[.(>MOD:50PR.D19S,BA)QAGXE*=C0K-Z!S[ MJ>!L:7$S&?3DG:)[/!D?3@-_'IN6U7RMJ60F2UX:*4[#^*BX&H*ZO+%\'[L* MH1I"326C"^]>BK'DB5WE/+?2#-F;&_6:Q4HG[$%\4*U>5OI9#^*$GC5EI0_U MU7JC0O];Z1-]-2/J%G0K[Z>\FAMU"^MA]U#,;>[0R>V'J2[,KB5U-O#LE@5@ MO;#DAA6Z:C&W.\9SSCGIL'-0WKSO(F%Q7@X9(>FO"-YR[R8#2^C,O*QQ#H@D MHGTP`.GGXD`,$..MR-<>:R.WS3B5BF_05PX0[U9 M[YZP/COZ72O/1N^_$C$_4N!$=J=UW-SG5GDY4=65T MEV)<*6:.@N/)O)7>E[W'2C^VM<-0VY^MA_PE^].M M:,J^@)&-N8!7:1]8(80NYYEDEO&@L:K=]J-,=$>\\>0Q]1ATD5SWB7A1D/)6 M8$2?E'@8!H;YT4B:+*&+Q*>\3DB4[AB8)`_L;K$,V)I@%.)71DGR23:Q,^5V MK'`]U(7]0BF+P:4X\="M'%>.8?^`.3= M!!B`_\;QI9?;NX:S\B9^9T?GSN$4Z!1IQ+U]A#Z@G[MSTI!9.+D$=U<(*HGM M)G^SJ%D+-&`5K=WD[E:.**VC[\)!:WRRW=GQ:!9=-T>PXG#>@AE3.*I?D<(6 MVP+2\[4?C.1;PD/'I_?,D5N0S0M_:5[S`7T`@&)&N`7P"GF?9D4_2')L+I/_ M[KA!NKOR'0BGFW._9/=F@63I4=U-CF_M.W7D_:=S)&`*8@4?_@-02P,$%``` M``@`3G<,1RPUC1K;*P``1<\"`!4`'`!C9&YA+3(P,34P-C,P7V1E9BYX;6Q5 M5`D``U.7RU53E\M5=7@+``$$)0X```0Y`0``[5U;<^,X=GY/5?Z#XU2EDJJX MW=?-3M=.4O)MHRJWI9+MV=V\3-$D)'&'(KT`Z;;FUP<`[Q(`@B2H`ZK],M,6 M<3GGX'8N'P[^]#^OF^#D!6'B1^'/IQ_>O3\]0:$;>7ZX^OGT\?YL?*U\641)Z7T^^5'ZZQ,CA'7N4HJ\G']]_^'+V M_H]G'SX^?/CCUT\?OK[_Z?^JI:/G+?97Z_CDW]W_H(7??SFC-3Z=+-XMWE58 M_+>3^R@DM/3FV0FW)Y,@.%FP6N1D@0C"+\A[ES4:9.R>4(&&Y.?3"H>O3SAX M%^'5.>WFTWE>\/2?_^DD+?SUE?BU"M\_Y<4_G/_UV^V]NT8;Y\P/2>R$;JTB M:TQ4]<-//_UTSK]62U,ZO+@H7B7KRWGZ,2U-_*^$]WD;N5RF&NR<2$NPO\[R M8F?L)SHH9Y\^O'LEWNE_LP[_A*,`+=#RA%/\-=X^HY]/B;]Y#M!I]ML:H^7/ MIZX7.FR! M0XB_])'7GG3-=@_)Q)R2VV$06C0>KU'LNTY@GJTIW00WJ!?Q61/&2;MTR/HF MB+Z3:>CY&+EQ+RKW6^M-\)5/W"`B"48SO')"_W>^?B:>QX?0"?HMT1:-&^3D M/MEL'+R=+>_]54@GH.N$\<1UZ3$4TZ-R'@6^ZR,B).,RHIMV&&/^!Q4XY*1%)G$G]PB&^.PF]*S]( M8N0)*_01A"$*AI;)/(KI5*0;?+#E=/@OZ!ZY":;#@\CUJQLD'O)N<+0YJ)S, M4&50=C>.CW]Q@@1]0P[[FVW=I/BQ.P"BD(ERMI27ZL-F[[X-RH'VN/'C=.:$'E5[F`Z`PD$4 MC]9]&>4S")RG*%7H^%9+]3M"^Y^L,!IH?7;NTR#?5^@I-LZ8O%&3VG$\A,LH%:H-QR[K;H^J!3(+(F9 M,X^Y62DYUZ$NSYQG@+T"R*4L!F^?GVFMCCR'B+VR["":4W-L++Z"V(>5GHZ MO"#LK!#5()--2N784H.-)\>J0K!QFAQ_YC/ M[Z$FBZBK@;ETU\A+@ER\A&G$7&N@(Q%1%9<2PV9F2'J9@/TZ/M`X9]WQC8LN MTX?HFK8=;1$S!>ZH6I7]Q9O@TW#N;-DIG,Y&9JOR3]F"9UO@_:/IY3(PL08E M?9%05041II,^47-I$/>D=A_#\E5.Y3F.;EBG"T22@&GALV>4ZF^])D+G/HUZ M&Y\(^D="I]`ULZ@&<"MJM&_&T7\7Q8C0HR6WX@M7/:GZNZF!0:+`]W+U>TXW M*1:W2EU[@LHE+P_H-;X(Z/)J+Y`#TC8V8>:N99N%6M`XM'"5SO=!YI]FCT,S M?NW@D'9,[/J&6!.LP7A!%V.`%33!F@4WV87`IZ'=[H`5&AX%: MQI<(QXX?WD8.]W.PX$.)-)BX_TA\S-S4#Y1BLD1X8#&9)FUH45:P8$L67D0A MX091YMZ_C`BU#`K';.9D&D:-ZTN*Y:(ROX^;(6AHL0F<6P.O0[6#<_+1H MU>_@?HRZVV\@UX6TDXP]![NZ'$HP^#FZGX'OOW#&G2`X/TA*>0]G&[1Y M0K@EF;6J`]*XIDU@-WE"9X5DVE$J:B"CURMN(['+2#6:Z2)#H<3A)RM'.?Y MG-%SCH*8Y+^H>K;*[(V)12LM#4)^[7F;+%/*5W4KA#AH)`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`A=< M*8//QR2#C@Z^4AI?CDD:;1U@I1C^<$QB,!*W+64#I&4,/$6D,?:2<9NUQ\Z, MJX%9)?-0[H9AF=='=)5:MKVV7Q_]J0&M6;)_E.IC2V!4*8WC52E[!,Y*\1RO M@MD][E1*YPA53S6ZI63]J/3,+B":4A1`NJ;PRF1[@=1`5?55(L2J@/M0A^9; M'/K(V/YXM&Q+`[H9YY^.EO-*!"'C]?/1\MH`H\OX_W*\_,O#SQGO?[`\WJ4% MA*RR+(E6@^_C+=D5(2;K`0=I`,8F5E6QV09,3<-N;2.WJH$UP.Q88KJ-H!T% MM_N17BB357M8E?@>B=4NC0RW'5^H[`B#/,4(`-#*,RNFGA-VCBH1B=+B0&D. M2D$R`5Z@T%W38?E-B9%KK'9$O`#!_O;)VA:$*=!_C=4LX:4!_JJJ804'>UZ1 M)@9N0:^)[9$SIT8#R\2T0K++)\HJ5O"@NMTF*6P'W4T09%6-T7,`M9]R'6&/ M+G4R'V4=$"X2$D<;A%ORT5`+)J7+WR.<$Z:ZDR@H:.12V#X1??)=! MI!JNE2GKP/E-=&V@79^"@O\Q8">[L"TWV^%!<7K>3UT3<>=B3H.DX-V#6FZS M(9BWPSO:>?!5'F&E"F\3S^V&O"/+5@RT]!))L[-!S>;17Q7I*:":[P/\EHAV M`%?M_U#O<[M[(_CD/PS78T2CZ#,L,J''@SW1Y],FN$F7W:GAJG232V<,%W?: M\JQVQL'?O-#3P>0^K!K07.Y?`-^&]12OGGQ:H6UI3.)&1U"!?-WU'<)?N#1Z M\W\S3I)&P(KL$D5^L9,]_THV=]5R@ MB6?+!7(CNK7_GJ9#RI_;W69/[(H"D;W;A.7L+@J'8*[2+,B;.@X.Z?PB^;WI M"X?XKF1:BLM:0S47>Y#$I?*B0W^E%LCK0/S!L=N(\+O,Z0O-"24RRX<2A>0" M4=4(I>4>G%=$Z&Z'Z)*7C5*?%D$"U^A[13/$5+/TGP-$Z&`%VXF7ZK/*W;)% M`T?.']`)N$,@-0@2N@ORNRI5&A5*9IL6+.8PU1?;#*962W9Q/,/[ZDDQ*YGS MH37GS2V"0#Y2+($4CY)_-I/;6\M>W@L0U5)[MVSB@'2+(*ZMJP,'JEM8T#4? ML9;-`^^HT@M=#RB$L;A7VQBQ:AFT,1/'D,6FO:)3\[MW.6+AL]OH[1X=-"2% M;)22A5]#6EO)P21BQ;ZR!Y+I<^B7F4O:'+Y'"*3I*\0NWG]PH,T!Y%%JOO`1 MP>&Y;?0EV0P=-B6$%L$4FX$<1K;5_KYOF].RPHJHZD2'!Z@#;2XV0(.&9[V7 M9]OFY*VF!-3+Q0:>X+41(=G5/Z1W+`E0L1;#@$W(HI7%U!8H#(43ND,QVR'2 M/2#?)-DQDL195I0==4Q8X=0^'N81;9OE(PZVG'+_I9)+]/K5#1+:,=L8F_DZ M,!2*4NTI*:X-S^X!)WQKUFS;$,&`GI1?;,4-*$)B0_8X0@G*0A_&F[='-NR@ M5X*B&JL=$2]0X*[`(7F*?35`;;\@4(Z3/'7UG#:+J*GEU=XA%!/?4`N8$]G; M>TV\2.I!<*-Z5W&'`6%1&VA6SG])X9'2W7JWD83'ZZOI+P[&CN2EW\;B,!`( M$F/?C3."'JD>31;WC^H\&,HZ()DQBI3!/94$5:8NPYV`R"E/N5L]RU1/]$K+ MPU!/>Y\UH^GVRT%0J]H*Q&5@`]@'L']J$;E&)1+LJ=RCFA>B%I9+I8/S:M4)TTYJ[:^R&9 MOS(/&SA.H<.[0":-?(.JBUJ5!Y]9%@GZ>!YB&TI""D\->.:LEL\[R7Q-M8U* MV+.?TB0AS?6`8F,,!,263_71 M8[Y.^`MH$Y*^_J8_7+V:A)!!08?FPJ$%[J(0U]91$ZC`;!]CE9(J[&&N?5#I M7)33^G]].O6QN][>HA<4*,(?FI6!^:H<.S>8/R_G;O68DM8$Y6@:4GV)!C:PX^6L;!I]8'4=`F"NUREQLL:VYD[?Q M0W!ITV@6^H#>]J&J"H(P*G4@Q1Q<'EI+NO@<IN,(/'$Z0X ME+CDUC5XN$(S]MO.!2(4@YX""SYY]`(3!Y*''='DUE.DR9O4)(\]T]0F&>C- M"L,BL&,BM#BSFQT-C8MBS_J#!\IT$T"CO2X4A0RC)X(P?UZ9[]PLNQ7E*/"=;#FU@1'T[F6\DFH!)>C5`W#0 MO8"XY!7$1:JI^Q+Q!!]HT`(0-BVAW-NJ) M9;!^WZ1IL%_HV5E1#?_BQ^L]'DB=B3K'%06BU)BFX?YRG%/E(Z)?7$R[0U;^AZ35(F$-=Z682FJ^X*0VCFT8PJSF>[M'O;0N!XQJYP'A/.Q]IU6I66`1Z< MMT5*#?[-$0*>Y&Y:(=_#>8+`YUAK%(PEHAL=>D;3\]PI<#XF','!W*M52;:P ME4>%QSFD#%O'AN%Q/7KG@H:K07(:-JQH^/U)+R/',/QWV:&M@J^4CP-.PV6$ M-WR]0.!/+A)"C0HZ(BZ5,4EG!_LG1NH,U\WU(#Q[(JKD7CU9:4LH3V?]-(P1 M1B0FW+G@S3`'/-$-]RYA6^%LR1=*]E6?T2Z-0\KE,MH\L4QB3$<1JRX3E@=Q ME2ZO*T1<[//UWR"2[NT:2>6>/T7%^J;[QDV$%^C9V:8^SQKAC<4M2AFS_VZW M'EZM4L\B;AJS_3?7,S-7BF[FZ9#+4_[+BAJC@V%.$R>8/07^BC/[S8E9(K+M ME1/OALQU:*@[OP2Y[U;1"]67?<;J9_8/QN'G"H?TIU^OZ283 MBW-)['V&19=Z?T](S-_`7&;YDIM1M:(Z%F!DCR;9EN1TJ5]FF>/H*7,AS)83 M=^VC%R13CC1KFJ6R:M1Q;?J!SA2RI$;K!8J_(Q3RZP:[LZU;&V8IIU)1#OC= M?B!.#$@WUJP1_J9!D&SHH3P-7;E^M%_(3-^;3;)!,?9?U;T+BD'L+-/Y3(GB M*;\/?Y;&P&X0E3`R8KF=2\W`#<+,[_C`S&'1J,F*@B"8')8(F/N6 M6=K\V9+O&%2]IDJUTE31J'AD_``ADZEQ0"U!W\';"HDJA)FT/%PH0-LW6#Q- M(=P`"T?M!RBLD9:KNL%W6'53:PAF)/YY;0>.1NS0KL<;--[CT'7W%--;ZH$I MI[A]P5&9I58NVGV-J>3GATYAI+$ZP">Z'9)2''?@$!X[)"0]7L#?5H"5CU#Y MSV3RV9[7!$W;SF]Y$'7/KR$DW]&'8S-^9\@):BHX#8_:`9AF4A>#S8BZ0\RF M'B%]FZ^O#+]?-7C&;;Y],IAP-(+2-M\3.8QZ(0R#@5_8`!*+,O9OU"WS&BC!=;LC7 M_8S@OC$-)[!^Y*DZF)7(:3EH=C_'W!B0JKGS-*0"/[IZ-Q#,\CVFFP=3JN"$ M[&82JJ3++'\[!25NXKHX01[=7&?Q&N'*#LM>KXU"9O,QPT96"I9Z9LS[<7J5 M(_0*\]5E3R_WO]HA`2MP83A,+[L.7WPU*>T^+V'TA25[! M"OI56$-)87BZM_!%E-Z+=G)L0"\W[*R MG7P](*RYG.2U(3A;H("Y).9LWE0T$06,2%7#(@Z4F"YUG:/@HC4H3:(1I,?9 MMIBJQ7UK.?BTJ0J(?%.:KE^?J4(OVX%V"AF1W[V+0H>J,[,0R26V7P@$4)A1 M\1B29^3R%`UJ9*2T_*BIAX)SQG0QL^62$Z:"<@K+'CI-8+->67LK0J+%'2&> MP(2`--5%F_$"0XEA-]9F7Z2_&^=ZMJ?-,?UV?!OP.-@FALTQ^&ZL M[^IHX-%T;=BBVD-1XU%E;X'[NP=@6*+6@$-V-6,:&O:QQO".+*!ADNFQ9+K3 M,L"+4ZO1*K89\J)M,17L"HQ8>/B*9E!295;5-BJY-.#GKUXK8PH]7D8! MM8JC#,;)`!0NDU&X*A:E/2G0)IL(Q_[OO'\&5TD3-]XBA]%[@Z1/CS37,Y1N MIQ#E"ZI8FRG>4?0>A78UF)0[5;HJ`-_,DI)\KNSZC1$RHUW`R&BSB4(.0U"] M-[)7#"9A3SKO%^@%A4E-GNH<8!H5[>-'Z;34JGJ$/`'Y9'=(NU3&_R6%C>S0 ME:L)LV6QU3)+V:5**_V_GYZ#?T..,,#0JKX9BGUV;J]]10JYW2)C3B@I$>'L9X6(CF"#,C[2;"'(C)09IT[O!SZ=K!H72^F>W# M'BDU@!64=0`Q%@TSLU[()$8E:S/=9P000759X*14M5NI^58Y"RL6HPP+T*H- M&&3&&GD)H]*`V:S"?@[0D9'YR2)VV35D%1!27=8T)?1(;NB?E8"8+X_/-Q7% MIS(\RE2"3;6,R*^NDTW#2X>L15(4ECLT/F<(/UC=C6Q^71\Q&FBHX=!WX8X! M+#2HE-JY4<:`,!IZC3=:@&.`(PTM),-&SAA`38,N4[F^-`;0$\QLLP:-L"D:FC?_#Y=2R0T$[L MII3)#ZHIRV-*I6CL1C[KP^84II,$R#421/1P(AC+M88VN+RJ#!IC,`7S'^UC MOO$]"DU85KG2[3,$&WG<`^"5(P9EE1Q9[C_MVW+#!<";GC?XX873YB1H>R<1 MZN8+RQ]LS=66R\`AI$CV/,,+?[6.KU]9&GJ"YG17164FZ.PK^2`)X7=K"^3Z MA(C2XD4"EK(US3/H!`'R+K:[1+?AOT6KP!=)E/",_7(@U-+UY< MC]\O"$^O^HEX4=$1T@QVU>,IGH8DQ@D[%'BRY?MGC!QO%O[B8)^=*PLG1K*M M2[LZ/&\LDCI;WOB8Q`O$GQ3T,C5?CSE5?0NXJS[BH<--I;Q5U,^6U8G#9U1; MAD1-P/-X@]!DPS(9:;%3EK:`-[V/&%*5FY! M+Z_6::D_P:)!?*T"//TJ1+.HI*$+A;1A]I)6Z"(&)*'&!5MD16+LV3+SF?^> MOE=2)+@0WX$TTR8L9]3$'(*Y2K-`5UB9B_@V"EQ#>>#7; M>/F%;X_L8.@X4CL-V,+?PB>_4047Y>]UMN1.6!V"-_9T$F'I[1"9A=>O+,-= MXI/U)CO*GF3G8G,]"&ZFH1MM4)$8ZI;UY"O3NZMJ6,2!\DQ4USD*+H"\9/GR MS-#F2H^ON"Q,>HB0A9=JSL9,)[^(,(Z^T\5ZZ3S3+_%6PDRK)FSA<%"@,O7^^J M="?-M(L$"U$TTX!'D-RAY[,RVVV,:1JZ,F\RBP80Q*&%NSO MZ\1C2(G0>=-K`GV,(>E!9^952*LQI#+HN:KW7#1C2%'0@F<-=_H851_-U+O@[\>:6MQKT9O.= MX`[CW0:J9/.5;\.LIX@S^!O3@S,LAFV5C(]:F6N!`BTY'K7"UAXI6C(^:L7, M`-R]E,2H=3AM>$;)K^W/*RONR\@CGV/+@Z#)9`,&`_Q=9=/\*A&L&;>?;(YI M*R]S2++=[8>R[54V&_G3QYV4`6WX##4JK(D&JEIC"H\,?6*2Z;'@4;1@VW6N MA?CH\<>3=KRDO%_2(\&JO(RA?0].L#(&:G7QWL+>;;W"7_%H9X#P^E\ZS'SL! MER1AKPW@%^3=1/@FB>D4RD,!$D[:MP-RPW;S'$1;A.XI3=3^%T^:NRA\H7LY M\OCH4-6%,E/]?AF1^"Z*_X;B,@`BDZYFKHEJOK/9M'T0Z333+2.;_ M^86.MA^N4A5!IID8[6)4,LJQ06SU?W/P;RC.(`-+RDVX4F3H&K3+4:1"_40%@A_I$MDR)F;%JD':D8HZ3YHYY4Q<&(%B!7*/M'SO1`DFWJ=522 MK(:N9TE,8B=DCS*D@:+T]IMI,>IT:>3V=1<*"2>Q6!\[O!MKULHY(M4?2W]I MZ&G97H-T]2:SUET!6;V<3%7"OTH!F,P:+"Y#[67D726X4/]3):3P=+)">?A< M981W;@F2G",4"B5 MHB*]1Z>&AN2!1S-KT<#6U$N;@`UD"V-N-1C5(-OH2.+>(-*Q`_-Q<*B+#4P/ M`'31#$W!WX[1VR]$L9`JNR-=Z.W8LF.%-D]6L?):ILUI>]B-X?)>-YZ;E!3P MRTP=7HDS%-00+8.Q0<8'%8/F@4K$;CBY-R&4N&E%3$\U)^H@S?@TC M^PYXO3%D"!MHH@[MUA]#_C'+1*OEYQ]#8C/+Y-H8+QU#+K4!9;I[X=?BI&J6 MS:RNT>0QI'$;2-1=W?ICR`(WC,C,X1/'D%?.LA6NA=\:0Q([R^0JQ`Z.(26> M63F:PT",(:O>,'-0]Y;<&/+Q#2.A`>]VC2&MW\B$*KGR-89\@4-"<>KIL)77 M$L:0D6]H4?5'GK3-8&?1#>[[9+-Q\':V3'F?N/0+2X##>`W84;%WL=M>XDG% M%409R+)T,0?&+WQGF>$B15O$?K&.GQU[N))_ZY$PHBM)!?72`9`D9QD_[M%MG;+3*IDI7#$/*\5VEHX6'MA-G^1S6A)?+YICW, MG8$.%!REA.F6M[M9#W\5QBQQQS4N=;_RP26_T_TQR]:^:7_4=\,:N2_LYC1V M=W#I[_9_I-*U;]JW(.VXQB0UYL#V^IWNCUFV]DWZMO2-:G3VG*@_R.U]NV\= M_H#7;=YPS$H<,YQ4WC"Z8XQ/'!8OT-YB>,/V#N^0>`/Y#F$O`%^#^)2_L$Q MP-#&_(\,B;7&A_@#@VSM,>[?4+K00:3CP/,>&FJEIV7;A.6HVX$DO97`\C<0 M$KD^@PGEV%'K2,]A*!F!'-7DAZN'*$/RZ`4%T3,C3&=NZ=2$!<^96?UZ0#J3?8%(#05!"OM-[Y[1 M?^M,@L9JAW;D#W2NB+WZ1B?8$7OX#S`HK:]F@?GJW[+@M>%8]63KGKX[AB!! M:SZU3N@QN.Y;<]Y$HW!E3YX>D>H)!H=(`8#:&1M$X19_TSH14+H04<(%L+R.Z3=!EF$[@.EWZ]0:CD&L4V5!ZUV%,MX<'[-!MR.HYOM*O M^OQW:=P2N30Y6Y55AEJS9(ZC&W8D3KR_)R1F$RG/%9BG"IR&J5[PX+QFR^N" M:EA+?_?YJD&Z@!R[B@91VT#YIK-$F.Y"32M7JPG+>10N.:I=YVNNOP@:>[!' M0LR(HA.XQDDUE'N%B(O]9\'Y;*Y=D.A8X!!"]U46@U0J=X*"(Z,72/N43(*+ M;4/2@.9Z1LX.23??_(`NV2BD9K7#K"\V65.U:Q8*W_OJU(Y%X\&DJIY0C?6. MBIO6JZ5Q?F7`!_ES/K*BH''X$IRA#/C(RW>GGB#WW2IZ.?>0SPC_S/[!Z/U< MH9?^]&MJ,@F'>^^S5=28FF/3S2;9H!C[KU3=E,\O4;'AY7&+5DZ0J\LRXL6%89X$S4)(5>M*L27+R\/%';6C&T4.1Z%Z`9_+ M5N\5N8;@1S5,J"$9>,2$%DS$)--6O$`GQ77I^*/%("W=<^*(\5=MA=N;W,.Q;88CKS'/=D*S@?-R) MD=K\"KPLUE=[.$_D1X=_&T:]B!5!.\;;/M_PDU*Y*EOR8\?'8Y^RVZ(%I.^MR[LD"$S@G"GO;+9B](LBUM$,)H+XP.?<'RQ[K. ME4_?:P>'=`_?M^K9FR8@4KM$[%*<>T-N(M!@>27W; MN%N@%Q1*WS[1J3E>,/6(@8\V1!IZ`=C`XO`'AW)9H+6]`;EL"#1J;]*J!Z%.?7->?:HL*&]3U,N`9&=E$#&%B5E^!Z-.G2.V4L*(TL[F M3XHDB\+4Q;.)DC">+9>(@89N_8W/H%5_0XYP.K:I#J+D<_I2OU2)"9PM*U`I MF5ZO41.8(Y;]OT:0^BG"YHIF9M0:!UTCH&MUNK1:!CNH&[UXP.>!M; M'#X*8Y)S75L'_(JCOCM5H76K]OI=0-08D).:K%:TLA&A(5N,HT1S!HZG^%'ISC`@[85(%0U"Y#!`]4/(NJ`'^&\3#HH?C M;DX;<'U$[.+RWE^%_M)W':H"NR[3C=B]YHQ42T=F-T(\-C+Y@6?9/"C>>RYG MKJW#KR351ME.0W;*17AK_9ZGHM1&R69;%ID[6T8=_1,GR+OUG2<_H(0@]H8S M?_R\\E/)VF6"V9582\?"+&\VCAXW2..4V=`K+K2X-48L'9W+*`BHKOD9O@='YEF5"F11.GR)M M"7\1'J4OLY6)3;(+_K:>O_B;:]\``#V%`<`%0`<`&-D;F$M,C`Q-3`V M,S!?;&%B+GAM;%54"0`#4Y?+55.7RU5U>`L``00E#@``!#D!``#EO7USW#B2 M)_S_1=QWP--W<>..*'=7L=[[=N]"ENU9[>.V%+(\<_MT7$Q0+)3$G2JRFF2I MK?GT#U[X7@0(L$`FRA,[V[8E,I&9S%\B`20R_^5_?]OOT`N.8C\,_O6'R4_C M'Q`.O'#C!T__^L/7+V^OOES?W/SPO__7?_TO__+_O'V+[N_1^S`(\&Z'7]'_ M\?`.1VZ"T8/[+0S"_2OZY#[B78P^^<'?']T8CQ#][P:%`?H_[^X_(>>G"4+/ M27+XY>>?__CCCY^B:)-1^\D+]S^CMV^SD?[">?H%+7YRG)]FI=_'F%^2,)_.WX]7;B?,P6?TRG?PR7O]_Y:?#PVOD/STGZ(WW M(WEX/']+WIBB^Y_N?RJ)]S_0ES"(R=/[@QN\HJO=#MW3MV)TCV,#-3RG1 M72HN(LH,XG_]H23AM\=H]U,8/?U,AIG^G#WXPW_]+X@__,NWV*^\\,WSR M\__Y]=,7[QGOW;=^$"=NX%5>I,2:7IVLU^N?V6_YT['_2\RH?`H]IB4%!I'P M"?JOM]EC;^F/B)K?3B<_?8LW/_PO.N"_1.$.W^,M8CS\DKP>\+_^$/O[PP[_ MD/[L.<+;9BYV4?0S??_G`#^1;[FA(ZSI"),%'>&_I3]F=O8#HD]^O;\1"K2N MT.(O_,H M8\?DR_8.T9^XN/XROO]Z$=XL<@4\Z\_]#7*S[FFZ#@5744X#H^1A[64SPUA"-;_MGND(^UW9!SJ M'7'P]NN7'Y"_^=<53Z48'_ZV,4X2!1G.%- M#3(\3@UQKCP5+9SII(+M&*4.C_./2M#Y"*2_VS.\@.LW< M"=-@H](L\":&P=C@@4SJW@*OE?*E9F_9PW!>).5`>2)<3,=!?!Y[CSAG"["#8T5DH#P-H'+S'Q,YE1FY/0G?V/AG;O[ M&$8?@A<_"H,]F9_V+G4_/ M,%@VH7=DP]/S!M/,*IK@4!$8N<8>>4AT9Z/2<,= M^A`ZL%%_Z@6$35YE8`5-R@HBXZ'*@(B.B"I#HG1,E`Z*^*C#.JF!E<0<629W M<*13(PJW:..^QHBZ%V)5&_H#S]V1O[D1^OWH1H1Y9G%1^.KNDM?,H""](GNR0+Y.HR3VRU;)G])CAO"0?,"5/MU$!>IQINB+:_& MB_5X7/*(>(,R\HC01W0`=+M-]UW2,7I=Q;W2$3==>WJ"&=I(<5=4%%?:`#(U=7X`%7A>HHK:T2%?5E,N"Y?<%1&E+1 M\>[Q]AALZEY$X06@H*:9&]60?+Q<3!?5,(82S.+KF,WF*4V0J,6$>!,X\93" M$A,R5GQ@2`CF(E+_$(E%'#(PD4.M'HI(U`(8?-Q%X1;'-*&6K-BP:$FD^-+P MX8:`$^59:#YW)E5`E2DB2A+^L,Z8H`Q5%0&WV(K)M<4*&V95F3X`X73/-G2$ M6PMM3P\/H#H+R@9%_IQ7D9.3L@,QYTE6F8"BC)0%4!%96`-&&C5@$3C(+/B9 MR-T%*=57X6%3X4<]DV*\<@08L@HZ9TC'IQPW3M#FB*T&4J,U*J#J5#DFEW-? M7'H]ALQV'IWM@BI^-9GJ*/+PZ@2%G566N=/*&L_@T)XXH6;:#P/Y2#(#2 M$1`=`FCJ[4D%_$B'BHMS8C23(:'WA%Y':(-C+_(/=&C025G;L"M3LY[R8)%[ MY_J;F^#:/?B)VVX-U:=!,%EA06?'878"0$J*7F%,B4%#[0S)G)ID!T+J+9', M$TLV/)8:3:T9.*>J@$')?Q[CA.V1/H3WF`KKL^RZF\`+]YCFD#R$%-QD/G[Q M-WCS[O5K3"\YWAYHP0$R/5]YB?_"3UM:;A3V,=2@^#3/O_+4,G-FV#S)\K@RPHA1?LO+ MS91IHY0XD&/I07#F*AB]M+J.5Z(X0CS/`G/*C4FY@R%?RX@K6%976W=TQMC[ MZ2E\^7F#?0K,&?T+Q>.LA$?RH[]=$9^RH7[EX\Y]JGWGT]\/@*J3096G&C+7 M3%/@9.\C2F!8<)S)OZ/&?]]6+C0-:LC-(IK9,<[(-MX?;'QD\)WAZOBJR:GS M^7JQ2G>#\\_;ZRU!\0[P.1),!I2@9:?W'#$<=3&&V=1M-OQB([=!6)#8;1]& MB?\/AH[;[7N\Q5&$-Y^P*SC847]OR(BMC1GE;935-*^&5:))[\ID5%%*%N`\ MI"=QG29QCP=BS`1(.]^CT0L](0&-SE3-M!*8*>G)T#S7--0]?L'!L;[R47AA M^#E0PHUJEN1BO%I-^8SX\(R1NZ?W4:DMN37;VF10BO@`:'.,**(2\A;,]45S MXI_ZCMN2[TA)FI6NJ6YDST+.FEQ&_;,"SKT*8"S-Q&UZ@9^7/_J!&W@$(_3" M$*NKY\?\NK?2%"%Y'6R6%O.D/GLM\PW?FBGFQ-DUN;1Z94;?ADG;E/2-<_>& MUNG;N'AJ;]$F"'Z#Q-_XNV/BO^"B M`.:';][NN,&;CT01=(_HF*02?'"C@/`?W^&([2)=L(\0'?V[K69P-4W7QC!]#CBY;@^F1C*F%Z/ M5Q.Y0_R-TH,ZSK9%0TXW#5V(9U*!H$%_U?I9+M"+??(#?)/@?4\NJR!_.?XI MYUD]`70QGQF-SM!OE`G$N+A,%]91B5)_95J)%^+E3B!JT*55/Y,]_NNSN\?O MP[WKU[=VE5\#]S<%+^HE_:C4'/'G80H>>7T=KDUWEE6>^)$8'##5G+9]6>A#%V[W]9T M/6\V>$L\^5ER\=NK%>N'O;,BLRLA#"SQ\Q]=/_J+NSOBHC60],LU/3\X+!J8 M4`]NU^ME%1J4&F+D2EVV(-%QMGB\_G@8X%>T=Z._XP2!U<93MK93H(C48!58 ME.81V7LV@$<[L'86>5,[&8@LF6V,26S54D+!&)4P=<9$)$K&37YE7N9SBB[R-*`#9II+L8CK(8@\VG3093F3M/I(6PZW=N[,>WVUKGZ5?^W[:^ MS8HO#X@$-8YT.BRFYY&,,#UF+TB/>+/Q5_1;^B=XY^0^I'F9;AIV&CD#P>(S]`,?QE??[T8]9R23V5S(+2M,!VM\;$H5MS"@[]\EZGAX: M9311B>@(962!,P(,"^R<*?!@*%0UU@H`E71E"_;$T9[H:6"L-%7S-H;2>T/OK:@P MI7HS=K5:S]-NA8UFQ*K,52@/NZ]B7E:Q-QA(5OF>BGF!JS["+0E\(*P_NS&M M*>U[>,1*WH'MJ.A`--]14=96;UZ$M4),I_?-!Q)O)Z\/D1O$M#(@_W61=^5+_=#6?RUP7;37*UK.<`\190"4>TGO6&1>(L]%G MKV4M1S>(`B7^T$8%ZGO/0;28-KG)1WT;I670/4K?*J=ZIL>2^MYS=&W)@N@] M^6RI#&DDFFW03]0C>1D1V.63A#/E;;/5=_CSD1ZRW6[9 MU:CTM^HFTX4X+-P[<*R^DS>?+&5N@(^-LL$1)X_""&7#CQ!G@#H+SH(UWJ%W MQ?%\S)#MT-,C[?!QYS_QNXY)B'Q*L5)LHA?-O.#H,;1/-Y.B_G+,5;$9\7H< M_)^L&,?Q0%3C>L\^?N%)`<2(ML>$)E#M_1UA+`R(@;$FV*PG2TRS7LDJ!K1> MLUF/U>*RNWXG2USYIY:+Z])78-UNSH=&!9N5=*?Z$_1M<7-22C:M6Z0$1.F) M,;9@KZJ;OK:?[J+P8QCMW9,Z%F[L>ZRB&*MPI+A45J5FP>:2(JNJB_C9:K9< MUO:2*CNE48BV=#R$LR($18FH1SHFFVC2@E(#UP$=2CUB[T2&0VR\IAH-;$QT MQ6H9LE'MV!?J147,M7W..LE0$\E".*:*MZ>V8M/6D*8WD>T$Z6C7DG`C8_DF M8$BG/VI-#].D`AN4R%C3R.B?2?=^"E=0&@;]]L!"=OC\L3ZUPA''>8 MYY)ENKC'\9%8)?UAV@J)K$+O62Y;-5_8 M!I#J6'036I559CEL&T]ZKX)-=M1[ON6TCF`GZ-O85I^GULMN/N$D#R;.$F'H M*4#&A_6>PZPB:XYE2\O@O-`"*Q?B5%3QUM'G*"G;'I>4IC!5I+F*B#A/+#$G MOGZF?[T)>#>8VZW@E4^^^^COB.!Z08CYT<%=F7&1E-&Y;@]]LH2UJL M8PS2';.KO)^FZ-41ROFTR0L"?P.>'IBK$3?X2JI4KU"JU_O--8UL0:MTR=,) MR2J,:"WO)B'2',V^;-*V?3-3;VZW?=;JYX->SHSV'L=>Y!\:CM_,T;5^%BHQ MJY[>.YE,#,POI:$O:<[HK#%>FC3+:D8;N?AVNZ4&[)SO<.J:M=N5Y'[O,U&R MM&3\>32M="$-C*KO2JUFG<+34HPY0L6XMON.LU55OV32&B/:YSHD6.GF-D1* MM<1E%"5F5;,/6UZ&=0(-'"EGU4U7BWJN88ERI6*R-9F%)D5W1*);AER)R;9` M5*0BHWF"I?'JZ2H/X3W>[K"79$Z!]OI,KZ]?)7G99T&Y\KY&@"S);Q@1Y"E'*"2JP4-2JNDG)1]9XKJ;=F#$)I5.PT+=>H6M8@ ME%J%#KEGM0Z:4&C>79[D%!K^?I9$;FT-[:2OP$9I'9K$+61N!K[WG3DAA:!O M$Q(P(I-VS&M5C2UXXB6+-3YP^@(PEC@7ZJ'^;+J6(VP M#4HE74``Z=H]^+23(IU,;_.:(BV=*5M>&A!0QOY1(CY";H(PZ M7_GT`KX#JRKX(=C(`6A<^EE%>EI.%^&"-!4>TW)$6W3HKT`F)_TE<:-D8.GG MK=(_XB<_H/4`>M:!@O,U+KTCE1[6^6KXK*H/5M62/:Z8%Q2M[RIHF8&`!+AC M;N9+O[^X^;+=8>/ZD_KX5"*TQI=X8:[Z>*I0`& MUYO]P?78Y1LO5X5;J"*[YF`G4@5&K0;7)MW9A5GJ3J0-+Y5>M0*I!3\:72"7 ME><';YU(%P>$1>FK":N"LJ*^%%M6[B M>$W"2IZGFUK=38!2>K0B%WPYMUK MG7$=\]*@"NTFU%E5WE$:._-)J\,H]5G,1T9\:'IL8[7WZ$MGZGXD%O:F!'4B M^FAJ=2>:NC:SM`YW1/*0WLY_P7E761;@NU[2E%&K_-K@2^UVGE1O'"Z=Y6*6 M+KG+5)&;D>6K.'K`PPI4#=QUS+BHDU-1<[(HH]MCTG#+2MRTN%EICE*-(^)W MW**F#?WGCDSJ00P2ONA"LUBA*VH*)"BI\%;H6KWHA@Z%(8,-=;9TELB+1E26 M;-2J&AR]*<&I*8$V'@XVZ!-#)]VBS\T<-DC0M^Y*0*"I/IL`'%\%&UK/1_!K M5EN7>!]ZA>A32UMAHT-8X`*Z\*T,C]5TO&[Q$3'#"N'@K2=T(V4F+.AU#*?* MNJ?I6970GNDF1YZ\SE,,%HVWK<9#JZMEEA%GUP]EH&IB&=: M"K;HT;`#<*>,J6^*+=9+!0A68G[@*B\]*J(1JAT580%NQ4:OB&2!/JW%=OM" M7HN(;>C6OT,UF4PGNO"V8$G?GR[:$6X]EEO6\]JZ@T)S&+`LAK3HQQ=VW'*/ M8QR]L/2^C\>$L,JZWP1>_3"@.YV!,:W%G,YDM2I@'08\C66$LG(P?!R4#<12 MOOA0*!L+#MH]JH2A.Q4^*@OOI^3JQWS08.^$@3K>]14*#'EY2OW)2!/)&R8'M_LZ-;J,O"6TRQ([$[G#$T-K^]81O MPF!#Q(ZR>2W':Z=I`B.$:3H*)YV6R27$^80&CB$S8I=1E>6LN18TG-(P5`'2 MI/H!QAZ?%J^.R7,8^?_`F_:O??(&#-;J;&@4W)S/FS"6QD<%17!K%"ASQ[J2J7S9]&A(_G`6=&[L-T5R&G5':S=<2X'21 M30P:7R@:&&"JUB8%2TD75@#E]IC$B1ML_.!)]7.67X&$3(D/C5NMDZD,-R6: MEH"GLY1B!(5R(<%@U&"+4BS550,,*&F9W?IC,,#1*B$Z6^2-[:I@852LF6,Z MR'0"#?'BYFQ1%/H3G_F!3J3Y!?WW\4_C\:18MOU/-!F/1Y/I=+0>C]F1`OWW MF/__:31*R^+^^S'`:#H>(6KX[)7WV&,[%6@Z83^=C>@>Y@%[-(%E]TK&F(Q6 MT]6(,,B'(/\C M`"-.QXAK0%16%!0^(_Q,<[9?\$W@A7O,65,'J-+K`R-4A2?U>'8^+G9C"]*( MT[83G.85X)PJX%,80^<#:!EO'9C*2H)!)I&?7A!BKL./__X.!][SWHU:ZFFT MO38H$N6\:.2!3W($ED@B2A/E1*$K;QB5UCE+VN$0J&:D5>0IZ,D.Q+WFK,D* M/+>]!HJX*B\Z`9D2XB#K.1N550%O\"6<%0U4CK8&+5F"MK9*ZI(W8#&F7SY\ M-IX*X05?*=V4A")0V5(2O=T$6Z`$7P"]SM-UA#=^0O^F^G%+;T"BJ&!#IQ?M M7(2B$>($TW_8MT8S)/XIQ%BYFY+P;#_S-GG&$?LGS^G^2EZ($A)M)>`YW:T& M+,5@36]68/!3ZW5JX0N0"/RD?3]W/A_/A-.8#7>6S4@HFL;LN4K<9H!2"'VR MX)IOC:4['-$?N$]86!)1]@HDBDI\:&3GKY;BB:R@:`F,.HO8`*2(B7B0B@B& MHP8SE"*IKA@KL/3@/N[$B0&-#T/BAW&@[)]GR^+X[-0_,UJV3#X=!!-./&+! MP+!2,3,I2@I%V(&/DY8=K5_R%:39C)@-C=)-Z[9]![OVT+O**-]YL''G_-0, MY2!ZA6\8DUV?32HU^U3V\5K>&Q95!:B7@LF"@Y!7:56^XJ6B^=Z M5&ST")JWO&?.:M+!"8#?:N]1&SQ'TW\*""6/%HG_&H2/M)8"7=.AF^!P3&+T MYA-^(9).?QPAH>(^^>ZCOVO3EG5^0G:E7E_MAFK%-P[\J[_#<1(&^%?L4O=# MB][!H'A\!SK#5Y/79U+1PM?S<[UL; MJ!2LE+\U;*`M8T4Y[%Q/)D68G5%$.4E+:EL:E-6IRWK(98TM*GRI9)ZU M\+I5215\A7L_CL/H%06T]XD-5<=:35*`K$8]688JU1E,\)X="-/S[#-G M-E'!F3WSF`EY3V8R/7DM0)O2;"91%0SRXN1V^\7=X;@%:?7G!D56;7"-"_M. M?DXV/95:^H(7X!!0]>B3F-G M,6V`A8V7,,)4A1JH@CU0(@=G#TXGN2CH^5AX;'2#JRLJVL9^-5 M#1V"4WB)9P2^P4:$S)3JZ-#J`40G+#[_=?U MZR_R983TG2$1(V-$W;!6RRP1BU=UN&ZX$0B[U#`GI]-=SL'PI&*2%5"UJ@<. M61]=CZ7ARNYKG3XX.(;*HZOW/QFO)Q7@9%1@+V"=*9"C)]"PJ&@RIU,HG`@/ M;__R=,&F1\$PH)DD-RV:B=6-!C8-\&RAFI%@0ZZ?Q+3$:#!RG3?&WD]/X;7=3,LS+1*"@)`FGT;+*X(=NR M!R9X>$!<-7.@NGVGLR4HB)YRJ\/C"$5GG0<][*$JH+V"#'JB)-' MQ(5G`Z#[P>.]?L5GV+L)R.@X3A!Q[Q@],MEC1AL:>SHF7$>CLK+@\4F#UMOM M1S^*DWO\^]$GJ[OTAH<:0&7O@R%4PI1&,;LL8?H$HI0\/3MD`Z!LA.S*D@T8 M-:8`!M*[R`\\_T#6:`?W]>TF_".@TN]"-T"/^,D/8K#["IUM6HS8-M59`%D< M>Y%_:+B"U/X\'"0+)G0L<"&"8$'."KQUE8[AZQ-%DOL487XC?R.7#0A3IT8G MP5!-'59AYG9;GH?9!*W[C9M(V("L!KZ4S=%Q%L+YKAB!.OY*1,KC5+8> M3F/3D?6PE-BU$E)%2C-RO;&+_$&REZ+\_]*5?'>94[7"^ MGLT7_/YO#8_E]Z2:?))/2N@R2'!*4!^5;@_+3@FM3#('>(N>,^O M$VLK$CZ^^(CQU3X\!K)]X*:GP:*&G`5E2YQ,LX.5DP"!$$.(:O:L,"I$1D58T#[_5VRVMQ^5ZZ MOE;[N.+7X;`DY$EY1W0Z68U%X,JHT]@[HV_39I,I\=-9+KVD?\@WG=Q]&"7^ M/_B)II51>+M-2_`IUQX\8#^U=`83/0T&QT_:';/6D\FZ.=2$;PAF1+;&`-*6 M5F`MYB:&SB?P)F!5?B3EJA1>`,-+AVI&B^E\M6Z&S`BR9)-I`7G=U')5)GYG M+-KSXX]MF@9I#WQ$=9H4-0,/(EGKKZ8GP6"CV1O+6:>[&5^\9[PY[I@E?0J# MI[?,G&HHBF$;@9TMJ6-&4A@,"=N"B=1B;HLTCH\NX?8JV-",'KILNP[WAS`@ MP]UN[[$7/@7^/WA]C+P:?9J+*MR2.HKM8+I[R]FHZ)KF@" MOG,.C#O9;(7HR'+7C6P<+,E)/]3#O7 M7)2C[:HP0[ZV;X7UY&^[:JV3RPW"X.W%NMU3WW2^YZUI'V8YN'6/NX0N&.AZ M@66W5[(4_'#'O-MM].&%R9*^(5S+=*4WZ-*R(Y,:E0I6,V%^#[T`P>F=9OMD M(Z,P0FQL^M/T::C5Z2#*RLXCZ)O(KR2J6W,*<294JHO;<[0*Y"G86=$]X2:M M5]$8J[4_/RS2FYE0/BR;+Z>3#,GI81DEACBU$ MS.9PJ^%T:H]R1-7T`PLJ,CT>\544D>_#4OII[RM)L2*%%T$`)N)&/:UCO5J< MP(Q1126R\/WE38OLG"OR\+AK,]EF]$G591\&I063E%ZU!H=ZM8=F8V=Y&C-R MLX2MJ&1>RF;PV5!B2<Z46""$OA8L6(\$'_DLUU5\O<= MIG^Y"C97I8QWX9=6>'507+7SHWX?9UX4G2K(TJ.)E#`[VBN3AH*;::&=NM!, M4K=%TN'@IFZO5>0IZ@D&A)'_0EAXP?E-0WJTD?WP,Q;/9ZTO#@K`-F[4+9%, M`AG\LO='I?NF9)[#8!.<62D9WIAD+^SJ+)G>-CDU6*BI6F45:$KJ`8:9'[@! M\0:[4A)PEH#@MW1;TZ4"`T`5UM0W-9;.N(Y&E`]1SJ0>H=(HP"5.>]4&SR[W MR3INZWLN"46_!N%CC*,7=FGW)C@!WG0L>@_$&0B8T>B\ MZSBGDS&E2BRN2;G%-)MQ)U.+H33G4K[. M5590C/9%\HAG(W_ZO(HR+5A>^XCZ[P^?N*S.G*JEK:;C59ZA7*2]W6Y1/@#* M1D#%$*Q6_=!9R'U)/[%'^K:4XKY4X-150)8!13T^3"EC=NL3,$E8']FE;&!- MQ9EQ1K[[+0R>_>9&Y8V/#.Y2JN.K&LUBL9JL4Z^14>@WW!:[A7,DF`PH00NT MSQ'#J8KQYOV_/?P(&K3+S+\`98/((.%V7CG^=DOO!^`@YIT6^/*(-5?\\NQ& M^-&-\U*X;:T_SR0Z9*!^%J<:F0GK[-"H:#1`9IGRD/F*E`TZ0FS8MVSQ@#KZNTMUY-QD\Y6*]RFS@1Y?F]P/8KRD%6*0 M59YH<-6>E-1AU&-V29QHC&5$Q'%(C]EQWJ/>%J=E$*DB)V;J@YC9_$BW'FA; M>C*')*\WP3:,]IPE69USE?<&WR918$ICR;[."N^D9%EU`TX8E2C#53,W+N[$ M`G%;-F",R^R<+_,P^S0:2"TV;U35U7]3Y(P5WHJ6EY#]2'Y6OVPF?W:@MLA" M!I2GPLD\[PF4V5;:/YA30XS<\'V1#4GF=)%LB,;(K6:6=4:6*V)H/-`C#34T M%$^"8"$?7CTHG$S'S4A@G;2MP$%'J1I1()=J>`R+JN67[J(F7MXX>Q^S,DQ(MYZG"QP?<5Q3QH+.+E9Z!9J2HD^/;6.#GFF:DXSV$<(+>[%AJIA]X MX1ZC`Q$SIE2A+M,:^G9MXJ$W+&%Z^N,OD/N.;=@J;R!*%6.#8Z!]&#W%K\J? M!70)C`'U4BF+V5KD#T:LKZC7"UX.8>S38ST=P'20;"I!"^TK%@8I:-ZROO?] MR*KM]SH(RN3L[W-U<&]=[##MQ!R7C-`F)U;Q`S(/5LANC?MB%6AWQP1O=+Y? MZ2UHEU:PHAX03YTVY\:.[%*Z%H&_J["\9_+^0&9/>F.#^KPB,A@A[YF>PQ$G MB%R/%2.F_4IQG/A[H-6MILFV8JZF-QO0IXN#Q#<[!_Q9D.[(3144#C]I?@:<@="0R)-FSME"UTM M%FG5D(Q.Y5IRJ5U]N$6-CX#=7.Y;*PRW'])8=X.VE7HC.%-%<<B`WI(19N5!!A/?8I0FI[`RL&=YV0;K-PN50ENH0!L*'7?B*<7J/ MH5371%Z:MOV]00';PHQ&*8UQ=NB6TGP;I;=^2E2!B]<:%I=-MU>>%]&\^(/[ M2IC8V3.E*IIG%78J^H%$VQ<%N3@[Q@'K/Q`T7>,)XNP>T:?ZCW?!?9A M:A0`)!MB7;V#U3R;GU7NWTBOWXRJKU&&T&^4(\18@EI20RK6`5/LT'[*,+"; MO)K)+VBM#_Q,J\K%Q'FS+Q\_A(F[*_^>RO(Y3/X#)X64YUA^I_%L\XM=A-!9 MF<^JD1%*F1%>660%OCE'',%Q$X0)1^@5)Z76K!9[R/Y5S'PEHULMOQ_32]:I MDKVR$C&_NHBBHD`C>Q:%K(11S,Y-[[]\M2*.ZPWTVIZR\Y?\KGQF=N$D2G]$ MGYL,#9!F)KX'[]HHF<8A1G9YJW>7.\H2Z+=AA$K,?F>NV,#W8/Z9NE/T1,+6 MA#5\H!V%:'X&Y8?^>6##?)?^5NHP!G'"XF\(ZIGIE'O+9EQI16[Q\Q#^KLZ$ M1H*S,Z^[)A9T<&K`U;0-R5T M@/8&?_M_\6OMLXF?&^@&4N/@&I=YYME)+K^RGQ)"C!(BI(:_E61`(D=7HB%N M*DG-*;NR)!9^,'MG.5H,<[SLS.TQB1.R$"/1@?AKR5X:%@D23I2-:#Z?+ZJP MX(EKC.PH*\=3H@R&$F/2.F=*.R""%`RT!J_'A0ONGU7IY-) M!1DP/67/X]]1Y'\XFS[M"-LHX5!V^M'?X>C:3?!3&(DCGNI3@UIM96@=1[>L M&"\C@S(Z4"9\AC".EC##V7.C`57-^E3JH:S['C_Y].YGD'QV]TV5!!H?&]2^ MJV.KGUA.YO.*@1=T$"4$9>'GB./HB3.;4=7(&P0'V>GY_.H_?FABV_*F%'N?W,5J5`S(;_SS&"46ET$^H MO3/@_"AE1#UA8Y(UWB[AIZ!(#0T&2CV(R>#TAN:O_\@OJ_M!?A^]C"ZH>[R.8V MN,?>,8K\X(D\\#FD.5+\G[2L0&MNM-DQ0#R6`<8UZHO.QW4/-T*/YLWI M7YB78TPKXY'\W^0DAONUN)08CV3(XZU6+MB!=5"6TX.R+LDW54!GVB\5W\," MG]3`,V/R:Q`^QCAZH;S>!(RKEYTSYDNA7%8 M*\F5X(,9V/U[UY,HNBL>&4*5I,]J?,R_)QJO': MV5\,VK<=]SQ+_<,W''E^C.\BWU/Q6,WO`?FA1F8TBA,OYJ<[\@75$[5PKQK$(DN[EP$(D)`6*IA8J@*=:0/8`[8"_!F_?^B[_! MP>;^M(>0]NO@\#OE2=DJ)XNQTX9"3AYE]-']X'V(^A4_K46;2O?JXQWHA4!= MLVT'HT!!MF'R`4?[#A^>O68)!BDO&DE.LYDB]BA=^R"G+RV#VG48L%8D1W>' MR/A[>F;[BMT(M.R!JF&JHBW7C6TH^TNX(\'PCF9K=IO[:@0L05Z5*^5EF9-? M\&C%8#&"I3/@.2K@*5B9J"^%J!%P$P-]4U9%:(.Z;,'JO1___6.$R1J6&`2. M$TVD-KX.C-,FGG1,M"5*I>01I8^R`2P#Z?GR\U0G0N;MELKI9W+:B%"9`;?A M4Z@I4'2^>\W_^F\^CHA^GE_920$0%F;>0JP)E42,.)8#8[G<+REKT`@M($/Y>G"664UTDHV62((WM#>G)1UY*E+ M.3C2),;8B"Z1;FQ!5%OW1OD[P)C2;G(X77/HT@YJ;*D:U7(\6ZQY MD8>24?%,R!)M6@ZA1'W8<@]]2%SW%R`2RVM`]"$V\QYE*<,M2IXQ54(#36!3M#\"@7;\9U(:V/+WH"8G$_9T+A9,CO)`!BEETE&B%\FF0!7 MR38FIV!FWJ"O,4U'?9O=GIG\:$7];`7#;)RN!6JR!5N.-K8<.[#E:-9F7S;6 M)*ABR[$06YWD5,668R^V'#UL.19B:ZJ-K:D=V)IJVMQLN6BX9UK%UM1";'62 M4Q5;4WNQ-=7#UM06;,DOQJMY38YU&7Z-_VMYNED?G)]9J10 MDTOS6C6R9V<>3,N\\,9QOWK\7)^5 M_=1M;S_P[T4-LBJG$&I0S`+H11?,5Q72/I:E19/B&(E59$Z7%QYOM$47@9LC M6_71#`+>[!NNDT17_W":1Z"C:&M"D7QQHW9$(WL5.O"H\:-1;^:TW,!(6);7 MDL,;8X*GS1I4Q`,--02&VAIA-"G'%O3]U4^>3_83XNJ&0G7WH;0Q\S\UK&IXWH#]Q^`"ZV0R-)PJEY?Q?Q#>&POO5MD? MG>ZXEF1`A1!TY[#IOLL(<5%0)@MZDTGSHST.T?(OF7G2_'B/GAO@UJO&1L>Z.$]?$T`YPEI.3^NIFO+<.4^C MXNCGDGWP63IF/C53`SW3VN9G6;YE9UE]H-:\'8P MU%2HR+AS_#XC5J,?@5<`94D#.GTI+]1U#AUGJGRJ2W*ML4`\1LNPT:,D04[ M_^[.L^KYI\/NOM2/Q.FE;]XVZ$K4@_8VH.T[M#M]%^Y\[[4M1)"^"Q$I MRQC2:)G;D'D3;IMSU&Q)N<%57;FX^==5J9-:7(DBNK-%%* M%`AG)B5UZI*Z%9J@"%,SR0J^%%1C(;JD2:%J[]J#-,T:%^OU;*6*-^"LT!X$ M;X&?%7FB6L:K@4;@3-$_A^'F#W\G_-C9KX=$5CJFN@M?3[/)*GT5"!F=&'?: M&!_,PFNF4#'BLFA&-I1O=KLC@8-[$WB-CE_PT-";O2<K:7J;*:-! M$V"]G_IUW\(-V#,%F90%H7(`S4(F9'$T/\H@VY1"/.2;CLU2FP'C?D]@D$3^ M-SD<&QX;')"G/*CZV_5LMDS+"%,JOS(JL*`\5YA)51AP8)XKCZ/]<88!IQ@? M!3P%LD-$=3?[@^M';$,E>N_'AS!V=[?;3V'P](E$GAM^9L'W-]LJ%'4B-6"T MV(4_Y2VX\6J<8RP;!H41R@9B!6W(4&_96.DQF7T'`_WKR*GK*-7+KJ07R-CV M'$"4X^#.F@3Q`H$7[C'=:/U(E$&;KOO!T0^>;@\XXKDC[_`VC#!_[L']AFGE M-9J0Z8D,Z0R*0_J$[FRJWP28+=.&'IP*/Y#X$5&[0\60J!@3/;)!4?H\&W:$ MLH&!/,-0FN(%Q$A8EY8P(`ZB&`/4,YP/DHJ#.%.A%^(G/GQ+(C>,-F0Y$KVR M?(;/1-7D3:)VPM]3UKK9G-DICVBWGU$50QU=X^G,A!^J,,9S=D:HREO>6;T? M7Q4F[LZPK^I'VXO\3#;5I,\UF=`A+\R7Z0+Y3%^G]4'@?&$^4;7T_1,]/;@/ M.F%!^0!F,L^2)5-_D),"[_-G1#2G@VC#XE5H;*=8:]:%!3CY%/+*`I)&TK(W MX/!29D.](\%T/1-@)J,'VCS:F(S-X%&0$0A!368H0=&)8BQ"DK1(I_P=>#1I M5J2/.]-4BWM4* MJ!7\*#OT^7JR5D-;01QP\C(M^*P"NT@J(CSR3DU5#7PU]5B#O^B(-U_!LTF.24;F.+KAC';%G5WK4-=D MH*V0.]&/'7B["5[(LC#4PEKY'5"R*/(?`24#F'# MP58O6BB5UF/]^,)<AZ_NCCH*W<.)DQ=!P5CG1GVWWIG(5Y4Y M9=O.)\X3N3(W1ADINT`GLDTYX!KU`@8V=O%R=QWN]R'O3!)?)4GD/QX3RMM# M>!V2E7$4^V'`Z_1\H:7M6D/8,Z@.#=/NK"HOU)SEJGS$R$=$?$C>!BE&Y4%I MKY[W_N[(*X!LM]ACMZL*3K)R5ZA@!A#U0VDP;4C_R'.):?EXCU%.?*JS($S@ MCU'.1].)[SA3NQ?A6$@,LL51A#=?$LFMU#.IVNQ8JJRJUVL#?`^MY$L.N0IBD0JL=2O-6#K+K33HUEJWPG[VC@1:&Q)>L;3Y***; MH^P*XCG&)B=LFW.19D/^\,N M?,68.Q84'FRX#&L(5=H^IEVY9BK=!"0<=[]T2JZ25N>65,-3?&[P6 MC@)3JJ61YNOU?)86Q^%D$:>+,L+H-S1008LFC]>3P!,K!&ZIJF-<:D!T!'G0?U1,7Q:E8#2%8Q):7V(YM\8%%RGGA5H&!.Q8:I16IM33AI MU(.A%2`?X38H'Q^4=OP^APD=\79+^U3OGER:51D@+V]? M7#0MYNU8,HY1Q%FFNV!2TC\-O8*V^K-4_?-M@"I'?.5M>4J;K15NMXBR2A]. MNTK?!*C:OJ[@&*4LHX=03AIDF6_UI^%)&)O-+\3LJQ.,LJV/T`['<1\H`MRT M`)I-2CL@$&8#$[6F]TO>^[&W"VF+Q=9+$.(W!HU=A6QH'!L4>2,I-520L^!* M@R$1G8XB#A?,MAIA-9Z5Z\42'+56`9>]`HLD[8K5T_5<#B7X>MW&I*R@"3QG MLMWL6J!CPY9^RM1'VLKI&6_H'F?,IM=[3/NT2W(AV]^$0)*8'?5][?6T#J@1 MRNBR'?QT7Y\$=QEQ8&29DIHWR*V(:@7&VLVS$6HM:@%%G&Q_LO0(!(9T-NK6 MD]7D!"R`^XY=1:@&:E`EH;MRSVHX/U#Z2"K#X,`5[HO6)`6%XKW[QZ]D91CY M[DYO[A._"`%;(3?JUU-FR^D)F`E9E-.U;>(S)#-#?T50*]#3:IB-F)+K!`1I M=[?RP^K\]T/B)AM4O8CP+&O:3MZ%/H?NQKVCPOU@=EXWBXHY5P0T&A@)-3PPP"S8,JSR33.=9 MKTY&`7$2(#T"SA;#T1"C;WN7&`LU;)&L$!%=>[T?H(H^72K6+!99`XS>R_&T M;0%T9K^T`V!)D9V6,CHV%,HI\7`5\"N`SV2&(,[FP^]'`K'VC]3\&HR]-_*B M8T7S$Q"PTC"<$#@>#(C7#!(F9%PB_2>$A2(#H$=JF@)(B95E(\Y:\AZ47[<( M=]HE#QQ)`(NR_'8`0'T^JK\`"@AM#[QVG+48 M&#;-.&=)R(N@G*($M&!PN]7)X6+3O)$GWQ:Y3>V?M.DE&/@T<**^KIA,TX:S M'_W`#3QZ!9V&,)_#8)O_H(*N4C)_,1XXP,[6`0,9K=)E":@D-BD`ED@%]H%+ M?7Z2O6P-V+13JV>3R>E:28`LFV8Q8[+75TWV8DYQ4FO3#`P&/7H?B*[:2@L&1$NK0JWF['3PEI M=4#>2\)++X`)11P.5"VV5\613"N`T%$##"!,],UGOIA4P&$'(+K)P;/>^)NT M8U_X%/C_P!MT##8X0IX`'ZP!RU.$Q07N!@:)`C0L`$2`;[?7$=[XR4?7H[/> M:[J0>Q=&4?@'[_1"?B,Y==(@,2B4U/G2.*Y99;DYA#RKY,H&0-D(Q2Y%/@C* M1H&"8E]ZX-%>Z`8%[D;(W=.&E.B1D<8;6!SJ&W<5I)J:LP7!O%P;ZPWO)GBB M81CU-X'Q6F-'>7MMN9BL6F!:D$:4MCW8/$OF!D@BOY!T(Y`4$I$"8VT#8I.: M;,'?K^XW?W_N#5/IX(5&F[)72( M_,#S#W2KELVBMD&US:[;,"M5FBW@O<=[E[C,X.D<^$J(``-8S)GZ5M]R.6F! M<#Z*U2`VI0M9(.R^N/XNJ]3.HV+;8-UN\6W`;E$D"+3#X.D!1WMZ]-.2/]+P MY)`@/1U>YX0KVQ,E5-X2$.Q9EZ)B%?JKFX"V*SI;NLHA^2&,DK1GRBX7>`-] MN">VM`IN!)J`!L=G(J$R/DH/`T&DX$#=1Z\7BV:4%`6P;<1+5U&=JJ@;)FI: M6]&K(LD6W)P:H0@Z-:5`H2=)V7D@@S77TT&N(9$A,K`Z+AJU8`,JWH\EA_BA$=S09< M]J`6WA2\4`)-P=H?DZ.[HX7DL4LS,PN]>'PPQ$9#@4`M,*C6`H<8\NHZMM,? MT`/TSL;$7K8*]90CC;3UJ:,'=,!LD1Y$UP,S>/Z(EBWK(3;7G9T@I?N?:FM$ M\=M6P92QI#'SS,9Z.&7T;05J!^'UD$JW/&*ZX9__S&[<5LQ;#[B%+B&0^ZO[ MGV%T?8R3<$_,0G(4T/#@@'@\'5V]'L9XEDZ1V?N@6__G2N(H2C(4-L0&5(:! M0&H8BP\VE+:_>[W'&X)!NMR](P/@*,*\DHBTJJ[Z^X/B0Y$IY?!JXJS2&:M$ M&Q7$44X=,?+`A7M[4@"?M?RGP-_ZGDNFK:]!^$C+/C,5W`2'8Q*C-Y_P"Y%Q M^N,(_=6-(O)83+.E[HB0SW1>*[>-T]':IF@\]K33=( M"C)[^$'[[%%Y9LC9HSRPQMG5+$V`3]^'GCVZ2^&H2C'8[-%D+I79XT18"*NF M6_JWV\JJ3)KP)'Y^0&L7,J&>&C1V9O6]`-!4)T,B.O,=[.VFI2V>(^,6X%^UJI=.% M,S;M9L#KWT'H,.MC>^)D0$N^F@67.6\#7FE/P#[M:!@GAH,85:+P7D:14_4Y M>;QPE+Q+/O"%!3&]**P:Q!RYCLC_,A59'CH^/)<2;<`1I?XQ;@6 M[CH_'+Q(9RY";QPCVE2N-B, M2L\,ZP.*@=4OX M[)A8/J,#%N!T%6,QG!@O.'H,>_L>D_R#4$&`'=TIGFO^JB8EN-MICUT:GH5R M0_J]3V=S1\\=V1`WG"LP!\1Q3R>Z,(*>^\6V)H2&73/S55;R]"&\#O?[,"AW MEWWO[XX)WBA]3!4Z8-!28$ZC=>I\(H1=N8`L'PJ5QQJA=#0+9E3S2FF>=9%; M\T4>UTNY0;,]*-:`@QCAJIJ%0?\?5QXK]$#6"W>\B/D.QQ_<:/=ZM0D/=/4@ MS?_5(#`HWE6Y4IYNG-DX7[G_@0KJJ"`_0FP`E(T`G6#9DQ(<NR.=85+R25G'0IP2):QI7,>-A5`N43_U)`!KT[WIH9F,'=3 M`Q":58Q=`N=675J,YP_;+?82G0E:B9)]^"ZSIVS@`]0,'TQ-W'>0U6J8H><9(IC,[O80R9-2\A9J"[?(: M\5VX\[U7_M\'_"UY1]CXN[9M"5,V=F>MXA3(DI36L2U0(`O`P\&G!4APG'[X=:&_J6Q*M$-_S M=!W&PL,N^4M#@E?*B;)AKF;9Q?X209121!E)1&D"0=*@G#SY)9,);$?"A6O&$B._,>-D9 M3HGU>N_$Q M2A:BE/) M"_G(E`(2*Z3\Y&F#7_`3"VE$DY;P^2$C!!$3&L=6DV7=?12YHQDYH+C`C'0U MX!3I]S$G!QHNAE7H:BH.!NQ*2WKJ/BR1?C4JXXXG3O+N29"0=,5^Q!?#Z46)"KJF;0. M4H&K2MY&3V[@_X/%(-)B9-:4J#PVW47(1T?%\."WA@"4YPRDO,&\ MC$DP5IR0L6]S<3[JO1][NY#NS;>E4A@?YE(\5P/OZK?]5EG.MA$<%JR@W\"S M-6"5>N+<+M8S22!HS$F)U`WBKY)G'%UY7G3$FT^^^^CO>`&(8T2O]XJ,3?[2 MD+Y$RHEZ1N)RGA[N,((HI8A*)(F;X$2!\&U04*<0U$T%M6)K6\D4*RAL5PH< MIN(8)_%G(K8"E.K/#HZ@&@,ZJ415X#!"(U20@H3+65*54!+D))#+:,+#1&!= MI^AHT@$8*$H@54-&\PM#PZ.1"_6S%&<]*6.D,JE8`10#\I70LBNH@>-$:G`G M8!'K`0PQE`\W?N:G6`_NM_1$5_8U1:\,C1H!'ZIV-9\LI],R;E)ZV=$JH9CE M&`!"QXB03IIS_);)EQ:Y2(A\CSC`6Q\T\4;%"D^`)-,*))3"ZJFP&I@$+P'` MJ9D3=4>]R.ZRYH`*3Q(64J(]Y2RH8LJ$I*4IZ4VZOLDJR(Q0@*U`E=P@FW`E MT0P$LG@9L.MP?W"#5^DE\J8G!\10P_`:%8NSBR%IU;.4#/#U[K-%XGWO")7W MWT;4`5AQ*UMB464\B(2'`<$K+]TM1;C.J,_0FR$$9MV\T&L0;4I-7!,$XZ? MW9@5'3JDA)G<6"8W&'Q;+5L*7KGFC%1&N,,1+>'B/N';[7N\=8^[Y":MR)"R M4_O,JF\-72^AG255Y;>*:L] M!FI>DEHO5],2J06^!G2-(W;(MN,_5;#9-UMWY?I8HNB-+VH#N4]WC[3'8 MT-WBNS#B>+2GS)JB]:S&LU56,"LGC@KJ*"5/X\!T@"PH M&CK\ZTGT20?1(>+!GL1/ZUGF0A]32=,8'V1/MR.&B]!03U<@4RJAA:,(;]CN M\YT;W4;LGL7F+^[NB$EL^^79C40)/HHO#SD%*W&D7FEUOLZ`F1'F9TDCVKZ- M%J+FU!$CCPA]Q`8`FK9[$-ZI"A]SX0]$^!=*%'1:US+=RG2OKBAX3#)>XJMC M\AQ&M`"?TL<_>0D,@W5.U-=)3K[W6L<>IXD*HC;@[3Q!FW$6!.9 MI1AGC0JR!5^L5(,.MM(7@''%N5!VZ>/98B['%"=H#YZZ""C%DB\4$!)'5?-K MPU!)*;;@Y_:8Q(D;;/S@2>/KEM\"1E*)%?4B5*NE(X=3B:H]F.HLJA18H5Q4 M2'0U&&<;Q.HZ@L<9BTV5OC)_$@Q/;'CU-K7SV5B`(49H9-&4U$&R)LC\@O[[ M^*?Q>%(LH_XGFHQ'XS'[_].@#[D)^O=C@-%T/$+45MB!^WOLL:1M-)VPG\[^ M)PK"ZBS'GBOA4I&0/?"MV+P8LL5W,;-K6R'^5S>*W*"YOU_KXX/ORXIY4;7; MA;.8SM.-V"HB44JOWUL;XHU74[(U>9MA9&O96C4E(',Z:022%O#/NGNC^/CX MG[1_(.OZ';P0ANC6,JM/>ZBZ*?0'YR`&O=6BBLABT[5%BT`S^<'U-^E=LZM@ M4RHM(*\4H_+FL#-]&SO*-W?'ZU6QN4JIYIV"Z*Q4+8<(XC1_#41FSEWHPK7`$6*A/!LV"`XS!X8>QIOX M(V'_/7Y,6#Z\TOVT]A<'G0';N%&ODC3.ZMID1'D<1LGF-T6LN+1F6&;G5.8- MDSF]&.)G,L/?YE(VVNI\J*0O:!1F'-WPNW1W["I=U@!0P13D[P-A4LJ43IBV M:H)FCL:4/.+T\]Z6\/@T*'\#3$77+E/@'CM?1X4`M)+]BW#=KF=;X'V[Y5L! M[*[P34"3U?T7&J6S'[]S8[RA52!(Z,Z"69H+J3(5GT4>V#ETX5E]BG,<1^H[ MZ(5TOCG#\()R!AA0V*_>/E(>4)D)=LF,+(4_?/-V1[:;RS>N>,\!"R*#X93; MX)AH6TZ_I&"^#VZ;ISD'BFV.J+/:H?W4)]^CVP8?,8YI/W/"M#@/0_X6D%=I M8$79GM?31:.S2&DB2A1E5.$Q?K:HO&I%FMN[2X7<8ISE^=J"6(E1BH`HT@TT MOM@TD0W5XN?C\@3/)!U3.\I^/T M,(2]"WIGN2/WC@KW0]GVB5F4#;DJ()C52DNYEI\8VG(UZYS.5ME.:/KU06\F M=Y;`49-@4`L6UV:MBPEBQ=@+GP*?WU9\G^;4W.,7'`C34*6O#&GG$CZ49_C% M-+N46R)'(^>,($HI`B'!F(SIS5OV9HPB3I>FG>8;:RR'Z@E#K\]5++*"HC85 MP<#*WS\>R<>EVFR#4\.C@\+H='SU[.?I9)S!IT0&&C3G2N2<2D1<`FU81PSY MF:T!-H3N+F2QLQ5MP6065X6+0#DP,-G1"[EW+EF2/!#O$[L>ZPXH60M(WA@4 M-$(V-&K++]<9=A@UQ,BA$CW8-80I&9VN,@Z'G58SK$)(KAB+D"2MH21_!QY- M>H6)9I-IU@A)8FNPZQIS3#F%QT&Q`5=-O$!O: MVC^%P=,#T2!EZ"K87+L'/W%W7[!WC%CS/X5/V$H"""5M?*F;W6P];4(0'>`M M,S^>YUO\.QT+?<*TP/+MX\Y_8JD:,:\LG?VZX`6JQ'2/^N)%IB,_\/P#S3/, M%1*6,/6^6-I>%7M"UV'`FMX\A'=^>D!FU3^9_ASV.#!Y[U+Y.^`.1K>?YWJZ'+P\'DFT@%M&3'60%P[7X&NC6KE"OY^;["F[;X$+W3])GC3!9JG@2XN:MQ MH4]QIRNT%?B39!TH:@P(BTGD>V1AREIH!>P/FJ/VXN[H^DEL!/+7AD6AE!>= M1/K\>"@CR3O*\6T"\I<263#T&136J0E+.\<=]T=VI/4>;WW/%Q\=M;XX*-;:N%%//".. M/0,<)XHRJNA-B2Y*"3.>_X(AM MA)8'&A&@=^=)_!YLP>U,60_)UN",CAA'?-Z?! M=W9M5Y+E.!RN.\"@"G%=[=F!=FY]U/B8[2G;1OT]4%37F%&.[J9+9RY!*]]^$K+4)Z]11A%C=^\MU'?^W;Y;/\VE5J%+"7?\^0HF+:D63A.+!IRZ[SGHIK,H0K=BFP M_T(WA"73Z^FS0$';"2/*$_Q\N9I6H[72_EI*#"1&.U.D)GCV+9)22':F7(V` M39.VV?'%H[NC55.AHS(AC.KA6+,^C"#ZB[O#M]MKUB6*'9M?[>D64E;,^I._ M]Y,['/T'=AL7:#JO#XU[#=X4[6N]&L]6#G<%E/I)@RV7C3`J:J/OZ"#H@"/T M2H89N(-+;PJ8E!7`Z:=9)%>I`K(QT*=<`708`)?2FQ(;FX*P)7AL,U0!"J4:`L;>9W>/*TQ)RR9J\G<:0`>@("(*S%'`4`DRD'&%]WD>]ALH!@X4;[ M9ZX^#H.E"@_J22[.I'GJ8N1H<0;>``H<26>(QVLMU3K$'9A\=!$ZY9J&XAG?1"H$"5.CUZ^X.B%S`"QN)&/Z.F!`Y0& M%M1+(4W7\P+]<78D.$(9,<#&/49DJUP1L"#%N,7"ZK&(2'Z+P"&]."Y_!QXH MFH5!)M.9TPX7X'OC!D7E2^.41IXO8,-5<25C5$!3YR1'47COX<"-_/`V:"X9 M)'AH\""\SH&B72R=]=Q)\Y@S&H@0`4IO_7Q1KX3 M+'Q^R*E.Q(3ZMNA\.J^"8X1*U*#W?\W(YW23;[`)KLWT*I.;5"4PR'G&FR-= M!%YY7G3$F^Q:@8_C!YK/UG9A6X/`H-A2Y4JC0$\!-DZ<;A6DY%&)/OJ-C0!_ MB[LO):1%%O:',,BJIV=JH,466*'9LD)@X:EKWU6\:FD0&,!!XF_\W3'Q7W!1 MG_S#-V]WW.`-;4XD-^E)>@"D_A$H=#+Q7&5RC#H!&`3R502`+O)FI+W?9'D\] MM#$UT$5Z/NTH8;;.BA'WAU6KPBL0!?/S_#`A,9CO[G:OZ'VKIE+IF)P^T3:`G>J1\[2RVQIN`Z/74^0RA5P!_91C<`O=F M\AO">L/Z#L<[-_8]VG>*[QMI'@CK40/Q:UHL:N0MS!JNG_P-OB(A^2)Z+$\40RN18,-[&G`#J!?B=ID`JXR1+B.9H>OM(F:FT MG1ZA@A_Z8L$1XBPAQI,M\128AD]"JB$U#.#QS,->X`\-?]#OPENJ1V"&Q[MD MK]DE0FG8G>H)UU8%?)`*YX[TN-^[T2O3=]K`]Q[O7'8Y+`F+;Y`N3G'^3>A% MQK>,5W3GOK+EZ=4?;I25C.)79OGE1;ZTI4T5ORN7JAAF]O")85WK1]>/_N+N MCO@JCC%;>Y=R-7_%;GR,:/&H>WK,3RL?T,!:-\/9Q!@@+M0`X\HH7B_6XU.W M23E`C`7B%QD3:6.V(FTZXP/QTG:<$[8+3NG;Y* M[7!Z!E';[.A,?298YW83O)"I+(Q>KPF7=.]0SV^UO`[BDN0\Z<0,#5D\.?$1 M2LE;Z$%,:J`>-66TK;E]H6;!S1A64!0L/$D(^H+C!&^:^EQ?>8G_DIUXJF.V M"TT0('=@5.>H?'6*[GQ$)&B5GHUJ(>A[UU;=$WS-=?7E:ZX8.WS"&;!I=A1= ME0OK/02+K^*D\-UK\4BZJF6+VG0=^Q-8ZHUM.3`=5(\GAZ3]ZM%"7ZD&U8ZN3^%3 MV>C)6(B>NN>.B^7.A"WR7>W<*H-M/)\TY'R(#RHKQV(CFY?/PZBN.8PK],(. M#NEY)-'D3;`-HSU\WQ5C(--Q/HJ*M\7KE'UBF75Z0,"=:1P?]X+!SIC M$&!OU)US]3!@-9W(/5-MS5IS33DKJ,2+U7YJ**4RG_57[#\]$Z_T]HK6K'[" M%2U]C?G2LGJ&R'7/4R9XJH1M;NQ\U+:YM#._$8A[PSM"\XDL9']UH[]CFADC M[\`N>6%(MR/D0MG:5\NL?75*C$W'.3G8/NVFY,M[W?`S_7U&#!2;K297P9E< M$W9A1EX;N^TU*_"C5S9ZNIA/U@HH@BZ1;51<$:CL*)2M:)QJ&(.NQXMIYL&? M[PA)'$7I*5P+R,1O#(HO(1O*MC:?.5D"'*.&_HQR>EG?,F!4&1+2Z2SD<*AJ M-<0JH.2:`<%2X\I;]&F;'QX208T![#]_X>UF>$+[1.O#=QP"'(?=^%:O.C2?+^3HU4A7 MX.<[*2?IG1F;P#^$+IG+H'=4$$UL(F%K<'1W"/]._^L'7I2>D+WQ`_2*W2C^ MT3XWS_VPF.0T+*4/-QGG2]OTTZ>[]U$N/73YY"7X-(4 MY%#?;)U-U\9<7,88OYW&6>,M9TK7%# M2!&W6&IHR^]6QL_N;H<><>HKDY#^PJ.MEI[8MG?RC-$.QS&.Z+^V=$N<[P>@ MEVQGG$1G>_(U63O2BW2K&A[#B)M5_>H7Y79YN;*;($XBUJHK9NTM'I[=(#TD M^!A&6^PG>',3\+G%-)@Z<'`)3EE?+)W-B8DQ'YT6XBLQFG8X20BKQ8=].*V>_\D,_I-/A_I?DI^]EC6W46ZV>X>PHC7[?C1ODLG M?"3FE)V!IT?@?R;$$SKUY#=!H5"CQMSWY+J5)%:_WN3,'2"O?F1N*A,%9=D5 M3!@6GY>2*BXL5`?\EI64E:I2W]:U^L\R26AYL$'G#W4#^+ZF%B9D#!;HP'F+`A_QDQ\$+3J\_)E0X&J'F>F:/N!W.I/9MVC2 M8.W[FO^,A=73V7HZ`YP:`==(MDR=AK_E3&N)],\YV1I6^;R;RO_9IF?+UJB: MUO!]3>J\5AG8R5-M^.]BOZG>P=,_SV1A M64S?Q08N:KHI]YS)RD9EY8;?^R_^AJSC[WNXKJ<\[B5,#ZK":/1)6>>=!H+RW0T,^`0_O)7J101NEDZ9B[7]'J("EO@'[1`E57'2)A>V]3'8=> M(7SB"OO['-]-Y/B7D#;`W9'8>NC8L3;RI4>/57'4&[RLG.5P[K%@\GN+(,]1 M?]5EON24P+WE,&#O/8)L^#87[S_O_?CO'R.,;P)B[SA.AO*>C>->JN]L$D89 MNM.EP?05D>>D'"+*(LIX_%X[,3^!EQ5]6/U;(%70C`63D!['O-248P?!@V.UM0H_E M`U1JBT,*J(K5^8ER7]J1=OV30A7<`7*68I]$X^2[U+9ZGTN6KXF/7H+DZF M>/?M2M/NG&&4PQ]D MR.]FLM.ZH[P:.[/5>M"Y+6#\?2\361=M#SEO]5C5`&B2ZJ)QP761[W\J.KUL M/]C'L7NBJ64=W^.]Z]-;GM-8@R$M[F?!Z^69#SH@G]T-R$5!)!H#TQ`O\;M6> MXZY4H9_\+49O_H,E-_XS3+V:,TS_<[..!5@X>=?8_Y`V`&(=9OI'DG3TRYZ0 M9:(INH/U9+I:SGJ?>D^FV[P+U($R>]%3K+FOT/=D>C*!9KSRQF47/VF:^Q+- MTV-57=_M5*CBKWN:]%J_X$4E0YQV8>BK(HQDI$M(@1"SKY,M::[#0%,3F0MN M#F9,O=]E$[!VE!K)>&CY")?HV*IEJ/\[7!*TI]QPU+>FYA,5FNS5WS_&=K M/#+$MVE>5;,.WGGK[FP+Z>E[\[W#EG+Z9VD4DLK)"E7=!%Z$R0/Q>YS^I>?E M=MNH%^236T11Q_ET,3;O@WE=OIP]]"9G\,>+K;+:A^*9@_W5_>;OC_LT78OZ M5+9A'Z.]^XH>,7(W&[YE249&!T(6$0[P,=@T9QM=BK=5=`$FO:O*M[M(;]J2 MUMG?.)?D,3LFMBVFSGQEKGU>X2,+?BZX)9(9Y0KV*3_P/))W%]R$P8Q^!)V- MWN4=$R0JNICY0)9+V>]WN'"?KY&O,?3HESD_&#B77DQ)A&>NQE_SK`&1'S#T M=&+N6\S4<@2^QSG'G!+G2DK\7BVUCUDMN1-G8@+%82N>B/:_/BP%>(P\3=]>G(!_I@BY;KQ`]4SDMVY&=[ M&Y.N_;R/^GTZ^UXWKY2'_ZYHH5WTUT^QJ)YZ^>? MP!GWMPND]:6LN*##.8:I9J0\]J5=SE$53!&PR_G2F1FO7I0VQ_T>:Q;UHW_# MEW+2N>M[K5#4SS=HJTP$UQ`.Q!L;NWRC];7LG+CZJSLD&NKBIR6ML'$Y6:V6 MXP%FH8NL+F1$M_W/,!=;2\B(?JUK.3V$)^QOCK!^+0-8(:@S+Q<_J9BM4K)< M+9QYI2)03YX1NJ;,<#-3+Q^H_ZD+^@,-/+_U\I6Z%_OYWN9(J-(^9WUGBV;9 MH4OY*(QZF3.G@0R:U7@Z'SL]KS[3W_97G,:UWM;(\W\6D-6@1 M'L7O=%%9`G>$>^K'G_#MMC3Q?DE"[^_I%2G3![VP:3^F.B/!P9ZH/*:T1_3NY"$?_")/ M_S50;N3$7_5;792KY#NB-W%\Q)N^KDPWCG$)SK")<74XS@U>A^:<(,[*Q=Y[ M/E^?C?OYJ5HNTHG)\&?$:PEU#KNUT,26J*Y.GR-=S!:"5`Q5$"VR56!0MX:V!ZK^_B;S]V`UAJS1+YL`2MWD;9@$!O"$YR_W MV[\!V(00,P;SDD2F3*].]A)^K'16\>INRZJP%V(6SY+:\P'WW_YFE=J2V?^B_*]`J=SEJ-MTJJ5NP&Q M:)9@_WD@_%T%FSMB"Y_=/7X?T@/*KFO!+D/9M#?0@7^=';NTL>"'WX]^\IIZ MD]\XF?]KZ>J^=XTX6AJQ9HE_!JBT5OI=]7]9GBCO$<%/HD2%+(U4J#'+Q$5X MKRZ2Z10DU*AR%JO>_I)MN M:&T!X:AUV;@D5ZTIFW+(-9\Y&J73E9UU8_N<[]5=]_IMU!SV933BZ7Y*K5Q5+V!*OY8MV#EU;H2BWN1CGCZQ[`?^2:%@+]R`7ENR0%' MZ:&OF[;X(B+3#`HKRA#+Y]JN4Z$PK0/OMO?XR8^3B$W=5!VWVX\^>?6I^5!: M]L+PJ1@2;E3;@Z_&L]DR2[(@]%!4(LC2):A];!G-P1,GC,DW*>0K$\SMG],$ M27,P)J-3R,@_%_MZ@.D+"N`J)2:TZ:$?Q'\A\&*A^M4Q>0XC_Q\\A-^'QR!1 M^EY2`N`>0<:=CG6MA1XBSD9`;GD(Y+(QH#V&.?E%'B0?`56&0'P,&SR*.1V< M>IA]VIJMZ=O;XWE40"[V1*WZ`UE*^$^!O_4]E[#E>905\CGNPIWO^3A^P-^2 M=V3POXM"2K67AUR"*'&D7AAX[&1ID`5A5%!&&6GT&R6.&'6H)7P/HG.@'O=D M9?/*DLGE6@"-^K4,N;(B4%<<"$(SM\'V'6ZW[$:E;-M,^/R0.!0QH9Z-L9JD M%P3YQA&U/G:5&72;S(Q8CI98@R&HS=`JH)%J`A0GZ2Y=N#^$`4L[5L!*XSL0 M>&EB1*.._7QN_'SQUWX1WSU M&+/26VU?M^D5"`PU\*$1]N15.?(%&=W*)001HTA,+:4)#::SQ72ZBSDXJB3F MV`@JD7*`,?71#]S`\]W=71C[;/FGC"WQJS`8$_*C;(3C^7K2@+6<,,HHVX0Y M0V*?8D];;``,MIJO`(MRI8%B\HN'`S?R0Y4HL?(L!.K*#.C86W;&FKYN1S#8 M71A'49C!$=)D3(V0.)$=!@-DS59);1!^LI,'![7^^NC*UC);S_(9IB"2IZ1< M)4GD/QX3]W&':9^T.S?"?>VUMS9%.U-*UKZ,-2OC:0:YK)@1@X6'R,ZJV&A4 M@!W`:`W3A"^``D4W-IG.)GEC)W7`6!">F1'<.16$^/Q";*7[F%#"CTY+RIIV`YB[D$D'244;J#S`8: MH6(HQ,:R!9(F%<)K;&!*`?/I#L5<^D@D,AQ:U8Q=CF$%Y=F!;'9N]MIZ<-SZ M'BAV:\PH3R*+>;;_W@36$3\G?46_I7_"'QF;E;R"RHI/H@V);P(OPFY,>VGF M*2XXJ^5F%V(%1BR':)/J[,!D^DD*_Z%L#J=O@N+RA!WUZTC.;"5#9H/5V@+) M,X46395V(4YHHG+,->O&3(9G^V`?MEOL)?X+%M;ETZ4Q>)ZG)H.JE=`<,AUD MK3%+0V11:P/:4#Y.?X7BFIS-`&HX<3O`:FA)^^Q5%Z(0`>%<;MAD\XZH+[(^ MNZ@/+$S@!4_?'R.:\<;NCO)PK%A@W&[YWQ/_<8>_8(\\FOA8?%)R%M&A@XO. MG"I/PM8VC'@[)':%&D=:[@ M,_Z#_:H3\HN7;0%ZSI&RV4['TZDZK@E]_H2-(.XH/,]W+]V!KW7'H$!"-W>W MUL+WQ(:5T5K5F'7@9+^L%6,4=KC2)V0+:!NY4S]RFBXFQGI5R>JUFD7\FBLM MP$]DG;GIC'D3NILU-::RI8QJ9WPH.P&Q"BUR"*RJA^&%OR)->#>AQJBRU<]7 M>3TZR93/!KW`57\?RDI#A$+V($Q82^W`\P_N#O`JN%'8*+@,#>V:.^BXW6XQ M9>$ZC).81FHD,J/>JNCJ*=PK5G@5Y%BCG2^-H@6K\FD&@2DGC3Q*FU5W2HF7 MNL8.7;*B#YE++BPCC1AM5")>:CX,=5YA6F[FC:H]E8N/C,C_GJ(P)A\["CV, M-^P6;^SN,/V)H'[9<*<7ZE"N'EHHZA`L8N'QTZ^8!I&R^:KRW-"117EPC5JI MJV7EVBZG@G[C=""3@[K+4]ZGJ[771O'Q\3^QE]`,XK#4C#OD$;)4[D%G^R:3 M.YG!3U1D<%;F"KD*-OLX]HNO@9\T_+@1'&>3@YF]._&JZN67Z]5T M59[1T^$0(8P*RNG>.ANR^5>]0K1EKA]`0Q/+-:02&@R@)N=$32.1CEQ='0T8 M.)SE;6K!1'>M@P08Q\<8_WZDQ1A>R'\^^0&^2?!>N-LA>GS(<$/`@_(L36PW M2TW(22%&"_U&J2%&#BKX,"*=TTFZP4*,%J.K1!HR?5B`&'E8WO@L'%8TP]GI M<.?F1\JE5P=\+,R-?(VIL0HK\ MAI=4"19@Y8'>PE?[@OQ1.(2P\95=[F2Y7HL"+D;)#EAT$$H0;HF%`D)&Q;0D MH"A48`,>R'BR*DZ"IP%1D;*@?LMV,A/,&HC2@BWK9$*V9GRTR`:%D9JYR6!2 M5H8E2'D?[EV_OO_>_CPL6C@3.K'[2HH73L\>Q'213X89B7R`J*F:7@MN2BJ! M0HZ_\=WH]8N[PPK5UX7/#XR<1B8T>OGE.>N$@B7%U\U(Y>A(-21*I&961XE8 M$6:.GWG/!T);UAQ!=$[2B<3@Q\QZ_*F>""XFR\4\/5I.&V?7`N$]=.(9U,-FS)G^JH/TVKX*8BNJ7Q5HNRBXC:NN(-?T3%TWN`1>Z0%'>S_@?=^> M(LSNBXF*!PF?'=K?B!A1G?[F\]DZ3;8KD4)N1HM5?!DX6]Z,3).Z3#DMJ.H] M9N1RZG*Q!-X=&2B,FCX>F`-HPU..=JE>3$/[(VX#-'T"$,9D>%6#&"^7,^<4 MO%L,B%AM]D]P2BC`@E-;A!-(%@C<-@LS-`!+5M\$NTSB[IMX,?9^>@I??MY@ MG^[?S>A?*!!GI6T[\J._/40NO4[PY77_&-:_P^GO!]B6.QE4O4W3Q$D7T>G[ MB!,8UGC/Y-]1X[]O>Q6:!K769A'-3`R1&WC/^(IBX5/H!A]=S]_YR:OXLD;+ M&X-/'%)V%&UA.5ZLG&4ZD7""Z`I1DHC21!E1H!L5)F6!9LO.'KQ/1*/M&20R]\9\-!9 MRHAZQ+A:E##$Z+$[4(LH'8?=YL*&F]4:AI MNW^E3&Q52LL\W[]FF.^BNR_=E3!,9'".HR@"ALX*[=/;L6HA-P$MS^*_=/-S M0A*6>#@1?ZHK56=*&_NU^39>=B4?QD*G9D8/;>YL>#UT\F-FE%'R8-IR0[JN M-M2W.2VI]B"6/5\/'Z,P2-)"J:52JM);Y6UO#;CT:6%%?5$PGZ4UU[X>WFXI MR:)Z;*G`+.RM<9HZ_H1 M>J&ET2F%W)Q24K2'#"'ADA^@G>\^LL.\@1,432BKZBR@)T1C8CDEL4!F0P7X MY=&@1&"37B!^"+,=8]X9J:6"K\IK0/Y!QI-R>]C)=)PZBXPJ>@B+PX2T>Q1D MU5WCTDXLD%8)_.9$=LX7>4A?H0+2NN-H519(=(W]IV%E8=UN$;E>;_SS&"=NWDN>>G$MUR`C^/%8U\CJ6Z7V#F\"+V(Z?NT/9 MZ"@=/NV`A:Z2)/(?CPF]94;C9\80/8#@/:+!TR?02YPUP?@%=09B!4V7-84#5UGB6VZV(MP4^\ M0[U3'BK1'Z%T9(L\@BEM\)32/L4+B3<&$V]1_MAOW?1CIZU0C[17))D"O'!_ M(&-QET=^%.`$O2%KY_A'Y`?DEYBVF,HW5^B[UCG"=O2W.KX6E5ODZ$Y]8 M248&WM4)>5,V?V<]GY[CZ^P,A(QIIKR[6O<#S?AGP+8_./_!U!+`P04````"`!.=PQ'BB2[%@A"``!0WP0`%0`<`&-D;F$M,C`Q M-3`V,S!?<')E+GAM;%54"0`#4Y?+55.7RU5U>`L``00E#@``!#D!``#M?5MS MX[:6[OM4S7_PZ:DZ-5,U?4_VV4GMS)3LMC.NXVZY9'>R]WE)T20D8XW4&DC"- M8++ZZ=77N]>SNXOKZU?__5__^B]_^U^O7Y\M%F>?TB0!<0PV9W\/00Q0D(&S M^^`E3=+UYNP6`0R2+,C(<&7]V]IAE M3S^^??OMV[/:7-Q\^O/FN]9=%FB?1CV?? MMWYU@4#QX8C0]./9AW?OOW_][J^OWW^X?__7'S^^__'=#_^OW3I]VB"X>LS. M_CW\#]+XW?>O28^/9XLWBSW5<-7__HO9T7C'U\P['3X]K%J M_O[MWS_?W(6/8!V\A@G.@B3L=*2#\;J^_^&'']ZROQ:M,?P1LU%NTI"AI$'@ MF;`%_=?KJMEK^BL"\^N/[]^\X.C5?]$/_@VE,5B`Y1FCX<=L\P1^>H7A^BD& MK\K?/2*P_.E5&"4!1?[[=W_Y^([V_[=/:9BOZ2I*HLLD@]GF.EFF:,VH?G5& MQ_VZN.Z0'P8(1"\P"=GZRU06A>DYV]W9,$#^HWY\@HF9(9@ M$-^F&-)/7,0!QG`)061.NN:X^V3BEI#;8Q(,!L\>00;#(+;/UC4YV-9@$/'E M$-9)NPCPXU6\P6P!\>]#F!^%GFG@Y0@6F]Q_`=E-BG%Q`MP"=/=(J*=B09Z5J)\' M&(:S)/H$XSP#$;?#$"`L43`V)K=I1I8B.>#C#:,#/H,[$.:(3`_`ER]AG$<@ MND+I>J\XV:'*(G97`42_!'$./H.`_IL>W;C^9>N>G&$,,DQF]08&#S!F!)=] MHGFRH$P@LA'HW.,AL(U#T-B(U:?#-<8Y%8[QQ6.0K`"9N;H](95058H9A?2+ MY\L;\`SBCS57UT2X1DQ2M(_B*$2.C:SU@]S@*Q9YNTZ>R7=21!9I,PW-[X8P MI!K:(A?DPD,YB,@BF1,!&;5V'KT`TH1".5^*6PUA<_"W+>)`OKB&6;%RDHB( M/50&`,DH@H?QMZSR&*`I[G&37/4=,I(>?R!:`0XN`A!K\`3`B;H\N7)Z*+@^@^I;\9%QAC:L;% MZE=`;:;D=G@&*%@!(D'FZX+.KYB2T!(SF:!]3@W&LV\!B@;=7)8IV=-Z^DI$ M"#I'B[NOU?H>:['P/C4RE^$CB/*X@A=3B9A)#60F4B+B$F+HRDSP(!5PV(?W M-,_EY]C!1;;I?7I)QDXW@*H"7XA85?Z+#<&6X6VPH;=PL1JIKLK^5&YX>@3> M?;6]748FUB+2YSD150"F,ND#49=&,4]J?V->&EWOPDIW'9'N9`[)'V@X-S,JT/&50:QK'!E=J?!]E M_6E^<6S&+P.4D`_CR@8\"J_BCSAC[YXJ"U;7ONI38[-:B_;-/AIGY@9%/(<,OCP]$[39X!C.$J&.3_F%T%/0_ MNZ<-1J:!:,87`&4!3&[2@-DYJ/.AB328A7_D$%$S]3VA&"\!&ADFVZ2-#64K M%FQ)W8L@P4PA*LW[%RDFFD%MF"V-3..(<4-)F3A4]L]Q.P2-#1O'N#7R'M3\ MXC08M[\LC+X[NAVC:_8;R70A_$C)WE/+U$/3)#I\DL8@B6C`>/%;^C$[X>[L MX^3SA)3.%V.:$Y"B+K3E!UG@/P;AFU7Z_#8"\"U!^SOZ`X7]N]?OWI=A__]& M?O7;C'PZHI^_BH-5-1RYID'\TZO=O[\=G9Y2-KPBRRV(_P$"=$EN/3)+'-*$ M3_5=,RXTS+[`%G**`QWQVB]/N-CV-%1H'.+4`PC:[([S`'2''; M?=-)9U&/RJ;E_F@LD!$O2'Z[_=%W3X:5D,7^/#XUQ:J_8,'M\34Y%E_^+]AP MR.*WVQM]1"5+$^;A++S+K?`+,;&R3ONB_`K&`%V0E;5*D1C7;JM]T;8`*TB/ MN"3[$JQY:Y';;'SJB'Y$Y^ANLWY(8PY9W;_7]+0O_1GJTA:@L!J(_+ASXW>S M[\H6;Y]8OM3K\!'&M;"P1.G:Y.ZHJ$@YN_LL11%`+"WT_;MWK\X(`T0K)++' M3<&KD$!&7080!JPE[0E3HF5N?GKUX=59C@ESZ5/A;3TL>+;DFP:?#R=\)'=; M@]/'$TY2.:5!ZKL34@K)L\'J^Q-6G'NIP>H42+"Y0DE35VR`6ULD?QO;[>ME&/;+G7K:)0?A!D=^SV5 ME-Z=O3ZK>W=^3I=G]5AGU6#_>=8:KK>ZN`SP`P,XQZ]70?!$=<;OWX(XP]5O M7AIX`C$7 M>=()9L&U(4;5V0CG+?!<16OS1 M'5T"/X*@D3LZ%2NUT\8YE5J@;K=U037'RUJ'!F4TU!Q&99I&=7)MOJ1)*)V+ M86.Z0(&6/J)!4>1_EW_DY-Z)61!,=A$@M"%TLTA5`;=Z?9UP)8[X$O$BZ>&* M@U*HE4[!=C,7M'XJ1>H%7>2LDI)RHTB[N.7A&22Y0L(4-)X`W0;`;[=W07V5 M$UD&/+4K94BY4/=SPU%75V%7RF,9$3L'T4L^V?=S:W:;(BT(X MU>[NF#?YX3B1TW"7#'WTIZ`?W*3)ZAZ@-0WZ5@#.:>F:8J4@(&CL@FYF'BKO M%A79_+;.J&ZM63W2^1UT!`CZ4W=SP0M-]0%1E7L_" M,%_G3,<@BA,,H6A6-#JZX$?F(%+F?E-G/J MBE78@7T-BM0'1G[,^QH4J8^/GG'"UZ!(?9QX6/@5]JB/A5KL\#7<41\C@6+E M:YRCZ4TU-)0QS8+X$)`0F%_:@&BZ`6N\/OA\!&O@)0CL:?#Q^5C6P*=KFF]@ M\?DDUH!%RX+1H.7S\:RSR42X^'E8FSHOVE#)C.V^QJ';P$T>NN!K6+I=Y'8" M#WR-4[>R404^FOV%J1\>9@,C]1IH_;2O#(%6YL1J#FIX9@:6<*PID:]+S7(PPL&=NI58VVY;W6H(&21J!J M`YCWRH+>LM+)(:M!^^B]JJ`/VFZ*6@.3]]J!!DRB6/T&)>\%?0V4N/&+#43> MR_0Z$,F.\8]^"O,F(4&[QEB.#/K13]F]+T[ZLFN#H)]2O)GGX[SOHIC1+,\>R>KX MLYE(,2<[/2;!0?%PK"[U9>M)4"XN2JS5Q7U6C^&FT.SLGB_-K:'H-!4^I!M$ MTF$J]*NWB:J7U[DQ!Z2\ZIX>OJ=TV,%O]Y3R/=7#)F[5J>A[VH=-S/B5+SW- M$>D+G);2X'ORB`7P9,>;KQ9-2Z#MGFU^E=*V#IC@8!O;*NS4\'*=D#_7JEI5 MO?>#JGIOT>WLW\G_BPS*LY]1BO'9YP"M8/(?+LPT^@&\_E>(*WOZ^MN3!:8T'8'T#,,);4-.XU` M+U\(W>1R)HY&8C]*VN$W+Y`BRNU3?>%]TA6-_-BF-#U-H= MY03A<@&>D_6Y%-:^$;5V5.:237A!4TF0K#RDH+F;@GEAF15:7=5E@)N`>'%[ M%]03U)H-+*"XV\9)T;;B+$E6E60AH'2WG5-JE:B'AQ!Q?T_PK@ZI$(\[-GEN<;WVBDF8.W-BN][V143T#D*Z[#R*M//4.H%3UM# M'E9+Q2^`Q`8QW\NB&"TCA=G"]U(H9BMJ1,>`[Z54S('F6.'[E4WYH0`I`2M6 MP<`;F+8,S\-JHTQ_!:F\T9VJ%7SO[[`"*-,_S89`5+N:?4\]57@GNXKWMJG6 M]_AO`W#$1Y7OP=X&((EWY*#H[H/(8#:`R=P&['N,M\A+U#%VB;PSOJ$;@19X91S\]_34DL7!TQ'.V!`N0MYGT3]S7-0]O4\7($R3$+)'(AI= M]3ZE)-ZB]!D2P,XW7S&(KI/:HCD+,_AXO']\Q M'.AO?INM4Y3!/]E*(6NZ6[9MBQN-#BY.O(^C9(+.\B=G=[?DM#BM0-%O6MPT3X$9 M,]3J.AF>:"'BNR`.$!3&#ZO[38.;ZC$R$T[:?:;!12VMET4-U?E$N@-,A#_V M%-I.V7!]]@3]I\'=;>?E-\R(U6:-VWD:?-6URDT/\YV.CI*6>(IQK:#OW6A^G@$\*%8U@;OCYT!ST\ M'/JM#]/!3TFQJJ3-D*"\'70F(%K:Q4E=RF##[(/S):L:1`LLD=L%,$.K@`=I M%Y<\W*>S\(\<(E"92)D_N_")E'\15@LU&6(2/))M3?9JMKF-@R2C<33DMRRQ M1Y=#\0!NZJ.F(0`1BXUE;WQ2U+56H[JC:W[8-IDS)R&^?`$HA%A2ME;5STW2 M\5.]Z=OOXS#3+5.*[T"8(YGB:32$DY3?,M(31!?IFA[(,MNNH+'C>KRU\U>_ M#N]N%Z=/G(_H_>V^A*5CU?<]B6U?:(MVEN_Y:F/CJQ,KT"_I[9!R'O:UBO4C M&GQ_DWQ?B.\_<;9/2M]!!%/O:\H4KM=!^8`GH#L/Z^K[\/LE!Y[N@%W4Y18? MWY]EWQ?*)CY$L;?/W4C/:#KL!WVX#K9RF8\<`U1>?3K!.C?)'7[6M/>(L#?QJD#91RDY(VPCH M;K#OH\\=[%G2,Y!7ITS?1U\]:#KQ3/8LU\=3F\T4UW$\#[X7=[.T>HV/["-Z M[7L(KL9BM>^%XDQQ-:OY,.P9CNE?^W;0VZD$,NA)CB+]]&/A2 M1P'?9:(MZN^_W!<--8Q3G",P1ZL@*6,29U$$"\*NDV6*UD60K9UR5(16.E&? M`:VRMA54SFWBYJWD^O%S+J'B=FZH)5<\RN!##.[RAZ+(>T;CMA[X,.OWDX_-7J`H MN8;;=`HT2Q>"H+$+NC\'+W"=KZ6KH=O&25ILFL#RR8M*D3/$M::HWU#JR8PBN"4MC>2?IQZ_*GH>UI M#*.@3&2Z;0D?=;)"$-Z#=PM6KNN52[62T%*&D()HG]RA(,-F`DOQ5HS$< M<_DE6),?6P1)I0J-CH[YN44P!-63#FHNNLVMW-?MT7-$#XCL/JW"&^;+KT0U M1=^(U@L0GA-M8Q;':9'+\\194S9&=#(C(4@"HMU_3?`3".$2$BU*NK"$[=U0 M_PBBG()>ADV4MW6A7=W`!+`'PX2\Z/6>'F?WDFII.CWM[)]'$"\78%4^?$H. M%B+[4%DHWKV4-3J,0U/S=$J>/::H,A.QM$@M&J4#."UUL&5"P!)I0M['*1?5 M@:)#?:>M&ZK)T?Z8QN0/<4P*^Q2F,H0=)F(JI<;#S,-7FD^ M/<(M.K79V^UI9[>K/W1)A'SJY0+TK.%N>-,QG,T%56+(;9M3G:7P-14O?#2K MA>5YUX9153&:@8-.#HN)4"Z7_87M75$/(QB@34OM4B#/;^_TN5&9SZC[5.2.8\_W M)[)DOI_.,W4"?TOC`A_[M:MIX"-;/$H_Z_Z>!G,#EE5'0:>PEXZF[OM2W#%G M=[)=VM;DHT"B*[JTL=CRL?J>(ZUOP.YDI#8A";Z_I*VTO[9JW&T%(/G^$KNA M<;<&2NB''Q3!^NWA\U>J9VT*' MQ:5[B:2IG7%0C+J?$%IQK0\*7O<35W4(A>^5N@>`IEF$Q=,2W$.`TP_"ZU=D M^RA05(4L^UXKV\YQIQ/G-ZB(M>=(#O0A#RI;?930ZKIO^Y6F]AI9G0`SWRM- M6X--'@/G>_%H@TC*[I[F!JA5:+WSU7_1$RZ^K[9"RUMO3]_%)8H9J0#[<`)L MUX78A>CC"2+^@<6/"ZY@^^X$V\Y6%(0159!]?X+,(.*A)9C4EZ6_MZ5.,'[G MR1I^O)?O41'2$\P(&'"5D*,GI'5JBUBI&># MN/VIDM)A5E+"-%8TR<$=0,\P9`]'R+-OI7V!3*S(^AXXK*LZ2C?C#L+'MRUWE%3YZ75$=F"U.BR%JJ-\^O[J MB5QME>_![7WK?0#,(+".*/1%'R>>KNA]H(L^/,<4VS)@7;'V@$12G0(D>]-=`ZQZZ3!O9+G$&R M7H#:>Z_3=5H\U77'BCH-QHQM]Y\6=VJ/LT[7:?#T&62/:53^&T17*9KAJE5% MM-RC.V1(*^Y3FJ=3)723?4^/O5#T;2&`N^=W7-`A"!0M+L/7@`F9QU]]U@T2T-&=!)>`+ZUY"9$ M9$CX%`-,)BO>S*)">I6>E@8#3(`_(ACGY(Q@22%M"B7"BLD($^:PD#M,IE)K MI&EQ/$>[EW>])JG=P)AS]8A.`E<*3[\PJJ;ZLYV''+3TQAT/7_M^-AUBCW3S M@D2-NT\_J,8<$=]-1";Z:\<\K:5%'2]Z"N/^('W-]S)6YM)8QR?01Q+PO;Q5 M#P%0@JET1GS=\T.D@$[$G8%%U->H'UM8-A*@KTXM6T@IK16^!L?:`M#`*.YK M),-0*"U9=7TM"NT6WK9IV=?0[U$/TX$Q.9-^O,$6<(,LS;X6C[8%[B"#H*\% MIOO:P/2N?EXTM7V[*$(KQ+V'PR+O"#<]R;.>P=.^H1.S2#N'QKE55&GV49 M@@]DI9,CXSYM5_.F$K[R%>:AHQX$$K?5N<>JB-E"8FO4R2)1[3@0E<^,S!"B M,DWY>EI_,.0#6W%@7I?/4LR3]KNPK3KU]#DSUQ+,9M#1YT,$N0T$%!MPKEDE`EQND.<3$HT&V/*7)93TZ@H3"/KL\#-!W?I M:5;I,UVK`/MZ^.,F[>[4TC2%-X7_K^59TNZV/,.#S5B^ MQ\6Z@EUF1_4]<'8*F&];\7U_078$S(VM,,.>DIV^(&_7C-%'[-^1MGH$GAA* M$9/S4-\2G3NA+Y7'&P8T$1R;C7[Y$L8Y^3`-E9J:UWI&J(ZD%'><[SOR9OFP M*]<(9F=L)\5.AE%^ON$/($G+'?.+!XC@3GR<7;ANG+Y.PB>>AN])BY8HNSDI M6!('&)=/>LE+KNPV=/0Z264G[4K`\AHJBEZ..6D;@JF,J9>C?F5WX,4J>Z/*\D>#?7DZW-U#9S==D[\ M\Y*C@-_&:=F*\36&3NZQ4H3T-7M[+`5#C:ZQ4NQ[^(.N'M-YV6?W#/(]4J$/ M3%N'GZ\YW7T@4DN-OL<9]%E0"CG5]V@"L9EBZQT(N7'`UWSJ/N$$MG4&WP46 MF96@C:M(,S\V?+2VJ)MQO3]@)38> M[Q\2F_RQY/9'`9D%$G27P&`?TW"R)L94[49;UF&(,, MSY*HJI5$5E[9)YHG"[H:41G/@IW$8C#Z:LH;#D4.86%[)UYM$36J=VZ4_1QY M5VDE#KKYT@3#J"QKQ'897$(0S3`M]9AM]*=KT)`N,*CIT-PXI,&7-$&=?:0* MY+#[C4-%2>8VLS>^4W3.FV7]/Y`L?10^;F[`,X@E[C/-SH[Y:ET[5PC\D8,D MW.@Q)>SIE*/FU%%EN4J[..7A.B$R)&9+Y+W4@RCK,14./AAS\&%B''PTYN#C M%#C@[4]IH(Q.SZEPA'>/5&/>Q&-,ALOZ7M1;@K*N3N*TFKM>7])4=)H>'XI[ M1K.S4Y^\]Z[L!V([QY'_]G\SVPD7:CUYW_?0`@-CC0K%'3WP:+"3F(5L[_(C MB0@RL#,H-_>.FNM[J%HODP871IZMT/?0[5'0^W`L$=VCH/?Q6(*]S4Q!6X%_ M`YRROCX[,QQ7E9%Q?V_*3"Z.I'ZHHWJ+JWS,%;>*/YLMB M4]?!)]<)P3\O"EQ-.9Y!E3MN-(J5#&'V$EJ-7HWZ18#0AA!33`'?@&S>WX5M MO"GMRELM'?%9,C>FHTP@5D(4?/4U21\P0,]4#6`W)'WJCG`4P^H`,(DI&?R5 MPT7*(*YDT!<<1V`T3TO2@T@O]H+3QS$7+,"UK$-V[4_%N_PJSQQT.<)>%+K^M*Z&YM:^3W<5S2ZZ3-&(E#@,,/H'B M_P;N\_W3=KBS4B\R*F4*WW<:YUL>H.9@K:J^?4BH8@%K;"S+*,J_=4*MQ[=^ M^^`$M\]!$M&Q8;Q9@`B`=6!64TV_OY-:.7QI2E;K1]+#V1NE?71GB3=GF!IR M-/XHS-5C1 M/;((W"G-I$K<'>;**^ZKRR0ZAOD1ESF0";C'%DMJ&UR%;?K8XDA'@]?6T754 ML:1B;PD7X_&,]T>C#VKZ=GJ%NAQ+U-#>G$GM63"P<1U-Q.`^\3>.C/`]\E## M+"F00Q0GT!&7"II%$2PHO$Z6*5HS"ES$:)WGF(@D9#9#,C^8T<1^1$#^/(.Z MGPL+.H\JL?51NM^*L^HWT&=XG+1;I^ MH"4WJ3S"%U/:SWE^`CA$D)T!"DCZCVLESK!Z=)U^FYP;5RE:@*?B>5)>6*&L M^80J5IUO%$_2J/M-B!OE4S7J?G;62OV9\@%;\8LUHJ;6Z*"^NSR(YP\Q7#%F M/P<9K:NX^11DVXYHS4X3>\]*/-?"'H[C>)OJ@\TOOP`1(QH=W?+S,]DX]+W* M>6+&CJB?DQ?&R*Z+(KH\.&#O_E',7H^!^O.+0?AFE3Z_C0"DK'Y'?Z`7TF$)5]JO4WH0IR@ANRFVIW MB]*'TO0P7\Z(H@V>@4C`T^QIE\JV8LHT@GNRVC'1Q?$YR+X!D+"THNT=TV\, MNY035*2+]LNN+YV?QF%M6"O\7<=QOB:"Q742BF6\W49VOKU>YVN0(?@B_SJG MF8O]?WT[ET;\-7\?_SZ\`:L@+FX]CN[#:V%EQBI=G:BR:X"HO?*>JO2\61,U M=1+M&-":[\R>39\1FB_9B4'.8*(82-4MC8Y.^,D?B.X'`[1I$2B+W12V=VGL MU;8'UL]B<0^,VK3[WL\R9PI#8]L>KH&H[TY);3.1AC?RF)XGTC9(U9M1:"-J M-J1?KEJ1'MH<3[NR5(/%442VVJVHIK&7CRV2RR[`$CGBV&*X[`(KO+.]?V)I M%%BY&D\%Y<<3E`90VC-J'%%0X:DVH"UH;=O4=I>TMH71UXBV,2"V'3KB:QS; M:,M;:'CS-2YV'ZMX0*"/K[7UQS^?%7XJ7U-!1P-6(T3&UZ3-,<\(A4/?U^S) M,2&51D#Y6KUTO'TO"^?<7T73PT=S2`!58]X]J6FZ..N$$3:XGG0S,0]X:*^@5H!+LU+\$AFU(R@Z;A(--(\CP>R:2'`) M31@%K]<9)55G]]H/[1NLT"^)#N"QG88AR$!'I?IX]`M02\2_2]5.:4*,RM7Z*6IG= MIH*(W7+X"](2AD%,/G.18K)2VTM="C0Z'EV2:Y.7\,A>B*E$I9\C73H M"9=*JO$UBF&8#*%2)H>%*AR*]8)&&L*LNO/J^+B0HC*\HIQ,EPMH,,-E\@Q1 MFM#O$[Q2&JS7HN!S\`+7^;J\E(L2YT)EK^]X#K7L1;H)XM96+2+%0QU=6][5 M3>4CX4K2]MF8C>&"RYTUM>.LWV))TF$2],L*N0@:NZ=[
R+&:QI+,5`NR' MBS2GT>GDNL@VF#IPM9C2&VF:'',JHQEVGB9?]P!I;B=Q;Q><+4!,(QUOZ;II MQ0Y(*C;(>DR(`VGQ#'D?*[;?XK+;U%-<%UX65Y-1=7&";D'3Y7;A&V=T(]$=;9J=-9WWKV;K%&7P3_9]FO%:S@<(!.&J^OTL MO;520_D,6A:'HKP$2UCE60=UNKGQ.K;I:M5Q*;5:P9];1[?2@V?U$ZX\LVG" M$AMY\RMLYC:^^!DD>0=/^0-0&AVGQX_4M*W5=0(\Z0:`=QI;.`PDUQ7J9H6@+K+.6_P&O9WDI-`,`Q#A*Z+CE&N*2JT+$`(B&(D>$E7UJMZ1/S#S1R3Z5NW*>W M`%$E[RI%+'"7I=J2M<,V\F6`$N%ZL_N-Z:"D""J1]G$8"Z-8F=U&-F.)RC&+ MLK;VJ:$7,F*[],6+M;+UZ>KEN#3FA[I&VZJ7E;PZ\IDU\E%@!]Y M*'+;N8T#LV]3:Q6RU;`_^A[M-"K"9E81WT.DQH):6^WQ/9YJ;(`M:P6^1V6- M>K2(A1/?H[;E'BTI, M`8*83-\S64PB4]OH*3UN-7`?_`).%"I9[T/-L,9F4_JET2OQV0E^;5:*7RKB MZ:&JK;/&:GQG-S/*?KB([Y,Q7HA-M;AWUK[WZ=CC8FHB[GB?U[T?J.T*[/O, M(G>9ITD?^9U,(N9%'&!LPN7P`*(0:W1#(#S5//Y5_Q>T'`6+^Q MG"3[\2C]DE.!:[Z\H^^,%L6A@S@&T?EFFV@3_@U&=9SV*`T&W&WGA%I6$?XJ M"%E]`$FB(Z>A>WJEB8S^&P%67*$&\(]SQ>`3!;T^J+6NPTK2=`.2+KG596FR^+`G0PY.<2 M&G=WS]N.Z5O*RHW38@M=6CX'&16--I)2W9(.[NF79=#P6EI*ZR<#8YP'20AH M/"2YA.DFJY_3I`^P,N?NJ2I(7+@>/Z98SHG*.P5QK6$>%)((\SF[2 M9$54W#63N#HW!$SCPBZ(+I\9'V4/X8KL.YX+[B^)?$+65S5)4A&:W];*FKS$ M&5S3FF97`40L6J-197F+3=K>!8XU'3.R!=9LJG%'-1=@JNXW'6Z*W)U/\!E& M((D6XMM$N_O4>*.!Q#UX8MVFQLLO[)BA!VS/F=H:8"K\+2#^G0B*X)I6)P=$ MQ3+CCMO=!6\_D\,3TZJ?`,^3RQ=:^#.'^'%=7@D/HOM%W<\%-]=)F*Y![2^[ MH5^"TF='9#TFQ('T1I3W<<-%L:S+I!VIS9'?UDV1H(2Z4CHFNE(F/$\12K^1 M17X1/)&_9!L!,T9#3(7':QK;5RP9B>E,I^=4."JKT`^9->$04^%Q`>CV)I0- MX5(RB)TR3T2&I)ZV%:@5C&J_R\H[J7O9H0Z!I^JA@H3*)V6GDIM1-2026 M7LL[S9P^_;.EJF&=)X"X?>P4\2!Z6?@(9E1.ODF#I-[IPAI[BAXVJ3HWIDK4 MPPI5E19[G][F*'P,,%"Y$+6[.8T]%GH6.P$/7'^>[[%0,B]FD^.JV$--&*.? M4=8F(`FW=`W21S]7DMRWW(WBXEC8?=]H"H=.-P7:1+;UO5300.#$JISOA7\& M`B?3-'POZ6,`W:Z([GN!'0-PS.(G?"^ATQLX6<"3[^^A#3S%=JQJ,F"V7SO:I,?]":R$7?R\1H8&0I MCLSW.C"C(]F.6_.]!(PNF!P'S*!R+7Y`HQ$Q[WO1%0.4!F=Y^5YP92B6ZCQ! M_VNKZ!UG\OA17XM=]%AG)A&#OM90L0Q;$33J:QD12V#QHS8;T(Y623`((&_0 M.EI%P#Q`O0'M:`5^"YDN#8I'JQMH1]4U6!V#AB`N7L*)^/&^!(\F-HHX/>_+ MYVC")$TJJ$#Z<.0@"8^N?=;[<8.0-'E14`IZ-U[.3YU0B8U^M&D3->>G:J.1 MNZ1Q*AU+M*I6GE07+VY*4K,!_33^:<7BMW$2[-C]K2>71=O8@4.6%OD.?`:W M<9#@R=1PF\5LSLDA&74>=9.^>JS9V46VR.Q;@*+M&M7;Y'?:.*Z@ M=A$\P2R(&9*8/E:&GD%TE:*K/"-+J/(-"C@Q'\=)-8IZ1]#2DLTZ68"8+J*+ M%&>8T?U`5U*I<^Y4I]TN23%L4"=U*=9/<;H!X([,#0P!?_-\29-G85>$0I#MDKK90I1VNJ>B7"2PP\2@()X MED2S:`T32#<,O;]TLJ_U^DXH$_Z4R[]G+J@4]"58RZ[G3A.7-$JAW6KDA,[6 M"\G5!3]?%A+`5R*_HEKV)!N2?U0QH53$H:WAW60XD[,'4M<)DXZ^DA,5+^Z^ M2D\O>1\GN<]U26X^ONWZV>>;IDWUA@@3="65YNR-[P0=%HNCOK)@\)PQ^=F"ZEFX(/" MHXZC8W?([#F`,3T\B-3[,[78VD9)];F#PFY>!`0PRO%U4IPIOP(:-$<4C6U)QB$C/LT&X;1IU/6JEITH="S$BL]\<6[]:&G>0:$H_X)H?B#ZE*-:D"VNT]H21AM5CE:9.MEW-#N[E8Y;'K%D M\GF:WNZOQ96)A@QGI\[3M_3^,6?>@TT)@_,8]CQ MFAE3+QS"I>^4ZYGJ!%"->%OV2$+H1\5R2[#T/M!^ M5#"/.SQ_5&AMN%'\C_^WYVP2)`OH!ASZ7O]S'*!']SKX7EUT8M.BY<+PO6SI MQ.9$Z4;VO5+JB/.QG9;O:V&JOE>- MG=BII!4"Z'N)VHG-"3=TU?>"MW;GP%[XCN\U<\=9^[JII[Y7VQT'W1&3#'TO MVGM@$R+(6_2]&O"8D8;=!UBD&42^U\P=&^;A87G[JQ,[L2(2=_EZ':#-?%D@ M-PO)7V@Y,HH4"WIR7%OBE.]OQQQ$CO8E@-0K,W;6`>]+AXA8UX#V,TJQ]=0K MR9<.$;&63Z,PJX^5U[+SG1-:!M_Y[<.AX[5ES=XJ`SPVBM*OGY`=Z>M37;5" MT77>K5$M),T?L<(&T*1D'B;74M[@7F`THF%RV6UM1K4@5"N/F M`WF60&-?RAH4C/94X)\%*)NVS65Z4\%5J'P/01MA&GJ<+?V"RGXH4$[`BI)Z M=#B/87'I%TUVF@C;"O"PH+3B$KA,3E,QEJ8Y*!CM=$?O1[3W/81M@M-C:$WP M/CM8&^ACIC0)QK.6$R8MF^XC=LLB4JL:+;$+RS<9([J%Q]3 M^IN3N[B/N]ABB;#NQ=&>FO9,KE:(Z17724:T20Q#7K$_-S1,&SFNUVXOGYPV M+EMGZ@+0*-@K[BIV?PTZ M$=W3XR?ZH\9":']^$N=`*58YN:NUOSU-I,:[FT6?FB8.#N_BWK1,",E]W[T: M7_5#E1]WU_M>;F1B\Z"\RT].WGV;N/3EK&'U1FANT;',S=[N%=]+CDQL2DS4 M;=]KF4QL:OK+L[Y7,YG81`TW!IZE:/5F] MRJN8B-L3973`&L*Y&UZ\46%0Q.CN0#S#NNY[,UT]5V^02? M8436V6*$AQ^UO^L,S0SUN??G@ M$5U`_/L5`O32`^26R?:%)_>['HHL(YT<)W/YW@1(DW/H9#5W.BW\P\SW\MP3 MGQ2^!+D_@_G$E*HZ0O=K6?)MU*N'D0FOBODNX=?-WV[B0>4ZZG595.BZ; M\CY.)%C;[\QL2ZK6QC\H^;YZXXU,=\YX8Z^)W#\&23?1A5:(&Z>>6`\*O$28 MIA)IU.]W`[X><7[-2S='9VRGM^Q-Z?-K=NK2PN-$:1M__X3NB-^? M:L6UX?Q-[U@Q(.TT)Y.;$^]V2N'@=B;A;'W>9VRGM^Q-Z3NHV;G9?EW!%JS- MP)/$8T"!?6NE&R6?"/4.?[^"[>"/>WU>T M3P^9.Y\":_>]%>S--?GCJ#E[:-.T;+BT.9G6PWU/?CBT.:'XP+TO\#M MH4W2KE7W*(K?'NPTC?U4^TF:F(AKT/N4QT.;0&/+K.^ID8B,[COYXG'S@^96GAUU_*'BU=7"*0SC-,04EVE>F'^%,9\>"FJ M[4D=R]?-_8;;"G<\DD3NYC&_Y&RM*%^F\ZG2WDB[Y)0SV&L"=LI(]3`T$ZGH M(3T>_$8][/9G49Z::%-ECI4"#)L7F*SNT\OU4YQN`)4F:U^OK@BMRVJ9KV/(-#4CWVO2CRKP:EP61Y?F,#+,UJ6E M?>8_N#3CGN>8,(TQP>D!)@5,400+^JZ398K6[)5V'(C:FW%S5$1I=) M1K;4/0K(W@ZK/^/R%HL^Y8C(`ESON_7A)[*6:#!327^Y7%9DO=,[1U3'V7"0 MB?!9A7P5!31++]P"B,NM+NXRU9_$M2J_H%3*+ M_IGCC"XD(A`A0&[F3Z#X_W52B$CWP4NYO:(EJ"'!U_<>./C`&-RJ]"8 M!ZE@RVGH)GJ`NZ#.-XHJO>I^5M:>X#.?84RV?YJ`SV1=$,V'+OQ"A)LGW!#% M7N-,:#XHJO+EI.QG>3Y*=Q'7.R9MZC3:H@E%DKKUQ.W[4X]!^&:5/K^-`*2$ M?T=_H/1^UZ*7_.JW0EWA3O;.GZW,Z?5ZG:]!AN`+.7#%\\EK-CX:-V`5Q`7/ MG-.(U\(*)I5V0&ZC-7W@D[Y"2.0-'BZBIB[6>;%4KY,(O-`WLYAXA'`A-"D. M=*VN4^1)>BQJ=G;!URVSN%*;9I!LI*<1KZ7;R!*>[G:^:?U++VA$5[%(R% M#=O+1S(H5.8@\L=&W,IJ*[;O$35VP#4R@`\J6>01I'+K@^\5@8Q0ZF<;]KTF MS^!;NG=HAN_UIH.Y*[Z21*;Z?W2TO7X[9\L,T2\TLM$7E%VRN)ZTUI M`/%+J9`X1BDFNWCYOHE,_)[M5:/K6SQV_,3[3A)9T>P^/_.U^KI#54Z-8TLG MZH^>Q%58X>?MEK6!G]ZQ64'YX03E+I3CDU)]IV31HAO=M4."II\5V3H&G>XYCVSW(3]&F M^J!MW>VG4%-Y"(&V0.AK`.HI6L`_J\[),7"`-C&GSSKD#QC\D9//7)(K-[-0 M"TR@%LRRHF8CBY!.0L#J@]:))6(]0:N?"\7A<_`"B5`LS??KMG%2NYR&4DM, M2:F'GR:L@+DI=K].D,`.OTSS)YDNRNXD8<`/7D(8"_P,$W.5H MTMV).LOH*VS73>S\?-D*SQ5IL!H]'7-$7R#L$"2U]&ITM/2(&HB7"[`J:ZM6 M^7-71%1*5MPU).TP#DVU!V269X_D.OJSN*[9XM6B43J`'9I9>$BYD5@,.=UF M$&.FY`!$GQX*5OS7Y32[.EF_W1M691P7-I\`[?+<=F[;"5"M>AE(V'P"M$M- MCKRF4Z!97D1$U'HBE,NO%&%[5]3#"`9HT[KJ%,CSV[O4Y78DU$Z=_+:`Z+M- M@",-M['84CA\SX;4E_MJ*Y^>CNE[@J1*X&@]B"D57'VWO??'22Y,^VYXU\'- M2!WUUU_U4=/5&WTOR:#2>SH;DZMG^"YAR;0K&3H[T<;^>E8T M$6I)[?ZG41BL&H$^YG]^1+^=Y[CAH'[*77<^A!UNQ.N$7!OYNMG:`E;T^KK@ZGK]1&BC5,P1N=:? M4AS$\^5-2CT$SR":80QTCX9>0]E)$TQ@1A"]S1_(X)7U7DZT?C\7L_(%?&M= MZ(A(=#G9S*VUHCMRH^[G@YBNFC\SC#*Z)."-:8EN-K)Q;OP9T M668:)Y6@I4L57ZUU=4MG*5>,[S$B>H`97&B^!X>8K3!=+=KW"!$SU+;//M\C M0`&$*E9RSQ/=+4#+1^VI?O0:=F&&KJY;Z[<8RA@ M4BW5]SG/U_@JQ$I>)[V]SFJXI33>&[P]A&*B5(GN#[Y73S5>6 MGAO)UPWWL94PJ]N(-$@EC"D.S$78"=QG\=>B"%)K("V[1>Y\/9 MC[IH'&<`U':I-J<;;YL8Q;83-G>QZ<1`ZA$_C:VEFH'.&S1BCD][J0,(2]UP M$A-XR#NJJ4@W(V=V1&M'$DGT#H0Y8@43+U_".">S>$56,!56\RI4TW0KCO`A MMW@IZF^RY:@/BMEHAW)Z]4;+=_]L/Q#M;=']N7.G='?4YOLFJ-RM$L0C2'%[ M2+LXC57D@JK/Q#1.-YT9X7J$^-P?IXPF!<6=G.;5;FL5M?X,`DI8-$\6]%*@ M\3LL0.5KDCY@@)XIX-<)N1>H1XE,50R+9WAU-ZG-3[F5V9JBW\S;3>0/#=X, M)3D;WSBD$]`RNKY+?KTO&*L;_CCEO^N$)MNG:#.1'&@./8K[2-;#24J'#%%M M%J9Q\&G,1B>>2LKZ<0I^,DS#;/'@%J_:I!OH)R`AYB6QQ(OK@\`C0X:1\!MA?(Z:`8CJ*[6WZD;>#&%[1C`YC0VUN?/-&2UQ_AX*KR[;=6H4_U]XP6UG$> M#4VP[56*+@#*`IC/#-@M2/=_:5UP< M0Q4]E.8[@)YA2-A1'"_R/BZ/#2UN..J^O85RG$=&`P5[LH.;V%:%Z(&(Z&JL ME],C0IODAS;)BITQ<%`7!\#0J1L(A&!4EX>(G971/F4&8WPZ57K`YLYL>#I; M=DEN)JI-?+OJP/EF9S)GWP(4F9PU-K[B.`5@_12G&P`*\04(&(H9+4P!*DLZ M_$G8`61W%PO!($G`\O?2['WP%/!HSVW;;)I-&*Q)C#.U\7O>F,SX"-^R9TV5J3OL;/[1WW, M<]CWDIK[F:TAIY3OY3G'G(%>TIOO%3_'-4=844&U^%%4>;PY`TRW(ONS+,5?46"J-DW_\?U!+`P04````"`!.=PQ'&MPB^&,2 M```QN```$0`<`&-D;F$M,C`Q-3`V,S`N>'-D550)``-3E\M54Y?+575X"P`! M!"4.```$.0$``.U=W7/;.))_WZK]'W!^N,I4C2P[3K(35S);_IQ5E6.I)&5V M]EZF(!*2>$,!&@"TK?WKKQO\$$12,"G)MK3'ET0FT(T&^H<&T&@`7_[^-`O) M`Y,J$/SKT>GQR1%AW!-^P"=?C[X/6A>#JT[GZ.\___4O7_ZKU2+]/KD6G+,P M9`ORF\=")JEF9$B?!!>S!1EX4S:C/Y(15?G[?;C MX^.QE'[*Y-@3LS9IM=("?HU%.2>?CM^_/_Y@I?1%Q/US\M'Z="49U9";^"#$ M.7E_/^ ML56K_R8#P17DGLTI7Y"+,"1]I%*DSQ23#\P_3I@J4UD"+DJE5[,F2HE,RGE M=)[/Z8IH'I7,?PJX9_"`-">?SDXL"@[ZB6;E+>!KV<;"VI"I!;F8##R;]'FZ M`@WF\75&9C?VQW:<:%<'H*GE8C6[8M[Q1#RTDT2LU%FQ(2(IH;^M(TU2D?9# M@=9G03D9))13L"=O6DZ"*>6J"O@#4[J<*DXKKQFG@:?*R4P24IT6J%3@E=-` MPAH*/9=K2"`E3Z.IG#!]3V=,S:G'JF(0[-R,<7TKY.R:C6D40H/\&=$P&`?, M/R)4:QF,(LU6,D1\F>5GY/*%>81#!%=_K/Y[='0BT)#>`=_)\1)#A?A M7()1YGH#RJ5DZ^F2KZD^=J6F`" MWRL2N/5W!DK+&!$<#[G/.([3ES3$X88,IHQIU6AN6\WU@`/74Z8#:)W::C34 MS^CR0T5=DG:*JNEM*!Y5A_N!9)XN5U(QFUM?GRKJ"_D2P[C1UWI]W0O-U%!D-F[9AETY MH3SXMZD.M+$28>";/RZXW[.J:AG()?%UH+Q0J$BR(7O2EZ'P_K"T_XJ%NK'T M-YP<953PAUU^`YM-8#,()AS&1H]R?>&9!57`)SW0HQ<`12TP5&3E5O%/>14/ MHMF,R@6:"*L`LBR!I$4T`-@$`#=4:/^?5?,\T>7FX[63@UNQI7K,IK\8";ZC-9"A3/;J@HY#!GS)B_EU` M1T$(LC(%DZDNK#.E]6FI@2OCR=3U]+_C(MV(>9]'3%*<<6^94HA53(.A33!T M)6:S0,>ZY3Y,Q7%FQ+BWHK=Z&*G)THV!LSP&+.X&!RO\&PQLAH$PI".!7H\' M=B$EA>;$A,T!4)V?6_L?BMK/6`MN]'\7>(PKG,Y?3"1K)@=;#R?0E+="7C&I M:<#O!.78BZ_92`^8%\G8R'M_1@$4T>%#4*X:,[DI5'9=IAM.'_-PPB(:L&P" MEF4S=L>X+P]]T%2MSZ!Q&%A]!>MZ7(1=8M@!3!<,53UP;%N&&PR?"@X##42X MB`0N8+A(+Z2-#W@S=%Q&8)&9PJG`"%)1NDTM1$56;ET7_'\I5V*Q;52]D1\P M&BGV9P0_;Q[J=_'UU&Z%EGC[4D;$<&J4N0][`:F']4WV!++"W5`J>!1M.)&"W3`J.!N=#N<&6&_I0:B! MI-V4Y(9.P5-9ZDUH(/,*;H4:R*C%T`V`@F^QS,70Z+]*Q/RRNUHKL0O?-^+0 ML!A`7X/`K<2"3W!E+0CC0<;3CJLG[ZZ9ID$3REM-JTE@5G?LC/LJ5=^5,/94 M)GZ`*R@NT/U`_9$'PHN4X<9.P<=8/0!M/;),V.M2'!/O:@0B*%$#O-<"W@[Q M]0R,MHAC;`S4;G!RSS2ZAV+G4.ITPHECE#H@8:(8>+A%&801S"!+"?*0V1%7 M-WKJA$?&P11I\8@O(X!9["0BN'UE#:BV!54/9J;0AVD8+DR+PT)AN>-]\^2% MD<_\6REF6P-M-R4YP7=6R]/:(I9())6)+(4BJ51D#&(UB-PY(C,OJ^T0S3Y: MNRP72C$3RV4Y/Q(:$+B/&I,P#J'U4'DPODPA;AQ6=OZNI(#]RX0AL31)@-'2 MXY,*A-1DIA_!66C?4H'3#I^"J7@^?9DVP`Y5;&TI+8['\EM?S<]G=RBTX MD^WMK%5[8.]S-0JMH=!D:Z=D$PD718*;B)3Q^EQYC6_-SPV)@GO9O345+^WB M4A$GSVQD-C0J@( MA@WYN$%1<$97.SC1H&,WZ,!S!974OSZC6[\%+S$R:K2W&^V9K?MLY]YLW%?; M%*A*Y]9MP8=;'DK0*/NEE)W-V+MS8Y4]2`GTPC@`3,1(/0S48N>$QH>"AW4= M-*PE0EPJ28M-/`2FX`8V+P@;U8TTWAF*][:"KF^>F/0"A>$?OS(%C=^5-T]S MYL&OH<`O]9%4NP0WN`INT\K@4L22)+Y\<"D+B84A0I)4'**%^=I@;EO,_9/A M/;BPH'Q@DD[8A5+1+%;)=X5JMSSMRPBWBT#_782T5H97( M0"PA"$J!6%KUXAM16D86$@O3X&QGMNV[N5^6^?W!]W1$J6.XRLC=2"DX.BM8 MI;04`L4L![X&!-N"P)LR/PK3WJYP,\+XLJ!/"B_`&05:>*X*6]+;,7,#I&+D M;8ND)68V0I&X4#-B+8LE2;D-8'9F-9(6-=-.F"(,Q\%9\I=A M80=AQ^8;PQ),4C+;P)GSX'N5`>R%!7`#L^"RK6"Y4NBE@N+HEHIJ8&H)&_-+ M!KI$WG3`,R$3<7GI%,W,^T'J!M:U8%T2(E[)&5"9S@VB@G>W-*R\\06\E*Z7 MPU1/"KQ+GO:9BD+%%Q!]]7XN+%0Z1:#W$`'I1%3'$G*6[WBN`%(S0CB ME>L**H8*5Z!Q*_[9VPX:`P"?\1]\<*7/QL2\I7*.+XE\/5(!#)@P)8V_4>DA MO?L5EO9<"N@CN#G:3MFF#`K4J\^^&,3DVB^1*N4PE6S\]0@?7&FE3UK\#A3' M3[,PS:(#C:5<+?D09*1^)#0,C]K[6_-5-5:H.!"45/PZ8W,@]0[IB(45JPQY M2ZI\AQP.I+;Y;EZATD!24FG[7H^RNG]IV\^QP%^KS[5\@:H+J0DO?3UFS0M. M)'XDZD[$T7$.$ORKE=*U\%/K]'WK[/3X2?F)B'4D6+9T/0E2NKH2.%]^6B># M*;_TJ:DV@^E#QJNUY%6_.4J?AZK4*C;E?4R(S?(9F^7TTS:2;";%9B*4/EY5 M%14I`1;ZL380\B^';8$#_%(7!L^]P^44IXPN_:.U9+*!("6O>E63Q";,_FHM MV=27)?=46"4Q4AK\L57A^4?'*I6>$9E?6R&B^'Q9)0DLLN3W5G`HO(9628@E M5?RSM6107X3>>::M6>DID?JTI/WFUS0CP]C,0W-),EDG!OBH2%-B8X(#S#("N&9 MX+`^E(M:%8YG1#I-&L7/6X$HYF3R+INA^\!D>A^'B9<81SS=N;0KOB[?`55U M0'$6WY/"8PJC\FX9*ZEH>:Z#J";\]O'O;VPV8M*N6CXEKD[\O.BY+V8T*.V0 ML2@OW1]G8"^3"R"Z8UB6,NA%`+`'QB.V4@EGOJTUM*S4"ZI(?Z/R#Z;30T8# M&C*5!8<6]58I^SXI,_67FKNDDS?^J)KB99.!SZ3EOC,5K);]$#I?64W,`)'> MJGUC'@LU-VN#L$FR2G:C_.L(SSD6QMV=;N92DD]5%J1"_]_(V6.('0XP)@J=LWB_SL\/K4]I$\)#BX9 M9^-`NUMH.\Z'A"UK*R=?PZ&`B4W(/&U?@I=TM0N]/*B:U*>D17?)W&Y4^`:X M?3.['A^%[>#5/5H*7`CTV3R>#EJ-X,RUTK-P@_[M.M;J\QGI>&JD!BF,%NQ: M5N0+&8*RRNJ9)R8\^#BZ*'8GM6+S;-W M9\(VKN0]3(UWUV0VMX-H->7)8!ZOG+,1+#TK`/\',:3_Q:A<:9XZ9-5ZU2N9 MD0##2Z9!T;P74O;)K%\+SQ@P/&IB%G96G$F9U:N4?8^LW0T0S#``V#K6\$^* MSY=IVQ/GSG8(WH!,\`Z?1QI65J/$<.#*?1JP!Y:;.5L3FDC;<-MCSI_)PRC M&2R-85E4WS.8T_T" MNNCRU%=A=;-KD.W!K/*3T[M#X>"UTF*O7O9!&,2[V&TBY.)*R#G8,1/*0_\A M0CS&J@H]J6+^?>I;WZ"Q,+*Y4)=\PCX)?1^A3.:IAAF>(J;A$-!K#SYK<]BX M"P#V$R;?KL_WXCD0G9@.-*91J-.NV"LX)ZMDWJ/I579W:[S5CMQZN`&*:['O M\[$4O*R.-8@.P6/9D\DVKSEHE:P!"EW-F6N?^AT(.D]#8S@-TX.]:27R:7N$ MQKY8H$R9$R#SA!24\6S.?5)((FP21`"S:`:#\"ADQ?J49#D`QP\&#,1&7'#3 M.2YFZ.!*)W5WP2Q`7WW.[U.+ZB`F(G&-3%UZD42'GQZ*Y`8-AF?F?28?)=!+ MA8%.%V$HS`YH?+*ST#2;,UI9C\6GLM^L3P_`I%#@W>7%V4M)VC[UV^5=&/9K M4Q=H^";'-5=O;7%ON1E`G9K@EL@'%?+*O#RNX&O7_0AV)F7 M:I1X'OH:S9^6M&4/S=IZGULU=^M,GV%GAN_65N&0R=EK-'ME4?9K'WFW[9%K MA'0\Z<'B]^5,C[O0+>.@]JD;)%=UO::1KU[D_P/C7FB,G1OUM27\!QGS0AU? MWXAO+L)_EO&.V^&5C':5PO8I:'7C^MJ75'5X'$&6.00C!,*Y5WYMN? MD+B"H-GCNA>1G@J9/L9J?#2N"KKI#B&LPOA=IB+TF50W?T9![):3*KY5;#`/ M`WTS'C.\CI#EL5Z;=(\08"Y&2[QOYH"'>8!`*1P?EML:^=I6H=@C%W/^^C>& M\0JX7#$)WWF@2SX7'5?;<-DK%U>E]T_+`D=J4^Y1D$@UV8NK:_/ MIPOL7-'(M'=YO7&:G-YAE^Z`Q0` M```(`$YW#$`Q0````( M`$YW#$<10(`0!C9&YA+3(P,34P M-C,P7V-A;"YX;6Q55`4``U.7RU5U>`L``00E#@``!#D!``!02P$"'@,4```` M"`!.=PQ'+#6-&MLK``!%SP(`%0`8```````!````I(%C'`$`8V1N82TR,#$U M,#8S,%]D968N>&UL550%``-3E\M5=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`3G<,1X>.7FVO?```]A0'`!4`&````````0```*2!C4@!`&-D;F$M,C`Q M-3`V,S!?;&%B+GAM;%54!0`#4Y?+575X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`$YW#$>*)+L6"$(``%#?!``5`!@```````$```"D@8O%`0!C9&YA+3(P M,34P-C,P7W!R92YX;6Q55`4``U.7RU5U>`L``00E#@``!#D!``!02P$"'@,4 M````"`!.=PQ'&MPB^&,2```QN```$0`8```````!````I('B!P(`8V1N82TR M,#$U,#8S,"YX`L``00E#@``!#D!``!02P4&``````8` ,!@`:`@``D!H"```` ` end EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`'!W#$>\2RS`W@$``(`=```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[C,!2%7Z7*%C6N?V`81-D`6T""%_`DMXW5.+9L4\K;8Z>`9JHR M@ADJG4U^>J[O.L3ODV M+)G7S4HOB8G9[(0U;D@TI&DJ/:J+\]LUA6!:FEQNA=)[7FGO>]/H9-S`UD.[ MTW7J%@O34.N:1YN7U"E;TU'6J\F=#NE&V]R";7HV"MLCKXO.OL)^;=YE=7X*8?= MA7]+9FP9FA^6?ZPH]__X+#LO<6W[JZ"?S([!^F!C*N?::C/L&]63"ZM?SJV^ M:J6VJD/N3`DLV>7Y.*[K$:66_^7]]M.:5R@3QF6P@-^%)T.U-ZGD.>[ M_]OXO>!P.[%````*P(```L```!?.0Q(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8<4M?'5$Q^ M#*G*_=ITJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V M[M,41Y26M#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V M+YRO+0O]C^AY%.!)T:'B1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C@KN_V/P" M4$L#!!0````(`'!W#$==-=7JS0$``/H<```:````>&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'/%V4M.XT`4A>&M1%X`Y?L@0$08,6%*LP$KJ<11$MMR5:MA M]VTR0.%11PPBG8DMV]*M?_2I5+[O4KUXCH4H'DY:$X)NBD'W5"";LM!MY2@NW+0 M'25(:B!CS4E"6'.T%L"U<+P6`+9PQ!9`MG#,%H"V<-06P+9PW!8`MW#D%D"W M<.P6@+=P]%:@MW+T5J"WDO;::+/-T5N!WLK16X'>RM%;@=[*T5N!WLK16X'> MRM%;@=[*T5N!WLK1VX#>QM';@-[&T=N`WD8Z*T&')1R]#>AM'+T-Z&TAM'+T-Z&TCM'+T=Z.TCMI+-N=-C-T=N! MWL[1VX'>SM';@=[.T=O/]$YM,\;UGSSNNFVZ=,VGX;#H#.^4WP[Q\BFGJ?#G MS9G6>5HIAM/UXBB>IKZ'A&^_.1_^`U!+`P04````"`!P=PQ'#N(\%`$#``!7 M#```$````&1O8U!R;W!S+V%P<"YX;6R]5TUOXC`0_2L6)WJ@85G42HA&HK35 M5J(+$BP]&V<@5AT[:SNH]-?O.`$::`(UA^7DV._-QYO)Q/2E:?`LLTMYNP M76#*6SEFRJB`(?H*EU08*%"?FSEFJ)*4RDU0/(VX?#-_TIEZH!;*K,.#PGI, M-43H],#Z?C/'_-I@GL)QAS&5*XC*V*^'.RWFH(W+]$?GNHV_O02[_<(VT(C+ MU81R;<+^VO;6P*S2VS*M[:55BA1S13?S&<9G&F1!#;CE76---:?2-HCA'_C8 M:11NB]U\+5)C=?BJ])N)`:SI!_O-?%G&EM>\&W9O1*5G+%>4<8F,Y0`E?,L8W1[XC3!1?G$P;`UR@5 MMDBUV_L,/8`Q&&&RX/)4S18&_F:NIQ^=6F^!27-&?4IJL,O M1(VPI>+N<-4!G:PR:7Y?Z--NJA0_S3A0M44&4<3=DHIBI/B_8IV;"SBWWE5L MD>$%G(E7Y5LD/_'DY)EZ?$6/E9W0=NK%3T M6;)M58\786_$B[-5T)_3;7MQ7H&O8EO]^3CMI^/'P0M'E%5_*T_[Z7Y_@GS6 MRX>S#:U&@Z.1?]037^YUY0O:T74L./P;$?X#4$L#!!0````(`'!W#$>5-F$* M/P$``&D#```1````9&]C4')O<',O8V]R92YX;6S-DTU/PS`,AO\*ZKU+VS'$ MHJX'0)R8A,00B%M(O"VL^5#BJ>N_)\NZ=@,NNW&K:[^/7\=)R2WEQL&S,Q8< M2O!7.U5K3[F=)6M$2PGQ?`V*^5&HT"&Y-$XQ#*%;$OP@O=XNW5UA`E.H`8%&CW)1SE)JE>]T:;1)1GT51D< MU\SCW`BYE"#NVJ'L=RIT1G#*'^0@^O;Q[Y\>8H8D7>7.R[ZJ:9I1,XYU8>"< MO,^?7N+9I%)[9)I#4'E)L;4P2XZ=W\;W#XO'I"JR?))FMVE>+/)K.IG28OJQ MG^S,WV!8=4/\6\='@W&[*+&&"W<;-2(N-WY&D`#/G;0HC;X(%S$GX@CSV\\O MX'@YJ!/&R[:!MC%.^"K>KR':OYRPLI5Q[2'U(SI[5=4W4$L#!!0````(`'!W M#$>97)PC$`8``)PG```3````>&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^ M[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZ MFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\,`* MI4Q>M5II`,,X? M+&A`T%116F]?(+3E'S/X%/F7/Z3H=,H%N M,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:CTQ4(,@T[.IU8 MSG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D00FTHVG09-CV MVJZ1IJJ-4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^'PZZ)QJO0=.MI M)B?]KFNDZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90:V1V[W4%<\%CN M.8D1_L;%!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0UL\IM5`:")K( M@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\ M+`GQ^R-;88C'(C MN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0'`*D"3&6 MH8;XM,:L$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V M5;SOX%^9PU"AR1&QT" M9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:CFED)O816:I^JAS0^J!XR"@7QN1X^ MY7IX"C>6QKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N! MLT$DN/R+RO`JQ`GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T M/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL@'37[]EUV MY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1 MT?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&ULK"0L1K=@N-?Q M+!3@9&`MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW M&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07 MIDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_IN MDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZS MAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MBOKJO3_DEG#NT M>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$, M>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$%7C&9MC:CY$X* M/-S^[PVPPL2.X>V+OP%02P,$%`````@`<'<,1PQ/Y,>,`@``4@T```T```!X M;"]S='EL97,N>&ULS5?=:MLP%'X5H8Z1PHCM=$W:U3:,0F"PE4%RL;LBQW(B MT(\GRUG2RSW/GJI/,OTX=F+JI_^S%.KF'7#CV8>S,__^_*:-]ZSC'`+'\26- M8#"\A-[S2?N^WTULG"WRX0O)_\7=HAYU4-=2W*49>RVH172U1^,$YPJS!,N. MZK;]3U;Y>D^2Q]]_.N@;SU/$(]\0>U6?Q&$F>-,N`^B`."P>P!)1'1^8\)F@ M0@*E^U$KL`A'#+N(6T1)(HD!,\0(73MX8`#;PE4<(UQ(F]ME:.?I^TTF.4\B MN*G^\],E#;L=S/((I;O+TT`Z+E$ZV!P MN37!#CIO(F2*99TY@!LH#BG.E)X@R7QA1B5R(UTH)9@V4H+F@B-J*#B,ILV<$VPS>:XMVD_'L0+5EF=0,]& M>4[7GRF9-176WCS[HH(]#M&$%"R')@XXWC3#3`)80++%49+:-_)(H MG^*5JCK86V5="@]=\FMJ.G[5&C6Z!=^Z/`3E38\76FOTU-'D79UNM*N3U;:Z&3?T(O_+9I7?>FW MCA,[AXD:!4E)J")\(P&9X]^=D4UWOO/-04)SIJOF#&&]"B7Z!VE+WF+RK^"U!+`P04````"`!P M=PQ'A-CW12P$``"8#P``#P```'AL+W=O9T(3[B*'5N/S]%Y M]/75G3X;^S@WYI']JI5VIW:2K+Q?GXY&KER)FKN_S%IH>K8PMN:>;NUR9!8+ M68I+4S:UT'Z4CJ@]5Z MD$H\".L(S/AZ_8/78I+\4@E3W/FK2GI139*";LVSZ/UAF_5Y(U6X.1H?):,` M>TUU:EEI*M'![E?2_=P\2%@E%KQ1_IZ"??WN)$FS(LN..T9X[4&*9X?`\`?C MI9=/XI[/)\DX8;SQYEHJ+^PE]^)O:YJUU$MB)6PAK?.SD&[[9BVUK.5+B)ON MW,H\_V.L?#':M(WH"^[//Q2CEV7O1<_G_X9*3)+C,0&?I)-S MJ:3_/4G::R5")J.M5-KN?[MBNNV@RMCG=;S9JZ MYO9W^.),+K6D([H!]T=7!KG/M$M2U-+=A46.I=ZE:` M?`;(YUW(-9>6/7#5"/9=<-?8KC\`\`4`7W8!-_J)&I#Y`ANE8_1JO-N,TK4- ME2`(>N=7%/BMY*WO6Z">H%%#ZUKZKH@!1M7U-&*%+K=`Z&D:%54I/C>V+6>+ MNJ7)4CN"L;.E112:FD94O11SC^^CD&G$R)DWY6,H(F5!X$H]#O[H-^';(HH]#O[@-^'K'V"RRGZG4?\ M?A_5]B*B4/4\HOK[J-8+1*'J>41U''6;2+IZ=@\0U=LP1%P?'H"'B$+;\^B> M86"5Z:/0]CQB^^`ZDZ/M.=J>1VP/ZTQD[-6;48THM#V/V!Z?8?ZP$86VYQ'; MWT-M:HDHM#V/V#Z(*L:XYT/;BXCM[Z%^"KE<>=PQ%6A[$;%].*H,46A[L??$ M3B@Z=E4-[D4+M+V(V#X<58&HW@8Y8GMTD7CS#%%H>['GSN0MOUZWH^W%'IN4 M+?,1A;87)YMST]M1B4Z+%%05#I*N_0R=Q,IPNJ2?;J]8'(6=1KC_3B?.21*. MA70";)2ZH/_N]*WA[>&I([^>)[_]#U!+`P04````"`!P=PQ'O4T;)TT"``#T M!P``&````'AL+W=O2A90^43[UBKOYRX:*C277%&LA.,'JVIJ1$)@@0UM&K] M(K=C+Z+(^4755A";_VL7\;>*W.I3(#J,C1Z#M6#6MEQ5M/ ML-/:W^#G'8Z,Q"I^5ZR7=^^>27[/^9OI_#RN_<#DP&IV4"8$U.[$0OM7KE_0\VS"$V`0^\ MEO;I'2Y2\>9F\;V&OD-;M;;MX4L4#C:W@0P&,AH(F32$@R$<#;!T"#*S\_I& M%2URP7M/=M3\;?RLY<($T9$]/1FIU\G&%':EBOQ:!#FZFC`/"F(56U#@48%T M;">`^"X[L7;R-6`'BG`>$#X"8'`36GLT;X\>[1'8(VN/7?F!8@N*9!X0.P&Q MM:<3`%!D\X#$"4BL?34!``4.Y@FIDY""'S\B6BN)`0$2$N!X'I(Y(1E`G#LE M`<@@6;!55D[$"OS1Q%(-D@6SP(&388=UA&0"Y!T]LU]4G*M6>GNN]%5O M;^03YXKI)((GG4RI2_#8J=E)F=?49`E%"3J*=[<:.Q;ZXC]02P,$%`````@` M<'<,1V\'K!D,!```;10``!@```!X;"]W;W)KKX`EZRJ%:E4Q2A(7U^7AN-JLIWW?VLVZ>>NKP]%_:Z/NK:[+]M^M MKYKSXPI6\X[OA]=]/^Z(-^OX4K<[U/[8'9ICU/J7Q]57>"BT'9&)^.O@S]W5 M[V@,_]0T/\:-/W:/JV3,X"O_W(]-E,/7NR]\58TM#4?^AQK]_YACX?7ON?7? MINX.\9_*SA=-]?=AU^^'M,DJVOF7\JWJOS?GWSWU84KXW%3=]!D]OW5]4\\E MJZ@N?^+WX3A]G_&?+*$ROD!1@;H4@!$+-!7H3P4Q)IOZ]6O9EYMUVYRC[E2. MLPT/`]Z.C0PM1T-GNF&-,NOX?6SG`Z(F9$O(,E$082](/!R? M#:$^AL"=7Q76N_OU^F.]P7J-]>G'B,<)2;$3B&B7Y6:9*F;*:+B?Q;!9#&;) MN*-8S(((I(E;A@IJQV7I_22636*QA5Q(@DAZU=O;(,BX+&!V')O#X:`F0@Y$ M7,K.#>5`QAIU/T?*YD@QA]#7+2(F21(K))DI;0+&)&.S9)A%"5DRNJBL,($% M0I"[['Z2G$V28Q(M)$'$.2M,8<%`BTD@8:-,NXG0ML929S$*)U)88BRN0L8&<5K4Z'MC*1-8C(ES65! M%`#HD,'AS:E0>48R)S%@K;0"F:F@"TKQ^E3H/.EVL9T9D.XIEX9")HI?JBI4 MIY'6JL2`UIFT#B',&AL2A_>P0GL:R;PB#/+O2UG(>7L(*W6D#UN'JDSKGQSTR M7D`&S0M/DZ:$9[DM,>P$SH][GY'E'+SJ-`K*2JHC!B31W3++27C+:723E2Q' MC$K`YM+B^<(E+N0VH!<>RE%05C(=,;^`,YFT["\NX'""IP'W`LT;3Y.F).,1 MHUV:2I(AS(#*`ZYMS2M/6[K=2N>QE1?3\[D\8[>+Z?CJQ="I?/5_ENWKX=A% M3TW?-_7T*NBE:7H_-)-\&;JW]^7NLE'YEW[\F8[]QK=AN-$WI_GEWN4-X^8_ M4$L#!!0````(`'!W#$<7CPYU)@(``),'```8````>&PO=V]R:W-H965T&ULC97=CJ,@&(9OQ7@!!;3^3:S)C)O-[L$FDSG8/:8MK6947*!U M]NX7^*S3-NBT!U7P>3\>D$@^? M'+AHJ=)-<42R%XSN;:AM4(!QC%I:=WZ1V[Y74>3\I)JZ8Z_"DZ>VI>+?"VOX ML/&)?^EXJX^5,AVHR-&4V]/G?N-CX\`:ME.F!-67,RM9TYA*>N2_8]'/,4WP^OY2_;N=KM;?4LE*WORI M]ZK2MMCW]NQ`3XUZX\,/-LXA,@5WO)'VW]N=I.+M)>)[+?V`:]W9ZP!/HO48 M
",1!,`;(<",=`>!=`8&;G]8TJ6N2"#Y[LJ7G;Y$GCPA31E3T]&:G7R=84 M=J6*_%S$.$=G4^<&"2SR`D@P3Y0C$4T(TN,[)8);">A\#D""?)T/;_-KR(>0 MOU/L+)+")`#!*XS)/%6ZJ%F7M=-E#2ZA:Y0(7``A&'[S8#D#SAI%3J,(C-8+ M1H`LJ=P3LPZQTR$&AVC!(?[2X9Z8=4B<#@DXQ`N[)'EHE[BH69?4Z9*"2[*P M'NGEY9,PS!:W27JS31Y8G\SIE(%3NN`$""%IF";9PH8J)Q"'6?*`$<%.)=NM MG;(%IY%Y0.J3=%FAJ\]G3X_L%Q7'NI/>EBO]);8?S`/GBNE*>*4K5OJ$G!H- M.RASFYBAX,R`AN+]Y0BK_+XM@\+O9M>UKY?O.\MV7>/%0G>^S^>:GJ,F^[Q_K5;TZUS7>#45GX M4HC`+_/#<;%9#^^^U9MU]=86AZ/]5GO-6UGF]3^)+:KSXP(6XXOOA]=]V[_P M-VO_8K<[E/;8'*JC5]N7Q\476&VEZ9&!^/M@S\W-;Z\/_JFJ?O8/?^X>%Z*/ MP1;VN>U=Y-W7NTUM4?2>NI9_D=-KF[WA[>_1^]=!;A?^4][8M"I^'';MOHM6 M++R=?J:(9/[_FM::MR-%EX9?X;OP_'X?N,_P2"S-P& MD@SDQ>#2CMM`D8&Z&FC60).!GMN"(0/SJ04?M0\]E^5MOEG7U=EK3GD_GF#5 MX77OI//L==W5=)D8?-9#+C;K]TTHUOY[[^<#(@?[37:*_17G\,\3@@(?8$ M(4(S4(I0$(*8AC*$0(.*IZDM4=+<-#BIRCA5&0S9N%I!NP21B$%21()@&LD0 MD8)QLT4&3'!?3>!4$Z`:)HZ$$)#.CB4]`>6(\Y0%E"/E3C=I(DJ&0MQ7%3I' M;H@AA_?M(V>O1&@?,;V"B#2"@5*"M%!,KR!D)#">M@AI$YC[FF*GIA@U,4E, M8M+DGFBD:?0C&4G(J%@!(RFFL0LS%B@03DW#ZVZF,?$FQ$@CF:&9$@4!ISTC M2AO-=..6*"6B&8L,@%L9EIB(Z<"$&*G8F7FA@)N:1!FAN*E)E`:84?M`NI5A M68J8\9,0`YJ!4H+8?"&RO(W7H>JSHVE)RBT)*V7$S/*$&!`"N+I`6+?:,A%G MH[,HX+#MB"DY9Q,`[BH.6#,C9EPDQ"QE%+&3C#"EF2[(1DK+FP7<(8XP,TN; MNY;#_4J=$+.4AI5&5,"5MFRD0'!C97O!()ZCS5W9`>LHEY"$F*5FHDD)4NQF M9?04LRDC"((9>TH(W;*PMD=,.PDQ2P7L'FS$`LF5YY$RVK#:".M2-F/;`>Y] M!V"9C[B-!S%%^@@ M,/J:RA>=!$9,STF7_+3]H&VFQ$(?S^@AXQ6:L0-)=Z2765?=.<10GYXFC$OT`SJDZBI/S MQ,G_)G?W#*5MGX=[O<:[[EZ M.[9X<7)Y>[E#_"+[6ZI/[Q-8I>!XG\%JBS>$5_>;]2E_M7_E]>OAV'A/5=M6 MY7"%]5)5K>UB%@]=['N;[RX/A7UI^Y]A+PKO"?&AK4[CM>?E[G7S+U!+`P04 M````"`!P=PQ'^^V,TG'M=[9>@MHD@CM.HK>HNW*R7MJ_]9FTN8U-W^FL?#)>V MK?K_MKHQU^=0A*[A6WT\C7-#M%E'M[A]W>INJ$T7]/KP'+Z(IU(FLV11_%WK MZ_#A>S";?S7F^_SPY_XYC&:>OX7D[[W.0=^_.ZR M_[X,=[+_6@VZ-,T_]7X\36[C,-CK0W5IQF_F^H?&,2P.=Z89EK_![C*,IG4A M8=!6/^QGW2V?5_N?/,8P.@`P`&X!MW[H`(D!\CU`+2.USI9Q_5:-U6;=FVLP MG*MYML73)._G)%/F8!K,,-5IR=DOE=JLWS:%6D=O1&?>B&,6`GD'O,C@+8" M:$5Q5N"Q%7"5RSV\2-J+1"\)YT4^]B+12Q+[S-$G.B*2A$(SJ4>*A!Y/@M/# M#0?1E[,_."N:,.SAA2:D0+9Q:$+-2C'U+YVH\*D+34EA^28Y.J%F)6(.V$X% M(O%@MJ!A*2SE)%N:W/V\R>W2V4'N"A]@"IJ8`G'(%@=QF)*[LC-3H&6?F0(: MFF!)ISA\HP8RAB"E$PGAL<<#34VPM%,=FAV0H)+B5L' M*.+V`I2L9.:S"FAV0HI>V&60>I4F=2=JCYT),GJR,T<9CQ0T\L"!BCN`H(BM M+F*QB#T.9D`##_",*+@3B!,E*7";$\I4D?N\5=',DWA0%-PI!$4.S9 MD@:>Q&,BM^=L433M3!EP!+[IR)$U0B005'$%1)%,EN1,?RA(!'D27-$(E(A3(%8QO M^"B2:?[Y,N3N%1]E6?[3=47TX?JEU?UQN98:@IVY=*.]&[FUWJZ^7F"^OOG4 MOA5/I;W`>D^S69^KH_ZKZH]U-P2O9AQ-N]SA'(P9]60L_C(5[*2K_>VAT8=Q M_IK-E;376/9A-&=W*W>[&MS\#U!+`P04````"`!P=PQ'8R2H=:`!``"Q`P`` M&````'AL+W=OV>]LX-.\9LW8/B]@8'T/Y/BT9QYU/3,3L8X$TD*YK3I?`JNMZ%`JM*MO(:H4!;@9H8:/?T/M\=M@$1 M`3\$3/8L)L'[$?$M)$_-GF;!`DBH75#@?CG!`T@9A'SC7[/F1\M`/(\7]>]Q M6N_^R"T\H/PI&M=[LQDE#;1\E.X5IT>81[@-@C5*&[^D'JU#M5`H4?P]K4+' M=4I_OF8S[3JAF`G%)P)+C:+-;]SQJC0X$3OP<';YSL--$/'*Q'NS?NRH:>+@ M57FJ\B(OV2D(76`2\3!C5@3SZE=;%/0:O8CTXM_TS25]DQQN9H?_(;"]%-@F M@>W?1DR8PX+9?&K"SO94@>GBU;&DQE&[M*5K=;V=]T4\DP]X50Z\@V=N.J$M M.:+S)QL/H$5TX-MG-[>4]/[]K(F$UH7PBX]-NE(I<3@L#V1]I=4?4$L#!!0` M```(`'!W#$>-^IPYHP$``+$#```8````>&PO=V]R:W-H965T&ULA5/+;MLP$/P5@A\0RK*<%H8L($Y0M(<"00[MF996$A&2JY"4E?Y]^9`4 MNS":B[B[FIF=Y:.N6'/F*U[4-S>X0#:_VG1*.Y\:CIF M!P.\B20E69YE]TQQH6E5QMJSJ4H\'I.\PC M[()@C=+&+ZE'ZU`M%$H4?T^KT'&=TI]B.]-N$_*9D*^$KUDTGAI%FT_<\:HT M.!$[\'!VF[V'FR#BE8GW9OW84=/$P:OR7&WRHF3G('2%2<3CC%D1S*O?;)'3 M6_0\TO//Z=MK^C8YW,X.=Y\+%-<"11(H_C=BPAP7S/T_3=C%GBHP7;PZEM0X M:I>V=*VNM_,ACV?R`:_*@7?PDYM.:$M.Z/S)Q@-H$1WX]MG=CI+>OY\UD="Z M$'[QL4E7*B4.A^6!K*^T^@M02P,$%`````@`<'<,1PN/`%2C`0``L0,``!@` M``!X;"]W;W)K*VROL0?L_#1K%G4]-RVQO@->1I"3+L^R&*2XT+8M8>S5E@8.3 M0L.K(790BIL_>Y`X[NB*SH4WT78N%%A9L(57"P7:"M3$0+.C]ZOM?A,0$?!+ MP&A/8A*\'Q#?0_)2[V@6+("$R@4%[IOS^GKY'`].;S[7F!S+K!) M`IO_C9@P^QGSXY\F[&1/%9@V7AU+*ART2UNZ5)?;>9_',_F"ET7/6_C)32NT M)0=T_F3C`32(#GS[[.J:DLZ_GR61T+@0WOK8I"N5$H?]_$"65UK^!5!+`P04 M````"`!P=PQ'CEB1>:(!``"Q`P``&````'AL+W=OU#I2@/[;,7!K!B>ZAMEO3OZPN0 MW6C5]@7/#.><.>-+-:-YL0.`(Z]*:GN@@W/CGC';#*"XO<,1M/_3H5'<^=3T MS(X&>!M)2K(\RSXPQ86F=15K3Z:N<')2:'@RQ$Y*!FOZE_BM-[]B5MX1/E3M&[P9C-*6NCX)-TSSE]A M&>$^"#8H;?R29K(.U4JA1/'7M`H=USG]*[@)(EZ9>&_6CQTU31R\KL[UKL@J=@Y"5YA$/"Z8#<&\^LT6 M.;U%SR,]_S>]N*87R6&Q./R/_N6U0)D$RK^-F##'%?/>);O84P6FCU?'D@8G M[=*6;M7M=C[D\4S>X'4U\AZ^<],+;``=H@/?/KN[IV3P[V=+)'0N MA!]];-*52HG#<7T@VRNM_P!02P,$%`````@`<'<,1V$+ER:B`0``L0,``!D` M``!X;"]W;W)K&ULA5/;;J,P$/T5RQ]0$R"[5420 MFE;5[L-*51]VGQT8P*K-4-N$[M_7%Z!)%;4O>&8XY\P97XH)]8OI`"QY4[(W M>]I9.^P8,U4'BIL;'*!W?QK4BEN7ZI:900.O`TE)EB;)#Z:XZ&E9A-J3+@L< MK10]/&EB1J6X_G\`B=.>;NA2>!9M9WV!E05;>;50T!N!/='0[.G=9G?(/2(` M_@J8S%E,O/A8=9K/#_'N!_%(@ MCP+Y5R-&S&'!;#\U86=[JD"WX>H84N'8V[BE:W6]G7?A$-D'O"P&WL(?KEO1 M&W)$ZTXV'$"#:,&U3VZVE'3N_:R)A,;Z\*>+=;Q2,;$X+`]D?:7E.U!+`P04 M````"`!P=PQ'VJN[RJ,!``"Q`P``&0```'AL+W=O[PS8@(N"7@,F>Q21X/R*^A>1'LZ=9L``2:A<4 MN%].\`12!B'?^'W6_&P9B.?QHOXM3NO='[F%)Y2_1>-Z;S:CI(&6C]*]XO0= MYA%N@V"-TL8OJ4?K4"T42A3_2*O0<9W2GZ*8:=<)^4S(5\)#%HVG1M'F,W>\ M*@U.Q`X\G-UFY^$FB'AEXKU9/W;4-''PJCQ5F^*N9*<@=(%)Q,.,61',JU]M MD=-K]#S2\Z_IQ26]2`Z+V>']UP+;2X%M$MC^;\2$.2R8AW^:L+,]56"Z>'4L MJ7'4+FWI6EUOYV,>S^037I4#[^`G-YW0EAS1^9.-!]`B.O#MLYM;2GK_?M9$ M0NM">.]CDZY42AP.RP-97VGU%U!+`P04````"`!P=PQ'$(ASSZ0!``"Q`P`` M&0```'AL+W=OP)$/ M);7=T=ZY8#+&C4MS\V8/$:4=7]%1X%5WO0H%5)5MXC5"@K4!-#+0[>K?:[HN` MB(!?`B9[%I/@_8#X%I+G9D>S8`$DU"XH<+\D)YA$V0;!&:>.7U*-UJ$X42A3_2*O0 M<9W2GTT^TZX3\IF0+X3O632>&D6;#]SQJC0X$3OP<':KK8>;(.*5B?=F_=A1 MT\3!J_)8K=8_2G8,0A>81-S/F`7!O/K5%CF]1L\C/?^:OKZDKY/#=>I>9%\+ M%)<"11(H_C=BPNQG3/'OD.QL3Q68+EX=2VH^?7:SH:3W[V=))+0NA-]\;-*52HG#X?1`EE=:_050 M2P,$%`````@`<'<,1UQ\&W^A`0``L0,``!D```!X;"]W;W)K&ULC5/;;MLP#/T501]0.8[;#8%CH.DPM`\%BCYLSXI-VT(ET9/D MN/O[Z6*[21%L>Y%(ZIQ#4I3*"5=2VSWMG1MVC-FZ!\7M#0Z@_4F+ M1G'G7=,Q.QC@320IR?(LNV.*"TVK,L9>3%7BZ*30\&*('97BYO0,H@Y!/_FC4_4@;BN;VH?X_=^NJ/W,(#RI^B<;TO-J.D@9:/ MTKWB]`AS"[=!L$9IXTKJT3I4"X42Q=_3+G3TG?I@JW*7O^'P+%I4"1!(J_M9@PAP6S_92$G=VI`M/% MIV-)C:-VZ4K7Z/HZ[_,XDP]X50Z\@V=N.J$M.:+SDXT#:!$=^/39S2TEO?\_ MJR.A=<'\XFV3GE1R'`[+!UE_:?4'4$L#!!0````(`'!W#$=>2K[1H@$``+$# M```9````>&PO=V]R:W-H965T6CG-"\VA[` MD7U#9?=,<:%I5<;: MLZE*')T4&IX-L:-2W/PY@L3I0#=T*;R(KG>AP*J2K;Q&*-!6H"8&V@-]V.R/ M14!$P"\!D[V(2?!^0GP-R8_F0+-@`234+BAPOYSA$:0,0K[QVZSYT3(0+^-% M_5N;$9)`RT?I7O!Z3O,(^R"8(W2QB^I1^M0+11*%']/ MJ]!QG=*?[4*[3&H4;3YQQZO2X$3LP,/9;?8>;H*(5R;>F_5C M1TT3!Z_*<[4IBI*=@]`5)A&/,V9%,*]^LT5.;]'S2,\_IV^OZ=OD<#L[W'TN M4%P+%$F@^-^("7-<,/?_-&$7>ZK`=/'J6%+CJ%W:TK6ZWLZ'/)[)![PJ!][! M3VXZH2TYH?,G&P^@173@VV=W.TIZ_W[61$+K0OC%QR9=J90X')8'LK[2ZB]0 M2P,$%`````@`<'<,1^$U\?BD`0``L0,``!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\0RK)2IX8L($Y1M(<"00[MF996$A&2JY*4 ME?Y]^9`4NS":B[B[FIF=Y:.N6'/F*U[4-S>X0#:_VG1 M*.Y\:CIF!P.\B20E69YEGYCB0M.JC+5G4Y4X.BDT/!MB1Z6X^7,$B=.!;NA2 M>!%=[T*!525;>8U0H*U`30RT!_JXV1^+@(B`GP(F>Q&3X/V$^!J2[\V!9L$" M2*A=4.!^.<,32!F$?./?L^9[RT"\C!?UKW%:[_[$+3RA_"4:UWNS&24-M'R4 M[@6G;S"/&H4 M;7[ACE>EP8G8@8>SV^P]W`01KTR\-^O'CIHF#EZ5YVI3[$IV#D)7F$0\SI@5 MP;SZS18YO47/(SW_F+Z]IF^3P^WL\.%C@>):H$@"Q?]&3)CC@OG\3Q-VL:<* M3!>OCB4UCMJE+5VKZ^U\S..9O,.K&PO=V]R:W-H965TV!]LX->\9LW8/B]@X'T/Y/BT9QYU/3,3L8X$TD*: M5F6L/9FJQ-%)H>')$#LJQ3X@O(?G>'&@6+("$V@4%[IK0.U4*A M1/&WM`H=URG]*8J9=IN0SX1\)7S)HO'4*-K\RAVO2H,3L0,/9[?9>[@)(EZ9 M>&_6CQTU31R\*L_59I>5[!R$KC")>)PQ*X)Y]9LM=T):&ULA5/+;MLP$/P5@A\0RK+%+=W.(#V M?UHTBCN?FH[9P0!O(DE)EF?9)Z:XT+0J8^W)5"6.3@H-3X;842EN_AQ!XG2@ M&[H4GD77NU!@5#\AOH3D1W.@ M6;``$FH7%+A?SO``4@8AW_AUUGQO&8B7\:+^+4[KW9^XA0>4OT7C>F\VHZ2! MEH_2/>/T'>81=D&P1FGCE]2C=:@6"B6*OZ55Z+A.Z4_^=:;=)N0S(5\)7[)H M/#6*-A^YXU5I<")VX.'L-GL/-T'$*Q/OS?JQHZ:)@U?EN=KLMB4[!Z$K3"(> M9\R*8%[]9HNT[?)X79V6'PL4%P+%$F@^-^("7-<,+M_FK"+ M/55@NGAU+*EQU"YMZ5I=;^=]'L_D'5Z5`^_@)S>=T):&ULC5;+CML@%/T5 MY`\8&R=^)'(L3::JVD6ET2S:-4E(;(TQ+I!X^O?EZ4E&"'L3'C[WG$LX%ZA& MRMYY@[$`'Z3K^2YJA!BV<X4TMP MSUO:`X;/N^@9;O=PHR`:\;O%([_K`Y7\@=)W-?AYVD6)R@%W^"@4!9+-#;_@ MKE-,4OFO)?W45('W?_X'CE@A(7$@&"/DS;]KH=S9=\;`,M&)&R&=YCE\^.HQ?&4R7!GU-)LG6#\2K`W!VBZQ\"W18/8.4\Z+9%Z1S!)L`B(6 MDR?S(KE7)+<$,"#B,`O^[\(K4EB"54#$8=;S(J57I+0$64#$8?)YD8U79&,) M0AOO,`LV'B9>%3VM*$);[T#%@KV'T*]CR[`([?X$6K#],/7KI)8B9(`)M,`! M<.77L85=A#PP@1:8`/K+']K:+D(VF$!+?.`_`:`M[R+H`PLJE_C`?PA`6^%E MT`<.M,0'_G,`VB(O@SYPH"4^\!\%T-9Y&?2!`RWQ@?\T@+;4RZ`/'.BK#^*[ MRY5@=M%O"`Z.]-H+<[=.L],[Y3G5E_,GO*X&=,&_$+NT/0<'*N05KV_B,Z4" M2_WD*8M`(U]2TZ##9Z&ZA>PS\[8P`T$']U2:WFOU?U!+`P04````"`!P=PQ' MLS@[,;$!```6!```&0```'AL+W=O+I-B!T/0B<.M@ M+-<*&:@/^&ZU/VX#(@)^.BTG"D:2O::5J[@.Z627C;1E`AT)]!.!)*-8Y@_F6)$;/2#;L3"[U=[# M31#QRLC79GW;4=/$QHO\7*QVMSDY!Z$K3"(>1\R,(%Y]T8+B)3J-=/HU?7U- M7Z<*U\F=[KX6V%P+;)+`)@G<9DLM)LQQPOQ'D]M%D^TH0/]A,F'6GTS(Q>`D MF";>3XM*W2N7YC9GYR=P1^/@/^!%WK$&?C'3<&7123M_?>*4:ZT=>/OL9HM1 MZQ_I'`BH7=A^]WN3[FT*G.ZF5SC_"HIW4$L#!!0````(`'!W#$=N)[I&L0$` M`!8$```9````>&PO=V]R:W-H965T\R#6.Q/3AKHZ>?T[35]&RO<1O?M M?_COK@5V46`WM9BMM1@QQQES^[E)MFJ230)W'YC,F/MW)NQB<`IT$^ZG(24. MG8US6[++$WA(P^#?X$7>\P9^QL!B/[_"Y5=0_`-02P,$%`````@`<'<,1Y:[3SBF`0``L0,``!D` M``!X;"]W;W)K&ULA5/;;IPP$/T5RQ\0LT#:9L4B M95-5[4.E*`_MLQ<&L&)[J&V6]._K"Y#=:J6\X)GAG#-G?*EF-*]V`'#D34EM M#W1P;MPS9IL!%+=W.(+V?SHTBCN?FI[9T0!O(TE)EF?9)Z:XT+2N8NW9U!5. M3@H-SX;822EN_AY!XGR@.[H67D0_N%!@=<4V7BL4:"M0$P/=@3[N]L#\AOH;D1WN@6;``$AH7%+A?SO`$4@8AW_C/HOG>,A`OXU7]6YS6 MNS]Q"T\H?XO6#=YL1DD+'9^D>\'Y.RPCW`?!!J6-7]),UJ%:*90H_I96H>,Z MIS]%OM!N$_*%D&^$+UDTGAI%FU^YXW5E<"9VY.'L=GL/-T'$*Q/OS?JQHZ:) M@]?5N=X]/%3L'(2N,(EX7#`;@GGUFRUR>HN>1WK^,;VXIA?)89&Z%^7'`N6U M0)D$RM0_RVZ-F##'%?/_D.QB3Q68/EX=2QJ^?79W3\G@W\^62.A<"#_[V*0KE1*'X_I`ME=:_P-0 M2P,$%`````@`<'<,1X'8,[6E`0``L0,``!D```!X;"]W;W)K&ULA5/;;IPP$/T5RQ\0LT"::L4B95-5[4.E*`_MLQ<&L&)[J&V6 M]._K"Y#=:*6\X)GA7&9\J68TKW8`<.1-26T/='!NW#-FFP$4MW M1#^X4&!UQ39>*Q1H*U`3`]V!/N[VQS(@(N"W@-E>Q"3T?D)\#WVWNX"2)>F?C>K!\[:IHX>%V=ZSS+*W8.0E>81#PFS&Y# M,*]^TR*GM^AYLOB<7ES3B]1AD=R+A\\%RFN!,@F4RXC%K1$3YKABR@\F[&)/ M%9@^7AU+&IRT2UNZ5;?;^9C',WF'U]7(>_C%32^T)2=T_F3C`72(#KQ]=G=/ MR>#?SY9(Z%P('WQLTI5*B<-Q?2#;*ZW_`U!+`P04````"`!P=PQ'3_B(W>.M+BME-G":X,F7UPP:6?,& M"2A.WN/F>#X8A17\KJ&7-W-D:K]P_FX6/_.3YYL2@$*F3`+1PQ6>@%(3I,%_ MA\Q/I#'>SL?T9]NMKOY")#QQ^J?.5:6+]3V40T$ZJMYX_P)#"Y$)S#B5]HNR M3BK.1HN'&/EP8]W8L7=_8G^PS1N"P1!\,6`'LF7^((JDB>`]DBTQ9[^`0Z_;MO7WK M*MPZ>ABO!X3W`:$+"(<6=W,M.LUYU.S7(=$L)!H"X@7(J#FL0W:SD)T+V/@+ MD%'SC>/:ST+V0T"P`!DUVW5(/`N)AX!P`3)JHG7(819R&`*6#G[4?#UX?'.9 M&(C2OAD29;QKE+M+T^[T+#T&]C)^RM.D)27\(J*L&XDN7.DK;6]>P;D"C?Y_0_4$L#!!0````(`'!W#$?+9P_@ MI@$``+$#```9````>&PO=V]R:W-H965T5=2VST=G!MWC-EF`,7M'8Z@_9\.C>+.IZ9G=C3`VTA2DA59]HDI M+C2MJUA[-G6%DY-"P[,A=E**F]\'D#CO:4[/A1?1#RX46%VQE=<*!=H*U,1` MMZY0!D0$_!0PVXN8A-Z/B*\A^=[N:19:``F-"PK<+R=X!"F#D#=^6S0_ M+`/Q,CZK/\5I??=';N$1Y2_1NL$WFU'20LBXSNE/62ZTVX1B(10KX3Z+C2>CV.97[GA=&9R)'7DXNWSGX2:( M>&7B>[-^[*AIXN!U=:J+_+YBIR!TA4G$0\+D*X)Y]9L6!;U%+Y+%O^F;:_HF M=;A)[MO_\"^O!GCU;&DP4F[M*5K=;V= M#T4\DP]X78V\AQ_<]$);0(?HP-MG=UM*!O]^UD1"YT+XV<&PO=V]R M:W-H965TYF&DJ@\S MSS1Q$E3`&2!-Y^_'X&/:5`?BOH1+UC[;-MX&+TZZ?FWV2K7!>UE4S7*V;]O# M=1@VZ[TJL^9*'U1E_MGJNLQ:8_TQ.]M7[N+GYOEC'1M4(5:MUV)S!S>5*J*HJMDG/]" MT0_/3OCYW%6_[[MKFO^2-2K5Q9]\T^Y-:\DLV*AM=BS:9WUZ5-`'V15[3&O^N/)_I,0D.$"!@(V"-BT@(.`#P(>3PH$",0@H&)2 M($$@/YI$)P41"*)!(/BD(`9![.N0@"#Y(@CMX^@?YFW69JM%K4]!<\BZ*4ZO M#5YW14SEP#S!QDR.OF;=3X_5XFW%&%V$;UVA,X;US(UCV#B3.H:/,[>.$>/, MG6/D.'/OF&B<>7!,/,X\.B89F-",&SIX['SPN!T\!@7FEPOP\P+"%N"V`"?G MK:QZ1MK>6H9>MA"HA0`+.F$A?"TD:B'!@HU;W`!CUD]"+OM$J$\$/ASSB6U7 M+(..IR4>+#$GYLXR(8B^?!/5)P`=-@V7N'1-=-IFC)G,H M$%\N0`F:@_ZV9Q`H11M!(8P\&9]$*4""$+]I1!GN!;GE\_''EP)$?6SP<%-^ M>;ZF`''O+N$IIQ!S,;&2I`#Q.?,UP_-.(*QKQ>>>1I=CEH*$)?2 MUPR/-85<"^91(L&CD'PC"G@>*012H//&#:^%(B(2LZAZO,`(ZL4@N4)XE*!H MCQGU[S'#`\D@D$*./^1'@&+I&Q6&QY)!+(7'@LD$WF7QC2[C&6+2XR$#)"F) M8X_5F>$18A`A$4]$""#_P<43Q%R"?+ZI\`2Q;R2(X0EB+D'H`M_M:[K/4:#( M%15RGDA!/#Z`.!XC#C&27Y;?LQ?U`/GXX&])#EF3Z*>X\W$0_^(3?MH@'+*= M^I75N[QJ@A?=FKU&OR78:MTJ4X1"]J+5![>S M';;7J_]02P,$%`````@`<'<,1SXO&_9%`@``*@@``!D```!X;"]W;W)K&ULE5;;CML@%/P5Y`]8&]]RD6,I%U7M0Z75/K3/)"&Q MM6!<(/'V[\O-3K)+$O,O>O%C_TBB+0'3/!.:@FDAC->8T*TDMKYCQ.][*F)U_->_9LYKK*_10*O M&?E=[V6EW$8!V.,#.A'YQKKOV)TATX([1H3Y!;N3D(SVE`!0]&''NC%C9Y], M(T?S$V)'B`?"L(^?D#A"<* MSK6(4@;J]$(%:S2YB;8LSF6Y,-U:']+6-](W^JK^!\ M;9O81:8L6G3$/Q$_UHT`6R;5?6^NY0-C$BM?T4L6@$HU[F%!\$'JZ43-N6UE M=B%9VW?FX>]!^0]02P,$%`````@`<'<,1_/C-)`L`P``'@X``!D```!X;"]W M;W)K&ULE9=-CYLP$(;_"N+>8)O/1`1I-R1J#Y56 M>VC/)'$2M(!3<#;;?U\;#^1#QM!+`.>9F7=L9K#C*ZL_FA.EW/HJBZI9VB?. MSPO':78G6F;-C)UI)?XYL+K,N'BLCTYSKFFV;XW*PB$(!4Z9Y96=Q.W86YW$ M[,*+O*)OM=5.)RP$EBI[?;YR6MFIQ55DT/2_L% M+S8$2:0E?N7TVMS=6U+\EK$/^?!CO[21U$`+NN/2128NGW1%BT)Z$I'_@--; M3&EX?]]YW[3I"OG;K*$K5OS.]_PDU"+;VM-#=BGX.[M^IY"#+QWN6-&TO];N MTG!6=B:V569?ZII7[?6J_HD0F.D-"!B0WJ"/HS=PP<"]&7A&`P\,O*F2?##P MIT8(P""X&03MY*O):J"*`?#(5:*"`U( M.NID/>YD`TXF9.(^9N*J.7=ASJ-Q!]ZC`T\Y\,#!7"=2,2DP(1H/XFN#^.#@ M:5&KE@G5FOCP9I`Y0FB86RDN",/`R*6*PY[K>49P#:!(#]V#@RD&VA0#2)'H M(LU5BHKYAF9(.Q&*2G74H)A0*R8$,:YAOA6#QZ9Q&K91V",U*#K2BHY`M&<0 M#0PV+VDZAOE*M,(PGB1ZKA4]!]&^8=GGW8*2<)A:*0K-(@.4]JZ\8)A:WR@R MGA=&VL3:89E98&@,/11.B(/U<:"9AQ,Z&'[JYM`#,9G>!+&K5^%.J!B`1DMF ME(/7#[B)18/U_1M[IK+Q0;DWK6XF/3<)"<:%/"/#0O1M&T/?CJ:XB/2U$/U'+>A;&NYZFNEK#5!H_EBG@*F/ MZX3=FKX7$6@SD793"+VHAYY[GG.WERUI?6R/'8VU8Y>*JVU5/]H?;5Z(W`L_ MC;_BQ0IKQE.\6*N#R\U]$I^S(_V9U<>\:JPMXV('WFZ4#XQQ*O2BF:C-DSBL M]0\%/7!Y&\JB5<<7]<#9N3N-]4?"Y!]02P,$%`````@`<'<,1Y/A)N$K`P`` MEPT``!D```!X;"]W;W)K&ULE9==DYHP%(;_"L-] MA03"AX/,K&*GO>C,3B_::U:C,@O$0ERW_[XA.>"ZAD!O!.)SWIPWAY`DN;+F MM3U1RJWWJJS;E7WB_+QTG'9WHE7>+MB9UN*?`VNJG(O'YNBTYX;F>QE4E0YV MW<"I\J*VTT2V/3=IPBZ\+&KZW%CMI:KRYN^:ENRZLI'=-_PLCB?>-3AIX@QQ M^Z*B=5NPVFKH864_H>46D0Z1Q*^"7ML/]U:7_`MCK]W#]_W*=KL<:$EWO)/( MQ>6-;FA9=DJBYS\@>NNS"_QXWZM_E79%^B]Y2S>L_%WL^4EDZ]K6GA[R2\E_ MLNLW"AYDACM6MO+7VEU:SJH^Q+:J_%U=BUI>K^J?R(4P?0"&`#P$#/WH`SP( M\&X!OC'`AP!_;@\$`LBG'ASE78Y?9J>&BP/!LN?%O#O!7PEX$N!*+[/L99(J(9"(5\\%)%Q:@-" M83C.9*!$?&*@MD#Y.)PV1;2F"(R*-E\5N%:,.TYL%($,(MFDR/8S,>HDT#H) MP$E@J$\PJSX!%!H;ZA/,JD_P'_4)M6]M"*YF"$3:88E`(#(46#$(11[Q74,1 M-P"ZR$/8()@-@MB/8\]0\T$0AT$\;3'6CE$,%F<((%<[2+)92,2&]W,-D&D> M`.)%R/=\P_A,2VT?D'%/2.\)5H<8F3RA:4\*(1XA.#*`V;36]@$9-X7UIF"= MT,_-WA2>-J40%,4AUGXP>D^34ML'9-R3I_<$*Y-IHJP!FC%'@0QB+R:!:9+> M)*=F:4_.G:9(OX`B'XQJIT8,1F%-'9GG#M;"!=*6I7='YKDCH^Z<#[O.BC9'N=]OK1V[U%SM MHX;6X4SQA+M=ZZ?V-5IND*8]Z\X@V! M,4Y%QNY"#/1)G)*&AY(>>'<;=A50YP;UP-FY/P8-9['T'U!+`P04````"`!P M=PQ'PG:\ZP$#``"S#0``&0```'AL+W=OK#]NR"@:A)S&)3NG\_?Q%*:Q)72"0V MYYY[[K%E?(LS'5[8@1#NO75MSY;^@?/C(@C8YD`ZS+[1(^G%+SLZ=)B+X;`/ MV'$@>*N"NC9``"1!AYO>+PLU]SB4!3WQMNG)X^"Q4]?AX=^*M/2\]*%_F7AJ M]@/<_ZEPR8,'L`,@%H M#!CSV`-"$Q!>`Z+)@,@$1*X98A,0?\@0Z-J5O;8$P)NYA8"<4YJ+4HB]<2Y4D1O$JB&PQ2F)7&I/`^I-*0*R(0`JPJD&_+@+2* M^PG6&I%.0*I9DOH3R5V9X:W,4)L5&K/2>8+HEB#2!)$AR&Y%]@JC`U<&@T`$ M8G`?M]8X"'*Q>,E]7.7(5VMSEI/IAJ*]W]`NWG'DR-S0YG-\SL-F=?L#FWJ\A=;,[GSPH-B2.8P,F] M/$M5VZGN7U#LAR`"QEX7"FBU%T%W>Q&RJT`.]AH0A"@#4QX;W-0.=J2J/U'I MPH)W-]*.#'O5"S!O0T\]UW>L<7;L-QY4N_%A?@47:VB9KT1_HKN)*WU9'/&> M_,+#ONF9]TRYN$>KZ^Z.4DZ$6O!-J#Z(#FHKRT2&.? M5OX'4$L#!!0````(`'!W#$?[#UODKP(``$$,```9````>&PO=V]R:W-H965T M!,[QF3PT;6]6(0[*??W4216.]91 M<ZX@?9-CU['@)Q MZ#HZ_'UD+3\N0A2>%EZ:[4[JA:BNHG/=NNE8+QK>!P/;+,('=+_$1$,,XE?# MCN+B/-#B7SE_TQ<_UHLPUAI8RU924U!U>&=+UK::2?WR'T?Z_S=UX>7YB?V; ML:ODOU+!EKS]W:SE3JF-PV#--O30RA=^_,ZP.@C)NU-)&'3T MPQZ;WAR/]ILB=F5P`78%^%R`R&1!X@J2FX+(*C.^GJBD=37P8R#V5-]M=*_@ M@R91S($R(]0^&<[![%1=O==)3*KH71-=8;#!/%H,'D3$$=$.(`7= MI(:`E)#,U)JQD!*V8C%+BT%Q3N:%9*"0S#(0,J'$85)TFZ$K+0Z%<>PA)@?% MY&Y;BWF"`KPOA7_*2E!!.94RMQWE=,K<=I1?21F*03MFV3-G"(&&$)I/FL/$ M$VX^0<9U8%@']@B:`TT*N86,"X'["#HU$I_;`C_]B/C'#,'//TH]@N9`D]MQ M"QD7DL%>LB]$#'YJ4>X1L7S>RBUD7$W$CB0.#&NGGD$\0*B2Z&O3W=LI]TV#:]"%ZY5'.C&>\VG$NF*.([96NG MYOGS1P([?#K"2(FKJCU4BG)HS\1>VRC`NNPZ3O]]]PMB)P/>7`R[?C/OS3`:S10G MUK_P/:7">VN;CB_]O1"'NR#@ZSUM*W[+#K23_VQ9WU9"'OM=P`\]K3;:J&T" M",,T:*NZ\\M"WSWV9<&.HJD[^MA[_-BV5?_O@3;LM/2)/UP\U;N]4!=!602C MW:9N:<=KUGD]W2[]>W*W@EQ!-.)W34_\[-U3XI\9>U&'GYNE'RH-M*%KH5Q4 M\O%*5[1IE"?)_-=4AN?O@_?O.EPI_[GB=,6:/_5&[*7:T/LX?K76Q^Y8.U@XGMM]6:>=:>?)_-/'EHSW`"L`8P&(P]N$%F# MZ-T@U9$:93JN;Y6HRJ)G)X\?*O6UR9V$]\J)].S)8+C,D_;9ZTR5Q6L9$5($ MK\K1!08TYL%@9A`K@X`D&3&!5(#*`!^C`.-@AL(B'!BB2P9S>1_90.&Z@_C2 M06P2MZ#9@`V$.'Q^@O<:$CL4O`6Y53S!6PE)'&K>@F9#_@B9 M%H)W&S*T&Y=8,KSDLR^4/-X!2.Y2\OGU='R$3`O!&P!9N!2\`8'+]X<0Y8'0 MH>0M:"Y@"[EQTX+W&R`.M0C7^\TGR+00O-N`[3;@X@*?-N`+XP;@/0!F!XXA M'?,3QY"1V#DC>)L`EY'#@N!<\301W@;`9>H`I[%C1+G5)#YX@,OD84$NZ<7; M#LQ.'G:VA-G1P\Z6,#E[!&?;04O[G=Z:N+=FQTZ8Y6"\'3>S>]#;Q3N\+`[5 MCOZJ^EW=<>^9";FCZ%5BRYB@4D!X*W.RE[OC>&CH5JC73"7+;%/F(-AA6`[' M#;7\#U!+`P04````"`!P=PQ'@SCTJ3@#```Y#P``&0```'AL+W=OB]EX[P5>5E/W7W3'&X]KU[O M99'6-^H@2_W/5E5%VNC':N?5ATJFFXY4Y![X?N@5:5:ZLTGW[JF:3=2QR;-2 M/E5.?2R*M/I[)W-UFKK,[5_\S';[IGWAS2;>F;?)"EG6F2J=2FZG[G=VNX*P MA72(7YD\U1?W3FO^6:F7]F&UF;I^ZT'F?=FEJ^T_I[6YZ#`QCY@8#P3!D@1"(AC'W?2@^ MC%GV&#&,>;"(]=CKC'A>?=;Q]-"2XPOOQY>;\04,$EX7X.\%A!'@*/`AD[+# M1"83@_&OAQ!D"($A8BI$8$(8#+L>(B!#!!@B&<[BP6"^@0A\WQ_)-OB0[2?$ MRB`@YI="@XY#TG%H'/.1.`N#`9X, C]V`'6Y&P0=<1Z3I"UVS$M<$P_>T; M=6T'6Y&P0=\9( M$PS;$Q?#V=XCJ"T8JWP9T+&P2_'`0H+3&?,O9$RW(6;1A^X0!,'8HGRD4,-V MZ);%L&?QD/H^"`S4@RP^$(QN-*SO-/%8G!Z46,2A6P.+L+_86(WI28Z_,,ET M;3$L+N$/9[LX@\A=B<"UG^`<6PP)^*09\*^WRR6"+!82T)4,?26/M+Q?3^D._DCK79963O/JM$G@6[#OE6JD5K$O]&# MN-?GV/-#+K=->QNUHVM.=N:A48?^H'H^+<_^`5!+`P04````"`!P=PQ'-+%^ M#\T!``#!!```&0```'AL+W=OP[(=[MX$^]#4(;`1CLM74@ICE!!8Q9([/P MO]'S:TDK/.]/[K]C;%D0CX)X%D3I54$R"I)O`NR3N;J>B"9E(<6` M5$_LQXXV!I?6Q#@C4XPR^^0\I=NILCB529H7^&2-+IC8,8^>B7\FJI'(9@2; M`(LIXLL4?O(A=OHH26\;))<&J3=(QC+6ER$[Q^2^C(E)?F8JS\1Y?CM(NA@D M'1>Y7UHD\T%&9KT8UC.59]+P_G:0;#%(YA?)PBL[XID\B:[LB&=6Z]6W(/CL MM/7D`'^)/-!.H9W0YN"Z\]4(H<%XA'>FJ-;<)_.`0:-M-[?5^E_,#[3HIPMC MOK7*3U!+`P04````"`!P=PQ'4-&9"C,"``!S!P``&0```'AL+W=O#:0;P[HRZ0S?0471L##@];L)GO&XPTH@A?G9T%A_. M`RV_8^Q-#[X?-B'2#K2G>ZDCB#I<:$/[7B>I._^&T'_WU(4?SZ_I7TV[2G]' M!&U8_ZL[R%;9HC`XT",Y]_*5S=\H])#IP#WKA?D-]F)["SOY')MZG!3+ M`=,8YFX2)9%4J=("B+.FV16!)C2PS3`X')9 M)'.*9""2>D0R6)'"(P),FB^+Y$Z1'$0RCXAEXG+E$6R9W_9_"P2(&6-59.C15HE!X-R^2I9\T:RZ3Y M?[PS&#E-S+16<3Y_>'T!PF7J?#CP`E^I'#_^8:,/G\>)G.@/PD_=*((=D^I+ M:SZ(1\8D52GH2;76JAWP-NCI4>K30O=L]P0[D&RZ;G&W?;;^"U!+`P04```` M"`!P=PQ'QCQSL&@"``!3"```&0```'AL+W=O2#>?S4-)C]FY.:7F8^]+O`9[4_ M"!4(BCSH>=NJ(2VO:.LQLIOY[W"Z@AJB$;\KSCOUE2Y7IK_&G"QH_:?:BH/,%OC>ENSP MJ1:?]/*#V!IB);BA-=>_WN;$!6TZBN\U^-N,5:O'BWF2`4MS$Y`EH)[0^[@) MH26$5T(T2(@L(1J;4FP)\5B'Q!*2!T)@-DMO=8D%+G)&+QX_8M6`<"KA3(E( M94_N+Y>O3FLR_?**_%R$"5KD16R^S&BE/"^E-!L:&@%T&N!Z%X@,@*1%0A=61I,V6&B MUR:QTR2V`O&]26M:P_1&:4`(P!$VB=,FL3;)0"T=)GUMDCI-4BN0#9ATF,EK MD\QIDAF!%+@V+#5=;#`HC@`8@"VRKD,&8:6!Q6`R"%L:6))FM["GQ4VZPUN#L"&L+V^J[BWH:=6 MF,^UC_;WX3M2!^A#?`ZG"^B(EW"Z-+?=5;[(CWA/?F&VKUKNK:F0Q[8^77>4 M"B)S!F_R?#_(&[Y?U&0GU#25&PO=V]R:W-H965TMLUA.]/IQ>XU;9R&*>`LT*;[]HNQG.U!=MQ> M-(%\^B791M(PWC>HJI%&4AG51-I/9=+QWU\ZF\J6ORD;GMW&DD)'X58I]]^Y[H()_ MD/)972S69Y-(Q2`J\=@KB6+X>!67HJJ4TN#Y#XC^]ZD,WW\WZM=CND/X#T4G M+F7UNUSWVR'::!*LQ:9XJ?I[N9\+R($IP4=9=>/_X/&EZV5M3"9!7;SIS[(9 M/_?ZESP",]R`@@$]&%#B-(C!(/8U2,`@\35@8,!\#5(P2'T-,C#(?`UR,,A] M#3@8<%\#M>=ZYR+?K2.'S2;>7LQV$^_])F;#R><=#_59'$_R5=$7LVDK]T&W M*]3S34X5WRJ=03P8SF\W/!JC;#L^'+/IZRS.XFGXJI0^,'1D+@R3V)E+S5#* M[,R5T7$P/PR3VIEKPV1VYL8PN9V9&X;;F87)R^%KZ>%KY:'S$W3RR,["$>"O%'A40KQ*!`L3@ULS1,[.$E0;TDH/#IU#4CD^D5 MTPR)QC\/3PSUQ,`3CE+440J.4KNCFQ0OG`+S66<.K$EN.0Q M<7(KS1%&J%^"&9I@!@EFF">F$]0,B]SYS0W&+)A66Z)J]K!S-.P$RX]&PF''_1:.1&@HXVUUOAR>%@"YUVYE MJ-1O:0C!`X("R8G];%T!Q*+8%@!(K8JPZ"3>F%+%',$CC<&`IV!.SK#)4!)FGGZPEL#@=[` MT=Y@%HG!R75FOS#8D34"C[:C:9X61,R1'=Z/B.D.:$,RV6DHYT>RTQAS8TO` M2.;F5H8COON'-R0"'8FC'0E:+D#'8IH#QVP/*+1<7,X1.MZ4"+0*GOMH?.H4 M,.L1TRI\ACV*EW@:'6_JW$?#,M]^9\"E>&VDNE`EKGV^ M!LA_^J1X/:-FTG7-TP`ED5=6>#&C##2RZ8('V?>R'M]:;*3LQ:`3G0RU M9RN*]>&B$IM>?/A_>?L'U!+`P04````"`!P=PQ'47BN MJXH#``!R$0``&0```'AL+W=OR:VI],^=";3A_99L66;"2`7<)S^?05:43M=RTH>PL5G]^Q* M.D?`[*S:U^X@91^\UU73S<-#WQ\?HZC;'&0MN@=UE(W^9:?:6O3ZLMU'W;&5 M8CL&U55$XSB-:E$VX6(VWGMN%S-UZJNRD<]MT)WJ6K1_EK)2YWE(0GOC1[D_ M],.-:#&+IKAM6=A M/-0@*[GIAQ1"'][D2E;5D$DS_X:D_SB'P,MSF_W+V*XN_T5TU#0F#6KR;8]F,Q[/Y)8TA#`^@ M$$"G`,*=`0P"V!20NQDX!/`/#)%I91R(M>C%8M:J<]`=Q;`\R*.&MT,2G3G0 MW7=Z8,><[3BTB]G;@L?I+'H;$EUAZ(A96DQV&[,R&'H;L09$,D$B721:*;VN ME)E**521WT_`KA.8FT\,$A37138C)C.M&HQ6R/AWGXFC3-PPD1@;#H-960RY M3Y*@)`DD0,?<8)86P^Z3I"A)"@FXHQ.+\9C9#"7)(`&Z!H'$8K+[)#E*DD." MW$%B,<5]D@(E*4P"ZIIXB_&8>!*C+.-MO4HS=GLEKP!$LO1R(?^'6P/N&G:[ M(H)7!.+.N*LB`!%^IR*#(\2O(HI7!'9!'?)832`/?1#<5`BX"G4I9`)Y2(3@ MED+`+VCJ<"\`%7[>17!?(6`:%+5[VY$%>;@QP:V%@&_0PL5C0(S[J`5W%P+6 MP7R&Y(-WP-9#J0@:,.4^#=,<0%2 MT!:C6,.)6;``8ISG'A*DN`0IJ(NA=E@`DP&E#T7J081KD((&&?=(D>`#FWQB M8''=4-`-2V[K9CF!?+K%=4.M;AP^L)Q`/OW@&S,%<3&'#RPMB/O(`E<@!05R M5(%VF1A0]A![#!S#]<=B('(]F5F0S];#\$V7@4BY3PK\F9I]YJ'ZQE,UJ(\[ MMOXE@$CJ^US-<`4R4"!/'*8"($*8+QF^$3+0*D>W7$N67'3F085KFH%Z:2KL7^@XNKD96N`87]D,+0IBBBY?=H]C+[Z+=ETT7 MO*A>OS>/K[<[I7JIT\0/>JX.4FRGBTKN^N$T&R;1?!(P%[TZVB\6Q5]0 M2P,$%`````@`<'<,1[YVL3=;`P``H0\``!D```!X;"]W;W)K&ULE9?;$!#!*2@(SMF<:'M!>=R>2BO2:V;#,!Y((< MIV]?0`NU,PLH-^;@;W=_K;0K-+^J\JTZ2:F=CSPKJH5[TOK\X'G5[B3SI)JI MLRSJ?PZJS!-=/Y9'KSJ7,MFW1GGF4=\77IZDA;NR^5<7726%O*Y=*I+ MGB?EWT>9J>O")6[WXB4]GG3SPEO.O=YNG^:RJ%)5.*4\+-QOY.&)1@W2$K]2 M>:UN[IU&_*M2;\W#C_W"]1L-,I,[W;A(ZLN[7,DL:SS5D?^`T_\Q&\/;^\[[ MMAUN+?\UJ>1*9;_3O3[5:GW7V&U`^:B#`0-A& M",$@_&3@F>RV<[-.=+*D6;'DH<;+QDGMV:DGI*KGNO59MK.]G+\O M&8OGWGOCZ(ZA+?,(#/>'F95AZ#"Q-D0X@FPFG6RGG3QU:DG/>'4VT)30^Y0$ M)B44'-!I!\&]`V8MF( M7L/0&1F1VS'"(G,<5<)!"<>B&,,5,`158IBU84@0#C,;PXB8#C-;\!/QZ0$) M=$`"!B2P(-P,R#!!Z/LC:A%H4$J(2@E!2HC5CF$V'1--!XG0(!$XB*<=Q&CQ MQ?;%1WQ40OMZ:A$!1(.1V5\#%, MU\@7&AO!.QN!UB;0K0`640]9=&""=R0"+4F@C;Z+TT$V*<'[#8%F(IB%"X%G M57PAJWAE$B@[@:Y8#INP@0(>^N$(MP(N"B(1CW`;G!N6CM<[@8(7(PUN`U`D M.+7*4HR'@M8@1AK88P]9=#"*]P\*%2TL>A@EZ)J@Q'Y-4(JK@&(-T4T!YKJ# M&",^^HD`$X!SPY+PXJ=0UZ'-EQ7#$\.^D!B\9"FW24RW<0L6HE]A76)0;E@2 MOLE3:`&?/TOO0\$.+D1L\:%&\4Y!H5/@@X(M"2!J\ZE`\;*F4-8A&^F_/?2Y M?7@W!Y%SEM*R=^+,Z/:?ZO-P_9/*@F]NPR9LY M09H'K<[=@;@_E2__`5!+`P04````"`!P=PQ'$I[/\2,"``#H!@``&0```'AL M+W=O@`I[PO]N:,>F=0C#R\1;>VRDGHCK*K[&[=N>#J)E0\#I81U^@ZL- M1%IB%+];.HF;?J"3WS+VK@<_]^L0Z!QH1W=26Q#5G.DS[3KMI,@?SO2+J0-O M^Q?W[Z9WH@ITZ^L>D'=35DVG#'.F'NP>XD).LO M(6'0DT_;MH-I)_ND`"[,'X!<`+H&E"9ORS%9OA!)ZHJS*1`CT=\.KI2::P]E M'*C4A*K:6')3=UV=ZQ3G57S61G<:&[BY:/!5$RM_+P3=0Q(+0<8`IL5C@^3> M(+4&B(BV)!/;F7DSL.G.%8S1-*BG0!!WLYV''0#,=J8*:O!:#""RH<*/&!2@NR M&APE^6-*Z:64CI+Z*-"NZDWI,'A!,1!X.69:@[(YD%.A*,D6D*"?Y'[B(I\E M6549@06O#B(_"3D2GOE$3H0CD/P'BF]VL9$& M;7S:(P(``.L&```9````>&PO=V]R:W-H965TN0^SW$1,Z'GSH3PMO[;41:@%4)9CC M+FV'>][2WF.X/OB?X/X(0R71BA\M'OG#M:>2/U'ZKB;?+@<_4#E@@L]"62`Y MW/$+)D0Y2?(O:_J7J0(?KR?W+[I![%URC&Q%O=/R* M;0V),CQ3PO6O=[YQ0;LIQ/$4P0K' M:(HHCZ)BFY,X.8GEP!6.T-M4.H$I184ND"%`1E-LH-/4#(G);.4:(5B M-/D.%HO/-C)W(G.+C%WOK=$<)\T3KT/AA!36(%V!3)HGF@,&3HI>5A:YZ^_+ M;`\:$$;H[I]R1PMM%4D!&%,/X7!![VL0%= M\7?$KFW/O1,5&ULC97=DIHP&(9OA>$"EG_8.LC,"G;:@\[L[$%['#4*LPFA M293MW3>_J+L8/1$(S_OF>Q/,5XZ$OK,60NY]8-2SI=]R/BR"@&U;B`%[(@/L MQ9L]H1AP\4@/`1LH!#LEPBB(PS`/,.AZORK5V"NM2G+DJ.OA*_78$6-`_ZT@ M(N/2CWP[\-8=6BX'@JH,)MVNP[!G'>D]"O=+_R5:K`M)*.!W!T=V<>_)VC>$ MO,N'G[NE'\H2(();+AV`N)Q@#1&21F+BO\;S/*447MY;]^\JK:A^`QBL"?K3 M[7@KB@U];P?WX(CX&QE_0!,ADX9;@ICZ];9'Q@FV$M_#X$-?NUY=1_WF.32R M>4%L!/$DB#.G(#&"Y%%!:@3I)(C<@LP(LO,,B5I+G5VM7`,XJ$I*1H\-0'Y. MT4+@5)H(9T\L%Q,[H3RIVHNJ/%59&)7!21I=,;%B5IHI'$BCD3,1B`)FJXC] MN1EB)8]O3U!KHG`@S5V3]1>3FV4FUV4F>K$2G3)]OF^07ANDVB`UJSU;I&96 MEDEN,[5ETMM,8YGL-K.V3'X_4#8;*#,&A2.099X=@2SSS1'(,%'H"&29![[$ M?#90K@S2Q%'(*C>3.':QMHQC%QO+.'9Q;9GL?J!B-E!A#')'(,VDL>N3>X!I M'F#67QD=*+@XO3"D!]4WF+?I_&5]&BCF;&&]'*=.AG!QYJJC<4\(AZ+<\$FL;2N:[?2`X)[+VT(NNNX_^H&3 MP7;3J:57_P%02P,$%`````@`<'<,1W.;)L(/`@``U`8``!D```!X;"]W;W)K M&ULC97+CILP%(9?!;%OL!VN$4&:3%6UBTJC6;1K M)YB`QF#&=L+T[>M;,HGD(6SB"__YOW,.P2XGQM]$2X@,/GHZB&W82CENHD@< M6M)CL6(C&=23AO$>2[7DQTB,G.#:!/4T0@"D48^[(:Q*L_?"JY*=).T&\L(# M<>I[S/_M"&73-H3A9>.U.[92;T15&5WCZJXG@^C8$'#2;,,GN-E!I"5&\:O&KWH9`YT`H.4AM@=5P)L^$4NVDR._.]).I`V_G%_5N.R?([EK@J.9L",6+][N!&J;GV4,:!2DVHJHTE M-W57Y;E*8%9&9VUTI[&!.ZN)LT]-I/R]$'0/65L(L@8)>FRPOC>(K<':99G? M9SD836*SM!KP&!%[$;$KLIA!6`V$<0P63.9>REPEF>L8RI=P/,1!X.69;@]!,SYQH03$0^BGNHT;KN7*<:F$]R$]"CA3[2(4#H:]`T(C^8WYL1M$L&=2G7WFC&H8DT2Y@)7J3JNNF.N"DD;J::;;9@]=NY!LO-PA MUXNL^@]02P,$%`````@`<'<,1UD7;0(E`@``/`8``!D```!X;"]W;W)K&ULC57;CILP$/T5BP\(8"[)1@0I`57M0Z75/K3/3G`" M6H.I[83MW]?V$'*1V>U+C(=SSIR9V$,VK52_]GUYJ&E+ MY(+WM--OCERT1.FM./FR%Y14EM0R'P=!ZK>DZ;P\L[%7D6?\K%C3T5>!Y+EM MB?B[HXP/&R_TKH&WYE0K$_#SS)]X5=/23C:\0X(>-]XV7)>I05C`KX8.\NX9 M&>][SM_-YD>U\0)C@3)Z4$:!Z.5""\J8$=*)_XR:MY2&>/]\5?]FJ]7N]T32 M@K/?3:5J;3;P4$6/Y,S4&Q^^T[&$Q`@>.)/V%QW.4O'V2O%02SY@;3J[#O!F M%8PT-P&/!#P1ICQN0C02HALA_I00CX3X*8,/I=A&E$21/!-\0+(GYG2$:PT7 M1D0K(UV]U(VUFL*V-L\N>8*3S+\8H0<,MI@=8);A/*0$R`WA:P-.%]AS9<"6 MCN<3%("(D\],/*O,FH@>3430B@AJB%=?"\2/`A#/G<4D4"E@PC#% MJWE4`:A5FD;SH!)`.,`O_]'WQ.DX&1TO76E>P#%@TD7L-`R@8A1:),[:`50Z ME&;]IDZ_Z>C7:64)?@&S3.8A!4#K_MTE:ZDXV6DET8&?.P6G M>XI.`W&+S25]BN_"=0%S[2:39STYT9]$G)I.HCU7>@38FWKD7%%M*UCH_[[6 MHWS:,'I4YG%I#@5,-]@HWE]G]?3!R/\!4$L#!!0````(`'!W#$>2"2$3L`(` M`,(*```9````>&PO=V]R:W-H965T[$+9 M!S\0(KS/NFKXW#\(<9P%`=\<2(WY"SV21OZSHZS&0B[9/N!'1O!6D^HJ@&&8 M!#4N&S_/]-X;RS-Z$E79D#?F\5-=8_9W02IZF?O`;S?>R_U!J(T@SX*.MRUK MTO"2-AXCN[G_"F8KD"B(1OPJR87?O'LJ^36E'VKQ8SOW0Y4#J9:-?E[,/Y/0TMP$:`FP(W1QW`1D">A*B`8) MD25$8R/$EA`_1`A,[=JY)18XSQB]>/R(U7D",PEG2D0J>](N+K^$UF3Z6^39 M.8_A-`O.2N@.`S5F83`IZ(2*"&0"SBR@[XH`-1WV!R@,(AV`+)^*K/X3 MZ4T3W:>)C%G(F(7"YP+1O4!D!"(M$,7Q?9*-QJ3&"XL!H!]3&`Q`:3]F:3#) M%/9C5E9G$C\O*'86%%M'1GSYQ&EI,M[2U)E!.F2I(2X,)H[Z(86!3/L1R]3Z MV0]9/8KTEC)QEC*Q7HPXGU.GF=/Q9H+0F8+>?F:G!4T&K"@L!CI/L7748@!* M!CQMA4:8`H"[)MOC$!HA`9W&`O@%9Y$["S3&60,:,J2PF,F0L;91#?J*QAY6 MX.YEH&UF8R1BMZWQ%VQ-W%DD(UJJ!4$TT`L+"YHZ3[7MJ6TT--"<5Q8$HL>N M&MQST:<6]#3XTP5TZWVXU?KU!=\`_["S`K@&-_J<8U/1!F@HY5NC;?T>I(#+?\$4:?)`#9;>HR$ZHUU0Y;T8LLQ#TV$Z,W=B: M_P-02P,$%`````@`<'<,1[T+B[9@`P``B1```!D```!X;"]W;W)K&ULE5C;0" MCM._+T*+8S<+*"_F=O;LZNP%Y,E%EJ_548C:>L^SHIK:Q[H^/3I.M3V*/*D> MY$D4S9.]+/.D;B[+@U.=2I'L6J,\<\!U`R=/TL*>3=I[3^5L(L]UEA;BJ;2J M6"OY%RE=U\6,WM5T5@\C$ME8427-X$PN198JI\?P'23]\*L/;\XY] MW2ZW"?\EJ<1"9K_377ULHG5M:R?VR3FKG^7EN\`U^(IP*[.J_;6VYZJ6>6=B M6WGRKH]IT1XO^DGDHAEM`&@`5P,/!@TX&O"K`;!!`P\-O`^#<-#`1P/?U$.` M!H'IHD,T"/_SX&AUV]PLDSJ934IYL:I3HBJ6/3;P4I$TS%:3D*K)= M3=YF/O!>&*Z%`0S6@(#?$WB:@&.4T7V418OQ]4HTAHV[\$@77FL>QY0';;?6 MD"!NYI#;#]MH&(O\6UAO-#X9C:\7?%,FO00!*7E@+GE(1A`B0405AL:L.TP\ M[B0BG42:P!N0 MQF@_;+PGY@@"GRY8[!P*U1\.T.%@CWLPM&P$N09ES>A)P#CZX?V)7"&(^?>I M_+3R30^P/RAZ=C`/@_(,*'RR7YEOWK`LH*/`GO?\H8H(NF$>>299H(<#"TV* M'$%&JM#S@74#(C"@B&EA8W-A@6YI<#&*L%_8%8)8,%9S'3`TK#F@^Q_8Z`MK MA1CH#0G?6#2N/R)Z!$`W`B(#"DXF"_@7DD7W(GCC7;!$4,P8#PRJ$^B7-&#/ M>@,Y6"*(><;JTMT-V-V^"45(JQM^05VZ(2$R43?ZTHP!^HT-\;BZ;8XW9$<#+*%(.``!M]QO.<# MG1NT`H)X$'^6UKG9<)V2@_B9E(>TJ*P763=[MW:+M9>R%@V/^]!$?A3)[GJ1 MB7VM3D.U)+U3UA>U/'4;_^N_#[-_4$L#!!0````(`'!W#$>PKXZ`U@$``,P$ M```9````>&PO=V]R:W-H965TA24NRO6![>.:==XQQ/@CYIAH` MC=XYZ]0V:+3N-QBK0P.K<$R;3R!C`ID2U@_Y>.3CB8]<`>R-N;8^44V+7(H!J9[: M;QUM#"ZMB%%&IA=EMLEI2K=117XNTI3D^&R%;ACBF)UGDBR[SY3_,MAXF#5" M;HWXX#/Q1N+_$(AO!1(O$(^=Q+1\J/121+`P_]I+,>DF< MQ/I!E9U'GM)H]<#*"!&R6GUL)9VUDH[;DLR567LOGGD*%VETGRI'BBS(\B\S M^.KD]?0(WZ@\MIU">Z'-(79GK19"@U$Q-0+4F*ME6C"HM9UF9B[]W^876O27 MNV.ZP(K?4$L#!!0````(`'!W#$?)/I:P"`(``+L&```9````>&PO=V]R:W-H M965TZ@TFD-[=A(3 MT!A,;2=,W[[>H(GD"32'>.'[O\5@NQ@9?Q<-(1)\=+07^Z"11G*`9.\,D4=11&89C!#K=]4!9F[I67!;M(VO;DE0-QZ3K, M_[P0RL9]@()IXJT]-U)/P+*`<]VI[4@O6M8#3NI]\(QV%8HUQ"!^MF04-WV@ MS1\8>]>#[Z=]$&H/A)*CU!18-5=2$4HUDU+^[4C_:>K"V_[$_M7$5?8/6)"* MT5_M23;*;1B`$ZGQA5!*##'[9M>]..]DF& M7)F_('(%T5R`DH<%L2N(YX)-:)):9R;7%RQQ67`V`C%@_;;13L&Y)E',0(41 M:IT,)SD522Y"%RP29=RVS]6N9 M>QWDS@%Z$'/"K'CC&Z_(QA'$RP1;;\SM^I@H]%HPT]I#K'4@V3%?%?%^5?P%02P,$ M%`````@`<'<,1UB2K>'P>0``3KL!`!0```!X;"]S:&%R9613=')I;F=S+GAM M;.R]W6X<278N>NUXBL1`#5-`LJ;^6>RV#5`4U4-;HFA1FK&/<2Z254DRIZLJ M:S*S)''@B\%^A>T;`WO?[.O]5/,D9_U%Q(K,R"+5W0;.A8'I4;$J,WY7K%B_ MW_J[NFZ2_;;XTSX_+_?;YN]_,YO/?I-\W:RW]=__YJ%I=M__]K?U\B'?9/6@ MW.5;^.6NK#99`W]6][^M=U6>K>J'/&\VZ]^.A\/Y;S=9L?W-/_Q=7?S#WS7_ M\+I<[C?YMDFR[2JYV#9%\YA<;KF%HMPFQTG]D%5Y_7>_;?[A[WZ+[_![\^1= MN6T>:GAGE:_:O_[C?CM()L,T&0]'L^Z/ZT$R/HW_Z,9S%A_/OYW=UDV5+9O_ MM_?-CX^[O/WC:'C\S^WOSN#I%;WQ9IW=MW^]R]9UIQG7QW5>%24.<)6\SIK. MOYZZNS]G>RXA_R^P*7&3J^RC:=Z9T#1;S^FL+&+`<]+9S#H"L8\"60 MQ]?DG_+'3AO[JFHO0=]R'A^/QL>344]7;XIU7B7G\-Y]677ZN2JWQ]ERF<,S M\,2*G^X;=+G9`(W=-.7RIS2Y(<)/WN^;NH'3`0O9F4,)L]O6T.JK;)UMESF\ M`P>MAE/SZ>9UW-ET`G(SH*T[X5RNH:VOR^NPGU M`YW:)7[(_[0O/F=K>+[3R=ERB9RC3JI\F<-#M^O.`E]N/\.;D=6[KO)=5JRH MG[)Y@'7FT70HK6Q@$Y?!B+MM`7^J8)FQ,1SO#BD[3;9YTQT/K/A]`2.5MJ)/ M_5B6JR_%ND/8'W*@W6*)NXUKT_[Y/G%/_-;LVZR&Z+==$4>7=_ MW++OLL?8FL/OU1Z&"#]7Y7JMV^I[U._",QZNRL=L'7O@=7Z7P_#AB1QV?=\] MW3*Y75D1RRWODG6YO3]N\FJ3K/+;SCZ$FW]@:*IGV7AL?!GV]]1PG_O>VV#, MSWT+CG0#)QV?6);;NE@AVX@\]_ZI;>!%.?``,INBP2-0\S&V/2_AX>3HJFSR MY.1E^RWB30_E&L95_RV=HN:Q0WIP:F7-:GS\^^3%<#`_R95-\SM>/T,LBR/O;DL*./ MQ\<[X15/E_\F3Q;B>CPB`]\&718WT>X^_$<]MUM<--F MMR4/E.A[72QQ-GTO\*'H^5&F#-WE7W?82D1**VLBZ(;'%1%50/!=LB"W@E[6 M)4E%G<,!HAV?QTU6_93'FOHQW^8H<>-#V6I3;$F"1P[3&=,#"%?""!6?)1 MDHM\\K)#&:^RNEAVA)UBO6^Z1T%4D3V>NJ:$/=GLX#$2:7KZC1!B_-B2&O%F M77YY_K'U9)_A#187?W%-<&C=R^V/^UK$'I@*Z"0@B(-.1I/!%_!;_$QJS1%- MN=B^3'95^1GH<)7Z@E9NOO\;9.L0.5%U8!&!7K(,4VU:-%_A./!\70M]1U17+[8L7ZB MN2]9A>I^_=S7?\R`0N#5"B@IJ_>5N[E1T%FM2!ZI0-F,\9\K/^6GCAZSJAK) M46TZZ63"O?L5L*MO)Z*87EP_16C7>V#@0#DX^UU4Q^V\D3W2<@%O@H;A*19Q MO(Y"JCW^@*3%'&0TZN@";H(R/_A?=[CMET2R>F)*,D`8"]PC#;X)06T,GCE5X MV5S=)/W2^6B0O/_PX]G5Y?]S]O'R_971QL,T.?KK7_X7?_/7O_SO!,X#7/`) M?@=,.-L^PI1*RGJLVJ MR.ZW0'=`P,"K/N?%FM44F.F>158\BB4N1()FSWJW1MLGWA^[`N=G@"T^Y.M= MLES#@8!1P"N;[">Z<&O4U$C5;(`DZ&J#GH%^J>'FH2KW]W"5-B;3;>]@/>') MO_[E/VO@8G<@TFWR`=RY>>*F_I](S;GQ,^=.Y(C;L:>T9&?K=?DNV\$@LZI1 M_9A-N9%ICT6M9S!3N'QJN@NJ771ZNH`AU\GOBMVN7"+_7H+R``/A<(P/7'P%4:+&_4Q>.TJJ_=.@ M\J\?\>D3?/I?@+H-C0-I$'Y]1Q(^:C'XLZ;_]GX;+QXG.'=>?&CB5574M]D6 M)-US(`-8^&V1XYW([% M7;&$`4,+N$RRZR*Z@`(-]`KL.QD1?=J+ZZRTRR5UFO-;Y]Q;&ASWH5J/&U3;#6!9R^1AG*X%,F6(PLWY97C[065 MWK!BY94")/AM";,D81B7#5D<+/Y^W=B1!_T9ZF^`QUQI_6F?%,6R-%'9WUD?T@C@1+Q)=@;79\=>6K`5`:RS'7 M+,>\%SG&4?MX'"%W8/=E+=PB%(2,$X20HUY>O[=$-VV;(E'V@=?#C:"C:_<. MR,`9_,;C]LL!I4(+9_M[6(]D-.'QPG@JE*S<:=/"$_X-Q[(ZAD4IZ68RO,O) M/6XO+RJ.;@_*8?6E*D`%$=[`GR[IR&*;,CJX@MR>N@>1ME^,T&CK28&; M;-!:`'NB1;W@U9!?.-'1#0[WRRI/UFB^V10UW[3PY(O)8)ALX':G>_$+Z%/P MU>E@;+\;F+,[F")7<.2VY]E@ MYGI./NU*6BF#-"5B'KX#M),2T>HM[SVF^,JVQ/Q>@_L/!$#)M+0=,+'@APSAKECCF05.="_V-1J\,UUOS9NRVB0WQY/D2]$\T+LW((!5 MWJ)^\96%$'(W,_$F7QX*$!'0F6GPJ'X)^D3&E^&)WN_P\XL31U7^#(FJ8T3\ M'4"G><**X[CCH[_9;^`YHNF;XGY+]S&&7+#'$HGJ&E2`9=RYV'[D@.@_AF%\ M>O?N[,._)N_?)#>7/UY=OKD\/[OZF)R=G[__=/7Q\NK'Y/K]V\OSRXL;@P8Q M(E>M`UL"/I%G@5ME6M2/JG#?HTN!DD M]VP[!6K'4($=WHNEZ#T.#RQW('JY9 M6#1[B&F]J=A?[]2E4+`UI3GA1;_$KG+T,?F7@M+MI`FUM81W5`*X&E[7V0>/LP M2[2L76-'H`P#6R*W8O$55%-R_N3H_&E[38DJ&[?R!5Y$<-\MR:!HQVV;IYEN MLD>D4KS'*?3#]OF(D44YW96FO;JSP2_@+S`-8X7>^`K6H/:#A'2+(\V(^T"3 M?]QO64-&]D/3L/WU]2)\A7OBDXVG.H>[`%F%GF0><3;;';>B6G#6SOBL?2`V M@\>3KJ_1\/B?Y*HKK?X*S1G:&W^O79P/S">6-"_$9ES3@O)Y=Q:C9R\I<"]X M`A<0P[$\?R;*$WI$PXL][&2-0#.,-5GSKF0@LFQ$F^%#3`J:K"/.-%]9[03' MYPW*INW^1G$3Y+5]U?:+Q8W0U$9?-^(CX)>9KL0H(EBH!3A]8Z M4V[O2_R2F&NJETKL_=@CM.(6+!7R(/D;KQ-'T["V1\5+.VKRU-QO130[*N`7 M'/:J0`$Z!S96F]N\^8*,RDX9%F4MRJEW*5`0VJX1\1^$;=`X4@/MV09SC-E! MN52(I^$#6@&9,B-A$QPM"@P[I[<_][P,=P'?L(NU14JV,@ M4Z`T&49R).V$WM`X>>#3,N9>3XJ5.,U!Q1O:Z9L\#L2X@;1OF5"NQV8*/W[S MI#>7Q"&X'$`;`28;>")@2;_&EH(43.OAN==QK<.D9S?4Q+(26!$"O"4K-Q6G2$ZOR`^ MI%@%*(TF^,T2U",N">T?:5>PQT5EYT+S14LV<;:<^*0]LL7VF)10])OFRX=M MN2[OV?MT+]&1-&IH&TA[G=]CH)X.-`.Q%?8E$YWUF4=_(UDGSM?$QL%UC^PXU&E1XR2I" MOC0VW4C3IM,T'"`X@/FC>!T28C9I4MZNBWN_.GB%F7NTPVPYU-X&^?$VV>^/ MZQWZ7I`R<`V8QWCCO]EE(%>QOO$9)"+0SH'+;W\"6MMAC)2;8U7P77"F2QL:H:A#Q!V\OQIQUF=H8!53 M1D^GSHS6B&QOKS.\`*N55V)$?$]JCG5C%5ZD4(RM^4JG$AJ`YO>XJ^L"Q)J: M14XU>KC72D_LX13HDD0:C!"P](BB+R&Q,U@W()ZOIP9GHB1@WD40F M$FLR%HK:'3FP<^1J%YZK\1>:S:F3"BI-U=#EFR9X-F&RZP(>7>FC;>@.+*OB MOD";]@;O<1:/Z7)%'5!(!-9[G=?*%KP2QY"5G`9)[VAV%2PW:8:X`')(>13L M0NRR9KX@'O+E3^SA%X9I+H/[]JV[;Y,SNF^#$QO*T?YNMM<\TI"HJF5%YQ^8 M4TVBC[K6OSR`H$R- MU)AO65*'2X4NN6#H:#MFOWG%.F2[Q=H)W#P7)\W=[5$4(YLWK*.8X"6_(KFC MZ#&G>+.LS28UD;7K/3(J;'.0W+!2#`-7RY%_+=#OC%VI;RD<[`L^#KJ%E?!6 MXA45+BQLUDTD$%5Y:7`QC/N3[3->[+32'QK5R"ZOIN>$'K3DR1KX*8?WT(/X M]("Q;M'%29H/2C'+!].:$U^;2.H#\P9'\GL[:"\:7?H[FY_AT18U!7IOV6VQIA;A^03M%WGD4]3(OBI)>@'X^8+%K4)3P MD8QM%E;%DT-%0@#:_ZWL\)`'@CA/\0\/9+WB9<:!^-5O>=M$.W$3$]]"6<%9 MKM%=^AEZ`O$)91\90F&-YX'_A1;"#IQD)@-7:I/]1&>,0BB#F#DFCM!HP!V8 M8([<\+[.^0#CVK/BG/NE=>O(?N/`LHE[7UL^P]>EM;\O6=>4-<5H"CC\N[WS MZRF2;>DZ>E]=Y^:0N>2/^]6],B_YY4CPJL+Q&.!(:-.':Y""'9Q!,3)-XC$Q M3B)"?TQUC0JGVA;1EK73V!V7^KM4W':I%?6B+QQ+GE(J[=F`'6J@B2?QH04Z!]S][P,R0\514<16"3\/>#N8J#Y%$,PR_ND7/34VW`U/C75$!OY!YH:6C3E#_KXDM MTPID24>*I;.!D4]\?=[G+HP+QX225R7<(Z.-Q/.!JK->#&L<-;&[W54V3-W91+!?!Q93[J;L,=^6^:AZ"H1@_%'?'>^Y%H_"< MJ\KO,6B+N:]ID89P'*"K&F6KZEZYS'*]82"/X`7MF[7N$72`YU\HHC)#85,B M8A^`ULOJ<1!H5.A:$,7/GNK<"L1B"``R`;6SIAA]5DPX^+OA=069W@VO:"TK MVR6(&9%=I299CUYS2YJBC\=@<]`Z++KP:'V.A'F1']'&&CE76G9;X_DV=`.% MO3O-GD[Q_@ZSS&A4X8JD[2V`*PW'HT[H;6X/*2R$XU$%B4W&<:^5%20P(M*3 M=Z%X&`CL=^2_!_!/2E]DA M3\2[C[D)+\KKR/KZA60AAFX7I`(3].8,41@UN%4[QR%RDB7-%.*#((H--EVA M;N&4C]?[RHJO@6OV@`4G#2XG'4[;.!S.6(]+:!QAU[8F M?+QLMRV*I=4V0LRA/X0L`XHK4?S0+0JAR*-#QF9M#K6=O*97U-B6(J47MPIRYX%$VQFP]M3C!&^Y@FVK(RD9&SAA*G4N)_$#C M9G=R8&T4#E4'R64^G!F]!NW4R[>2>AD39JWY0,FRV-NR+W_3>`/T(.G/\E1F M:N0UU$2H!QTTC=U%#6(F'"[(.(TX1O-0IDT7X//]A@SX)U9]*V%@BRE#,YQVZ6S!/0ZS;_=MA51$.FU9CQF!GJ^TW=`U; M#3;6]U%E05/;Q1L@`-SH`Q+_LC>^!.FGI`=$A3R,M2@2#4*[^4DICFH524"-9QNQ:=H MD'QP]\@=F?N6')2D=Q2XSE+@1W!>)IR7G#`6AM+.ANB+BV/C:KI&W4K%U$`? M0U5I27-@7MDP%CCKMQ++49O+;L#OVF(S*&A7$\:J#/,C@SG&OAH5<>("\?'<4M$2$`'>T\AAI-U&B MW$198USH![NBGIJ"]5G3>.2.#\S6KCV5,UXHV>6VA'7]$XR]:"@^DUC7GS`I M1;Y0AN^6X:85`&1[XB`T?%,25$+_3G@%BK!;!T,0E9!T'>OAP17$QNIR;2/T M..*S:'N%,.>4EG]=_(0.7?*UHAT`T^._8LY'9%1:BK83H90&4C4_YRW]UPU+ M1(&"6!/V:CJ]\N_UX4'CZ\C)#+T7C(]UX33<%'O0"B?%4?0AN@>9F-S M'S(`,.G+NW;4&:]1R\%K(FX5/X*%#7_V6D[EQX6L?;M<-=&1'4_3XI[09Y;X=SXBQ%6)1 M(_\W&R+Y8J9CB(%L(>/\@H'4;&)PT8]HN2W7G_-:[/Q1AXT6CME=2%%`%,/` MZR.+KQRK(ESC#31=@,;^FK,1H-\'G-M;%4=,E_X%H6V9C\H!NXS*0VS%4%.H M15,G<1'#!@/I^+X7*LA)F'#]BV@,BZJSDK>!TY]"3R1-@$.2"[F;#P6=E]T$ M@5;\AY[+P&ATEG,E+0<6@WTM,0VOUAD\?;-\*$GUY7Q'ZZG=E*`:&,RV"1][ MA]]S0@\+2,Y]BDWN*-=?2X>0D:`AP4$C02U@!?XR3J8E-@JK[?+A$1 M/4@"R1-[H`D0\3`,[?@.K4]DCC&!UFAYWF.!`84"K8B^N,\9]$$A+RJ8[&-% M?NM'\^>\*H]!E]R1'%'OK2:-DO.&;74)Q??F>*/[B+S(]%.)TB<'I1U(,$:= M`H84>40_@MH-C8:/)=&3-9^L`9.,A=PW_W>4%!TN[I"5E3%:"--X&Y)?F M-CX7-:61WQF7XT0^H7I_6[/XF8S5K_7 M=@Q>&\QXXOY5%.=G92AP:74<&J5--AY`R7=5.&]Y8%WCURQ_@C'ZK$4B4LRI M$SW7=B[C,W^0G(2`O!\R-.'"^MA,8I>YD*._CNFX%>OKP0#:V>T'(B$XMQ7N M61LPP5MT(#779;MWZ./R^KWX+B*JG3BWK'T>+E;^T6L:F!=GB5`ULCA0M_6\/M+?%A=3""6%RQG%.K-=N@$'>2 ME+1JX[[=<)GT''DA1A":]8+V#5VX)`AH$UX<&3"T@F!@#UI+3!2.+W6YGKT> M`9L1;TWJ*ONBO>4>8V4T33OK_LT9X*:3$9\*,<&NH2,*Q^!#/D$S";>X3":/`5"82VM')&5*`!<:]5F@C]4&NS&./ ML6LGIE&L7!TX@/V]F9/+P.A!I_[GEN#F)1X'R5<1QSD/PMD(/H?Z9)\);3G9 M.NC$TK"T)0]4DVS]2"G/$!U`[!]@IP+/H;>.19MQI65?#CNNHG)*.BM4>*3 MCD^2Z=/FR?3Y1JURT#DIP`O!,HV%;+3(&NIW_KK*_4US`&KE0XY&P`!.H"JW M\'DI:?&7F%/ZJ.!6?-BK>ND&"89D(0(<(J']S=G-*\J1EX,3??S3#DG47)4# MZN)X>)I:'R-S^7-9'!$[ST'4!;95T<`8.,H#/V"/KK>;3_3+\7"""$],''_] MRW]<(ARGT[8=D.G1S?ZV*7?%,EE,9L>3X/EM;;V&JO$;KNTD+E MD?'[^8.:&8^;7\.P`E,FA0[A6'%T0(G'F+A[4]XU"+)E_%`GL^'Q=/B2@<)\ MT[CH>`J!?/%;\;'5QMVQZ#RPZXA!.'N*<6=K.L+H[%<"6\I"D5.>C2B*J&S7 M,AQK&B;;RL]^6UF([,AL1K9P/Y<^W7XUR=^3"C-!U/%S;3*(2DHNL0K5P):I;0=%0%D+B;,L);Q0SADO/5R<]+9$\ M@B@&%T;!(L?HI?8?K@DDA0`?_+QK#MFT<@`&D8O##A[?@`#.,A@-F;BLFSX; M(:"7\4L&H_+],)/6KDMRDQ4>B0^A)8Q*&]>`("3`N><=0]U2HBO[45<2,6?L M3GJ93(FV#I(D]3[T0FFD'/*>:8LX7#/ULBIV6LR*))@GI.,6\$=MV#F=._`? M'@HO0;`N[45XYOQU&$#P&)[+^!HG'=>"]C8RW\$!\&;Z?!:_='826A3#"!]K MO##6=NK-PM;)3>0+7RN^2!;1IHX"H'1P=P@G^BWA-0OJ]#70'L'N=2K29!6> MJ-H_<0!G9S)(KBX^0M/O;VZ@Z:OS]^\NDNN+#\G-[\X^7!"PSM*F'_<"53N< M$4&7IETGPXKUHG??%KKXDJ-U)%\=9Q(BO-W3^5?X6V+MFKJFR#:J3?* M:9HZ-1&;-3HYS&/.:`/DBF&U:0;MB2.>I/'GW$/=]8'`U"Q&:`Y+ZFYN"SS M5-0I`'.U:!7IQ&#:M7^>H_K"RAIXPB"7IF@G(3A--Q6*AGQC[MCKY$R=PX'8UJ#Z0-BC"W'X8'W#:D10^PQ/6=D4)PX MX9)"&K18U"JRVFKJ2M1M6V=N':?1U-@+C4\@<@(RGR8S=#H[H2^.IF/X8,Y6J^\[F.V)PDYY@N;)&7@O*.K^C@]59X^AKEH^#-UG M0,8'P0O_H?^ZT[/V:[)(<34!9PN10B^M)3@=1Y?@=;XM"38#E_$/[3N@CM\H"_'T_3T=$)?CM.3^:FY8+Z&,68*/L+R M,(SKEFRN[\U%U.E":S99C-+I9.H6[KS_9-'SLW0RFZ7CQ="]GZ6S>LVP'JE;T_!9T="Q;">0P'(R9,(:#Q0E_ M,9TSI<"G,9#*L]JSLPQ;'$VB+8;,ZHF-?]:EV;,6J0NU$M,K45O\OHRQ*"<( MF#:+2@ZRJ)LX`JRR+6IIRMX9HW0&TL9H-DVF\]-T-)^H;TZ')^EDM/C&EO4S MWG8W.YFGP]-YLABGH]-AZ\]G],#'HW88ENT39COBHS8=I?/1)/C\Y&&S_R7C MR02F/7KJ0+OG'8*J^1`5)>`TC=/%<,@GVG\V4@=/SUA?[>-T/)RFP]D0S^#I M.#V=S]5W)^D"FIK/.D4\58+X.V]*[M9U\(^]=LK7(7#.*4BQ9Y_%D='3Y!B%TWP)50.E<9*QT.>;F($K!$1J+ MOA8--_OREZ$6^,`Z\BX2!<8V`+V"M^NB?J!%)_7O&+8,.!K=9"CEH7IL5".(:*[+:THQ%_WZ,HJC(U[7GJ(D@< M'EQ$$4PLMHTH@EW@"@5_*[`5C*`[>%"F@0CA3IDXG1(4!&# M=TSW[EPEGU`--D=R)G23&P'_>=>%$7J1@$PQ!>'J!0D!\O_R MI5%Q?*:OGFSKS5-L"__?D`?(?HV"VW#:^K.+X?1?.<]Y>G)RVIXG??ESY@F2 MS\G4_MN:*\E"K3^CI"BN1F&JXBS#_#H/HJ0BN26`0ISW2P_+UXXSD%7IP,HT8X0D]EXIC\; MYTOLH.S9B8U!.)Z(H'P*?\UF8_-$A]J&UU'2O M*],"++5$%U"?1S-^G?YY8I93(1LKJ/-?3XYU-(*6[3OR9]A1R&CD-+;/9Q_6 MBI5-?!KW&G?9D9@B12GN7"F?#^8+2*,]"9Z)0`XL\Z007EG6SY8,$<=HLS3A:D9-2 M6<+J$W](1++6\A`_TJ-B]1Q$,=<65=(BQ+;(I;>#(CBP*`('K.?`;UC`ZC)% M^KJ/W=&/?PC,KCJ@HYT=@`EB5*W.VV8M^(][QJ4**URR#*-)$FLTND6!A?AC M10H')=T3E%0.A^>^*O<[:H@KNKBXW]0X72QS!-061%A2^4/<"MT;"8&ABKV/-W2\*HKN^`NQ_.2VH2/< M]].CTO8/*/NS07)Y]7M0[M]_P%(;40'/TG\=.75N'*'17@M<$:D$$PL>8-TP M$(6$B2E*.>.3$_,A^Y*\<^FSD\4BF0Y/Q8#BI_8B.9F,X/_GBWFD$$EE*U\Q MVK"21B+E+-F9@4^?62SQ_M6:#[!`R8=/%Z^3LZO7R?N/O[OXD+R]/'MU^?;R M8]_Z.=RNVGE*?/IPIH;+Q@5-S[U";'=-KZORCDO182`V!C>#J#3B99T0/)AD MZ^H$7WINLI@D:/VS*X?1QHZWL)#$0M]H=`(7^]R<6YSU&\993\:+4_@!Q397 M]!:(_Z]_^9_6>9[0_06G;CP9PG!!C@@*<$8?G8^3DZ'A+;2KY&PQ\^D\08F: M":.SB`%30*%R,1W2O_-1AV#.*6O?S_9*MY<7%&Y&TZO?4Q47W@37\&^T):/A\-6,;(@G"7K8EHP7.>'$NYBN+=L MV<>;QQJ#.6RU0KA4Z8F4)=I[X>N^&RY?@'X)9-)H][96-VY9I;1JI.==N7Y$ MGQH&US[@TU7.UA?J\OK\0]H-W8!'UL>4ED"_8U2KT)P1-`7D`A:N(0Q!Z@3` M2EZ_Q#6!\)U1;66R]W,,8V>];'+*EFI34#53P3E#:8F@?]BX@,D8>*9X!1`< MHE/#$J/IX8;FR(F&\0-L5K%'G%`)TMQ6C<5!.=QIMUL_>M@,#VAB8;<[S>G6 MZ!*7<8)80Q(4ZOT^&]+#@G#.FTOH]G`856Y+N@6C9S1?CFF39P?)&Y0R;$SV M*)$RI\D-5D]"^C7=8GK8#B&/[WQY8;(`^:'MI%`+<%(I;VIO3!"?@/JIS,6; M_!8X.%#&R)6HY,64XEQFE6]LN$56W1:V3)?+$3@#0D7+2'*F?CV3G#J4XNH\ M9X1@!+M;9PXE-`LS>''/54S9+9+\@VP_CZA+3@`+Y.W.'OU" M&+E92ID9G2?&&_#0)ZN`KCA_5T)R?)PWA;>I>IZC07)3H%BCOPM!G1CXQ7); MG/!^2Y;8`%FF::N4!9&9<4%<5VDJHH?0D%)H`Z M\,!!$KW/S@9,"'``"'ZY62PE5!74O:$!X%]>[WYRG* M;Q.]9PQH([1[9$^P/0+2TL!\ZE_&D/M0YKL_(PI#R;21>*)#MH=-X"#9\H!K MC<6R5&N":T!*7PPRJHCDPZG4^G90Z>$B&I()UYE41##&)A7!\"9B-N:+\6SJ MP0DG\S&5+@X@&?OK>IB>(777N3LDTS>DY,5LJ/`2YR>+R)!,H(VUJZGH&!,^ M;^2E5_@SC#50<.UW_-<*#FR-JA`7!&']<.]L<:PN[ITW(!F7M'&;PU'X[%"R M&?Q?)%=27RB4)%T!< M*IS^5<7`'#KVICZ(1HIY=Y"#[;<6J.F^?7OVZOV'LX^7[Z](UWU[>7YQ=8/U M7<]^_'`A<25OO5)WKLJ^PSJ+1)[\#M0/#'NG9"]X'!_#U*,@"6J<)N>@J[S^ MRD/DI]JR60C-\*Z,&?89OSX8M'.T\(VM79@&]Z\"U0+RJ*2*T,R^$/8$+>.;O&,!R)SJYC"G2K@.N&2V+INK!>)?-Y2 MK",;2..R.$< M<\NR<&T`49R0T=Q-K#)<5TA!#I7%Z:Z**$!(@$[18ZXT=(-@J,J M;%2&+=\>H@V%/?/@>Z!F+G3+#_FUUB]DBZF"R^7XM[]/4:=R0GL&=8U/KL MQXOD$OBJJMNIX"3%'V3.O`(0!!V)#GP9=WFN^K0I^R_F(^*4R%D^HY.=S,&^/:/XZ\^!;I^&5CXU4.#0"Z<& MC-)Q6^1.V?[(*-U6?46+L[]>;&"OS8XF6X"$]0;I0K'+`JU4%B)]UI7X.2`U M!&\_!+?M-`]LUTT-[J%Y=VI<_R.$%=4R2'!BC882;Q5KB-6X[E?UKDK?)2D^ MSD#)%_(,39%^%$]/E;6G23JWDYV,W:WY331B6HC\5$6D!64>PY_C.^7,WRDT MQ6<-6\W=\-Q?%]G7N@!2*CTE0 M"J.VK'^!J,7'A99#UR4M,%*2!H/&=762)X7` MVNCY0I5!85Z+&K.NZ&H'O^%P>9)QFSQ'D*6S]KI9>?KHQ60ZY76S?II6V0/& MIO-5$6CGK`@>P&@.$L)R`G*%Y=F$WC)S?D&!,R39PHN[=;9L1991!5R7"(#G ME^&'U/;C:@69-0(8Z+3A*$4(X)(,@'VDB!)#)@@<+8*(-QS?18$2F`HL$W0% M$\@EJD+;@-@MU):DZY$U#9[?[##&G9[O$I?UE4Z8)TNND(X=P^MJ.J<2(0.) MB&B7*&%0WG&U1GF[IB3PT*VA$5$B!_V%Q(9)-=[K&QH:W45M6:M,`PL M3E1KB@\K>C&F;_E%K`C'9$4('0EL-<`;3`HJ6")SY5AP)9TERYXZ.A*P?:>I MP=];2KOWH3CG8&?T8E5*E3_E494X$?@K:)L1"E'\Q..TEAM]BSQUNZ7*@AG( M*BY:,7+G\3K$YB$@<'W"`QG%;0D:H#1L(I0:$+"+^,`=@J$WSE,?3*6U*^T) MP8$ZA8%\*CQE]-G<_PQO45IHL1PF*4(U.`LW@"9ZD M'#N=UK6R9-K*4G)`67J.BJ0E*@RT497-)>RD]N1,9D8]2^O9BM1`[V81M53" MMH,#TU3:WWUTL?C8X@T=3;Q:^P,"@1I?7[SZB$:[?\RV%+\4U%3KX]9ORXS] M%S>:2*5 M&#CA/I5I>_?(FLK;\GJ7)$/Y-9C&EH#P#%/3'PDA!5HEEU5E03L77VT8V^O6 M6XS#90+2H]4F&=Q&G,`M!ZI1QYE(-1$=`C=E)]#^C083O_%G#!]48LB6!=2U M=ID7P\'<3=/M`/1VC-TY2$ONQ7ARM'%:M@IHW85742;>PVS+39C..RVS@-\" MW_7MHB1K5EF!579@#(W+H7#`X^/!QL&"N=;0@4`"]!>4P;K)1(MO=CX$^C=8`;W2/HT706(+*X(XD+B?%& MP3L4V%3K@\1OSKU]!I\SMSFE%XGD#K0RF;[VA2SQ\H6WW#$1VN?J MK>G><="SHLDI`X-3LUME5=$I:VDIK`Y=J6#'S`;C8X7"BK M#%0L.EONV]90X@8VXU)L@6SV(?G(H3@TI>F<7>\'\T"+[B'!T5?T(I'3N,R+_ASVTC\9._D+@I'\(3DP2&4 M/(+Q:*H%M%C0RV4\L*=]'09F%1XJ:6H+[0`-RH7["G30L/74<<^RV5M4$"#RID(R7QF6T%E;E*`\&E+WT%"PEL MUXM6,*;)-)TN)N'Z)GWKFTJN7VL5W#*^F`].YWY1GEP#9#0^&U$B14Z9P901 MR=0-4S]CP"OI,'(F;XE(& MH\5W*2O_Z\WYGXHG+?M9B6J:`(QD4W\5D MA,\BT+IV,ONQ2X]4A]M=V<#:L)AC)SPV`-9B@4A4V=0YA(67X/NRQ`BB-L(2LC[>5ZW.9?#HS8QF-.C5T-9GS2@^LYTK0XH*?4CM&< MP;\-^M;6GT2WZA:FW97QE;>>6J46__3U1UT= M^U)[1%?9HY/L\'H.:W-A]"6&^=QQB-AD=I(.3RQMT%?3P=#)>YJ7.?():K(H M@`ST7=O>\6_-\+"*<$[-X)!^,&5%?2EVU]D+WFT3,_DFWN2+F^62$WH`D7R^ MO)RG`(C)!K8I>/+OA<$XU$\+0_+7O_Q'%.MD@L$K")=S,IC,S8_B#IF-9["X M"_CR9&HN1"Y<)4>CDW2QF"8OD_%@,C-2>PM_&$_2Q11_.`592/49ZB<>)Q+[ M&Q+>B04?F4ZGZ0C.BUW#@,C8+)(Q4!HN-)U_=T[B>,QQJ&9G+7)<(*9*#8RM MMZ4)*:.:>[0:C&R+AXZB-+`:%HI@%>%I=:NIQ92U*L1:NW)D9#`2G@"YJ5@*FM/1I48&,+_G MF2#:YH*0:F8#H)23P71$:>\GLR$0A)\>/IZ<`I^>3$Z3Q6`\!`J8#$'ZGDM& MO=[S<8I)_Q\?=&'UP@W'%8`*2SZ3SD0EX%!P,A:7ABU\@<;BE"[%T&A M*$3C>.2#.1LLX+])@KX+.&K^0:7.3H<#X-'?)5-8WP7^.QPL9OCO:`#<^#OS MH4>)'0WFI_#8"+@X_;,XX;^&\([K)]19-4PM_<>RE,6T%@'.VAU(%$+\_LC] M1J4LD"?NJ^10(\R#K9OIXN;ZFJLO80$G#.RC=PF/8U\%_E"&A?HL[B!\4H"4!4J.;E\> M'/-``T?S>4*(D;J#::5E<2JG')>5*/+SP\VGVF:GW>8N-J;P=@>'M.=J"5.' M^*(M&[N5W$,T1F$!<`GX++:RC"3ZB^L'WV/SM.TKDB[MCP6Y435?F&'&D8A> MT):7CONJH+0N5LKE;$.R>3E,(,8[XA9)R<>O<:L\*J8?B46L`+&@:XRW;-5* MVJ/1-)T.$5)H/IB>BO3EGE(2]HCBKE_R8[&^6J(V@X;;=J_@,G3\][7P:%&1 MCU]UJUYWBL\\L91A+@0=V4P'$:$X3MDN=@SNGD";YU)WK?+3^<[7?$'II2(O ML5005CTUKKRDR`ZZ`U\L^<(G5G=BS8T5-X@QGLR4[V0\>6;8>]NRI66@3G!+ M$A9--_&BZ=:,%HEN2)2>![$E.D@0Q6J+'R-JLA'KXKP.;<.V621SN<3D)%FNX,.E_:YTVH+G7DIJ/Q"XRA]:7=);0Q+ MO0O96U.TT#*'!VK5F8$ED'O[[>]`Q?UZ0O!Y"ZX`E$M4"T^12^'_G>*M%D_G M6)PFXU$RFLR3\=C<9#:EBN]<;`M^`4%Z#FW\Z$]1TCI%X\DX.3U-IA-H:CHS M0$8CHH[)"0T!:]",%C,3%:0J28$.@MU?3`8G3F3"H$PB.YU2%6Q(P(?\=CCK M#IQ[O,?NI7PLQNJC0_IJYZG&N436RC>":3?(V^OC7+/&.?=;1>%-6(.> MX(6]4\DGD865O\G7-A@;NN8[9OA7`AN`U&YA+Y[SS$'C^FB0O/IT@6\,YTZBEY,M8D^YE-7MU+6*MW;R^YJKHRAZN` MZ,MW_\*!51F>]\],$80^IBF7LZ5MP#$"TPI2QS;_XC/V&9*6G(SY>LW*W*K< M`A-Y?75&O2WOX!,%8*LT?WL)K8KL?EL2L#E6WFH\8)3#D"#RQ)!"G#`ZZ_Z8 M"WA>`9/;4D8K53:HQ959$Z*B=FWAO:BG1D(N3",E`BRVGS-*B**T'4Z0R1WP MT%**)E*53EH38G=UN<98E@I5IMCH@@!`X_8#)7-8?H?]WK[`?4NR,J`7U+I< MAST\,OTJDZT(6[FV8^+-W#VMA>C$SC[E@%*9J88:5_,)5T8/7A9_?!# M<@J7]&0^/1#W`9('GH0?XS7X@KR\I^"TT&H6`S,%#F"C4*O&XY-T,=5^,DG//CP?6^D= M3_'=GK"#7?@::?,2\,:4>=9)V#?>+>5>!"_ M:Z.&_&D<8`*36F&[M.;:D<>-J^7H;,.E/8M^*UK/V_**-AH[M`;'VPJB=UHA M^:'O2DFA=GZ14TC#`@C-2K2%$.)*/.;"^QM)8NXRK!1WD9<5H@ER!MXX/ M,?ZGFT4\J*BH)>C'W`L$U*U0R4<=I>C`8C]52WM@4'1KPXG4^B M`?W,6WLB42RGU4[.#AXL%X+#ZO&P7BND3"I,UG!):9LKJZ%N@SL=.96[$!WU M)W'J%R$"#XH$9,H87)Q^"_3>0CH&R4BQL:(!R^86=7P8=##I!`\,R47_B4E$ M=7.L]R.NY@2*M.DJTHP)V7:=M5!\6MVK'UU6)N&.;#$0[6WP9!W$6EEG' M"S_FF74XW+"J"7E?>R:'(OT]+&&M2N-2?`6P>UT_"@-=).E9?8O!'XABBDR" M+%4-R^JA97G"&^WA`=R@3'Q0OE0A1>A6$O!`\HQH2A8)Q&"M<6>L0&EFFZ/X MDU4%15*O"%;I,QW8+[[J%O5@,ZX,3@.G9D'$`A`\5Q":X6CD&'L83>%75MMP M-E<[-1?Y0-VY'&NZSP;)&X8.V93HA!)SN&R8!LCW];T=TIJ$<4I`@-"(87E/ MBUXT)%Y;&"WLG(RYT(X)W`77]F2S5B)=;3@6ICC=+Q82'E-5\]9F^-< ME2E(IJSD30Q&,^EG&:$1HFOHQ;`HE1T4Y#9.U+U;CS-6VQXMT[@E2AJ M!P)+!`"W"M89P+S2>&Z,VX+3B/4L$83L/@A;YF98MQ_0QN=!:Z`!!6[S. M2$[Q<\;LX(X9'9;CX^_)[5?7WSM,",F3Y MF5U9:A['#H['PJN!L#`WV@<&7W@+#^%\5NRGN"TQG]GC8"G%R3P?+B<0WDR@ M:NLQ!ZXYT1:48>1LDMP M$+A6WK4KL(B<12+7'$S)/Z;8Y.]1&L-_X&LFX^!=? MI10Y90)1G1%)\!$]`?/>6_)IE:'C4_)#3SR]^>1+J0(B-1HIR]W2",:[MJ>J M-?\.M,]90[Q'W!C.5\%69Z<&&QNR0"+IV<=W879L*H`'&=:9@75I_GR/!$$6 M&`>01;`*]`0M&?O*I602"S54K]0;+)"X`PVQ@S3;R;25S!<4:>!.0,$"[^?1 MJ6,G>*%3N.7.QV^V)B1>AJ"%DYEBBV(JLBUH8AC8-;#3H;67*:%?'[->^?+> M83!D8^M09E^2%79O2+;*55W1+5'%U=G-Z[-_-C^NRUN8,-,(41CA-J"L MJ=);JXQZL+6]Y';H#?YB99V>8A]H9E_=9#]A5J>L).G2CCK4+@0369.L6["4>3]04[2@X39%/L`O5G7QGD^KN*Q(7;?B) M?,M+ZPR(F2=O`K61F0.A4_H`.WI(_0_BBUOTV6&E[[6`?G0-X@(*Y"_;CWW( M&?>8+3 M*-T-;E&&=.]NY#E:^^BF)]NUK#*$<*0C./U++-W@LY=XX:9IXF5D4`XDQM)' M%-EX+R<51TRR07^&^F-;7^9V+.VSGK<3$XPDU!V89!J$HZJT2*.JWM&:8:F` MENE917VK64KUVNLG#$1H787X`#EG9`U]*\>H\S#*='BMW7N M6DX*(M;W!6XOV`@A]M!2ZY,1U64@=9:X&_L@A>F.AH/AL)W123>X":(%PU=# M+N.\TVYPN%\V/;%.+`8AWP^L6TT\.(5%I9F<>L5F8,Y(!@<1>K\4+Y+T[23N MGKH:W/J)<:UOJ8BBS*6%XR,]SP8SCS9A<_1,:";GY*0LL/P?\@W!*]L6_PNL M^_-T.%U0H9PX"4G:H>DK7(G<+-?HK4*F'8PVL74)K(*NU3-3""&MT=5WNXPFA6NSV(WH("C$N[0C5);M-QG/<1Y M!TMQVG()FRZ>ZF&6Z8U0D'9V MS0H#`[HY_4?2:3A\4[ M]*6QHW>6VX!2E73B4)5(VA6'H\8W%=8O=>QQ!_<'1_#X@(G4"TDH#;BR2W4: M.+JW#&_(,U=UYM4+:GW$>,Z1&QE[O+23HN.2CBZXK==GEU'"0`T52>LM;>V, MA"LLFVMM+'(&3'R11&[/)#3Y%O0D9R&W\6G,"4PH<6CRL,20!,1@70YH]X_V M/DC>.[NZM:I&K4KF$'394VX+$W4FW.;>>FG[Y)Q$KA[8P8L9_`+^HG$-XRM8 M/Y!;A8*V,D&-WOYQOVT5O+']]?4B?(5[XI.-ISIOR+9J]"3S&)C)(:?;&9^U M#US<"T9%YJ'1\/B?Q)14VLAMP42;*1/1Q7F'TW]B(>E"HBPZ6E?[=UI_9@_. MA/GL'2!WM,-J]>R<"-7A&JA@JJ8DG=P%Q_`FJN0A.?-B?7^PI=?Q/F!QG;1? M"5^BTC&^SJS$7ZG<=.4&]^\DK7=,7S<>>GR["HHF-=K$;IZFTI"^B8"H7&8& M0L_VOL0OB1>G>JER+H>./38^=ZL56(:%KE1`(SHCK)]*PA25WX&]XS8EL'8Y M@7;*L"AKT=9\D`[!%.UL+0Z0([%@DF%'!368M]*PV10LE9R)63E0?ZY6C&]_ M[GG95CIFTQ52D`3L8_';HEH=8Z[*HQT&U:YK.A$0W:\182?NC[6?0Z(S#+:O>?-D\ZK4.F*QP%B_PK1;(4J]X;YR[NBM0R3G]Y1, MX9S>`12@('64EZ4]Q)7=8GQ(L0K$*@M^LP3UB$M"^T>*`^QQ4=FYT'RQK`5Q MMESCIV"RJY3_UN6:L:O[LERQ*1]T#::_S>X:B]D75T+/")0'EZEW2#N;1;1FZ'UD^"C$=S`F4.L-28Q.\/UGH(2-"8,#`TO M2'./!HPM^PAL\7(F`OO]<;U#ARW2'4'6$P?S87]FE^TP[!I?LG#>M]GV)Z#D M'6CBC9MC5T'0RTS:)<5>P^!]'*PU1C04;A&^6C1[A0-+3V*Y^DH#,KM0\;H= MGM4*H,-5Y>?4YMT%%&'[0YF3X/-ERZVMH(OP_W57"I"FI@Z1O=K80=8&T-.I MLS\UHFC8R])A!I>Q@LOBC1*1N*#@-CSSZ(O:UA27S-7!!NTJB>2DT,7$U!3H M"B9';9>`%=I?H*=8<4!0Z>F[H$*!V>GJ>+9F$S"Q9:;J7)%8A\0F0@)"-##9 M12[F_MJ47>0]@?D-\T-FP^^HL^GI=VUT8Y4'8^O>?"$7EIKS.ZS_11:ZJU(4 MZT MZ;W,ZL,ST1,Q;B*)3"369`QON3OR[F6!3.[",[FG?C?G;:ZH#C:H8U5#DD!* ME3!@;=8%/+K2G,!P4?NJN"^VY)INK.F&;GH%N0W;0[4%G$'Y9T3@`N;'PIZ39>3\WWRD"^Y`+WEKQV;?"`+O'6R`&(VY-T%?.+Q@#V$ M*H$7,ZS$0L!"K*27!'QN@!/6),4I"85!SCD2`L5S,H4Q8)BN'&*DI5PB!:J* MM!=O$B4(F#IGQ9^+K!)7Q'1?O%&#H:.%5R(E67MNM^@\G3(7)YA*B#U:IF$7 MQ%">R\U^1ZEW.F`*,[#)F"AJ`R$.49N#Y(;-`8CDZY>#W,ZIBU>4;REFCZM* MWKIX^E58%UUXNIM(('7STN!B&/D]_0ABEKX*?Q!;>-G MM5;"@`%_>"#+'V\4Q:2Z^;2\:J*JN8F)#Z&L@)=@CC^"KF("%XIJ,H3"QO`$ M?A9:"#MP!HL#"0#A`FN;[!#6G@G@5ZPQCM!S@CERPUCQD%B`17E1U%KY=62O M/C\K2VC#35@W2V)6< M^JM?W'.N9F&USP,S52`?J<4TB"O)2XP&<;Q>U84I$GJ\["S`G6QS(EA"Q4A8?HKJA_8'.:J].)[->525&9 M\$#%Z"3*5S\DWEZ&,.$%DM!7?M@9,V`?N'XH6<>D.HUC:CC1K"[QL4%T.+*Y+/3.JMO)1)%-$IB]>3-?WBL@:5EXN>A M2??US5DC7=U%['2110FJ7!J[*);G4"$/OLVZRX"`+LU#,!3CA^)D"L_K:!2> MSV%(8N52B5ND8;%T,$H7^=Y]KB&.=)UI*JAI?+/6$85N\?P+-K1#1$>;(X5!#-**K=[AN#S6%0798(1]?G2%A=`!?NG);9;4V(>'1?A;T'1=/KO>2D M=%8D;6\!7("<^N).Z&UN#VE2NX*B2('PG*YO)F('1Z):\BX4#QN82X[V&&R/UKL-)*X%$A(ME]=/<%\B$W;MBN."&E:0F^TBQG] M=\HGDASPB9#('_>+&&OW(&?F1I#&E>)&"DK-P@J1CC4-P;4DV;6^DN2*8;HL M]CY?\37&DZ%3/J.0QC01Q8:G28\:.L%DOX%NCFVQR%24%2S^:^'+B"^C/UV= MT.4Z*S8&+C\0;&`J%]VI(H4PMZ(!JO0:6P]RASR1*\C=.6/0Z\CZ^H5DD8=N M%Z0"$_3FK&P9X^"ZG>-P.]IY6]_4AYL4E/)7%1Q:VU.E^IGH3.YR8CV9P^9: M/C97J9`0HHE4*JX_@AAAUEG5*M]+002:\#F*/J183E,IN\70;#5GSY4HJHCJ MKR./#AF;M9#4=O*:7EV67L*IPQP:@YDM/B/,;IH6Q::S$NVPXCL+$%X>#X>B;0Q1`^LF^YE8MX2@);S[/7"`JFXZVGEH\ MF'WM`'%8-1$$:&PV)?*CE.15VY0J'"HHD*:S9+L>DG;QM;=2?*U']'WRA4`8 MMN8.)0OC:'M+OAEOG<>Z,GV%X90-'WF5"`NF57*G79DV9160]%X7IM*2G6]M"0]>XU9?#W=Q0 MF%I>>VTAI$ML9.M8D25IUDZ\I-H*"C$V]9,$0Y?XTQ4OPE;Y+;ROUFAA0*$W M#*Y8N9Q2I`*_6Z'9#Q8-:*JN18SEBCI*+](>1L?5/)/U=PGRV">[QE.)7=J[ M@R^&"(]A$[MHS4_\W($4LYF?"EM@EQM2]0/'JWGA$;46=?B]`15GYQ7E+SQ MD&_CR@J/0>0DUBY004(]V@2J'$=/MPA'56SG6K^N$ZS8\AFE76^PQ-0TCF@2 M,,+2?L*D&;*1(I)8J*^1(A9*`4E,3U&K2@1J!'F#3M$@^>#+S9,I4FKTZAT- ML=PS$\Y+3I@M7]O>$'W-<A#6"BM'?Q] M=G.>++`H=OR-'U5,#'JVT'D`VJIXO>`*!#9*!LQ.G(U%F#$]`3>5-7N(WUM' M\'`F*)?<$#B_BKW%=Q4G$F,P[)WVH6G'6:(<9UEC7%P/.^>>FH(-&:#QB!01 MF.%=>[D/>5)@#9Q@CVF%E)7YF8$%_H3)-/*%,N2W3$NMZ"[;$T<8$D1=*2$P MVN,57K(BCM?!$$1IM:!VY//"%<3&ZG)MPR\Y^K=H^\D0<)B6?UW\A/YTP,>S6=7A^DT.S!0>/KR/T,O1>, MC[7U--P4>S@+!:!JV&'*%X"<;S:FT]0C0&J8PNVQM26DD->HY76517+45(@+ MT='=I;@)0N^F;JOE"0N45/&=.C[&O-+&/B9^KR$M8G^ M]K&4W2A6=IQ%CW_J,L%#IY!#_9&(`#:5\F7.M5,P:2E@G%\(+I:,(!X]@I'M MR+[>ZX#2XC>[/RD(BV)">'UD\96C6,1WO(&FBV&:O.;,%*R7C'-[JX+$25!@ MU&_S43F4EU$9BNTL:@JUV!)(Q"24;2U1]T->.*D41(8H.HX+<.0P"`O24HGL MRQ!)3Z%^E=UDD58\38#L$:T8)P*WQD)_[G.!*6-?2W!(K"Q)$I0E(>C]2$45 M`9$@6]P;:UM`S%*V&.GN#@6/)V_4@^&0`GN*Z MY0,37;IN82A?OU?AL^/71BE%AVO?"GZ9#]$5_Z&QI@1M8.&U&22V,+J_?B^\FHCB*<\_Z)^#:YA^]/K,*[O,@48PN.*YTD?:L"V=9NIF:;L:Z M'%$ODQ`A(/0.NZ"#TAJPJ<$(8D'CIO%=!V5&@K-`3M M&[K.&1%9F2"C>D3++H-A4&B_,4=R;K'0%.Q?3H@!JIS,>;-8X]Q=2?- M461A'3C`\Z!.G&0GV]Y3_W-+ONLI8PYW51#\1U!$U"?[?&C+;;EL&9:V+8+B MDZT?*;D>'K!N#+9^D'/$)T@XQZI-UK,"$D?)-S%1!KU-2LJ*%6IO?&7YB*M@ M`Z<*%%R*=WL+NN333W@<4P$H4;_SUU7N;[#GX]Q\R-&LF9QY3GY=E5OXO,RC M`<=//8]7Q;OL48'>^*!D]=*-E"07L"C2)=ZIM8GR[>*K20JTO`Y55G'JGLPL#/0,=8*,A![=+W=?*)?CH>3%)YE8OSK M7_X#M/Y]XVP']H?DZ&9_VY2[8IDL)K/CR?#E]^:&!/F[1WNV-(@'`QO<*E0^ M,O\_?U`S'),8%FH85F"8I5`M'"N.#BC_&'/,;\J[Y@M"\/JA3F;#X^GP)4%M MJ*9M.6DX+OBM@\EW=SJZ3^PZ8M#3GG(8V)^`8$9[ILB]R&K.%&`\NGA2RW"L M<9PL13_[;67OLB.S6`/";1TP0/O5)%\'>._:=*&".GQ!K1!9FW.`VHW6\>D$ ML:M=_(GXM-R,3'=&G1&3T\4[Z)CV_68:6]?`0Y!QU4"RBPE[T.X[B[IB.8?' MLV:<49>PA.3*52`OJ#0*E/1B$<:*@;$AC=\XX?;RDGF_W.*XE0-'8GO0RH1&D'MI/Z MF`.-%RI%_R4'@)@G5I+\(S MYZ_#)H+'\%S&USCI.$JTOY7Y#@Z`-]/G*_FELY/0HA]&5%F;BK&68&_DMD$! M1+[PM>*+9-]MZBBT3^I*!SAB^1HDHX6,X)P7YR<$"A\ M.IV=,*;[=`P?S-EJ];V7.(,Z=:PO'P9C,.2[N"?Y=*L.<2B+4T8LT[%O^3!" MFH%+'#BKL74TN]-K`YQKY4KJ"[>6@*K#=9?@=;XM"<(!E_$/[6K2H@_M;1HW M44XN)!(E"Z?FT9Z/1BG(1>D4#M$H'8Y@..,%?3F>IJ>G$_IRG)[,3\T%!Q5A MT(T"&R`*Q)6K'7#8]^8B:NRE-9LL1NETXLN4GO?;2.CY63J9S=+Q8NC>N'EZ M7Q:GZGDY.T]F\9]FZE.%K+L1_6\9J'U"]@S$3 MQA#K;-,7TSE3"GP:2PF%)]L+*BBX%D>36(MMWG6M=OZUW7D%&7<11('^8N;X M!*$IU#8;?LJ%<)[!%E,7O2*V(Z)NXWR6>+?9+G_-"I4W<6!/91S1X([6TCM* M9R#&C6;39#H_34?SB?KF='B23D:+;VQ9/^.-#[.3>3H\G2>+<3HZ';;^?$8/ M?!QKAYS>/M&V(S[:TU$Z'TV"ST\>;OM?,IY,8-JCIQB(>]X!8^K"UJI`M2UH MS!S$?Y9"K\&,=9K\.!T/I^EP-L0S?SI.3^=S]=U)NH"FYK/Q@7S@=]X65O=* M('WYPV<>@4?[8=\Y*_L6M&Z+&$BPE<^01Q*;(R_R2!?**`X@V(,I(BW$XJO#-4VP+_]^0I<%^C>=Y.&W] MV06>^*^<)];K.6W/D[[\.?.$`W$RM?^VYDI'I/5GMQP%EDZG=`UKC0%R.?=EZ^.T.?%/_XL?D]O4CY`FTX+W;%6)37_C3`IC,YY@,5!^R?Q MEBDRO?')B?F0?4G>N;CUR6*13(>G_73F7WK6>J=78'ZONP]QKK+N-U5=[E!+N,D0CHW0=F M.>*5G!C,49#(>!U,3\]-%I,$Q4([472WNP0AYE+,]D>C$SA9M?_J@O?)2+A:T"E][*]8VGRI9+UZW:8D_*=O:]X7$[C=6R#N`+4?X$GQ=X MCR8G@\G<_"BH_L"*@5DMX$O@6!=2$&`%W`C$T06PS60\F,R,Q*O@#^,)K"7^ M<#H8SE6?(:OR.@?V-^SPJ,XJULE[I7(PGC@-AI;G]XP@55;PK0_YP6\[Q5:D MM;+56JY:HQN3%,+/KEW4L;OA1#%QLR+FS!M8?X^&JUN.+K4[D9R)[<`N9W)- M87"=WS\X;^.Y\C:^+>[@E<3I3>0%#IIIU3 MX^C.SN9,H>5\$G-)J(J04GC\BB*9<9V/)%%A&&(0<8:;6,SC<1#SJ#SG[E2:+VT[D,("^C5U_(O`Q8[<_I$W M?C98P'^39#X8XE;Z!Y6S?3HU?DR2QX$#_288P)WU MH1Q.(->-[Q:UP"3YC&C<3&]0!SZ-ZN=NZ6;XY& MTW0ZQ#ME/IB>RO%S3RE^"5<.//:2'XOUU6*<;$Z0=CNKO`0Y"8N)^5E>^FI` M9SYF^H+OR=C58\MS^?=4K+6[7RD22/.Y&_%'7G-J5N0(=#9`AD9K+07L?N^* M(K$7!==:`C6<0A`R#>1S'SV?&" MFPEG&P_3\2EQQ?&A:TE6D"]T@5IUQFI!G.X1,IMXU7] M7A5;`K*/RHY:GHX73+9.N,##0:FCI0^=9G"8;1A*+1S3`GYD:H!L!"M;`U0$ MT)%$?ST>V$Z;A;L+;YU3/`/X?Z=HAHMG4H/8.1XEH\D\&8_-C0,>8%L%M@6_ M`!^=0QL_]F<$C"?CY/0TF8(2,9K.#!#2B.ACO]2H#JXO M]^T3$&QUB4C:WT%#PW^7_/[ODM__7?+[.26_#U9E/$[.?&$UI;HE1Z^Q).^Z M\_;9_G[@"JO5T4J,_[A?#URMN$\WKY.C%R]?)+^5^_?`.T.1.:(_6KN:--A] M9CMP]Y\\<^X0--`(4-_D%#AYZ,UI3^L\Z[#U0YQ.E'Q9Y52RO9)_>XLA*Y<8 MLM*I%>R%B!#XPV,&E&O.,/GWI#6Q_J;\^:AY\O!RSS)HLZ0JMB="DZZ@IZOG MZ:)X?TOV$U=&S^KS_Y[$M_R3*EF7]):LBT6FA.7Q"C7PL`!A4O84.N3*N'=4 M&9=BJ/KVV_S-W^".=];J^GWR;^](4.[LXWG@]@M$3AHNOMNW)-?1@H(^^.3? M$W^..N^&BQ)?B%BYP.>O_?MV(<">N;/0U[=`-\&:4,:7\62G*KFK-?N,&KJM8,,H:\;,"CHHA[Q3-SZ@/0BX%HC& M_IOH.`EJ@A![525!^BZJT3BXCSLCLU!$-MY:T9,-LVYU3-UILH-#=HCL8F\? MN`#"QS&7(%4`))WI8?70[_XK9B4U`GJG-8OV/#V-?7MFDT4^^-(!>DB\C[]L MF7^5/IZ:]#0ZZ9-%=!-^!:*W5`U/](D;TLO[IWLY2'7MD@8"^/R8ZC#<)]_Z MUK(,R2\NR^#2G:(E$Y9-`-(7#4VV5M/^]T-PP6]LANX(>[=*$JE(*CY!S+G$ M4NL%^J7-(*)>3U,87M8?5G:5;5S>T%7^I3_?1+R,_D5(#]CR_.MD)\6E?_G0GX>L*9_4]3[.82_+`8\^?DQX(=;CB[QM\:`=UFBC_;N]<[] M_.#OP,K2;O_Y$=Z=-Z,!WX>4AU:H9D0E>O["_^+X[B=7YOF!VC_K31G8MYW9 M7ST66Q_DN*)ZIH*B^[MJ,1.X"I'IJMOYH-#FIA6-^`YAAO6&RNK*6GL6^HPS MF'+4VS>0ZU,&@&\,[_YU6@N><2'=/[_M)X*YG^Y"!5JSUDT707*$7JB7O6_U M148?)[]>#+0F=?^34YKT17;HSHK7*>N&UG:$U?Y0L][@7AB4#^]]_MIUWA[_ MHK.,RR*&MTWKEIVUYBV$IQ"(N&;Y`S?<`LWKE/$H2,W7(\AP- MB.V7\&/QI9$D_X/AKW\KP:^=^YHY1L^@G[TV:1!/?&TQ.C3CO'9,XPG+Z?/[ MC,8M?_!"6R`[Z+$0YL>O,``53WT>A+_[X7S[(?E&7U7@$VKY3'HN[UTU2$8G M!WU!VAO5_\R3WJ@#LWY_9]GU61^[?K_%,(P.RSYT#C\*W+NOFB&L,I4/8[X= MA(<@Y.P]AS0K:$G)I'^.\TH@GQEPT;[?*M>VO'M]=29U%KTK^DD'U]&/H*F\ M9$7PF5S@(A:)CLB8MMZX4F[63UP]$86H_=R/HDKU/W&Y7N]1B4E1QAST'[D^ M(7\'XD91UZBWDY.!_2E=H\5F_RX'">/K$_V\*T`%;-#X<,#LA\K^QCUHT1BR MY4.1$UIHD,'A-A03&F:@R?\L3V91S=%IZ&$@IU.$_E682Q,%ND(.3I? MI+,I8=I(Q(%R(%6$#5_/3`KY]FEUDC5VV:;KO1?+A^ZPOMS MVX^Q=1MML'4RSRI[M"B0N#UW6&\A1X@O!\%-G)T6\S'IX>_3&;7SLX>*#C?. MJ[+?=?E2`IO4<'RWAS1SR,(:@X@*`SZG8W;DT2HSX#:P6*R!:HWQK@R&50() MC9&EYQ&:ZLO]_4,8+!<.2VK8(;YA]B@@2[9F^(MQNAB?8,(Z(=3Z$9=2?-)7 M9%KM7(T_WESRVC$".K,("+;;P1PX;](-QVX= MH5,B-T(';W+'P;7!L%D6E]+/%@?++@&2BD5M9C&X2PM=-$59^+Z;Z>F3W"MJ M7B-58RE*-X/N'18O6D>H5KZ6W#?;!.B:&BV>K;T_)]YT>Z8AZ"2SXWC9]TBB:A4CGN"F/Y1$L&H>%7)G;7ER<)50[ M5G+*?.B(%+?VR@86Z;-M((M2!MQ%\030OH.Z34BNH/L#4=UOU6Q!FJTW3XZD0G,<_MJ M0%*JJ3N3G3.P07[_9^?KVG?7JSL"'7M0'BCPV#=MNRD4&]&S&Q_ZZT[&)&JG M^T;M2^(JJLNUS>E0ZGC/"M>=X(\6(&8?1[9!$T_]+F3$-T+^W3`5H>SHOJQVIA7"DX/9*?@<+0)[,`U:&H*Q+``!:NNJ2,?Y@*892 M1N6D(K/S%P)EPP;<8C1L,X'`Z//_]79MO6W=,/BOG(<-Z(.3SG8NSLN`=-FZ M#@L0H/X#I['=&G/MPG::]-]/O$BBCDCIV`[ZM,XYNE,DQD`Y79I5E(_-2*VXEQ952HYTEWT%0RS:1S3,J8K/D#N!7K5/!WF!_"VKYC->,K M)AJ,=W,$A0Y4]Z[@RLS3+Y*\U;&Y5N!LOFI_$'<2&OY54YW!;YT9R`E`01E8 M59)?+G#"96F#X$_P-8#7E/.#E9-#$4[OAL!<7=[Q3Y'M(E'>FGSR(=C9W;MH MC4(3XWW;[,#4P.\.R5=<)OE#E"SJ_#"D6PEKV+NEXW96RCIT(SF%'9=S3++ZDB)5E1`J<9G@,C64@+"_2P'C`@@A-WS$5"_EVQ@)#<[Q;H^VLGG01!X3$"3`41[+U8 ME\D7S?D:=O]3)E8Y0"(A]D[,U<#P-_5J&BC4:+UKIDED1H\D-@V59*O(D?'- M^62LNNVZ-3902\V4`_!D>'JHB2WG7@]&*A.@A+P+EF MFK**FW6`*GM,[#=J)%:&]#V4]/38(.K35*F5F#SU'&^7WR58'D7M&2,B.)`O M,'1=.&77KQN3G$H%'_GYF9!GU&4U6FUVMPI8Q"WZJCGS2@GO::CZA`J*'&68*\^%*@51%%N4^IF%P=&"` M8,H\4P83DDO4%V2D!:%IF%/BTUM4B\1E:"PNLBWB!DMDECOL^.IYF8[Q/RS1 M(8Z@`3\6FKPREZT0VCLU.!AK)=H2]$+3)GOL!^3M2R@=J!.D!@Y3;&CG3Y5= MC2P/MA6/5)]B@OH3)6:?D_/IWJ@,_?GQX4$)!!#YZQ)'-IY8;EX/+I.@E')9 M.I%$3^XQUP,7C_$:KW!4^6<0U!I'"EEH7*U$9!,U%,22%(=C*4HIN0Q0TA3XDF:)?UENH]ZBZ M[_I\>I!(>7I9!W5T36LNUZR`7'@&,YJH"LA10];6<<.#CX/VHP]N(H-:JRHT MJ,VIT%2E`>ORO`IFJ.G3MK`TC==D)W%5?+0V0VKNQ)766'E!9\H2 MP'SF2!,C[5F+$*#YKP`(FOT*,*#*C]?:EY-K[RZ=$$93PCG22!6JP,5T3$2NU[$LP2'Y.'Z,O0`GF;T MJ/@>"&WS+T3;S#S.)HRGM5>I;3U;F9]_;/YVM]O__C]02P$"%`,4````"`!P M=PQ'O$LLP-X!``"`'0``$P``````````````@`$`````6T-O;G1E;G1?5'EP M97-=+GAM;%!+`0(4`Q0````(`'!W#$=(=07NQ0```"L"```+```````````` M``"``0\"``!?&UL4$L!`A0#%`````@`<'<,1Y4V80H_`0``:0,` M`!$``````````````(`!,0@``&1O8U!R;W!S+V-O&UL4$L!`A0#%``` M``@`<'<,1YE&PO$V/=% M+`0``)@/```/``````````````"``9<2``!X;"]W;W)K8F]O:RYX;6Q02P$" M%`,4````"`!P=PQ'O4T;)TT"``#T!P``&```````````````@`'P%@``>&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`<'<,1V\'K!D,!``` M;10``!@``````````````(`!&PO=V]R:W-H965T&UL4$L!`A0#%`````@`<'<,1_G);]8:!```)A0``!@````````````` M`(`!N"0``'AL+W=O*@``>&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`<'<,1PN/`%2C`0``L0,``!@``````````````(`!MRP``'AL+W=O.6)%YH@$``+$#```8 M``````````````"``9`N``!X;"]W;W)K&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`<'<,1Q"(<\^D`0``L0,``!D``````````````(`! M&S0``'AL+W=O&PO=V]R:W-H965T2K[1H@$``+$#```9```````` M``````"``&UL4$L!`A0#%``` M``@`<'<,1^$U\?BD`0``L0,``!D``````````````(`!ISD``'AL+W=O&PO=V]R:W-H965T'",W&UL4$L!`A0#%`````@`<'<,1^X)<9AQ M`@``NPD``!D``````````````(`!-3\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`<'<,1Y:[3SBF`0``L0,``!D````` M`````````(`!K44``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`<'<,1\MG#^"F`0``L0,``!D``````````````(`!A$L` M`'AL+W=O&PO=V]R:W-H965T%0``!X;"]W;W)K&UL4$L!`A0#%`````@` M<'<,1_/C-)`L`P``'@X``!D``````````````(`!75,``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`<'<,1_L/6^2O`@`` M00P``!D``````````````(`!6ET``'AL+W=O&PO=V]R:W-H965T# M./2I.`,``#D/```9``````````````"``8)C``!X;"]W;W)K&UL4$L!`A0#%`````@`<'<,1S2Q?@_-`0``P00``!D````````` M`````(`!\68``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`<'<,1W*J^4C\`P``"Q4``!D``````````````(`!_FT``'AL M+W=O&PO=V]R:W-H965T^=K$W6P,``*$/```9``````````````"` M`?)U``!X;"]W;W)K&UL4$L!`A0#%`````@`<'<, M1Q*>S_$C`@``Z`8``!D``````````````(`!A'D``'AL+W=O>P``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`<'<,1W.;)L(/`@``U`8` M`!D``````````````(`!M(```'AL+W=O&PO=V]R:W-H965T2"2$3 ML`(``,(*```9``````````````"``5:%``!X;"]W;W)K&UL4$L!`A0#%`````@`<'<,1[T+B[9@`P``B1```!D````````````` M`(`!/8@``'AL+W=O&PO=V]R:W-H965T M&-``!X;"]W;W)K&UL4$L!`A0# M%`````@`<'<,1UB2K>'P>0``3KL!`!0``````````````(`!()```'AL+W-H E87)E9%-T&UL4$L%!@`````X`#@`.@\``$(*`0`````` ` end XML 14 R46.htm IDEA: XBRL DOCUMENT v3.2.0.727

Business Combination - Schedule of Pro Forma Results of Operations (Detail) - Jun. 30, 2014 - ImmuMetrix, Inc. [Member] - USD ($)
$ / shares in Units, $ in Thousands

Total

Total

Business Acquisition [Line Items]

Net revenue $ 6,776 $ 12,700

Net loss $ (518) $ (2,288)

Net loss per common share - basic and diluted $ (0.51) $ (2.26)

X

- Definition
Business acquisition pro forma earnings per share basic and diluted.
+ References
No definition available.
+ Details

Name: cdna_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted

Namespace Prefix: cdna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionsProFormaRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=cdna_ImmumetrixIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 15 R33.htm IDEA: XBRL DOCUMENT v3.2.0.727

Inventories - Summary of Inventories (Detail) - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Inventory Disclosure [Abstract]

Finished Goods $ 343 $ 277

Raw Materials 388 409

Total Inventory $ 731 $ 686

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 R25.htm IDEA: XBRL DOCUMENT v3.2.0.727

Organization - Additional Information (Detail)
1 Months Ended 6 Months Ended

Aug. 13, 2014

shares

Jul. 22, 2014

USD ($)

$ / shares

shares

Jul. 01, 2014

Jul. 31, 2013

USD ($)

Jun. 30, 2015

USD ($)

CommercialTests

Segment

Jun. 30, 2014

USD ($)

Aug. 10, 2015

USD ($)

Schedule of Capitalization, Equity [Line Items]

Number of commercialized testing solution | CommercialTests 1

Number of operating segment | Segment 1

Issuance of additional shares pursuant to exercise of underwriters' overallotment option | shares 220,000

Underwriting discounts and commissions $ 0 $ 909,000

Net proceeds from issuance of initial public offering $ 467,000

Shelf filing date Aug. 10, 2015

IPO [Member]

Schedule of Capitalization, Equity [Line Items]

Common stock shares issued from IPO | shares 4,000,000

Public offering price per share | $ / shares $ 10.00

Underwriting discounts and commissions $ 3,000,000

Proceeds from initial public offering net of underwriting discounts and commissions 39,200,000

Offering expenses 3,700,000

Net proceeds from issuance of initial public offering $ 35,500,000

Common Stock [Member]

Schedule of Capitalization, Equity [Line Items]

Shares issued upon conversion | shares 6,048,220

Subsequent Event [Member] | Maximum [Member]

Schedule of Capitalization, Equity [Line Items]

Shelf filing maximum authorization amount $ 75,000,000

Convertible Subordinated Debt [Member]

Schedule of Capitalization, Equity [Line Items]

Shares issued upon conversion | shares 510,777

Convertible note principal amount $ 5,000,000

Amendment [Member]

Schedule of Capitalization, Equity [Line Items]

Reverse stock split, ratio 0.145985401

Reverse stock split 1 for 6.85

Reverse Stock Split effective date Jul. 14, 2014

X

- Definition
Number of Commercial Tests
+ References
No definition available.
+ Details

Name: cdna_NumberOfCommercialTests

Namespace Prefix: cdna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Sale of stock pursuant to exercise of underwriters over allotment option.
+ References
No definition available.
+ Details

Name: cdna_SaleOfStockPursuantToExerciseOfUnderwritersOverAllotmentOption

Namespace Prefix: cdna_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Shelf registration date of filing.
+ References
No definition available.
+ Details

Name: cdna_ShelfRegistrationDateOfFiling

Namespace Prefix: cdna_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Shelf registration statement authorization amount.
+ References
No definition available.
+ Details

Name: cdna_ShelfRegistrationStatementAuthorizationAmount

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Stockholders Equity Reverse Stock Split Effective Date
+ References
No definition available.
+ Details

Name: cdna_StockholdersEquityReverseStockSplitEffectiveDate

Namespace Prefix: cdna_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.14)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_NoninterestExpenseOfferingCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCapitalizationEquityLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Stock Split

-URI http://asc.fasb.org/extlink&oid=6525746

+ Details

Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityReverseStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=cdna_AmendmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R42.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock Incentive Plans - Summary of Unvested RSU Activity (Detail) - 6 months ended Jun. 30, 2015 - Restricted Stock Units (RSUs) [Member] - $ / shares

Total

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of Shares, Unvested beginning balance 0

Number of Shares, Granted 114,400

Number of Shares, Vested 0

Number of Shares, Forfeited (1,600)

Number of Shares, Unvested ending balance 112,800

Weighted Average Grant- Date Fair Value, Unvested beginning balance $ 0

Weighted Average Grant- Date Fair Value, Granted 6.49

Weighted Average Grant- Date Fair Value, Vested 0

Weighted Average Grant- Date Fair Value, Forfeited 6.49

Weighted Average Grant- Date Fair Value, Unvested ending balance $ 6.49

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R37.htm IDEA: XBRL DOCUMENT v3.2.0.727

Debt - Additional Information (Detail) - USD ($)
6 Months Ended

Jan. 30, 2015

Jun. 30, 2015

Dec. 31, 2014

Debt Instrument [Line Items]

Aggregate principal amount $ 20,000,000

Interest rate, description Draw A and Draw B each bear interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the lender.

Interest rate basis spread 2.00%

Loan agreement initiation date Jan. 30, 2015

Maturity date of term loan facility Dec. 01, 2018

Principal pay-down of loan begins date Jan. 01, 2016

Deferred principal amortization description Principal pay-down of the loan begins on January 1, 2016 with the loan being payable in 36 equal monthly installments. The principal pay-down of the loan may be delayed to July 1, 2016 with the loan being payable in 30 equal monthly installments, if on December 31, 2015, the Company has achieved certain net product revenue milestones as described in the Loan Agreement.

Debt discount and issuance liability component, current $ 176,000 $ 76,000

Debt discount and issuance liability component, non-current $ 214,000 $ 11,000

Prepayment penalty on loan 0.00%

Loan agreement description The Company agreed to issue to the lender detachable warrants to purchase shares of the Company's common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche.

Estimated fair value of warrants $ 90,000

Default interest rate description Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.

Default interest rate percentage 5.00%

Interest Expense [Member]

Debt Instrument [Line Items]

Loss on extinguishment of debt $ 600,000

Common Stock [Member]

Debt Instrument [Line Items]

Warrant to purchase of common stock, shares 34,483

Warrant to purchase of common stock, per share $ 6.96

Warrants To Purchase Common Stock [Member]

Debt Instrument [Line Items]

Expected volatility rate 39.83%

Contractual term of years 5 years

Risk-free interest rate 1.18%

Underlying common stock price $ 7.06

Dividend yield 0.00%

Draw A [Member]

Debt Instrument [Line Items]

Loan agreement, amount borrowed $ 16,000,000

Pay-off of term debt 11,300,000

Non-refundable commitment fee 160,000

Draw B [Member]

Debt Instrument [Line Items]

Loan agreement, amount available to borrow $ 4,000,000

Non-refundable commitment fee $ 40,000

X

- Definition
Debt Issuance And Discount Component Of Recognized Debt Liability Current
+ References
No definition available.
+ Details

Name: cdna_DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Debt Issuance And Discount Component Of Recognized Debt Liability Non Current
+ References
No definition available.
+ Details

Name: cdna_DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Estimated fair value of warrants.
+ References
No definition available.
+ Details

Name: cdna_EstimatedFairValueOfWarrants

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage of default interest payment.
+ References
No definition available.
+ Details

Name: cdna_PercentageOfDefaultInterestPayment

Namespace Prefix: cdna_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Prepayment penalty.
+ References
No definition available.
+ Details

Name: cdna_PrepaymentPenalty

Namespace Prefix: cdna_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Percentage points added to the reference rate to compute the variable rate on the debt instrument.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Date the debt agreement requires the first payment to be made, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentDateOfFirstRequiredPayment1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_DebtInstrumentDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentDescriptionOfVariableRateBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the fee that accompanies borrowing money under the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentFeeAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Description of the frequency of periodic payments (monthly, quarterly, annual).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentFrequencyOfPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Discussion of the facts and amounts pertaining to each failure to comply with an affirmative or negative covenant of a long-term debt instrument, including violating payment terms or an inability to meet certain minimum financial requirements or achieve or maintain certain financial ratios. The discussion would generally be expected to also include whether or not the failure can and will be overcome and a description of the terms of any waivers, including the amount of the waiver and the period of time covered by the waiver, and if reclassification of long-term debt to current has been made in the current balance sheet.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(c))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Agreed upon price for the exchange of the underlying asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Risk-free interest rate assumption used in valuing an instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Date the credit facility first became available, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LineOfCreditFacilityInitiationDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
No definition available.
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=cdna_WarrantsToPurchaseCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=cdna_TrancheATermLoanFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=cdna_TrancheBTermLoanFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R47.htm IDEA: XBRL DOCUMENT v3.2.0.727

Subsequent Event - Additional Information (Detail) - USD ($)
6 Months Ended

Aug. 10, 2015

Jun. 30, 2015

Subsequent Event [Line Items]

Shelf filing date Aug. 10, 2015

Percentage of commission on gross proceeds of sales price 3.00%

At Market Issuance Sales Agreement [Member]

Subsequent Event [Line Items]

Sale of stock description It may sell shares of its common stock from time to time in an aggregate amount not to exceed $19 million per year per the 2015 ATM Agreement and not to exceed $75 million in total per the Shelf Filing.

Subsequent Event [Member]

Subsequent Event [Line Items]

Sale of common stock, aggregate amount per year $ 19,000,000

Subsequent Event [Member] | Maximum [Member]

Subsequent Event [Line Items]

Shelf filing maximum authorization amount $ 75,000,000

X

- Definition
Sale of common stock amount, offering limit per year.
+ References
No definition available.
+ Details

Name: cdna_SaleOfCommonStockAmountOfferingLimitPerYear

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Shelf registration date of filing.
+ References
No definition available.
+ Details

Name: cdna_ShelfRegistrationDateOfFiling

Namespace Prefix: cdna_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Shelf registration statement authorization amount.
+ References
No definition available.
+ Details

Name: cdna_ShelfRegistrationStatementAuthorizationAmount

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Stock offering costs commissions percentage.
+ References
No definition available.
+ Details

Name: cdna_StockOfferingCostsCommissionsPercentage

Namespace Prefix: cdna_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1B

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4582445-111684

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569655-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

+ Details

Name: us-gaap_SaleOfStockDescriptionOfTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=cdna_AtMarketIssuanceSalesAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value Measurements
6 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. FAIR VALUE MEASUREMENTS

The Company records its financial assets and liabilities at fair value except for its debt, which is recorded at amortized cost. The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:

• Level 1: Inputs which include quoted prices in active markets for identical assets and liabilities.

• Level 2: Inputs other than Level I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

• Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table sets forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis, as of June 30, 2015 and December 31, 2014 (in thousands):

 June 30, 2015

 Fair Value Measured Using

 (Level 1) (Level 2) (Level 3) Total
Balance

Assets


Money market funds
 $ 33,463 $ — $ — $ 33,463









Liabilities


Contingent consideration
 $ — $ — $ 963 $ 963









Debt
 $ — $ 15,104 $ — $ 15,104









 December 31, 2014

 Fair Value Measured Using

 (Level 1) (Level 2) (Level 3) Total
Balance

Assets


Money market funds
 $ 36,779 $ — $ — $ 36,779









Liabilities


Contingent consideration
 $ — $ — $ 1,074 $ 1,074









Debt
 $ — $ 12,204 $ — $ 12,204









The following table presents the issuances, changes in fair value and reclassifications of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):

 Level 3

 Contingent
Consideration
Liability Warrants to
Purchase
Convertible
Preferred
Stock Derivative Liability
Related to
Subordinated
Convertible Note Total

Balance as of December 31, 2013
 $ — $ 525 $ — $ 525

Issuance of financial instruments
 2,313 — 239 2,552

Change in estimated fair value
 (1,239 ) 14 (239 ) (1,464 )

Reclassification to stockholders’ equity
 — (539 ) (539 )









Balance as of December 31, 2014
 1,074 — — 1,074

Change in estimated fair value
 (111 ) — — (111 )









Balance as of June 30, 2015
 $ 963 $ — $ — $ 963









The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers between Level 1, Level 2 and Level 3 categories during the periods presented.

In determining fair value, the Company uses various valuation approaches within the fair value measurement framework. The valuation methodologies used for the Company’s instruments measured at fair value and their classification in the valuation hierarchy are summarized below:

• Money market funds - Investments in money market funds are classified within Level 1. At June 30, 2015 and December 31, 2014, money market funds were included on the balance sheets in cash and cash equivalents.

• Contingent consideration - As of June 30, 2015, the Company had a contingent obligation to issue 227,845 shares of the Company’s common stock to the former owners of ImmuMetrix, Inc. in conjunction with the Company’s acquisition of ImmuMetrix, Inc. (see Note 11). The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States by June 10, 2020. The Company recorded its estimate of the fair value of the contingent consideration based on its evaluation of the probability of the achievement of the contractual conditions that would result in the payment of the contingent consideration. The fair value of the contingent consideration was estimated using the fair value of the shares to be paid if the contingency is met multiplied by management’s 65% estimate at June 30, 2015 and December 31, 2014 of the probability of success. The significant input in the Level 3 measurement not supported by market activity is the Company’s probability assessment of the milestone being met. The value of the liability is subsequently remeasured to fair value each reporting date, and the change in estimated fair value is recorded to a component of operating expenses until the milestone contingency is paid, expires or is no longer achievable. Increases (decreases) in the estimation of the probability percentage result in a directionally similar impact to the fair value measurement of the contingent consideration liability.

• We determined the estimated fair value of our debt using the present value of payments discounted at an average borrowing rate from of a peer group of public companies, which is a Level 2 observable input.

• Warrants to purchase convertible preferred stock—Prior to the Company’s IPO, the Company’s warrants to purchase convertible preferred stock were classified as Level 3. The valuation of the warrants used assumptions that are inherently subjective and involve significant management judgment. The significant unobservable input used in the fair value measurement of the warrant liability was the fair value of the underlying convertible preferred stock at the valuation remeasurement date. Generally, increases (decreases) in the fair value of the underlying stock would result in a directionally similar impact to the fair value measurement of the preferred stock warrants. A gain of $245,000 and loss of $283,000 in estimated fair value was recognized in other (expense) income, net in the statement of operations for the three and six months ended June 30, 2014, respectively. Upon the Company’s IPO in July 2014 certain warrants to purchase convertible preferred stock were converted into warrants to purchase common stock which were reclassified to equity and are no longer subject to remeasurement, while other warrants to purchase convertible preferred stock expired pursuant to their terms.

•
Derivative liability related to subordinated convertible note—On April 17, 2014, the Company issued a $5.0 million subordinated convertible promissory note to Illumina, Inc. that had some features that constituted embedded derivatives. The Company determined that the optional conversion or repayment upon a change in control is an equity call option with a potentially variable value to be received and meets the definition of a derivative which would be required to be bifurcated. The estimated fair value of this embedded derivative was affected by the estimated probability assigned to the various scenarios for the host instrument. As of April 17, 2014, management estimated repayment upon a change in control within the loan term at a 10% probability. As of June 30, 2014 management estimated repayment upon a change in control within the loan term at a 5% probability. The $239,000 original estimated fair value of the embedded derivative liability was included in accrued and other liabilities. At June 30, 2014, the fair value of the derivative was remeasured to $120,000, resulting in a gain of $119,000, which was recorded in other (expense) income, net in the statement of operations for the three and six months ended June 30, 2014. Upon the Company’s IPO in July 2014, the subordinated convertible note was converted into common stock, and so the embedded conversion option was extinguished. Accordingly, the fair value of the derivative became $0, and a gain of $120,000 was recorded in other (expense) income, net. The significant unobservable input used in the fair value measurement of the derivative liability was the probability assigned to the various scenarios. Generally, increases (decreases) in the probability of the factors primarily impacting the valuation would result in a directionally similar impact to the fair value measurement of the derivative liability. Changes in estimated fair value were recognized in other (expense) income, net on the statements of operations.

The Company’s liabilities classified as Level 3 were valued based on unobservable inputs and management’s judgment due to the absence of quoted market prices, inherent lack of liquidity and the long-term nature of the financial instruments.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R43.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock Incentive Plans - Schedule of Shares Issued and Associated Expense (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Mar. 31, 2015

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Number of Shares Issued 11,628 8,663 20,291

Fair Market Value per Share at Date of Issuance $ 6.48 $ 5.56 $ 6.48

Fair Value of Shares Issued $ 75 $ 48 $ 123

X

- Definition
Share based compensation arrangement by share based payment award shares issued in period fair value.
+ References
No definition available.
+ Details

Name: cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodFairValue

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share instruments newly issued under a share-based compensation plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 23 R29.htm IDEA: XBRL DOCUMENT v3.2.0.727

Net (Loss) Income Per Share - Potentially Dilutive Securities Excluded from Diluted Net (Loss) Income Per Share (Detail) - shares
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total 2,204,050 1,092,966 2,204,050 7,812,652

Convertible preferred stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total 0 0 0 6,048,220

Convertible Subordinated Debt [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total 0 0 0 233,311

Shares of common stock subject to outstanding options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total 1,515,154 469,163 1,515,154 907,318

Shares of common stock subject to outstanding common stock warrants [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total 576,096 82,190 576,096 82,190

Shares of common stock subject to conversion from preferred stock warrants [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total 0 541,613 0 541,613

Restricted Stock Units (RSUs) [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total 112,800 0 112,800 0

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdna_PreferredStockWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R28.htm IDEA: XBRL DOCUMENT v3.2.0.727

Net (Loss) Income Per Share - Computation of Basic and Diluted Net (Loss) Income Per Share (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Numerator:

Net (loss) income $ (3,185) $ 877 $ (5,457) $ (427)

Add: interest expense related to subordinated convertible note, less gain on change in fair value of derivative related to subordinated convertible note 0 15 0 0

Net (loss) income attributable to common stockholders $ (3,185) $ 892 $ (5,457) $ (427)

Denominator:

Weighted-average shares used to compute basic net (loss) income per common share 11,835,405 1,013,128 11,824,993 1,012,769

Effect of potentially dilutive securities:

Employee stock options 0 381,434 0 0

Convertible preferred stock 0 5,355,280 0 0

Subordinated convertible note 0 189,726 0 0

Weighted-average shares used to compute diluted net (loss) income per common share 11,835,405 6,939,568 11,824,993 1,012,769

Net (loss) income per common share - basic $ (0.27) $ 0.87 $ (0.46) $ (0.42)

Net (loss) income per common share - diluted $ (0.27) $ 0.13 $ (0.46) $ (0.42)

X

- Definition
Interest on subordinated convertible note net of gain on change in fair value of derivative related to subordinated convertible note.
+ References
No definition available.
+ Details

Name: cdna_InterestOnSubordinatedConvertibleNoteNetOfGainOnChangeInFairValueOfDerivativeRelatedToSubordinatedConvertibleNote

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 40

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1930-109256

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 40

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1930-109256

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 28A

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1500-109256

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetIncomeLossAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R44.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock Incentive Plans - Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Share based compensation, Total expensed $ 411 $ 137 $ 692 $ 185

Cost of testing [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Share based compensation, Total expensed 54 9 69 9

Research and Development Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Share based compensation, Total expensed 89 21 136 22

Sales and marketing [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Share based compensation, Total expensed 36 8 56 9

General and administrative [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Share based compensation, Total expensed $ 232 $ 99 $ 431 $ 145

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R30.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Recurring [Member] - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Assets

Money market funds $ 33,463 $ 36,779

Liabilities

Contingent consideration 963 1,074

Debt 15,104 12,204

Fair Value Measured Using - (Level 1) [Member]

Assets

Money market funds 33,463 36,779

Liabilities

Contingent consideration 0 0

Debt 0 0

Fair Value Measured Using - (Level 2) [Member]

Assets

Money market funds 0 0

Liabilities

Contingent consideration 0 0

Debt 15,104 12,204

Fair Value Measured Using - (Level 3) [Member]

Assets

Money market funds 0 0

Liabilities

Contingent consideration 963 1,074

Debt $ 0 $ 0

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of contingent consideration in a business combination that is classified in shareholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value of financial and nonfinancial obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_LiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value Measurements - Summary of Issuances, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments (Detail) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended

Jun. 30, 2015

Dec. 31, 2014

Significant Unobservable Inputs (Level 3) [Line Items]

Beginning Balance $ 1,074 $ 525

Issuance of financial instruments 2,552

Change in estimated fair value (111) (1,464)

Reclassification to stockholders' equity (539)

Ending Balance 963 1,074

Significant Unobservable Inputs (Level 3), Warrants to Purchase Convertible Preferred Stock [Member]

Significant Unobservable Inputs (Level 3) [Line Items]

Beginning Balance 0 525

Issuance of financial instruments 0

Change in estimated fair value 0 14

Reclassification to stockholders' equity (539)

Ending Balance 0 0

Significant Unobservable Inputs (Level 3), Derivative Liability Related to Subordinated Convertible Note [Member]

Significant Unobservable Inputs (Level 3) [Line Items]

Beginning Balance 0 0

Issuance of financial instruments 239

Change in estimated fair value 0 (239)

Ending Balance 0 0

Significant Unobservable Inputs (Level 3), Contingent Consideration Liability [Member]

Significant Unobservable Inputs (Level 3) [Line Items]

Beginning Balance 1,074 0

Issuance of financial instruments 2,313

Change in estimated fair value (111) (1,239)

Reclassification to stockholders' equity 0

Ending Balance $ 963 $ 1,074

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) of financial instrument classified in shareholders' equity measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_MandatorilyRedeemablePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareholdersEquityClassAxis=us-gaap_ContingentConsiderationClassifiedAsEquityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727

Net (Loss) Income Per Share
6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Net (Loss) Income Per Share

3. NET (LOSS) INCOME PER SHARE

Basic and net (loss) income per share has been computed by dividing the net (loss) income by the weighted-average number of common shares outstanding during the period.

For the three months ended June 30, 2014, common share equivalents have been included in diluted net income per share, as the effect to net income per share is dilutive. For the three and six months ended June 30, 2015, and for the six months ended June 30, 2014, all common share equivalents have been excluded from diluted net loss per share as the effect to net loss per share would be antidilutive. Our common share equivalents include convertible preferred stock, the subordinated convertible note, options and warrants to purchase common and convertible preferred stock, and restricted stock units. Common share equivalents for convertible preferred stock and the subordinated convertible note are determined using the if-converted method. Common share equivalents for options and warrants to purchase common and convertible preferred stock are determined using the treasury-stock method.

The following tables set forth the computation of the Company’s basic and diluted net (loss) income per share (in thousands, except share and per share data):

 Three Months Ended June 30, Six Months Ended June 30,

 2015 2014 2015 2014

Numerator:


Net (loss) income
 $ (3,185 ) $ 877 $ (5,457 ) $ (427 )

Add: interest expense related to subordinated convertible note, less gain on change in fair value of derivative related to subordinated convertible note
 — 15 — —









Net (loss) income attributable to common stockholders
 $ (3,185 ) $ 892 $ (5,457 ) $ (427 )









Denominator:


Weighted-average shares used to compute basic net (loss) income per common share
 11,835,405 1,013,128 11,824,993 1,012,769

Effect of potentially dilutive securities:


Employee stock options
 — 381,434 — —

Convertible preferred stock
 — 5,355,280 — —

Subordinated convertible note
 — 189,726 — —









Weighted-average shares used to compute diluted net (loss) income per common share
 11,835,405 6,939,568 11,824,993 1,012,769









Net (loss) income per share


Net (loss) income per common share - basic
 $ (0.27 ) $ 0.87 $ (0.46 ) $ (0.42 )









Net (loss) income per common share - diluted
 $ (0.27 ) $ 0.13 $ (0.46 ) $ (0.42 )









The following potentially dilutive securities have been excluded from diluted net (loss) income per share, because their effect would be antidilutive:

 Three Months Ended June 30, Six Months Ended June 30,

 2015 2014 2015 2014

Shares of common stock subject to outstanding options
 1,515,154 469,163 1,515,154 907,318

Shares of common stock subject to outstanding common stock warrants
 576,096 82,190 576,096 82,190

Shares of common stock subject to conversion from preferred stock warrants
 — 541,613 — 541,613

Subordinated convertible note
 — — — 233,311

Convertible preferred stock
 — — — 6,048,220

Restricted stock units
 112,800 — 112,800 —









Total common stock equivalents
 2,204,050 1,092,966 2,204,050 7,812,652









X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value Measurements - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended

Jun. 30, 2015

CommercialTests

shares

Dec. 31, 2014

Jun. 30, 2014

USD ($)

Apr. 17, 2014

USD ($)

Jul. 31, 2014

USD ($)

Jun. 30, 2014

USD ($)

Jun. 30, 2015

USD ($)

CommercialTests

Jun. 30, 2014

USD ($)

Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]

Transfers between Level 1, Level 2 and Level 3 categories during the periods $ 0

Number of commercial tests involving the measurement of cfDNA to be completed | CommercialTests 1

(Gain) loss in estimated fair value $ (245,000) $ 0 $ 283,000

Estimated fair value of embedded derivative liabilities $ 239,000 239,000 239,000

Fair value of derivative $ 120,000 120,000 120,000

Gain on derivative $ 119,000 $ 119,000

Illumina, Inc. [Member]

Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]

Subordinated convertible promissory note issued $ 5,000,000

ImmuMetrix, Inc. [Member]

Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]

Number of commercial tests involving the measurement of cfDNA to be completed | CommercialTests 2,500 2,500

Milestone description The milestone will be achieved if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States no later than six years after the closing date of the acquisition.

Contingent consideration maturity date Jun. 10, 2020

IPO [Member]

Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]

Change in control for repayment 5.00% 10.00%

Fair value of derivative $ 0

Gain on derivative $ 120,000

Contingent consideration [Member] | ImmuMetrix, Inc. [Member]

Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]

Contingent obligation to issue common stock | shares 227,845

Milestone description The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States by June 10, 2020.

Probability of the achievement 65.00% 65.00%

X

- Definition
Change In Control For Repayment
+ References
No definition available.
+ Details

Name: cdna_ChangeInControlForRepayment

Namespace Prefix: cdna_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Contractual Obligation Maturity Date
+ References
No definition available.
+ Details

Name: cdna_ContractualObligationMaturityDate

Namespace Prefix: cdna_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair Value Input Probability Of Achievement
+ References
No definition available.
+ Details

Name: cdna_FairValueInputProbabilityOfAchievement

Namespace Prefix: cdna_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair Value Measurements Inter Transfers Between Levels
+ References
No definition available.
+ Details

Name: cdna_FairValueMeasurementsInterTransfersBetweenLevels

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
+ References
No definition available.
+ Details

Name: cdna_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems

Namespace Prefix: cdna_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of Commercial Tests
+ References
No definition available.
+ Details

Name: cdna_NumberOfCommercialTests

Namespace Prefix: cdna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of equity interests issued or issuable to acquire entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)(4)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Including the current and noncurrent portions, the carrying value of convertible subordinated debt, as of the balance sheet date, initially scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX210.5-02.22))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Article 5

-Subsection 20, 22

+ Details

Name: us-gaap_ConvertibleSubordinatedDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value of the assets less the liabilities of a derivative or group of derivatives.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611

+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (a),(c),(d),(e)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

+ Details

Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=cdna_IlluminaIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=cdna_ImmumetrixIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContingentConsiderationByTypeAxis=cdna_ContingentPaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R40.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock Incentive Plans - Summary of Options Outstanding and Exercisable Vested or Expected to Vest (Detail) - Jun. 30, 2015 - USD ($)
$ / shares in Units, $ in Thousands

Total

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Number of Shares, Vested 576,815

Number of Shares, Expected to vest 938,339

Number of Shares, Total 1,515,154

Weighted-average Exercise Price, Vested $ 5.14

Weighted-average Exercise Price, Expected to vest $ 8.20

Weighted-average Remaining Contractual Life (Years), Vested 7 years 4 months 28 days

Weighted-average Remaining Contractual Life (Years), Expected to vest 9 years 3 months 18 days

Aggregate Intrinsic Value, Vested $ 1,750

Aggregate Intrinsic Value, Expected to vest 396

Aggregate Intrinsic Value, Total $ 2,146

X

- Definition
Share based compensation arrangement by share based payment award options expected to vest outstanding aggregate intrinsic value.
+ References
No definition available.
+ Details

Name: cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment award options expected to vest outstanding number.
+ References
No definition available.
+ Details

Name: cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber

Namespace Prefix: cdna_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment award options expected to vest outstanding weighted average remaining contractual term.
+ References
No definition available.
+ Details

Name: cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm

Namespace Prefix: cdna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award options expected to vest weighted average exercise price.
+ References
No definition available.
+ Details

Name: cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice

Namespace Prefix: cdna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment award options vested outstanding aggregate intrinsic value.
+ References
No definition available.
+ Details

Name: cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment award options vested outstanding number.
+ References
No definition available.
+ Details

Name: cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber

Namespace Prefix: cdna_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
+ References
No definition available.
+ Details

Name: cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm

Namespace Prefix: cdna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award options vested weighted average exercise price.
+ References
No definition available.
+ Details

Name: cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice

Namespace Prefix: cdna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 31 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Balance Sheets - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Current assets:

Cash and cash equivalents $ 36,894 $ 36,431

Accounts receivable 1,706 2,687

Inventory 731 686

Prepaid and other assets 674 542

Total current assets 40,005 40,346

Property and equipment, net 2,559 1,968

Intangible assets, net 6,650 6,650

Goodwill 12,005 12,005

Restricted cash 147 147

Other noncurrent assets 0 25

Total assets 61,366 61,141

Current liabilities:

Accounts payable 1,203 1,128

Accrued payroll liabilities 2,051 1,684

Accrued and other liabilities 1,840 1,616

Accrued royalties 268 241

Deferred revenue 500 505

Current portion of long-term debt 2,380 5,961

Total current liabilities 8,242 11,135

Deferred rent, net of current portion 1,554 1,684

Deferred revenue, net of current portion 417 471

Long-term debt, net of current portion 13,389 5,451

Contingent consideration 963 1,074

Other liabilities 28 28

Total liabilities $ 24,593 $ 19,843

Commitments and contingencies (Note 7)

Stockholders' equity:

Preferred stock: $0.001 par value; 10,000,000 shares authorized at June 30, 2015 and December 31, 2014; no shares issued and outstanding at June 30, 2015 and December 31, 2014 $ 0 $ 0

Common stock: $0.001 par value; 100,133,900 and 100,000,000 shares authorized at June 30, 2015 and December 31, 2014, respectively; 11,838,794 and 11,803,970 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively 12 12

Additional paid-in capital 201,595 200,661

Accumulated deficit (164,834) (159,375)

Total stockholders' equity 36,773 41,298

Total liabilities and stockholders' equity $ 61,366 $ 61,141

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.9)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.5)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of obligations incurred and payable, pertaining to costs that are statutory in nature, incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include, but not limited to, taxes, interest, rent and utilities. Also includes the aggregate carrying amount of liabilities not separately disclosed.
+ References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedRoyaltiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.26(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707

+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R45.htm IDEA: XBRL DOCUMENT v3.2.0.727

Business Combination - Additional Information (Detail)
3 Months Ended 6 Months Ended

Jun. 30, 2015

USD ($)

CommercialTests

shares

Dec. 31, 2014

USD ($)

Jun. 10, 2014

USD ($)

shares

Jun. 30, 2014

USD ($)

Jun. 30, 2015

USD ($)

CommercialTests

Jun. 30, 2014

USD ($)

Business Acquisition [Line Items]

Number of commercial tests involving the measurement of cfDNA to be completed | CommercialTests 1

Stock-based compensation $ 692,000 $ 185,000

ImmuMetrix, Inc. [Member]

Business Acquisition [Line Items]

Acquisition date Jun. 10, 2014

Estimated purchase price $ 17,200,000

Business acquisition purchase price, cash $ 600,000

Milestone description The milestone will be achieved if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States no later than six years after the closing date of the acquisition.

Number of commercial tests involving the measurement of cfDNA to be completed | CommercialTests 2,500 2,500

Milestone measurement period 6 years

Business combination pro forma removal (addition) in income tax benefit $ 1,500,000 1,500,000

ImmuMetrix, Inc. [Member] | Contingent consideration [Member]

Business Acquisition [Line Items]

Shares issued, shares issuable upon achievement of future milestone, and options assumed | shares 227,845

Milestone description The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States by June 10, 2020.

ImmuMetrix, Inc. [Member] | CareDx, Inc [Member]

Business Acquisition [Line Items]

Acquisition-related costs 1,600,000 1,700,000

Stock-based compensation $ 200,000 $ 200,000

ImmuMetrix, Inc. [Member] | Series G Preferred Stock [Member]

Business Acquisition [Line Items]

Shares issued, shares issuable upon achievement of future milestone, and options assumed | shares 911,364

Estimated fair value $ 14,200,000

ImmuMetrix, Inc. [Member] | Series G Preferred Stock [Member] | Contingent consideration [Member]

Business Acquisition [Line Items]

Shares issued, shares issuable upon achievement of future milestone, and options assumed | shares 227,845

Estimated fair value $ 963,000 $ 1,100,000 $ 2,300,000

ImmuMetrix, Inc. [Member] | Series G Preferred Stock [Member] | Stock Options [Member]

Business Acquisition [Line Items]

Shares issued, shares issuable upon achievement of future milestone, and options assumed | shares 23,229

Estimated fair value $ 369,000

X

- Definition
Business Acquisition Cash Consideration
+ References
No definition available.
+ Details

Name: cdna_BusinessAcquisitionCashConsideration

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Business Acquisition Cost of Acquired Entity Transaction Costs Expensed During Period
+ References
No definition available.
+ Details

Name: cdna_BusinessAcquisitionCostOfAcquiredEntityTransactionCostsExpensedDuringPeriod

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Business Acquisitions Pro Forma Adjustment Increase (Decrease) in Income Tax Expense (Benefit)
+ References
No definition available.
+ Details

Name: cdna_BusinessAcquisitionsProFormaAdjustmentIncreaseDecreaseInIncomeTaxExpenseBenefit

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Contingent Consideration Milestone Measurement Period One
+ References
No definition available.
+ Details

Name: cdna_ContingentConsiderationMilestoneMeasurementPeriodOne

Namespace Prefix: cdna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of Commercial Tests
+ References
No definition available.
+ Details

Name: cdna_NumberOfCommercialTests

Namespace Prefix: cdna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when the business acquisition agreement was executed, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of equity interests issued or issuable to acquire entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)(4)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=cdna_ImmumetrixIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContingentConsiderationByTypeAxis=cdna_ContingentPaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=us-gaap_ParentCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 33 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727

Organization
6 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

1. ORGANIZATION

CareDx, Inc., (“CareDx” or the “Company”) is a commercial stage company that develops, markets and delivers diagnostic surveillance solutions for organ transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient’s lifetime. The Company’s one commercialized testing solution, the AlloMap heart transplant molecular test (“AlloMap”), an FDA-cleared test, is a blood-based test used to monitor for acute cellular rejection in heart transplant recipients. The Company was incorporated in Delaware in December 1998, as Hippocratic Engineering, Inc. In April 1999, the Company changed its name to BioCardia, Inc., in June 2002 to Expression Diagnostics, Inc., in July 2007 to XDx, Inc. and in March 2014 to CareDx, Inc. The Company’s operations are based in Brisbane, California and it operates in one segment.

Reverse Stock Split, and Increase in Authorized Shares

On July 1, 2014, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to reflect a 1 for 6.85 reverse stock split (the “Reverse Stock Split”) of the Company’s outstanding common stock and convertible preferred stock. The Reverse Stock Split became effective July 14, 2014. The par value per share was not adjusted as a result of the Reverse Stock Split. All authorized, issued and outstanding shares of common stock, convertible preferred stock, options and warrants to purchase common or preferred stock and related per share amounts contained in the financial statements have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented.

Initial Public Offering

On July 22, 2014, the Company closed its initial public offering (“IPO”) of 4,000,000 shares of its common stock, and issued an additional 220,000 shares of common stock on August 13, 2014 pursuant to the exercise of the over-allotment option granted to its underwriters. The public offering price of the shares sold in the offering was $10.00 per share. The total proceeds from the offering to the Company, net of underwriting discounts and commissions of $3.0 million, were $39.2 million. After deducting offering expenses payable by the Company of $3.7 million, net proceeds to the Company were $35.5 million. Upon the closing of the IPO, all shares of convertible preferred stock then outstanding converted into 6,048,220 shares of common stock, and a subordinated convertible note previously issued by the Company in the principal amount of $5.0 million converted into 510,777 shares of common stock. In addition, all of our convertible preferred stock warrants were converted into warrants to purchase common stock.

Shelf Filing

On August 10, 2015, the Company filed a registration statement on Form S-3 with the Securities and Exchange Commission which will allow the Company to raise up to $75 million from the capital markets. See Note 12.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R35.htm IDEA: XBRL DOCUMENT v3.2.0.727

Commitments and Contingencies - Additional Information (Detail) - Unpaid Royalties [Member] - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Sep. 30, 2014

Loss Contingencies [Line Items]

Settlement and mutual release agreement, counter party name Roche

Settlement and mutual release agreement, date September 2014

Maximum number of days from end of calendar quarter for royalty payment 45 days

Settlement and mutual release agreement, terms of agreement In September 2014, the Company entered into a settlement and mutual release agreement with Roche whereby (i) for the period beginning July 1, 2011 through June 30, 2014, the Company agreed to pay the amount of $2,827,220 in settlement of past royalties due; (ii) for the period beginning July 1, 2014 through September 30, 2014, the Company agreed to pay royalties based on the same combination services percentage used to determine the past royalties due; (iii) for the period beginning October 1, 2014 through September 30, 2017, Roche and the Company agreed to a downward adjustment of the combination services percentage used to determine the portion of the AlloMap testing revenue that is royalty bearing under the terms of the license; (iv) the Company agreed to report and pay quarterly royalties within 45 days of the end of each calendar quarter; (v) Roche agreed that, subject to the Company's timely payment of all applicable royalties through such date, no further royalties will be payable by the Company for periods after September 30, 2017.

Royalty expenses $ 254,000 $ 362,000 $ 509,000 $ 678,000

July 1, 2011 through June 30, 2014 [Member]

Loss Contingencies [Line Items]

Past due royalties $ 2,827,220

X

- Definition
Accrual for environmental loss contingencies maximum payment period.
+ References
No definition available.
+ Details

Name: cdna_AccrualForEnvironmentalLossContingenciesMaximumPaymentPeriod

Namespace Prefix: cdna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_AccruedRoyaltiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingenciesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the other party to the settlement agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

+ Details

Name: us-gaap_LossContingencySettlementAgreementCounterpartysName

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The effective date of a duly executed litigation settlement agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

+ Details

Name: us-gaap_LossContingencySettlementAgreementDate

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the terms of a settlement agreement which resolved the legal matter, including the nature of the consideration, timing of payment, and the nature of rights obtained or lost (for example, but not limited to, patent, trademark, copyright, license and franchise rights).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_LossContingencySettlementAgreementTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=cdna_RoyaltyAgreementLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=cdna_ScenarioOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accrued and Other Liabilities (Tables)
6 Months Ended

Jun. 30, 2015

Payables and Accruals [Abstract]

Components of Accrued and Other Liabilities

The following table represents the components of accrued and other liabilities (in thousands):

 June 30,
2015 December 31,
2014

Professional fees
 $ 113 $ 273

Test sample processing fees
 383 318

Accrued overpayments and refunds
 117 146

Clinical Studies
 289 144

Deferred rent – current portion
 230 202

Capital leases – current portion
 62 70

Other accrued expenses
 647 463





Total accrued and other liabilities
 $ 1,840 $ 1,616





X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R36.htm IDEA: XBRL DOCUMENT v3.2.0.727

Collaboration and Licensing Agreements - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended

Sep. 18, 2014

USD ($)

Jul. 31, 2013

USD ($)

Jun. 30, 2013

USD ($)

Jun. 30, 2013

EUR (€)

Apr. 30, 2012

USD ($)

Jun. 30, 2015

USD ($)

Dec. 31, 2014

USD ($)

Jun. 30, 2014

USD ($)

Jun. 30, 2015

USD ($)

Jun. 30, 2014

USD ($)

Dec. 31, 2012

USD ($)

Jun. 30, 2013

EUR (€)

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Description of agreement expire term The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.

Upfront license fee payment $ 1,000,000

Non-refundable and non creditable payment received $ 250,000

Research and development expenses $ 2,510,000 $ 792,000 $ 3,931,000 $ 1,512,000

Previously unrecognized license fee 500,000 $ 505,000 500,000

Revenue recognized under collaboration and licensing agreements 1,800 0 31,200

Amortization of upfront license fee 0 15,000

Reimbursement of research and development expenses 1,800 16,200

Upfront cash payment $ 503,000 € 387,500

Refundable upfront payments 344,000 € 250,000

Common stock value 12,000 12,000 12,000

Shares sold for consideration $ 467,000

Revenues recognized from the arrangement 16,000 1,000 33,000 1,000

Royalty revenues 89,000 59,000 179,000 117,000

Royalty revenues receivable balance $ 179,000 54,000 $ 179,000

Up-front Payment Arrangement [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Previously unrecognized license fee 611,000

Laboratory Corp of America Holdings [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Consideration of arrangement of license $ 1,000,000

Description of agreement expire term The license term in the 2012 Agreement was the later of 10 years from the date of the agreement or the expiration of the last-to-expire patents and patent applications included in the CareDx technology licensed to LabCorp, unless the license was terminated by mutual agreement.

Termination of collaboration agreement date Sep. 18, 2014

Research and development expenses $ 500,000 $ 3,600 $ 0 $ 32,000

Termination agreement fee $ 500,000

Diaxonhit (DHT) [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Common stock value $ 503,000 € 387,500

X

- Definition
Collaborative agreement contract value.
+ References
No definition available.
+ Details

Name: cdna_CollaborativeAgreementContractValue

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Description Of Agreement Expected Expiration Year
+ References
No definition available.
+ Details

Name: cdna_DescriptionOfAgreementExpectedExpirationYear

Namespace Prefix: cdna_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Potential Refundable Portion of Upfront Payment.
+ References
No definition available.
+ Details

Name: cdna_PotentialRefundablePortionOfUpfrontPayment

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Royalty Revenue Receivable
+ References
No definition available.
+ Details

Name: cdna_RoyaltyRevenueReceivable

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Termination agreement date.
+ References
No definition available.
+ Details

Name: cdna_TerminationAgreementDate

Namespace Prefix: cdna_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Termination fee.
+ References
No definition available.
+ Details

Name: cdna_TerminationFee

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Upfront Payment In Cash
+ References
No definition available.
+ Details

Name: cdna_UpfrontPaymentInCash

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the amortization of deferred leasing fees incurred by the lessor and amortized over the term of the lease. Such fees represent (a) costs to originate a lease incurred in transactions with independent third parties that (i) result directly from and are essential to acquire that lease and (ii) would not have been incurred had that leasing transaction not occurred and (b) certain costs directly related to specified activities performed by the lessor for that lease. Those activities are: evaluating the prospective lessee's financial condition; evaluating and recording guarantees, collateral, and other security arrangements; negotiating lease terms; preparing and processing lease documents; and closing the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 17

-URI http://asc.fasb.org/extlink&oid=6748888&loc=d3e40246-112709

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfDeferredLeasingFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicensesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash received from licensees for license fees during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_ProceedsFromLicenseFeesReceived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

-Subsection 1

+ Details

Name: us-gaap_RecognitionOfDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Repayment received or receivable for expenses incurred on behalf of a client or customer, other than those reimbursements received by landlords from tenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 45

-Section 45

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=51671805&loc=d3e60722-111653

+ Details

Name: us-gaap_ReimbursementRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=cdna_LaboratoryCorpOfAmericaHoldingsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=cdna_DiaxonhitMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727

Business Combination (Tables)
6 Months Ended

Jun. 30, 2015

Business Combinations [Abstract]

Schedule of Pro Forma Results of Operations

The following table presents pro forma results of operations and gives effect to the IMX transaction as if the transaction had been consummated on January 1, 2013. The unaudited pro forma results of operations have been prepared for comparative purposes only and are not necessarily indicative of what would have occurred had the business combination been completed at the beginning of the period or of the results that may occur in the future. Furthermore, the pro forma financial information does not reflect the impact of any reorganization or operating efficiencies resulting from combining the two companies (in thousands, except per share data):

Three Months Ended
June 30, 2014 Six Months Ended
June 30, 2014

Net revenue
$ 6,776 $ 12,700

Net loss
$ (518 ) $ (2,288 )

Net loss per common share - basic and diluted
$ (0.51 ) $ (2.26 )

X

- Definition
Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionProFormaInformationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 39 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary of Significant Accounting Policies
6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The condensed balance sheet as of December 31, 2014 has been derived from audited financial statements as of that date but does not include all of the financial information required by U.S. GAAP for complete financial statements. Operating results for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.

The accompanying unaudited condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K filed on March 31, 2015 with the SEC.

Use of Estimates

The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers, (v) the fair value of assets and liabilities, (vi) the valuation of warrants to purchase convertible preferred stock, (vii) the determination of fair value of the Company’s common stock, (viii) the fair value of contingent consideration in a business acquisition, (ix) the fair value of the embedded features associated with the subordinated convertible note, (x) the fair value of the embedded features associated with long-term debt, (xi) measurement of stock-based compensation expense, (xii) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xiii) any impairment of long-lived assets including in-process technology and goodwill and (xiv) legal contingencies. Actual results could differ from those estimates.

Concentrations of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper, and various bank deposit accounts. These financial instruments were held in Company accounts at two financial institutions. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.

The Company is also subject to credit risk from its accounts receivable which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers. For the six months ended June 30, 2015 and 2014, approximately 50% and 49%, respectively, of testing revenue was derived from Medicare. No other payers represented more than 10% of testing revenue for these periods. At June 30, 2015 and December 31, 2014 approximately 40% and 78%, respectively, of accounts receivable was from Medicare. No other payer represented more than 10% of accounts receivable at June 30, 2015 and December 31, 2014.

Cash Equivalents

Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist primarily of amounts invested in money market funds and checking accounts.

Impairment of Long-lived Assets

The Company evaluates its long-lived assets for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. The Company then compares the carrying amounts of the assets with the future net undiscounted cash flows expected to be generated by such asset. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value determined using discounted estimates of future cash flows. The Company has not identified any such impairment losses to date.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which the Company would transact, and it takes into consideration the assumptions that market participants would use when pricing the asset or liability. The Company’s assessment of the significance of a particular input to the fair value measurement of an asset or liability requires management to make judgments and to consider specific characteristics of that asset or liability.

The carrying amounts of certain of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. The carrying amounts of the convertible preferred stock warrant liability and contingent consideration liability represent their fair values.

Testing Revenue

The Company recognizes revenue for tests delivered when the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery has occurred or services rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured.

The first criterion is satisfied when a third-party payer makes a coverage decision or enters into a contractual arrangement with the Company for the test. The second criterion is satisfied when the Company performs the test and delivers the test result to the ordering physician. The third criterion is satisfied if the third-party payer’s coverage decision or reimbursement contract specifies a price for the test. The fourth criterion is satisfied based on management’s judgments regarding the collectability of the fees charged under the arrangement. Such judgments include review of past payment history. AlloMap testing may be considered investigational by some payers and not covered under their reimbursement policies. Others may cover the test, but not pay a set or determinable amount. As a result, in the absence of a reimbursement agreement or sufficient payment history, collectability cannot reasonably be assured so revenue is not recognized at the time the test is delivered.

If all criteria set forth above are met, revenue is recognized. When the first, third or fourth criteria are not met but third-party payers make a payment to the Company for tests performed, the Company recognizes revenue on the cash basis in the period in which the payment is received.

Revenue is recognized on the accrual basis net of adjustments for differences between amounts billed and the estimated receipts from payers. The amount the Company expects to collect may be lower than the agreed upon amount due to several factors, such as the amount of patient co-payments, the existence of secondary payers and claim denials. Estimated receipts are based upon historical payment practices of payers. Differences between estimated and actual cash receipts are recorded as an adjustment to revenue, which have been immaterial to date.

During the three and six months ended June 30, 2015, the Company changed its revenue recognized from one and three of its payers, respectively, from a cash basis to an accrual basis based on the Company’s consistent history of obtaining reimbursement from these three payers. The impact of this change in accounting estimate is to increase revenues by $79,000 and $127,000 and to reduce net loss per share by $0.01 for the three and six months ended June 30, 2015.

Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are excluded from revenue in the statements of operations.

Collaboration and License Revenue

The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis.

Cost of Testing

Cost of testing reflects the aggregate costs incurred in delivering the Company’s AlloMap test results to clinicians. The components of cost of testing are materials and service costs, direct labor costs, including stock-based compensation, equipment and infrastructure expenses associated with testing samples, shipping, logistics and specimen processing charges to collect and transport samples and allocated overhead including rent, information technology, equipment depreciation and utilities and royalties. Costs associated with performing tests (except royalties) are recorded as the test is processed regardless of whether and when revenue is recognized with respect to that test. As a result, our cost of testing as a percentage of revenue may vary significantly from period to period because we do not recognize all revenue in the period in which the associated costs are incurred. Royalties for licensed technology, calculated as a percentage of test revenues, are recorded as license fees in cost of testing at the time the test revenues are recognized.

Business Combinations

In accordance with ASC 805, Business Combinations, the Company determines and allocates the purchase price of an acquired business to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, royalty rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.

Goodwill and indefinite-lived intangible assets including acquired in-process technology are reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that goodwill or indefinite-lived intangible assets may be impaired. The Company’s goodwill evaluation is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company assesses qualitative factors to determine if its sole reporting unit’s fair value is more likely than not to exceed its carrying value, including goodwill. In the event the Company determines that it is more likely than not that its reporting unit’s fair value is less than its carrying amount, quantitative testing is performed comparing recorded values to estimated fair values. If the fair value exceeds the carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, then the Company would calculate the potential impairment loss by comparing the implied fair value of goodwill with the carrying value. If the implied fair value of goodwill is less than the carrying value, then an impairment charge would be recorded. The Company performs its annual evaluation of goodwill during the fourth quarter of each fiscal year. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of the asset to its carrying value, without consideration of any recoverability test.

In those circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, Distinguishing Liabilities from Equity, the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company remeasures this liability each reporting period and records changes in the fair value as a component of operating expenses.

Transaction costs associated with these acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company’s operating results from the date of acquisition.

Stock-based Compensation

The Company uses the Black-Scholes option pricing model (“Black-Scholes Model”), which requires the use of estimates such as stock price volatility and expected option lives, to value employee stock options. The Company estimates the expected option lives using historical data, volatility using data of similar companies in the diagnostics industry, risk-free rates based on the implied yield currently available in the U.S. Treasury zero-coupon issues with a remaining term equal to the expected option lives, and dividend yield based on the Company’s expectations and historical data.

The Company uses the straight-line attribution method for recognizing compensation expense. Compensation expense is recognized on awards ultimately expected to vest and reduced for forfeitures that are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on the Company’s historical experience.

Compensation expense for stock options issued to nonemployees is calculated using the Black-Scholes Model and is recorded over the service performance period. Options subject to vesting are required to be periodically remeasured over their service performance period, which is generally the same as the vesting period.

Warrants

The Company had freestanding warrants enabling counterparties to purchase shares of its convertible preferred stock which were converted to warrants to purchase common stock on the Company’s IPO date.

In accordance with the accounting guidance regarding distinguishing liabilities from equity, freestanding warrants for convertible preferred stock that are contingently redeemable are classified as liabilities on the balance sheet and recorded at their estimated fair value. These warrants are remeasured at each balance sheet date and any change in estimated fair value is recognized in other (expense) income, net, on the statements of operations.

Upon the completion of the Company’s IPO in July 2014, preferred stock warrants were converted into warrants to purchase common stock, and, accordingly, the liability was reclassified to equity and became no longer subject to remeasurement.

The Company has issued warrants to purchase shares of its common stock in connection with financing activities (see Note 9). The Company accounts for these warrants as equity at fair value on the date the warrants are issued. The fair value of the outstanding warrants is estimated using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the warrants, expected volatility and risk-free interest rate. Certain of these inputs are subjective and require significant analysis and judgment to develop. For the estimate of the expected term, the Company uses the full remaining contractual term of the warrant.

Comprehensive Loss

Net loss and comprehensive loss are the same for all periods presented.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled to when products are transferred to customers. On July 9, 2015, the FASB decided to delay the effective date of the new standard by one year. The standard would become effective for us beginning in the first quarter of 2018. Early application would be permitted in 2017. Entities would have the option of using either a full retrospective or a modified retrospective approach to adopt this new guidance. The Company is currently evaluating the impact of adopting the new revenue standard on its financial statements.

In April 2015, the FASB issued ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). This ASU requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is applicable to the Company beginning January 1, 2016. However, early adoption of ASU 2015-03 is permitted and the Company adopted ASU 2015-03 as of January 1, 2015 using the retrospective method as required. Debt discount and issuance costs, current, as of June 30, 2015 and December 31, 2014 were $176,000 and $76,000, respectively. Debt discount and issuance costs, non-current, as of June 30, 2015 and December 31, 2014 were $214,000 and $11,000, respectively. There is no impact from the adoption of ASU 2015-03 on the unaudited condensed statements of operations or in the loss per share calculations.

In April 2015, the FASB issued ASU 2015-05 Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) (“ASU 2015-05”). This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This ASU will be effective for annual periods, including interim periods beginning after December 15, 2015. Early adoption is permitted. An entity can elect to adopt the amendments either (1) prospectively to all arrangements entered into or materially modified after the effective date or (2) retrospectively. For prospective transition, the only disclosure requirements at transition are the nature of and reason for the change in accounting principle, the transition method, and a qualitative description of the financial statement line items affected by the change. For retrospective transition, the disclosure requirements at transition include the requirements for prospective transition and quantitative information about the effects of the accounting change. The Company is currently evaluating the impact of adopting ASU 2015-05 on its financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Balance Sheets (Parenthetical) - $ / shares

Jun. 30, 2015

Dec. 31, 2014

Statement of Financial Position [Abstract]

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 100,133,900 100,000,000

Common stock, shares issued 11,838,794 11,803,970

Common stock, shares outstanding 11,838,794 11,803,970

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727

Subsequent Event
6 Months Ended

Jun. 30, 2015

Subsequent Events [Abstract]

Subsequent Event

12. SUBSEQUENT EVENT

Shelf Filing

On August 10, 2015, the Company filed a registration statement on Form S-3 (“Shelf Filing”) with the Securities and Exchange Commission which will allow the Company to raise up to $75 million from the capital markets. In addition, on August 10, 2015 the Company entered into an At The Market Issuance Sales Agreement (the “2015 ATM Agreement”), with Cantor Fitzgerald and Company (“Cantor”) under which it may sell shares of its common stock from time to time in an aggregate amount not to exceed $19 million per year per the 2015 ATM Agreement and not to exceed $75 million in total per the Shelf Filing. Cantor may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The NASDAQ Global Market, on any other existing trading market for the Company’s common stock or to or through a market maker. Cantor also may sell the shares in privately negotiated transactions, subject to the Company’s prior approval. The Company will pay Cantor a commission equal to 3% of the gross proceeds of the sales price of all shares sold through it as sales agent under the 2015 ATM Agreement.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727

Document and Entity Information - shares
6 Months Ended

Jun. 30, 2015

Jul. 29, 2015

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q2

Trading Symbol CDNA

Entity Registrant Name CareDx, Inc.

Entity Central Index Key 0001217234

Current Fiscal Year End Date --12-31

Entity Filer Category Non-accelerated Filer

Entity Common Stock, Shares Outstanding 11,887,409

X

- Definition
Document And Entity Information [Abstract]
+ References
No definition available.
+ Details

Name: cdna_DocumentAndEntityInformationAbstract

Namespace Prefix: cdna_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 43 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727

Organization (Policies)
6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Reverse Stock Split, and Increase in Authorized Shares

Reverse Stock Split, and Increase in Authorized Shares

On July 1, 2014, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to reflect a 1 for 6.85 reverse stock split (the “Reverse Stock Split”) of the Company’s outstanding common stock and convertible preferred stock. The Reverse Stock Split became effective July 14, 2014. The par value per share was not adjusted as a result of the Reverse Stock Split. All authorized, issued and outstanding shares of common stock, convertible preferred stock, options and warrants to purchase common or preferred stock and related per share amounts contained in the financial statements have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented.

Initial Public Offering

Initial Public Offering

On July 22, 2014, the Company closed its initial public offering (“IPO”) of 4,000,000 shares of its common stock, and issued an additional 220,000 shares of common stock on August 13, 2014 pursuant to the exercise of the over-allotment option granted to its underwriters. The public offering price of the shares sold in the offering was $10.00 per share. The total proceeds from the offering to the Company, net of underwriting discounts and commissions of $3.0 million, were $39.2 million. After deducting offering expenses payable by the Company of $3.7 million, net proceeds to the Company were $35.5 million. Upon the closing of the IPO, all shares of convertible preferred stock then outstanding converted into 6,048,220 shares of common stock, and a subordinated convertible note previously issued by the Company in the principal amount of $5.0 million converted into 510,777 shares of common stock. In addition, all of our convertible preferred stock warrants were converted into warrants to purchase common stock.

Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The condensed balance sheet as of December 31, 2014 has been derived from audited financial statements as of that date but does not include all of the financial information required by U.S. GAAP for complete financial statements. Operating results for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.

The accompanying unaudited condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K filed on March 31, 2015 with the SEC.

Use of Estimates

Use of Estimates

The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers, (v) the fair value of assets and liabilities, (vi) the valuation of warrants to purchase convertible preferred stock, (vii) the determination of fair value of the Company’s common stock, (viii) the fair value of contingent consideration in a business acquisition, (ix) the fair value of the embedded features associated with the subordinated convertible note, (x) the fair value of the embedded features associated with long-term debt, (xi) measurement of stock-based compensation expense, (xii) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xiii) any impairment of long-lived assets including in-process technology and goodwill and (xiv) legal contingencies. Actual results could differ from those estimates.

Concentrations of Credit Risk and Other Risks and Uncertainties

Concentrations of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper, and various bank deposit accounts. These financial instruments were held in Company accounts at two financial institutions. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.

The Company is also subject to credit risk from its accounts receivable which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers. For the six months ended June 30, 2015 and 2014, approximately 50% and 49%, respectively, of testing revenue was derived from Medicare. No other payers represented more than 10% of testing revenue for these periods. At June 30, 2015 and December 31, 2014 approximately 40% and 78%, respectively, of accounts receivable was from Medicare. No other payer represented more than 10% of accounts receivable at June 30, 2015 and December 31, 2014.

Cash Equivalents

Cash Equivalents

Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist primarily of amounts invested in money market funds and checking accounts.

Impairment of Long-lived Assets

Impairment of Long-lived Assets

The Company evaluates its long-lived assets for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. The Company then compares the carrying amounts of the assets with the future net undiscounted cash flows expected to be generated by such asset. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value determined using discounted estimates of future cash flows. The Company has not identified any such impairment losses to date.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which the Company would transact, and it takes into consideration the assumptions that market participants would use when pricing the asset or liability. The Company’s assessment of the significance of a particular input to the fair value measurement of an asset or liability requires management to make judgments and to consider specific characteristics of that asset or liability.

The carrying amounts of certain of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. The carrying amounts of the convertible preferred stock warrant liability and contingent consideration liability represent their fair values.

Testing Revenue

Testing Revenue

The Company recognizes revenue for tests delivered when the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery has occurred or services rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured.

The first criterion is satisfied when a third-party payer makes a coverage decision or enters into a contractual arrangement with the Company for the test. The second criterion is satisfied when the Company performs the test and delivers the test result to the ordering physician. The third criterion is satisfied if the third-party payer’s coverage decision or reimbursement contract specifies a price for the test. The fourth criterion is satisfied based on management’s judgments regarding the collectability of the fees charged under the arrangement. Such judgments include review of past payment history. AlloMap testing may be considered investigational by some payers and not covered under their reimbursement policies. Others may cover the test, but not pay a set or determinable amount. As a result, in the absence of a reimbursement agreement or sufficient payment history, collectability cannot reasonably be assured so revenue is not recognized at the time the test is delivered.

If all criteria set forth above are met, revenue is recognized. When the first, third or fourth criteria are not met but third-party payers make a payment to the Company for tests performed, the Company recognizes revenue on the cash basis in the period in which the payment is received.

Revenue is recognized on the accrual basis net of adjustments for differences between amounts billed and the estimated receipts from payers. The amount the Company expects to collect may be lower than the agreed upon amount due to several factors, such as the amount of patient co-payments, the existence of secondary payers and claim denials. Estimated receipts are based upon historical payment practices of payers. Differences between estimated and actual cash receipts are recorded as an adjustment to revenue, which have been immaterial to date.

During the three and six months ended June 30, 2015, the Company changed its revenue recognized from one and three of its payers, respectively, from a cash basis to an accrual basis based on the Company’s consistent history of obtaining reimbursement from these three payers. The impact of this change in accounting estimate is to increase revenues by $79,000 and $127,000 and to reduce net loss per share by $0.01 for the three and six months ended June 30, 2015.

Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are excluded from revenue in the statements of operations.

Collaboration and License Revenue

Collaboration and License Revenue

The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis.

Cost of Testing

Cost of Testing

Cost of testing reflects the aggregate costs incurred in delivering the Company’s AlloMap test results to clinicians. The components of cost of testing are materials and service costs, direct labor costs, including stock-based compensation, equipment and infrastructure expenses associated with testing samples, shipping, logistics and specimen processing charges to collect and transport samples and allocated overhead including rent, information technology, equipment depreciation and utilities and royalties. Costs associated with performing tests (except royalties) are recorded as the test is processed regardless of whether and when revenue is recognized with respect to that test. As a result, our cost of testing as a percentage of revenue may vary significantly from period to period because we do not recognize all revenue in the period in which the associated costs are incurred. Royalties for licensed technology, calculated as a percentage of test revenues, are recorded as license fees in cost of testing at the time the test revenues are recognized.

Business Combinations

Business Combinations

In accordance with ASC 805, Business Combinations, the Company determines and allocates the purchase price of an acquired business to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, royalty rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.

Goodwill and indefinite-lived intangible assets including acquired in-process technology are reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that goodwill or indefinite-lived intangible assets may be impaired. The Company’s goodwill evaluation is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company assesses qualitative factors to determine if its sole reporting unit’s fair value is more likely than not to exceed its carrying value, including goodwill. In the event the Company determines that it is more likely than not that its reporting unit’s fair value is less than its carrying amount, quantitative testing is performed comparing recorded values to estimated fair values. If the fair value exceeds the carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, then the Company would calculate the potential impairment loss by comparing the implied fair value of goodwill with the carrying value. If the implied fair value of goodwill is less than the carrying value, then an impairment charge would be recorded. The Company performs its annual evaluation of goodwill during the fourth quarter of each fiscal year. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of the asset to its carrying value, without consideration of any recoverability test.

In those circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, Distinguishing Liabilities from Equity, the Company recognizes a liability equal to the fair value of the contingent payments the Company expects to make as of the acquisition date. The Company remeasures this liability each reporting period and records changes in the fair value as a component of operating expenses.

Transaction costs associated with these acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company’s operating results from the date of acquisition.

Stock-based Compensation

Stock-based Compensation

The Company uses the Black-Scholes option pricing model (“Black-Scholes Model”), which requires the use of estimates such as stock price volatility and expected option lives, to value employee stock options. The Company estimates the expected option lives using historical data, volatility using data of similar companies in the diagnostics industry, risk-free rates based on the implied yield currently available in the U.S. Treasury zero-coupon issues with a remaining term equal to the expected option lives, and dividend yield based on the Company’s expectations and historical data.

The Company uses the straight-line attribution method for recognizing compensation expense. Compensation expense is recognized on awards ultimately expected to vest and reduced for forfeitures that are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on the Company’s historical experience.

Compensation expense for stock options issued to nonemployees is calculated using the Black-Scholes Model and is recorded over the service performance period. Options subject to vesting are required to be periodically remeasured over their service performance period, which is generally the same as the vesting period.

Warrants

Warrants

The Company had freestanding warrants enabling counterparties to purchase shares of its convertible preferred stock which were converted to warrants to purchase common stock on the Company’s IPO date.

In accordance with the accounting guidance regarding distinguishing liabilities from equity, freestanding warrants for convertible preferred stock that are contingently redeemable are classified as liabilities on the balance sheet and recorded at their estimated fair value. These warrants are remeasured at each balance sheet date and any change in estimated fair value is recognized in other (expense) income, net, on the statements of operations.

Upon the completion of the Company’s IPO in July 2014, preferred stock warrants were converted into warrants to purchase common stock, and, accordingly, the liability was reclassified to equity and became no longer subject to remeasurement.

The Company has issued warrants to purchase shares of its common stock in connection with financing activities (see Note 9). The Company accounts for these warrants as equity at fair value on the date the warrants are issued. The fair value of the outstanding warrants is estimated using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the warrants, expected volatility and risk-free interest rate. Certain of these inputs are subjective and require significant analysis and judgment to develop. For the estimate of the expected term, the Company uses the full remaining contractual term of the warrant.

Comprehensive Loss

Comprehensive Loss

Net loss and comprehensive loss are the same for all periods presented.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled to when products are transferred to customers. On July 9, 2015, the FASB decided to delay the effective date of the new standard by one year. The standard would become effective for us beginning in the first quarter of 2018. Early application would be permitted in 2017. Entities would have the option of using either a full retrospective or a modified retrospective approach to adopt this new guidance. The Company is currently evaluating the impact of adopting the new revenue standard on its financial statements.

In April 2015, the FASB issued ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). This ASU requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is applicable to the Company beginning January 1, 2016. However, early adoption of ASU 2015-03 is permitted and the Company adopted ASU 2015-03 as of January 1, 2015 using the retrospective method as required. Debt discount and issuance costs, current, as of June 30, 2015 and December 31, 2014 were $176,000 and $76,000, respectively. Debt discount and issuance costs, non-current, as of June 30, 2015 and December 31, 2014 were $214,000 and $11,000, respectively. There is no impact from the adoption of ASU 2015-03 on the unaudited condensed statements of operations or in the loss per share calculations.

In April 2015, the FASB issued ASU 2015-05 Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) (“ASU 2015-05”). This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This ASU will be effective for annual periods, including interim periods beginning after December 15, 2015. Early adoption is permitted. An entity can elect to adopt the amendments either (1) prospectively to all arrangements entered into or materially modified after the effective date or (2) retrospectively. For prospective transition, the only disclosure requirements at transition are the nature of and reason for the change in accounting principle, the transition method, and a qualitative description of the financial statement line items affected by the change. For retrospective transition, the disclosure requirements at transition include the requirements for prospective transition and quantitative information about the effects of the accounting change. The Company is currently evaluating the impact of adopting ASU 2015-05 on its financial statements.

X

- Definition
Initial Public Offering [ Policy Text Block]
+ References
No definition available.
+ Details

Name: cdna_InitialPublicOfferingPolicyTextBlock

Namespace Prefix: cdna_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the fair value of warrants accounted for as a liability.
+ References
No definition available.
+ Details

Name: cdna_WarrantPolicyTextBlock

Namespace Prefix: cdna_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 05

-Paragraph 4

-Subparagraph (a)-(d)

-URI http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457

+ Details

Name: us-gaap_BusinessCombinationsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f(1))

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_CompensationRelatedCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61082-112788

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61044-112788

+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 50

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51666513&loc=d3e63676-111659

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_CostOfSalesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 05

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51717228&loc=d3e202-110218

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section CC

-Subsection 3

+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition for multiple-deliverable arrangements including, at a minimum (as applicable): (1) the nature of such arrangements, (2) the significant deliverables within the arrangements, (3) the general timing of delivery or performance of service for the deliverables within the arrangements, (4) performance-, cancellation-, termination- or refund-type provisions, (5) a discussion of the significant factors, inputs, assumptions, and methods used to determine selling price (whether vendor-specific objective evidence, third-party evidence, or estimated selling price) for the significant deliverables, (6) whether the significant deliverables in the arrangements qualify as separate units of accounting and the reasons that they do not qualify as separate units of accounting, if applicable, and (7) the general timing of revenue recognition for significant units of accounting. This element is applicable to all multiple-deliverable arrangements, including software arrangements (for example, software products, upgrades or enhancements, postcontract customer support, or services).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 25

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51671369&loc=d3e50766-111635

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 25

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51671369&loc=SL6750900-111635

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionMultipleElementArrangements

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21459-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_StockholdersEquityPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Revenue:

Testing revenue $ 7,044 $ 6,710 $ 14,139 $ 12,544

Collaboration and license revenue 85 66 205 156

Total revenue 7,129 6,776 14,344 12,700

Operating expenses:

Cost of testing 2,508 2,403 5,218 4,565

Research and development 2,510 792 3,931 1,512

Sales and marketing 2,526 1,610 4,549 3,084

General and administrative 2,329 2,316 5,034 4,111

Change in estimated fair value of contingent consideration 142 0 (111) 0

Total operating expenses 10,015 7,121 18,621 13,272

Loss from operations (2,886) (345) (4,277) (572)

Interest expense, net (256) (644) (1,083) (1,192)

Other (expense) income, net (43) 366 (97) (163)

Loss before income taxes (3,185) (623) (5,457) (1,927)

Income tax benefit 0 1,500 0 1,500

Net (loss) income $ (3,185) $ 877 $ (5,457) $ (427)

Net (loss) income per share (Note 3):

Basic $ (0.27) $ 0.87 $ (0.46) $ (0.42)

Diluted $ (0.27) $ 0.13 $ (0.46) $ (0.42)

Shares used to compute net (loss) income per share:

Basic 11,835,405 1,013,128 11,824,993 1,012,769

Diluted 11,835,405 6,939,568 11,824,993 1,012,769

X

- Definition
Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs related to services rendered by an entity during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51673353&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net amount of operating interest income (expense).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.10)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueServicesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
No definition available.
+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 45 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727

Commitments and Contingencies
6 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

7. COMMITMENTS AND CONTINGENCIES

Royalty Commitments

In November 2004, the Company entered into a license agreement with Roche Molecular Systems, Inc., or Roche, that grants the Company the right to use certain Roche technology relating to polymerase chain reaction, or PCR, and quantitative real-time PCR, in clinical laboratory services, including in connection with AlloMap. This is a non-exclusive license agreement in the United States covering claims in multiple Roche patents. The Company had disputed the combination services percentage Roche sought to apply under the agreement. The combination service percentage is a multiplier used to calculate royalties where licensed services are sold in combination with other services. From July 2011 through September 2014, the Company withheld payment of such royalties pending resolution of the matter. On February 11, 2014, Roche filed a demand for arbitration with the American Arbitration Association seeking a declaration that the Company had materially breached the Roche license agreement by failing to report and pay royalties owing to Roche in respect of licensed services performed by the Company after July 1, 2011. Since July 1, 2011, the Company fully accrued the unpaid royalties on the balance sheets, and the amount of the unpaid royalties has been reflected as an expense in the Company’s condensed statements of operations in the periods revenue was recorded to which the royalties relate.

In September 2014, the Company entered into a settlement and mutual release agreement with Roche whereby: (i) for the period beginning July 1, 2011 through June 30, 2014, the Company agreed to pay the amount of $2,827,220 in settlement of past royalties due; (ii) for the period beginning July 1, 2014 through September 30, 2014, the Company agreed to pay royalties based on the same combination services percentage used to determine the past royalties due; (iii) for the period beginning October 1, 2014 through September 30, 2017, Roche and the Company agreed to a downward adjustment of the combination services percentage used to determine the portion of the AlloMap testing revenue that is royalty bearing under the terms of the license; (iv) the Company agreed to report and pay quarterly royalties within 45 days of the end of each calendar quarter; (v) Roche agreed that, subject to the Company’s timely payment of all applicable royalties through such date, no further royalties will be payable by the Company for periods after September 30, 2017; (vi) the Company and Roche agreed to mutually release all claims under the license agreement through the settlement date; and (vii) Roche agreed to dismiss the arbitration claims. For all time periods, the contractual royalty rate in the license agreement was or will be applied to the applicable combination services percentage to determine the royalties’ payable for the AlloMap service.

Under the license agreement, the Company incurs royalty expenses as a percentage of combination services revenue and classifies those expenses as a component of cost of testing in the statements of operations. For the three months ended June 30, 2015 and 2014, royalty expenses in connection with the Roche agreement were $254,000 and $362,000, respectively. For the six months ended June 30, 2015 and 2014, royalty expenses in connection with the Roche agreement were $509,000 and $678,000, respectively.

Contingencies

The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, or results of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accrued and Other Liabilities
6 Months Ended

Jun. 30, 2015

Payables and Accruals [Abstract]

Accrued and Other Liabilities

6. ACCRUED AND OTHER LIABILITIES

The following table represents the components of accrued and other liabilities (in thousands):

 June 30,
2015 December 31,
2014

Professional fees
 $ 113 $ 273

Test sample processing fees
 383 318

Accrued overpayments and refunds
 117 146

Clinical Studies
 289 144

Deferred rent – current portion
 230 202

Capital leases – current portion
 62 70

Other accrued expenses
 646 463





Total accrued and other liabilities
 $ 1,840 $ 1,616





X

- Definition
The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock Incentive Plans (Tables)
6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Option Activity and Related Information

The following table summarizes option activity and related information:

 Stock
Options
Outstanding Weighted-
average
Exercise
Price

Balance—December 31, 2014
 1,031,804 $ 7.36

Granted
 525,078 7.74

Exercised
 (17,884 ) 2.35

Forfeited
 (23,844 ) 9.06





Balance—June 30, 2015
 1,515,154 $ 7.03





Summary of Options Outstanding and Exercisable Vested or Expected to Vest

Options outstanding and exercisable that have vested or are expected to vest as of June 30, 2015 are as follows:

 Number of
Shares Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual Life
(Years) Aggregate
Intrinsic
Value
(In thousands)

Vested
 576,815 $ 5.14 7.41 $ 1,750

Expected to Vest
 938,339 8.20 9.30 396





Total
 1,515,154 $ 2,146





Weighted-Average Assumptions Used to Fair Value of Share-Based Awards

The fair value of stock-based awards was estimated using the Black-Scholes option-pricing model using the following weighted-average assumptions:

 Three Months Ended June 30, Six Months Ended June 30,

 2015 2014 2015 2014

Expected term (in years)
 5.8 5.3 6.0 5.1

Expected volatility
 40.04 % 42.18 % 40.85 % 41.84 %

Risk-free interest rate
 1.69 % 1.74 % 1.87 % 1.70 %

Expected dividend yield
 — — — —

Summary of Unvested RSU Activity

Unvested RSU activity for the six months ended June 30, 2015 is summarized below:

 Number of Shares Weighted
Average
Grant-Date
Fair Value

Unvested balance at December 31, 2014
 — —

Granted
 114,400 $ 6.49

Vested
 — —

Forfeited
 (1,600 ) 6.49





Unvested balance at June 30, 2015
 112,800 $ 6.49





Schedule of Shares Issued and Associated Expense

The shares issued and associated expenses were as follows:

Service Period Three Months Ended
 Number of
Shares Issued Fair Market
Value per Share
at Date of
Issuance Fair Value of
Shares Issued
(In Thousands)

March 31, 2015
 8,663 5.56 $ 48

June 30, 2015
 11,628 6.48 75





Total
 20,291 $ 123





Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs

The Company’s results of operations include expense relating to employee and nonemployee stock-based payment awards from stock options and RSUs as follows (in thousands):

 Three Months Ended June 30, Six Months Ended June 30,

 2015 2014 2015 2014

Cost of testing
 $ 54 $ 9 $ 69 $ 9

Research and development
 89 21 136 22

Sales and marketing
 36 8 56 9

General and administrative
 232 99 431 145









 $ 411 $ 137 $ 692 $ 185









X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

+ Details

Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the changes in outstanding nonvested restricted stock units.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the following for fully vested share options (or share units) and share options expected to vest at the date of the latest statement of financial position: the number, weighted-average exercise price (or conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term of options (or share units) outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727

Net (Loss) Income Per Share (Tables)
6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net (Loss) Income Per Share

The following tables set forth the computation of the Company’s basic and diluted net (loss) income per share (in thousands, except share and per share data):

 Three Months Ended June 30, Six Months Ended June 30,

 2015 2014 2015 2014

Numerator:


Net (loss) income
 $ (3,185 ) $ 877 $ (5,457 ) $ (427 )

Add: interest expense related to subordinated convertible note, less gain on change in fair value of derivative related to subordinated convertible note
 — 15 — —









Net (loss) income attributable to common stockholders
 $ (3,185 ) $ 892 $ (5,457 ) $ (427 )









Denominator:


Weighted-average shares used to compute basic net (loss) income per common share
 11,835,405 1,013,128 11,824,993 1,012,769

Effect of potentially dilutive securities:


Employee stock options
 — 381,434 — —

Convertible preferred stock
 — 5,355,280 — —

Subordinated convertible note
 — 189,726 — —









Weighted-average shares used to compute diluted net (loss) income per common share
 11,835,405 6,939,568 11,824,993 1,012,769









Net (loss) income per share


Net (loss) income per common share - basic
 $ (0.27 ) $ 0.87 $ (0.46 ) $ (0.42 )









Net (loss) income per common share - diluted
 $ (0.27 ) $ 0.13 $ (0.46 ) $ (0.42 )









Potentially Dilutive Securities Excluded from Diluted Net (Loss) Income Per Share

The following potentially dilutive securities have been excluded from diluted net (loss) income per share, because their effect would be antidilutive:

 Three Months Ended June 30, Six Months Ended June 30,

 2015 2014 2015 2014

Shares of common stock subject to outstanding options
 1,515,154 469,163 1,515,154 907,318

Shares of common stock subject to outstanding common stock warrants
 576,096 82,190 576,096 82,190

Shares of common stock subject to conversion from preferred stock warrants
 — 541,613 — 541,613

Subordinated convertible note
 — — — 233,311

Convertible preferred stock
 — — — 6,048,220

Restricted stock units
 112,800 — 112,800 —









Total common stock equivalents
 2,204,050 1,092,966 2,204,050 7,812,652









X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock Incentive Plans
6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Incentive Plans

10. STOCK INCENTIVE PLANS

Stock Option Plans

Prior to its IPO, the Company had one active stock option plan, the 2008 Equity Incentive Plan (“2008 Plan”), one assumed stock option plan, the ImmuMetrix 2014 Equity Incentive Plan, and one terminated stock option plan, the 1998 Stock Plan.

Upon its IPO, the Company reserved 838,695 shares of common stock for issuance under a new 2014 Equity Incentive Plan (“2014 Plan”). The shares reserved for issuance under the 2014 Plan also include shares returned to the 2008 Plan as the result of expiration or termination of options, provided that the maximum number of shares that may be added to the 2014 Plan thereby is limited to a maximum of 865,252 shares. The number of shares available for issuance under the 2014 Plan also includes an annual increase on the first day of each year equal to the lessor of:

• 357,075 shares

• 4.0% of the outstanding shares of common stock as of the last day of the immediately preceding year; or

• such other number of shares as the Company’s board of directors may determine.

The following table summarizes option activity and related information:

 Stock
Options
Outstanding Weighted-
average
Exercise
Price

Balance—December 31, 2014
 1,031,804 $ 7.36

Granted
 525,078 7.74

Exercised
 (17,884 ) 2.35

Forfeited
 (23,844 ) 9.06





Balance—June 30, 2015
 1,515,154 $ 7.03





There were 444,108 shares available for the granting of stock options, restricted stock units and restricted stock from the 2014 Plan as of June 30, 2015.

Options outstanding and exercisable that have vested or are expected to vest as of June 30, 2015 are as follows:

 Number of
Shares Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual Life
(Years) Aggregate
Intrinsic
Value
(In thousands)

Vested
 576,815 $ 5.14 7.41 $ 1,750

Expected to Vest
 938,339 8.20 9.30 396





Total
 1,515,154 $ 2,146





The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock at June 30, 2015 for stock options that were in-the-money. The fair market value of the Company’s common stock as of June 30, 2015 was $6.50 per share.

The weighted-average grant-date fair value of options granted during the three and six months ended June 30, 2015 using the Black-Scholes Model was $2.10 and $2.62 per share, respectively.

Valuation Assumptions

The fair value of stock-based awards was estimated using the Black-Scholes option-pricing model using the following weighted-average assumptions:

 Three Months Ended June 30, Six Months Ended June 30,

 2015 2014 2015 2014

Expected term (in years)
 5.8 5.3 6.0 5.1

Expected volatility
 40.04 % 42.18 % 40.85 % 41.84 %

Risk-free interest rate
 1.69 % 1.74 % 1.87 % 1.70 %

Expected dividend yield
 — — — —

2014 Employee Stock Purchase Plan

Our board of directors adopted our 2014 Employee Stock Purchase Plan (the “ESPP”) in March 2014 and our stockholders approved the ESPP in July 2014. However, our ESPP was not made available to our employees until January 1, 2015. The first offering period of the ESPP began on January 1, 2015 and ended June 30, 2015. Under the first offering period, 36,696 were purchased under the ESPP. At June 30, 2015, the proceeds from the issuance of shares were $0.2 million and a total of 186,473 shares of our common stock is available for sale under the ESPP.

The option price per share of common stock to be paid by a participant upon exercise of the participant’s option on the applicable exercise date for an offering period shall be equal to 85% of the lesser of the fair market value of a share of common stock on (a) the applicable grant date or (b) the applicable exercise date.

Restricted Stock Units

The Company’s 2014 Plan allows restricted stock units (“RSUs”) to be granted in addition to stock options. The RSUs vest annually over four years in equal increments. RSUs were granted by the Company for the first time in March 2015.

Unvested RSU activity for the six months ended June 30, 2015 is summarized below:

 Number of Shares Weighted
Average
Grant-Date
Fair Value

Unvested balance at December 31, 2014
 — —

Granted
 114,400 $ 6.49

Vested
 — —

Forfeited
 (1,600 ) 6.49





Unvested balance at June 30, 2015
 112,800 $ 6.49





Non-Employee Director Equity-Based Compensation

For the three and six months ended June 30, 2015, the Company paid a portion of its non-employee directors’ compensation through the award of common shares. The stock awards are classified as equity-based compensation expense. Expenses associated with the awards were $75,000 and $123,000 for the three and six months ended June 30, 2015, respectively and are included in general and administrative expense in the condensed statement of operations. The shares issued and associated expenses were as follows:

Service Period Three Months Ended
 Number of
Shares Issued Fair Market
Value per Share
at Date of
Issuance Fair Value of
Shares Issued
(In Thousands)

March 31, 2015
 8,663 5.56 $ 48

June 30, 2015
 11,628 6.48 75





Total
 20,291 $ 123





The shares issued at each date were for services performed during the three-month period that ended one day prior to the date of issuance.

The Company’s results of operations include expense relating to employee and nonemployee stock-based payment awards from stock options and RSUs as follows (in thousands):

 Three Months Ended June 30, Six Months Ended June 30,

 2015 2014 2015 2014

Cost of testing
 $ 54 $ 9 $ 69 $ 9

Research and development
 89 21 136 22

Sales and marketing
 36 8 56 9

General and administrative
 232 99 431 145









 $ 411 $ 137 $ 692 $ 185









At June 30, 2015, there was approximately $3.7 million of total unrecognized stock-based compensation from stock option and RSU grants, net of estimated forfeitures, related to non-vested stock option and RSUs granted that will be recognized on a straight-line basis over the remaining vesting period of 3.2 years.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727

Collaboration and Licensing Agreements
6 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaboration and Licensing Agreements

8. COLLABORATION AND LICENSING AGREEMENTS

Laboratory Corporation of America Holdings (“LabCorp”)

In April 2012, CareDx and LabCorp entered into a collaboration and license agreement (“2012 Agreement”) to develop a lupus flare predictor test. The agreement provided for CareDx to license technology to LabCorp. Of the total arrangement consideration, the fair value of the license was assessed to be $1.0 million. The license term in the 2012 Agreement was the later of 10 years from the date of the agreement or the expiration of the last-to-expire patents and patent applications included in the CareDx technology licensed to LabCorp, unless the license was terminated by mutual agreement. The agreement provided that CareDx and LabCorp would share equally the costs of developing the lupus flare predictor test; however LabCorp’s share of the development cost was subject to certain limits at each stage of the arrangement.

Under the agreement, in 2012 LabCorp paid the Company a nonrefundable and non-creditable upfront license fee payment of $1,000,000, and a nonrefundable and non-creditable payment of $250,000 for certain lupus samples. The Company was to receive royalties in the high single digits from LabCorp on net sales of the commercialized flare predictor test or other tests developed using the samples sold.

Phase 1 of the project was completed in the first quarter of 2014.

On September 18, 2014, CareDx and LabCorp terminated the 2012 agreement. The termination agreement provides that:

• CareDx transfer and assign to LabCorp, 300 “SAGE I” clinical samples and related clinical data and documentation that CareDx obtained from patients during the discovery phase of the collaboration;

• CareDx grant a perpetual, non-exclusive worldwide, fully paid, sublicensable, royalty-free license to use any collaboration intellectual property and data for any and all purposes; and

• LabCorp pay $500,000 to CareDx within 30 days of CareDx’s delivery of the clinical samples and clinical data and documentation. No further royalties, milestone fees or other fees will be payable by LabCorp after the termination date.

During the three months ended December 31, 2014, the Company delivered the clinical samples and the related clinical data and documentation to LabCorp, and accordingly recognized the $500,000 termination fee and the remaining $611,000 previously unrecognized license fee.

During the three and six months ended June 30, 2014, the Company recognized $1,800 and $31,200, respectively, in revenue under this arrangement, which consisted of amortization of the upfront license fee of $0 and $15,000, respectively, and reimbursement of research and development expenses of $1,800 and $16,200, respectively. Such revenues are included in collaboration and license revenue on the unaudited condensed statements of operations. No revenues were recorded in 2015.

Included in research and development expenses were $3,600 and $32,000 for the three and six months ended June 30, 2014, respectively, for development costs associated with the 2012 Agreement. No research and development expenses were recorded in 2015.

Diaxonhit (“DHT”)

In June 2013, the Company entered into an exclusive Distribution and Licensing Agreement with DHT, a French public company, whereby DHT will have the AlloMap test performed in a European laboratory and commercialize the test in the European Economic Area (“EEA”). The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.

Consideration under the agreement includes an upfront cash payment of approximately €387,500 ($503,000) that is designated to offset royalties earned by the Company in the first three years following the first commercial sale. The Company is entitled to receive royalties from DHT as a percent of net sales, as defined in the agreement, of AlloMap tests in the mid to high teens. Approximately €250,000 ($344,000) of the upfront payments is refundable under certain circumstances. Upon confirmation that the CE mark was in place, the Company also received an equity payment of DHT common stock with a value of €387,500 ($503,000). The CE mark is a mandatory conformity marking for certain products sold within the EEA. These shares were promptly sold by the Company in July 2013 for total consideration of $467,000.

Other consideration that may be earned by the Company includes agreed-upon per unit pricing for the supply of AlloMap products, and additional royalties that are payable upon the achievement of various sales milestones by DHT. In this arrangement, there is one combined unit of accounting.

Commercial sales began in the EEA in June 2014. Total revenues recognized from this arrangement for the three and six months ended June 30, 2014 were $1,000 and for the three and six months ended June 30, 2015 were $16,000 and $33,000, respectively.

CardioDx, Inc. (“CDX”)

In 2005, the Company entered into a services agreement with CDX, whereby the Company provided CDX with biological samples and related data and performed laboratory services on behalf of CDX. Each company granted the other a worldwide license under certain of its intellectual property rights. Pursuant to this agreement, CDX pays royalties to the Company of a low single-digit percentage of the cash collected from sales of CDX licensed products. In 2009, CDX terminated the services portion of this agreement, however, the royalty obligation from CDX continues until the tenth anniversary of the first commercial sale of a CDX licensed product. The first commercial sale of such product by CDX occurred in 2009, therefore the royalty obligation to the Company continues until 2019. Two board members of CDX serve on the Company’s board of directors and are affiliated with stockholders of the Company. Royalty revenues, recorded when earned, were $89,000 and $59,000 for the three months ended June 30, 2015 and 2014, respectively, and were $179,000 and $117,000 for the six months ended June 30, 2015 and 2014, respectively, and are included in collaboration and license revenue on the condensed statements of operations. The Company had receivable balances from CDX of $179,000 and $54,000 at June 30, 2015 and December 31, 2014, respectively.

X

- Definition
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 808

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727

Debt
6 Months Ended

Jun. 30, 2015

Transfers and Servicing [Abstract]

Debt

9. DEBT

On January 30, 2015, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) which provides a secured term loan facility in an aggregate principal amount of up to $20.0 million. The Company borrowed the first advance of $16.0 million (“Draw A”) on January 30, 2015. Under the terms of the Loan Agreement, following a six month period from the closing date and until any time before December 31, 2015, the Company may, at its option, borrow from the lender a second advance of $4.0 million (“Draw B”), subject to the Company’s satisfaction of certain conditions described in the Loan Agreement. Draw A was used to payoff the Company’s existing term debt of $11.3 million. A loss on extinguishment of $0.6 million from the pay-off of the existing term loan was recognized as interest expense during the six months ended June 30, 2015. Draw A and Draw B each bear interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the lender.

The maturity date of the loan is December 1, 2018. Principal pay-down of the loan begins on January 1, 2016 with the loan being payable in 36 equal monthly installments. The principal pay-down of the loan may be delayed to July 1, 2016 with the loan being payable in 30 equal monthly installments, if on December 31, 2015, the Company has achieved certain net product revenue milestones as described in the Loan Agreement.

A fully non-refundable commitment fee of $160,000 was paid on January 30, 2015 when Draw A for $16 million was received. An additional $40,000 loan fee will be payable if Draw B for $4 million is received. The loan has no prepayment penalty. Commitment fees are included in debt issuance costs which are amortized to interest expense using the effective interest method over the term of the loan. Debt discount and issuance costs, current, as of June 30, 2015 and December 31, 2014 were $176,000 and $76,000, respectively. Debt discount and issuance costs, non-current, as of June 30, 2015 and December 31, 2014 were $214,000 and $11,000, respectively.

In connection with the Loan Agreement, the Company agreed to issue to the lender detachable warrants to purchase shares of the Company’s common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche. The fair value of the warrants are reflected as a discount to the debt. As a result of Draw A, the Company issued to the lender a warrant to purchase an aggregate of 34,483 shares of the Company’s common stock, at an exercise price equal to $6.96 per share. The fair value of the warrants was estimated to be $90,000 on January 30, 2015, using the Black-Scholes Model with the following assumptions: expected volatility of 39.83%, a contractual term of 5 years, risk-free interest rate of 1.18%, underlying common stock price of $7.06, and dividend yield of 0%. The warrants are included in stockholders’ equity with the offset to debt discount that is amortized over the term of the loan using the effective interest method. The warrants are not subject to remeasurement.

The Loan Agreement requires collateral by a security interest in all of the Company’s assets except intellectual property and contains customary affirmative and negative covenants including financial maintenance covenants, and also includes standard events of default, including payment defaults. Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. At June 30, 2015, the Company was in compliance with all loan covenants.

X

- Definition
The entire disclosure for certain contractual rights to receive money on demand or on fixed or determinable dates with evidence of deterioration of credit quality since origination that were acquired by completion of a transfer for which it is probable, at acquisition, that the investor will be unable to collect all contractually required payments receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5212-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15029-111544

+ Details

Name: us-gaap_AccountingForCertainLoansAndDebtSecuritiesAcquiredInTransferDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TransfersAndServicingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727

Business Combination
6 Months Ended

Jun. 30, 2015

Business Combinations [Abstract]

Business Combination

11. BUSINESS COMBINATION

On June 10, 2014, in accordance with an agreement and plan of merger, the Company acquired ImmuMetrix, Inc. (“IMX”), a privately held development stage company working in new technologies using cell-free donor DNA (“cfDNA”) technology for the diagnosis, treatment and management of transplant rejection, immune disorders and diseases, including the development of a new, non-invasive test designed to detect the early stages of solid organ transplant rejection. The Company acquired all IMX assets associated with transplant diagnostics, including related immune repertoire and infectious diseases. An IMX successor company retained the limited assets not associated with transplant diagnostics. The acquisition was structured as a tax-free reorganization.

The Company acquired all of the issued and outstanding capital stock of IMX for the total estimated purchase price of $17.2 million consisting of $600,000 in cash; 911,364 shares of the Company’s Series G convertible preferred stock with an estimated fair value of $14.2 million, including 23,229 shares of the Company’s Series G convertible preferred stock with an estimated fair value of $369,000 as a result of the Company’s assumption of IMX outstanding stock options; and an additional payment of 227,845 shares of CareDx Series G convertible preferred stock if a future milestone is achieved. The Agreement provides that the milestone will be achieved if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States no later than six years after the closing date of the acquisition. All shares of Series G Preferred Stock and options to acquire Series G Preferred Stock converted into common stock and options to acquire common stock, respectively, immediately prior to the closing of the Company’s initial public offering. The additional shares to be paid for the achievement of the milestone will also be issued in common stock. The fair value of this contingent consideration was $2.3 million at the acquisition date, $1.1 million at December 31, 2014, and $963,000 at June 30, 2015.

The intellectual property acquired includes an exclusive license from Stanford University to a patent relating to the diagnosis of rejection in organ transplant recipients using cfDNA. The license provides for the Company to pay royalties to Stanford University on sales of the Company’s cfDNA tests.

IMX’s post-acquisition results of operations for the three and six months ending June 30, 2015 are included in the Company’s condensed statement of operations.

Pro Forma Impact of the Acquisition of IMX

The following table presents pro forma results of operations and gives effect to the IMX transaction as if the transaction had been consummated on January 1, 2013. The unaudited pro forma results of operations have been prepared for comparative purposes only and are not necessarily indicative of what would have occurred had the business combination been completed at the beginning of the period or of the results that may occur in the future. Furthermore, the pro forma financial information does not reflect the impact of any reorganization or operating efficiencies resulting from combining the two companies (in thousands, except per share data):

Three Months Ended
June 30, 2014 Six Months Ended
June 30, 2014

Net revenue
$ 6,776 $ 12,700

Net loss
$ (518 ) $ (2,288 )

Net loss per common share - basic and diluted
$ (0.51 ) $ (2.26 )

The unaudited pro forma consolidated financial information was prepared using the acquisition method of accounting and is based on the historical financial information of the Company and IMX, reflecting the Company’s and IMX’s results of operations for the three and six month periods ending June 30, 2014. The historical financial information has been adjusted to give effect to the pro forma events that are: (i) directly attributable to the acquisition, (ii) factually supportable and (iii) expected to have a continuing impact on the combined results. The unaudited pro forma consolidated financial information reflects: (a) the removal of acquisition-related costs of $1.6 million and $1.7 million incurred by both CareDx and IMX for the three and six months ended June 30, 2014, respectively, including the removal of $0.2 million of IMX stock-based compensation expense that resulted from modifications to options in anticipation of the acquisition; (b) the removal of a $1.5 million tax benefit for the three and six months ended June 30, 2014 that resulted from the acquisition; (c) the addition of salaries, benefits and fees for IMX employees and consultants retained after the acquisition. Acquisition related expenses are primarily included in general and administrative expenses.

X

- Definition
The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R34.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accrued and Other Liabilities - Components of Accrued and Other Liabilities (Detail) - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Payables and Accruals [Abstract]

Professional fees $ 113 $ 273

Test sample processing fees 383 318

Accrued overpayments and refunds 117 146

Clinical Studies 289 144

Deferred rent - current portion 230 202

Capital leases - current portion 62 70

Other accrued expenses 646 463

Total accrued and other liabilities $ 1,840 $ 1,616

X

- Definition
Accrued Clinical And Cost Of Other Studies Current
+ References
No definition available.
+ Details

Name: cdna_AccruedClinicalAndCostOfOtherStudiesCurrent

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued Over payments And Refunds
+ References
No definition available.
+ Details

Name: cdna_AccruedOverPaymentsAndRefunds

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued Sample Processing Fees
+ References
No definition available.
+ Details

Name: cdna_AccruedSampleProcessingFees

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligations incurred and payable, pertaining to costs that are statutory in nature, incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include, but not limited to, taxes, interest, rent and utilities. Also includes the aggregate carrying amount of liabilities not separately disclosed.
+ References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of capital lease obligation due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_CapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DeferredRentCreditCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727

Inventories (Tables)
6 Months Ended

Jun. 30, 2015

Inventory Disclosure [Abstract]

Summary of Inventories

The following table summarizes the Company’s inventories (in thousands):

 June 30,
2015 December 31,
2014

Finished Goods
 $ 343 $ 277

Raw Materials
 388 409





Total Inventory
 $ 731 $ 686





X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R26.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary of Significant Accounting Policies - Additional Information - Concentration of Credit Risk (Detail)
6 Months Ended 12 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2014

Services Revenue [Member] | Customer Concentration Risk [Member] | Minimum [Member]

Concentration Risk [Line Items]

Concentration risk, percentage 10.00% 10.00%

Services Revenue [Member] | Customer Concentration Risk [Member] | Medicare [Member]

Concentration Risk [Line Items]

Concentration risk, percentage 50.00% 49.00%

Accounts Receivable [Member] | Credit Concentration Risk [Member] | Minimum [Member]

Concentration Risk [Line Items]

Concentration risk, percentage 10.00% 10.00%

Accounts Receivable [Member] | Credit Concentration Risk [Member] | Medicare [Member]

Concentration Risk [Line Items]

Concentration risk, percentage 40.00% 78.00%

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueServicesNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=cdna_MedicareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R41.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock Incentive Plans - Weighted-Average Assumptions Used to Fair Value of Share-Based Awards (Detail)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Expected term (in years) 5 years 9 months 18 days 5 years 3 months 18 days 6 years 5 years 1 month 6 days

Expected volatility 40.04% 42.18% 40.85% 41.84%

Risk-free interest rate 1.69% 1.74% 1.87% 1.70%

Expected dividend yield 0.00% 0.00% 0.00% 0.00%

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 57 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Operating activities:

Net loss $ (5,457) $ (427)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

Depreciation and amortization 358 222

Stock-based compensation 692 185

Amortization of deferred revenue (59) (23)

Amortization of debt discount and non-cash interest expense 450 349

Revaluation of contingent consideration to estimated fair value (111) 0

Revaluation of warrants to estimated fair value 0 283

Gain on remeasurement of embedded derivative 0 (118)

Non-cash income tax benefit 0 (1,500)

Changes in operating assets and liabilities:

Accounts receivable 981 545

Inventory (45) (96)

Prepaid and other assets (108) (2,152)

Accounts payable (116) 1,123

Accrued payroll liabilities 367 (196)

Accrued and other liabilities 274 2,117

Accrued royalties 27 721

Net cash (used in) provided by operating activities (2,747) 1,033

Investing activities:

Purchase of property and equipment (733) (164)

Payment for acquisition, net of cash acquired (Note 11) 0 (376)

Net cash used in investing activities (733) (540)

Financing activities:

Payment of initial public offering costs 0 (909)

Proceeds from debt, net of issuance costs 15,625 4,982

Proceeds from exercise of stock options 42 5

Principal payments on debt and capital leases (11,724) (1,827)

Net cash provided by financing activities 3,943 2,251

Net increase in cash and cash equivalents 463 2,744

Cash and cash equivalents at beginning of period 36,431 5,128

Cash and cash equivalents at end of period $ 36,894 $ 7,872

X

- Definition
The amount of amortization of deferred revenue during the period.
+ References
No definition available.
+ Details

Name: cdna_AmortizationOfDeferredRevenue

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Increase in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

+ Details

Name: us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the period in accrued salaries.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedSalaries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpensesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInRoyaltiesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_OtherNoncashIncomeTaxExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow associated with security instruments that either represent a creditor or an ownership relationship with the holder of the investment security with a maturity of beyond one year or normal operating cycle, if longer. Includes repayments of (a) debt, (b) capital lease obligations, (c) mandatory redeemable capital securities, and (d) any combination of (a), (b), or (c).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 58 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727

Inventories
6 Months Ended

Jun. 30, 2015

Inventory Disclosure [Abstract]

Inventories

5. INVENTORIES

The following table summarizes the Company’s inventories (in thousands):

 June 30,
2015 December 31,
2014

Finished Goods
 $ 343 $ 277

Raw Materials
 388 409





Total Inventory
 $ 731 $ 686





X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 59 R27.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2014

Summary Of Significant Accounting Policies [Line Items]

Cash equivalents maturity, description Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.

Impact on revenue, change in accounting estimate $ 7,129,000 $ 6,776,000 $ 14,344,000 $ 12,700,000

Impact on loss per share, change in accounting estimate $ (0.01) $ (0.01)

Debt discount and issuance liability component, current $ 176,000 $ 176,000 $ 76,000

Debt discount and issuance liability component, non-current $ 214,000 $ 214,000 11,000

Loss Per Share $ (0.27) $ 0.87 $ (0.46) $ (0.42)

Name of the New Accounting Pronouncement ASU 2015-03

New Accounting Pronouncement, Early Adoption, Effect [Member]

Summary Of Significant Accounting Policies [Line Items]

Debt discount and issuance liability component, current $ 176,000 $ 176,000 76,000

Debt discount and issuance liability component, non-current 214,000 $ 214,000 $ 11,000

Loss Per Share $ 0 $ 0

Statements of Operations $ 0 $ 0

Change in Accounting Method Accounted for as Change in Estimate [Member]

Summary Of Significant Accounting Policies [Line Items]

Impact on revenue, change in accounting estimate $ 79,000 $ 127,000

Impact of change in accounting estimate The Company changed its revenue recognized from one and three of its payers, respectively, from a cash basis to an accrual basis based on the Company's consistent history of obtaining reimbursement from these three payers. The impact of this change in accounting estimate is to increase revenues by $79,000 and $127,000 and to reduce net loss per share by $0.01 for the three and six months ended June 30, 2015.

X

- Definition
Debt Issuance And Discount Component Of Recognized Debt Liability Current
+ References
No definition available.
+ Details

Name: cdna_DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Debt Issuance And Discount Component Of Recognized Debt Liability Non Current
+ References
No definition available.
+ Details

Name: cdna_DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent

Namespace Prefix: cdna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Summary Of Significant Accounting Policies [Line Items]
+ References
No definition available.
+ Details

Name: cdna_SummaryOfSignificantAccountingPoliciesLineItems

Namespace Prefix: cdna_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
An element designated to encapsulate any additional information related to cash and cash equivalents not otherwise addressed by the existing taxonomy. Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_AdditionalCashAndCashEquivalentRelatedText

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of the effect on income from continuing operations, net income (or other appropriate captions of changes in applicable net assets or performance indicator), and any related per-share amounts of the current period when a change in accounting estimate affects several future periods.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e777-108305

+ Details

Name: us-gaap_ChangeInAccountingEstimateFinancialEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Describe the name or caption for the new accounting pronouncement or change in accounting principle.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Indirect Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6515603

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section S99

-Paragraph 5

-Subparagraph (SAB TOPIC 11.M)

-URI http://asc.fasb.org/extlink&oid=26874127&loc=d3e31137-122693

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6507316

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Direct Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6510796

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Accounting Change

-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 11

-Section M

+ Details

Name: us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleName

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 156 292 1 false 50 0 false 7 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.caredxinc.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Balance Sheets Sheet http://www.caredxinc.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.caredxinc.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Statements of Operations Sheet http://www.caredxinc.com/taxonomy/role/StatementOfIncome Condensed Statements of Operations Statements 4 false false R5.htm 106 - Statement - Condensed Statements of Cash Flows Sheet http://www.caredxinc.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Statements of Cash Flows Statements 5 false false R6.htm 107 - Disclosure - Organization Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Organization Notes 6 false false R7.htm 108 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies Notes 7 false false R8.htm 109 - Disclosure - Net (Loss) Income Per Share Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net (Loss) Income Per Share Notes 8 false false R9.htm 110 - Disclosure - Fair Value Measurements Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements Notes 9 false false R10.htm 111 - Disclosure - Inventories Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock Inventories Notes 10 false false R11.htm 112 - Disclosure - Accrued and Other Liabilities Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Accrued and Other Liabilities Notes 11 false false R12.htm 113 - Disclosure - Commitments and Contingencies Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 12 false false R13.htm 114 - Disclosure - Collaboration and Licensing Agreements Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock Collaboration and Licensing Agreements Notes 13 false false R14.htm 115 - Disclosure - Debt Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsAccountingForCertainLoansAndDebtSecuritiesAcquiredInTransferDisclosureTextBlock Debt Notes 14 false false R15.htm 116 - Disclosure - Stock Incentive Plans Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock Incentive Plans Notes 15 false false R16.htm 117 - Disclosure - Business Combination Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Business Combination Notes 16 false false R17.htm 118 - Disclosure - Subsequent Event Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Event Notes 17 false false R18.htm 119 - Disclosure - Organization (Policies) Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies Organization (Policies) Policies http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 18 false false R19.htm 120 - Disclosure - Net (Loss) Income Per Share (Tables) Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net (Loss) Income Per Share (Tables) Tables http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 19 false false R20.htm 121 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) Tables http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock 20 false false R21.htm 122 - Disclosure - Inventories (Tables) Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables Inventories (Tables) Tables http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock 21 false false R22.htm 123 - Disclosure - Accrued and Other Liabilities (Tables) Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables Accrued and Other Liabilities (Tables) Tables http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock 22 false false R23.htm 124 - Disclosure - Stock Incentive Plans (Tables) Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock Incentive Plans (Tables) Tables http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 23 false false R24.htm 125 - Disclosure - Business Combination (Tables) Sheet http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables Business Combination (Tables) Tables http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock 24 false false R25.htm 126 - Disclosure - Organization - Additional Information (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureOrganizationAdditionalInformation Organization - Additional Information (Detail) Details 25 false false R26.htm 127 - Disclosure - Summary of Significant Accounting Policies - Additional Information - Concentration of Credit Risk (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationConcentrationOfCreditRisk Summary of Significant Accounting Policies - Additional Information - Concentration of Credit Risk (Detail) Details 26 false false R27.htm 128 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) Details 27 false false R28.htm 129 - Disclosure - Net (Loss) Income Per Share - Computation of Basic and Diluted Net (Loss) Income Per Share (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShare Net (Loss) Income Per Share - Computation of Basic and Diluted Net (Loss) Income Per Share (Detail) Details http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables 28 false false R29.htm 130 - Disclosure - Net (Loss) Income Per Share - Potentially Dilutive Securities Excluded from Diluted Net (Loss) Income Per Share (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureNetLossIncomePerSharePotentiallyDilutiveSecuritiesExcludedFromDilutedNetLossIncomePerShare Net (Loss) Income Per Share - Potentially Dilutive Securities Excluded from Diluted Net (Loss) Income Per Share (Detail) Details http://www.caredxinc.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables 29 false false R30.htm 131 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureFairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasis Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) Details 30 false false R31.htm 132 - Disclosure - Fair Value Measurements - Summary of Issuances, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfIssuancesChangesInFairValueAndReclassificationsOfLevel3FinancialInstruments Fair Value Measurements - Summary of Issuances, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments (Detail) Details 31 false false R32.htm 133 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation Fair Value Measurements - Additional Information (Detail) Details 32 false false R33.htm 134 - Disclosure - Inventories - Summary of Inventories (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureInventoriesSummaryOfInventories Inventories - Summary of Inventories (Detail) Details 33 false false R34.htm 135 - Disclosure - Accrued and Other Liabilities - Components of Accrued and Other Liabilities (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureAccruedAndOtherLiabilitiesComponentsOfAccruedAndOtherLiabilities Accrued and Other Liabilities - Components of Accrued and Other Liabilities (Detail) Details 34 false false R35.htm 136 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Collaboration and Licensing Agreements - Additional Information (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureCollaborationAndLicensingAgreementsAdditionalInformation Collaboration and Licensing Agreements - Additional Information (Detail) Details 36 false false R37.htm 138 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureDebtAdditionalInformation Debt - Additional Information (Detail) Details 37 false false R38.htm 139 - Disclosure - Stock Incentive Plans - Additional Information (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformation Stock Incentive Plans - Additional Information (Detail) Details 38 false false R39.htm 140 - Disclosure - Stock Incentive Plans - Summary of Option Activity and Related Information (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityAndRelatedInformation Stock Incentive Plans - Summary of Option Activity and Related Information (Detail) Details 39 false false R40.htm 141 - Disclosure - Stock Incentive Plans - Summary of Options Outstanding and Exercisable Vested or Expected to Vest (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionsOutstandingAndExercisableVestedOrExpectedToVest Stock Incentive Plans - Summary of Options Outstanding and Exercisable Vested or Expected to Vest (Detail) Details 40 false false R41.htm 142 - Disclosure - Stock Incentive Plans - Weighted-Average Assumptions Used to Fair Value of Share-Based Awards (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureStockIncentivePlansWeightedAverageAssumptionsUsedToFairValueOfShareBasedAwards Stock Incentive Plans - Weighted-Average Assumptions Used to Fair Value of Share-Based Awards (Detail) Details 41 false false R42.htm 143 - Disclosure - Stock Incentive Plans - Summary of Unvested RSU Activity (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureStockIncentivePlansSummaryOfUnvestedRSUActivity Stock Incentive Plans - Summary of Unvested RSU Activity (Detail) Details 42 false false R43.htm 144 - Disclosure - Stock Incentive Plans - Schedule of Shares Issued and Associated Expense (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureStockIncentivePlansScheduleOfSharesIssuedAndAssociatedExpense Stock Incentive Plans - Schedule of Shares Issued and Associated Expense (Detail) Details 43 false false R44.htm 145 - Disclosure - Stock Incentive Plans - Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureStockIncentivePlansSummaryOfExpenseRelatingToEmployeeAndNonemployeeStockBasedPaymentAwardsFromStockOptionsAndRSUs Stock Incentive Plans - Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs (Detail) Details 44 false false R45.htm 146 - Disclosure - Business Combination - Additional Information (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureBusinessCombinationAdditionalInformation Business Combination - Additional Information (Detail) Details 45 false false R46.htm 147 - Disclosure - Business Combination - Schedule of Pro Forma Results of Operations (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureBusinessCombinationScheduleOfProFormaResultsOfOperations Business Combination - Schedule of Pro Forma Results of Operations (Detail) Details 46 false false R47.htm 148 - Disclosure - Subsequent Event - Additional Information (Detail) Sheet http://www.caredxinc.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation Subsequent Event - Additional Information (Detail) Details 47 false false All Reports Book All Reports In ''Condensed Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Statements of Cash Flows'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. cdna-20150630.xml cdna-20150630_cal.xml cdna-20150630_def.xml cdna-20150630_lab.xml cdna-20150630_pre.xml cdna-20150630.xsd true true XML 61 R38.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock Incentive Plans - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended

Jan. 01, 2014

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Mar. 31, 2015

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair market value of Company's common stock $ 6.48 $ 6.48 $ 5.56

Weighted-average fair value of options granted $ 2.10 $ 2.62

Share based compensation, Total expensed $ 411 $ 137 $ 692 $ 185

Total unrecognized stock-based compensation expense related to stock options and RSUs 3,700 $ 3,700

RSUs granted remaining vesting period 3 years 2 months 12 days

General and administrative [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation, Total expensed $ 232 $ 99 $ 431 $ 145

Restricted Stock Units (RSUs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

RSUs vest annual equal increments (in years) 4 years

RSUs granted period 2015-03

2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares reserved for issuance of common stock 357,075 838,695 838,695

Maximum number of shares may be added to the plan hereunder 865,252

Outstanding shares of common stock, in percentage 4.00%

2014 Equity Incentive Plan [Member] | Stock Options, Restricted Stock Units and Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares available for grant 444,108 444,108

2014 Employee Stock Purchase Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares available for grant 186,473 186,473

Shares issued under ESPP 36,696

Proceeds from the issuance of shares $ 200

Applicable exercise date an offering period shall be equal to percentage of the lesser of fair market value of common stock 85.00%

X

- Definition
Share based compensation arrangement by share based payments award grant date.
+ References
No definition available.
+ Details

Name: cdna_ShareBasedCompensationArrangementByShareBasedPaymentsAwardGrantDate

Namespace Prefix: cdna_

Data Type: xbrli:gYearMonthItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards other than stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Discount rate from fair value on offering date that participants pay for shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of an employee stock purchase plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=cdna_TwoThousandAndFourteenEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=cdna_StockOptionsAndRestrictedStockUnitsAndRestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value Measurements (Tables)
6 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value of Financial Assets and Liabilities Measured on Recurring Basis

The following table sets forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis, as of June 30, 2015 and December 31, 2014 (in thousands):

 June 30, 2015

 Fair Value Measured Using

 (Level 1) (Level 2) (Level 3) Total
Balance

Assets


Money market funds
 $ 33,463 $ — $ — $ 33,463









Liabilities


Contingent consideration
 $ — $ — $ 963 $ 963









Debt
 $ — $ 15,104 $ — $ 15,104









 December 31, 2014

 Fair Value Measured Using

 (Level 1) (Level 2) (Level 3) Total
Balance

Assets


Money market funds
 $ 36,779 $ — $ — $ 36,779









Liabilities


Contingent consideration
 $ — $ — $ 1,074 $ 1,074









Debt
 $ — $ 12,204 $ — $ 12,204









Summary of Issuances, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments

The following table presents the issuances, changes in fair value and reclassifications of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):

 Level 3

 Contingent
Consideration
Liability Warrants to
Purchase
Convertible
Preferred
Stock Derivative Liability
Related to
Subordinated
Convertible Note Total

Balance as of December 31, 2013
 $ — $ 525 $ — $ 525

Issuance of financial instruments
 2,313 — 239 2,552

Change in estimated fair value
 (1,239 ) 14 (239 ) (1,464 )

Reclassification to stockholders’ equity
 — (539 ) (539 )









Balance as of December 31, 2014
 1,074 — — 1,074

Change in estimated fair value
 (111 ) — — (111 )









Balance as of June 30, 2015
 $ 963 $ — $ — $ 963









X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Large accelerated filer

Accelerated filer

Non-accelerated filer

x (Do not check if a smaller reporting company)

Smaller reporting company

Business Combination - Schedule of Pro Forma Results of Operations (Detail) - Jun. 30, 2014 - ImmuMetrix, Inc. [Member] - USD ($) $ / shares in Units, $ in Thousands	Total	Total
Business Acquisition [Line Items]
Net revenue	$ 6,776	$ 12,700
Net loss	$ (518)	$ (2,288)
Net loss per common share - basic and diluted	$ (0.51)	$ (2.26)

Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Finished Goods	$ 343	$ 277
Raw Materials	388	409
Total Inventory	$ 731	$ 686

Organization - Additional Information (Detail)				1 Months Ended	6 Months Ended
Organization - Additional Information (Detail)	Aug. 13, 2014 shares	Jul. 22, 2014 USD ($) $ / shares shares	Jul. 01, 2014	Jul. 31, 2013 USD ($)	Jun. 30, 2015 USD ($) CommercialTests Segment	Jun. 30, 2014 USD ($)	Aug. 10, 2015 USD ($)
Schedule of Capitalization, Equity [Line Items]
Number of commercialized testing solution \| CommercialTests					1
Number of operating segment \| Segment					1
Issuance of additional shares pursuant to exercise of underwriters' overallotment option \| shares	220,000
Underwriting discounts and commissions					$ 0	$ 909,000
Net proceeds from issuance of initial public offering				$ 467,000
Shelf filing date					Aug. 10, 2015
IPO [Member]
Schedule of Capitalization, Equity [Line Items]
Common stock shares issued from IPO \| shares		4,000,000
Public offering price per share \| $ / shares		$ 10.00
Underwriting discounts and commissions		$ 3,000,000
Proceeds from initial public offering net of underwriting discounts and commissions		39,200,000
Offering expenses		3,700,000
Net proceeds from issuance of initial public offering		$ 35,500,000
Common Stock [Member]
Schedule of Capitalization, Equity [Line Items]
Shares issued upon conversion \| shares		6,048,220
Subsequent Event [Member] \| Maximum [Member]
Schedule of Capitalization, Equity [Line Items]
Shelf filing maximum authorization amount							$ 75,000,000
Convertible Subordinated Debt [Member]
Schedule of Capitalization, Equity [Line Items]
Shares issued upon conversion \| shares		510,777
Convertible note principal amount		$ 5,000,000
Amendment [Member]
Schedule of Capitalization, Equity [Line Items]
Reverse stock split, ratio			0.145985401
Reverse stock split					1 for 6.85
Reverse Stock Split effective date					Jul. 14, 2014

Stock Incentive Plans - Summary of Unvested RSU Activity (Detail) - 6 months ended Jun. 30, 2015 - Restricted Stock Units (RSUs) [Member] - $ / shares	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Unvested beginning balance	0
Number of Shares, Granted	114,400
Number of Shares, Vested	0
Number of Shares, Forfeited	(1,600)
Number of Shares, Unvested ending balance	112,800
Weighted Average Grant- Date Fair Value, Unvested beginning balance	$ 0
Weighted Average Grant- Date Fair Value, Granted	6.49
Weighted Average Grant- Date Fair Value, Vested	0
Weighted Average Grant- Date Fair Value, Forfeited	6.49
Weighted Average Grant- Date Fair Value, Unvested ending balance	$ 6.49

Debt - Additional Information (Detail) - USD ($)		6 Months Ended
Debt - Additional Information (Detail) - USD ($)	Jan. 30, 2015	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Aggregate principal amount	$ 20,000,000
Interest rate, description		Draw A and Draw B each bear interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the lender.
Interest rate basis spread	2.00%
Loan agreement initiation date		Jan. 30, 2015
Maturity date of term loan facility		Dec. 01, 2018
Principal pay-down of loan begins date		Jan. 01, 2016
Deferred principal amortization description		Principal pay-down of the loan begins on January 1, 2016 with the loan being payable in 36 equal monthly installments. The principal pay-down of the loan may be delayed to July 1, 2016 with the loan being payable in 30 equal monthly installments, if on December 31, 2015, the Company has achieved certain net product revenue milestones as described in the Loan Agreement.
Debt discount and issuance liability component, current		$ 176,000	$ 76,000
Debt discount and issuance liability component, non-current		$ 214,000	$ 11,000
Prepayment penalty on loan		0.00%
Loan agreement description		The Company agreed to issue to the lender detachable warrants to purchase shares of the Company's common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche.
Estimated fair value of warrants	$ 90,000
Default interest rate description		Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.
Default interest rate percentage		5.00%
Interest Expense [Member]
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 600,000
Common Stock [Member]
Debt Instrument [Line Items]
Warrant to purchase of common stock, shares	34,483
Warrant to purchase of common stock, per share	$ 6.96
Warrants To Purchase Common Stock [Member]
Debt Instrument [Line Items]
Expected volatility rate	39.83%
Contractual term of years	5 years
Risk-free interest rate	1.18%
Underlying common stock price	$ 7.06
Dividend yield	0.00%
Draw A [Member]
Debt Instrument [Line Items]
Loan agreement, amount borrowed	$ 16,000,000
Pay-off of term debt	11,300,000
Non-refundable commitment fee	160,000
Draw B [Member]
Debt Instrument [Line Items]
Loan agreement, amount available to borrow	$ 4,000,000
Non-refundable commitment fee		$ 40,000

Subsequent Event - Additional Information (Detail) - USD ($)		6 Months Ended
	Aug. 10, 2015	Jun. 30, 2015
Subsequent Event [Line Items]
Shelf filing date		Aug. 10, 2015
Percentage of commission on gross proceeds of sales price		3.00%
At Market Issuance Sales Agreement [Member]
Subsequent Event [Line Items]
Sale of stock description		It may sell shares of its common stock from time to time in an aggregate amount not to exceed $19 million per year per the 2015 ATM Agreement and not to exceed $75 million in total per the Shelf Filing.
Subsequent Event [Member]
Subsequent Event [Line Items]
Sale of common stock, aggregate amount per year	$ 19,000,000
Subsequent Event [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Shelf filing maximum authorization amount	$ 75,000,000

Stock Incentive Plans - Schedule of Shares Issued and Associated Expense (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares Issued	11,628	8,663	20,291
Fair Market Value per Share at Date of Issuance	$ 6.48	$ 5.56	$ 6.48
Fair Value of Shares Issued	$ 75	$ 48	$ 123

Net (Loss) Income Per Share - Potentially Dilutive Securities Excluded from Diluted Net (Loss) Income Per Share (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total	2,204,050	1,092,966	2,204,050	7,812,652
Convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total	0	0	0	6,048,220
Convertible Subordinated Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total	0	0	0	233,311
Shares of common stock subject to outstanding options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total	1,515,154	469,163	1,515,154	907,318
Shares of common stock subject to outstanding common stock warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total	576,096	82,190	576,096	82,190
Shares of common stock subject to conversion from preferred stock warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total	0	541,613	0	541,613
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net income (loss) per share attributable to common stockholders, Total	112,800	0	112,800	0

Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Assets
Money market funds	$ 33,463	$ 36,779
Liabilities
Contingent consideration	963	1,074
Debt	15,104	12,204
Fair Value Measured Using - (Level 1) [Member]
Assets
Money market funds	33,463	36,779
Liabilities
Contingent consideration	0	0
Debt	0	0
Fair Value Measured Using - (Level 2) [Member]
Assets
Money market funds	0	0
Liabilities
Contingent consideration	0	0
Debt	15,104	12,204
Fair Value Measured Using - (Level 3) [Member]
Assets
Money market funds	0	0
Liabilities
Contingent consideration	963	1,074
Debt	$ 0	$ 0

Fair Value Measurements - Summary of Issuances, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Significant Unobservable Inputs (Level 3) [Line Items]
Beginning Balance	$ 1,074	$ 525
Issuance of financial instruments		2,552
Change in estimated fair value	(111)	(1,464)
Reclassification to stockholders' equity		(539)
Ending Balance	963	1,074
Significant Unobservable Inputs (Level 3), Warrants to Purchase Convertible Preferred Stock [Member]
Significant Unobservable Inputs (Level 3) [Line Items]
Beginning Balance	0	525
Issuance of financial instruments		0
Change in estimated fair value	0	14
Reclassification to stockholders' equity		(539)
Ending Balance	0	0
Significant Unobservable Inputs (Level 3), Derivative Liability Related to Subordinated Convertible Note [Member]
Significant Unobservable Inputs (Level 3) [Line Items]
Beginning Balance	0	0
Issuance of financial instruments		239
Change in estimated fair value	0	(239)
Ending Balance	0	0
Significant Unobservable Inputs (Level 3), Contingent Consideration Liability [Member]
Significant Unobservable Inputs (Level 3) [Line Items]
Beginning Balance	1,074	0
Issuance of financial instruments		2,313
Change in estimated fair value	(111)	(1,239)
Reclassification to stockholders' equity		0
Ending Balance	$ 963	$ 1,074

Fair Value Measurements - Additional Information (Detail)					1 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2015 CommercialTests shares	Dec. 31, 2014	Jun. 30, 2014 USD ($)	Apr. 17, 2014 USD ($)	Jul. 31, 2014 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($) CommercialTests	Jun. 30, 2014 USD ($)
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Transfers between Level 1, Level 2 and Level 3 categories during the periods							$ 0
Number of commercial tests involving the measurement of cfDNA to be completed \| CommercialTests							1
(Gain) loss in estimated fair value						$ (245,000)	$ 0	$ 283,000
Estimated fair value of embedded derivative liabilities			$ 239,000			239,000		239,000
Fair value of derivative			$ 120,000			120,000		120,000
Gain on derivative						$ 119,000		$ 119,000
Illumina, Inc. [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Subordinated convertible promissory note issued				$ 5,000,000
ImmuMetrix, Inc. [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Number of commercial tests involving the measurement of cfDNA to be completed \| CommercialTests	2,500						2,500
Milestone description							The milestone will be achieved if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States no later than six years after the closing date of the acquisition.
Contingent consideration maturity date							Jun. 10, 2020
IPO [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Change in control for repayment			5.00%	10.00%
Fair value of derivative					$ 0
Gain on derivative					$ 120,000
Contingent consideration [Member] \| ImmuMetrix, Inc. [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Contingent obligation to issue common stock \| shares	227,845
Milestone description							The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States by June 10, 2020.
Probability of the achievement	65.00%	65.00%

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 36,894	$ 36,431
Accounts receivable	1,706	2,687
Inventory	731	686
Prepaid and other assets	674	542
Total current assets	40,005	40,346
Property and equipment, net	2,559	1,968
Intangible assets, net	6,650	6,650
Goodwill	12,005	12,005
Restricted cash	147	147
Other noncurrent assets	0	25
Total assets	61,366	61,141
Current liabilities:
Accounts payable	1,203	1,128
Accrued payroll liabilities	2,051	1,684
Accrued and other liabilities	1,840	1,616
Accrued royalties	268	241
Deferred revenue	500	505
Current portion of long-term debt	2,380	5,961
Total current liabilities	8,242	11,135
Deferred rent, net of current portion	1,554	1,684
Deferred revenue, net of current portion	417	471
Long-term debt, net of current portion	13,389	5,451
Contingent consideration	963	1,074
Other liabilities	28	28
Total liabilities	$ 24,593	$ 19,843
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock: $0.001 par value; 10,000,000 shares authorized at June 30, 2015 and December 31, 2014; no shares issued and outstanding at June 30, 2015 and December 31, 2014	$ 0	$ 0
Common stock: $0.001 par value; 100,133,900 and 100,000,000 shares authorized at June 30, 2015 and December 31, 2014, respectively; 11,838,794 and 11,803,970 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	12	12
Additional paid-in capital	201,595	200,661
Accumulated deficit	(164,834)	(159,375)
Total stockholders' equity	36,773	41,298
Total liabilities and stockholders' equity	$ 61,366	$ 61,141

Business Combination - Additional Information (Detail)				3 Months Ended	6 Months Ended
Business Combination - Additional Information (Detail)	Jun. 30, 2015 USD ($) CommercialTests shares	Dec. 31, 2014 USD ($)	Jun. 10, 2014 USD ($) shares	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($) CommercialTests	Jun. 30, 2014 USD ($)
Business Acquisition [Line Items]
Number of commercial tests involving the measurement of cfDNA to be completed \| CommercialTests					1
Stock-based compensation					$ 692,000	$ 185,000
ImmuMetrix, Inc. [Member]
Business Acquisition [Line Items]
Acquisition date					Jun. 10, 2014
Estimated purchase price			$ 17,200,000
Business acquisition purchase price, cash			$ 600,000
Milestone description					The milestone will be achieved if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States no later than six years after the closing date of the acquisition.
Number of commercial tests involving the measurement of cfDNA to be completed \| CommercialTests	2,500				2,500
Milestone measurement period					6 years
Business combination pro forma removal (addition) in income tax benefit				$ 1,500,000		1,500,000
ImmuMetrix, Inc. [Member] \| Contingent consideration [Member]
Business Acquisition [Line Items]
Shares issued, shares issuable upon achievement of future milestone, and options assumed \| shares	227,845
Milestone description					The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States by June 10, 2020.
ImmuMetrix, Inc. [Member] \| CareDx, Inc [Member]
Business Acquisition [Line Items]
Acquisition-related costs				1,600,000		1,700,000
Stock-based compensation				$ 200,000		$ 200,000
ImmuMetrix, Inc. [Member] \| Series G Preferred Stock [Member]
Business Acquisition [Line Items]
Shares issued, shares issuable upon achievement of future milestone, and options assumed \| shares			911,364
Estimated fair value			$ 14,200,000
ImmuMetrix, Inc. [Member] \| Series G Preferred Stock [Member] \| Contingent consideration [Member]
Business Acquisition [Line Items]
Shares issued, shares issuable upon achievement of future milestone, and options assumed \| shares			227,845
Estimated fair value	$ 963,000	$ 1,100,000	$ 2,300,000
ImmuMetrix, Inc. [Member] \| Series G Preferred Stock [Member] \| Stock Options [Member]
Business Acquisition [Line Items]
Shares issued, shares issuable upon achievement of future milestone, and options assumed \| shares			23,229
Estimated fair value			$ 369,000

Organization	6 Months Ended
Organization	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. ORGANIZATION CareDx, Inc., (“CareDx” or the “Company”) is a commercial stage company that develops, markets and delivers diagnostic surveillance solutions for organ transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient’s lifetime. The Company’s one commercialized testing solution, the AlloMap heart transplant molecular test (“AlloMap”), an FDA-cleared test, is a blood-based test used to monitor for acute cellular rejection in heart transplant recipients. The Company was incorporated in Delaware in December 1998, as Hippocratic Engineering, Inc. In April 1999, the Company changed its name to BioCardia, Inc., in June 2002 to Expression Diagnostics, Inc., in July 2007 to XDx, Inc. and in March 2014 to CareDx, Inc. The Company’s operations are based in Brisbane, California and it operates in one segment. Reverse Stock Split, and Increase in Authorized Shares On July 1, 2014, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to reflect a 1 for 6.85 reverse stock split (the “Reverse Stock Split”) of the Company’s outstanding common stock and convertible preferred stock. The Reverse Stock Split became effective July 14, 2014. The par value per share was not adjusted as a result of the Reverse Stock Split. All authorized, issued and outstanding shares of common stock, convertible preferred stock, options and warrants to purchase common or preferred stock and related per share amounts contained in the financial statements have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented. Initial Public Offering On July 22, 2014, the Company closed its initial public offering (“IPO”) of 4,000,000 shares of its common stock, and issued an additional 220,000 shares of common stock on August 13, 2014 pursuant to the exercise of the over-allotment option granted to its underwriters. The public offering price of the shares sold in the offering was $10.00 per share. The total proceeds from the offering to the Company, net of underwriting discounts and commissions of $3.0 million, were $39.2 million. After deducting offering expenses payable by the Company of $3.7 million, net proceeds to the Company were $35.5 million. Upon the closing of the IPO, all shares of convertible preferred stock then outstanding converted into 6,048,220 shares of common stock, and a subordinated convertible note previously issued by the Company in the principal amount of $5.0 million converted into 510,777 shares of common stock. In addition, all of our convertible preferred stock warrants were converted into warrants to purchase common stock. Shelf Filing On August 10, 2015, the Company filed a registration statement on Form S-3 with the Securities and Exchange Commission which will allow the Company to raise up to $75 million from the capital markets. See Note 12.

Collaboration and Licensing Agreements - Additional Information (Detail)		1 Months Ended				3 Months Ended			6 Months Ended		12 Months Ended
	Sep. 18, 2014 USD ($)	Jul. 31, 2013 USD ($)	Jun. 30, 2013 USD ($)	Jun. 30, 2013 EUR (€)	Apr. 30, 2012 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2014 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Dec. 31, 2012 USD ($)	Jun. 30, 2013 EUR (€)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Description of agreement expire term									The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.
Upfront license fee payment											$ 1,000,000
Non-refundable and non creditable payment received											$ 250,000
Research and development expenses						$ 2,510,000		$ 792,000	$ 3,931,000	$ 1,512,000
Previously unrecognized license fee						500,000	$ 505,000		500,000
Revenue recognized under collaboration and licensing agreements								1,800	0	31,200
Amortization of upfront license fee								0		15,000
Reimbursement of research and development expenses								1,800		16,200
Upfront cash payment			$ 503,000	€ 387,500
Refundable upfront payments			344,000	€ 250,000
Common stock value						12,000	12,000		12,000
Shares sold for consideration		$ 467,000
Revenues recognized from the arrangement						16,000		1,000	33,000	1,000
Royalty revenues						89,000		59,000	179,000	117,000
Royalty revenues receivable balance						$ 179,000	54,000		$ 179,000
Up-front Payment Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Previously unrecognized license fee							611,000
Laboratory Corp of America Holdings [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Consideration of arrangement of license					$ 1,000,000
Description of agreement expire term									The license term in the 2012 Agreement was the later of 10 years from the date of the agreement or the expiration of the last-to-expire patents and patent applications included in the CareDx technology licensed to LabCorp, unless the license was terminated by mutual agreement.
Termination of collaboration agreement date									Sep. 18, 2014
Research and development expenses	$ 500,000							$ 3,600	$ 0	$ 32,000
Termination agreement fee							$ 500,000
Diaxonhit (DHT) [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock value			$ 503,000									€ 387,500

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,133,900	100,000,000
Common stock, shares issued	11,838,794	11,803,970
Common stock, shares outstanding	11,838,794	11,803,970

Subsequent Event	6 Months Ended
Subsequent Event	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Event	12. SUBSEQUENT EVENT Shelf Filing On August 10, 2015, the Company filed a registration statement on Form S-3 (“Shelf Filing”) with the Securities and Exchange Commission which will allow the Company to raise up to $75 million from the capital markets. In addition, on August 10, 2015 the Company entered into an At The Market Issuance Sales Agreement (the “2015 ATM Agreement”), with Cantor Fitzgerald and Company (“Cantor”) under which it may sell shares of its common stock from time to time in an aggregate amount not to exceed $19 million per year per the 2015 ATM Agreement and not to exceed $75 million in total per the Shelf Filing. Cantor may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The NASDAQ Global Market, on any other existing trading market for the Company’s common stock or to or through a market maker. Cantor also may sell the shares in privately negotiated transactions, subject to the Company’s prior approval. The Company will pay Cantor a commission equal to 3% of the gross proceeds of the sales price of all shares sold through it as sales agent under the 2015 ATM Agreement.

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2015	Jul. 29, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Trading Symbol	CDNA
Entity Registrant Name	CareDx, Inc.
Entity Central Index Key	0001217234
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		11,887,409

Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Condensed Statements of Operations - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue:
Testing revenue	$ 7,044	$ 6,710	$ 14,139	$ 12,544
Collaboration and license revenue	85	66	205	156
Total revenue	7,129	6,776	14,344	12,700
Operating expenses:
Cost of testing	2,508	2,403	5,218	4,565
Research and development	2,510	792	3,931	1,512
Sales and marketing	2,526	1,610	4,549	3,084
General and administrative	2,329	2,316	5,034	4,111
Change in estimated fair value of contingent consideration	142	0	(111)	0
Total operating expenses	10,015	7,121	18,621	13,272
Loss from operations	(2,886)	(345)	(4,277)	(572)
Interest expense, net	(256)	(644)	(1,083)	(1,192)
Other (expense) income, net	(43)	366	(97)	(163)
Loss before income taxes	(3,185)	(623)	(5,457)	(1,927)
Income tax benefit	0	1,500	0	1,500
Net (loss) income	$ (3,185)	$ 877	$ (5,457)	$ (427)
Net (loss) income per share (Note 3):
Basic	$ (0.27)	$ 0.87	$ (0.46)	$ (0.42)
Diluted	$ (0.27)	$ 0.13	$ (0.46)	$ (0.42)
Shares used to compute net (loss) income per share:
Basic	11,835,405	1,013,128	11,824,993	1,012,769
Diluted	11,835,405	6,939,568	11,824,993	1,012,769

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. COMMITMENTS AND CONTINGENCIES Royalty Commitments In November 2004, the Company entered into a license agreement with Roche Molecular Systems, Inc., or Roche, that grants the Company the right to use certain Roche technology relating to polymerase chain reaction, or PCR, and quantitative real-time PCR, in clinical laboratory services, including in connection with AlloMap. This is a non-exclusive license agreement in the United States covering claims in multiple Roche patents. The Company had disputed the combination services percentage Roche sought to apply under the agreement. The combination service percentage is a multiplier used to calculate royalties where licensed services are sold in combination with other services. From July 2011 through September 2014, the Company withheld payment of such royalties pending resolution of the matter. On February 11, 2014, Roche filed a demand for arbitration with the American Arbitration Association seeking a declaration that the Company had materially breached the Roche license agreement by failing to report and pay royalties owing to Roche in respect of licensed services performed by the Company after July 1, 2011. Since July 1, 2011, the Company fully accrued the unpaid royalties on the balance sheets, and the amount of the unpaid royalties has been reflected as an expense in the Company’s condensed statements of operations in the periods revenue was recorded to which the royalties relate. In September 2014, the Company entered into a settlement and mutual release agreement with Roche whereby: (i) for the period beginning July 1, 2011 through June 30, 2014, the Company agreed to pay the amount of $2,827,220 in settlement of past royalties due; (ii) for the period beginning July 1, 2014 through September 30, 2014, the Company agreed to pay royalties based on the same combination services percentage used to determine the past royalties due; (iii) for the period beginning October 1, 2014 through September 30, 2017, Roche and the Company agreed to a downward adjustment of the combination services percentage used to determine the portion of the AlloMap testing revenue that is royalty bearing under the terms of the license; (iv) the Company agreed to report and pay quarterly royalties within 45 days of the end of each calendar quarter; (v) Roche agreed that, subject to the Company’s timely payment of all applicable royalties through such date, no further royalties will be payable by the Company for periods after September 30, 2017; (vi) the Company and Roche agreed to mutually release all claims under the license agreement through the settlement date; and (vii) Roche agreed to dismiss the arbitration claims. For all time periods, the contractual royalty rate in the license agreement was or will be applied to the applicable combination services percentage to determine the royalties’ payable for the AlloMap service. Under the license agreement, the Company incurs royalty expenses as a percentage of combination services revenue and classifies those expenses as a component of cost of testing in the statements of operations. For the three months ended June 30, 2015 and 2014, royalty expenses in connection with the Roche agreement were $254,000 and $362,000, respectively. For the six months ended June 30, 2015 and 2014, royalty expenses in connection with the Roche agreement were $509,000 and $678,000, respectively. Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, or results of operations.

Debt	6 Months Ended
Debt	Jun. 30, 2015
Transfers and Servicing [Abstract]
Debt	9. DEBT On January 30, 2015, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) which provides a secured term loan facility in an aggregate principal amount of up to $20.0 million. The Company borrowed the first advance of $16.0 million (“Draw A”) on January 30, 2015. Under the terms of the Loan Agreement, following a six month period from the closing date and until any time before December 31, 2015, the Company may, at its option, borrow from the lender a second advance of $4.0 million (“Draw B”), subject to the Company’s satisfaction of certain conditions described in the Loan Agreement. Draw A was used to payoff the Company’s existing term debt of $11.3 million. A loss on extinguishment of $0.6 million from the pay-off of the existing term loan was recognized as interest expense during the six months ended June 30, 2015. Draw A and Draw B each bear interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the lender. The maturity date of the loan is December 1, 2018. Principal pay-down of the loan begins on January 1, 2016 with the loan being payable in 36 equal monthly installments. The principal pay-down of the loan may be delayed to July 1, 2016 with the loan being payable in 30 equal monthly installments, if on December 31, 2015, the Company has achieved certain net product revenue milestones as described in the Loan Agreement. A fully non-refundable commitment fee of $160,000 was paid on January 30, 2015 when Draw A for $16 million was received. An additional $40,000 loan fee will be payable if Draw B for $4 million is received. The loan has no prepayment penalty. Commitment fees are included in debt issuance costs which are amortized to interest expense using the effective interest method over the term of the loan. Debt discount and issuance costs, current, as of June 30, 2015 and December 31, 2014 were $176,000 and $76,000, respectively. Debt discount and issuance costs, non-current, as of June 30, 2015 and December 31, 2014 were $214,000 and $11,000, respectively. In connection with the Loan Agreement, the Company agreed to issue to the lender detachable warrants to purchase shares of the Company’s common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche. The fair value of the warrants are reflected as a discount to the debt. As a result of Draw A, the Company issued to the lender a warrant to purchase an aggregate of 34,483 shares of the Company’s common stock, at an exercise price equal to $6.96 per share. The fair value of the warrants was estimated to be $90,000 on January 30, 2015, using the Black-Scholes Model with the following assumptions: expected volatility of 39.83%, a contractual term of 5 years, risk-free interest rate of 1.18%, underlying common stock price of $7.06, and dividend yield of 0%. The warrants are included in stockholders’ equity with the offset to debt discount that is amortized over the term of the loan using the effective interest method. The warrants are not subject to remeasurement. The Loan Agreement requires collateral by a security interest in all of the Company’s assets except intellectual property and contains customary affirmative and negative covenants including financial maintenance covenants, and also includes standard events of default, including payment defaults. Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. At June 30, 2015, the Company was in compliance with all loan covenants.

Accrued and Other Liabilities - Components of Accrued and Other Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Professional fees	$ 113	$ 273
Test sample processing fees	383	318
Accrued overpayments and refunds	117	146
Clinical Studies	289	144
Deferred rent - current portion	230	202
Capital leases - current portion	62	70
Other accrued expenses	646	463
Total accrued and other liabilities	$ 1,840	$ 1,616

Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014
Operating activities:
Net loss	$ (5,457)	$ (427)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	358	222
Stock-based compensation	692	185
Amortization of deferred revenue	(59)	(23)
Amortization of debt discount and non-cash interest expense	450	349
Revaluation of contingent consideration to estimated fair value	(111)	0
Revaluation of warrants to estimated fair value	0	283
Gain on remeasurement of embedded derivative	0	(118)
Non-cash income tax benefit	0	(1,500)
Changes in operating assets and liabilities:
Accounts receivable	981	545
Inventory	(45)	(96)
Prepaid and other assets	(108)	(2,152)
Accounts payable	(116)	1,123
Accrued payroll liabilities	367	(196)
Accrued and other liabilities	274	2,117
Accrued royalties	27	721
Net cash (used in) provided by operating activities	(2,747)	1,033
Investing activities:
Purchase of property and equipment	(733)	(164)
Payment for acquisition, net of cash acquired (Note 11)	0	(376)
Net cash used in investing activities	(733)	(540)
Financing activities:
Payment of initial public offering costs	0	(909)
Proceeds from debt, net of issuance costs	15,625	4,982
Proceeds from exercise of stock options	42	5
Principal payments on debt and capital leases	(11,724)	(1,827)
Net cash provided by financing activities	3,943	2,251
Net increase in cash and cash equivalents	463	2,744
Cash and cash equivalents at beginning of period	36,431	5,128
Cash and cash equivalents at end of period	$ 36,894	$ 7,872

Stock Incentive Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Jan. 01, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair market value of Company's common stock		$ 6.48		$ 6.48		$ 5.56
Weighted-average fair value of options granted		$ 2.10		$ 2.62
Share based compensation, Total expensed		$ 411	$ 137	$ 692	$ 185
Total unrecognized stock-based compensation expense related to stock options and RSUs		3,700		$ 3,700
RSUs granted remaining vesting period				3 years 2 months 12 days
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, Total expensed		$ 232	$ 99	$ 431	$ 145
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs vest annual equal increments (in years)				4 years
RSUs granted period				2015-03
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance of common stock	357,075	838,695		838,695
Maximum number of shares may be added to the plan hereunder				865,252
Outstanding shares of common stock, in percentage	4.00%
2014 Equity Incentive Plan [Member] \| Stock Options, Restricted Stock Units and Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant		444,108		444,108
2014 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant		186,473		186,473
Shares issued under ESPP				36,696
Proceeds from the issuance of shares				$ 200
Applicable exercise date an offering period shall be equal to percentage of the lesser of fair market value of common stock				85.00%